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FOREWORD 
This toxicological profile is prepared in accordance with guidelines developed by the Agency for 
Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The 
original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised 
and republished as necessary. 
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health 
effects information for the hazardous substance described therein.  Each peer-reviewed profile identifies 
and reviews the key literature that describes a hazardous substance's toxicologic properties.  Other 
pertinent literature is also presented, but is described in less detail than the key studies.  The profile is not 
intended to be an exhaustive document; however, more comprehensive sources of specialty information 
are referenced. 
The focus of the profiles is on health and toxicologic information; therefore, each toxicological 
profile begins with a public health statement that describes, in nontechnical language, a substance's 
relevant toxicological properties. Following the public health statement is information concerning levels 
of significant human exposure and, where known, significant health effects.  The adequacy of information 
to determine a substance's health effects is described in a health effects summary.  Data needs that are of 
significance to protection of public health are identified by ATSDR and EPA.  
Each profile includes the following: 
(A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a hazardous substance to ascertain the levels of significant 
human exposure for the substance and the associated acute, subacute, and chronic health 
effects; 
(B) A determination of whether adequate information on the health effects of each substance is 
available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects; and 
(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels 
of exposure that may present significant risk of adverse health effects in humans. 
The principal audiences for the toxicological profiles are health professionals at the Federal, State, 
and local levels; interested private sector organizations and groups; and members of the public.  We plan 
to revise these documents in response to public comments and as additional data become available.  
Therefore, we encourage comments that will make the toxicological profile series of the greatest use. 
Comments should be sent to: 
    Agency for Toxic Substances and Disease Registry
    Division of Toxicology and Environmental Medicine 
1600 Clifton Road, N.E. 
Mail Stop F-32 
Atlanta, Georgia 30333 
 
vi 
The toxicological profiles are developed in response to the Superfund Amendments and 
Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive 
Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund).  This 
public law directed ATSDR to prepare toxicological profiles for hazardous substances most commonly 
found at facilities on the CERCLA National Priorities List and that pose the most significant potential 
threat to human health, as determined by ATSDR and the EPA.  The availability of the revised priority 
list of 275 hazardous substances was announced in the Federal Register on December 7, 2005 (70 FR 
72840). For prior versions of the list of substances, see Federal Register notices dated April 17, 1987 
(52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 
FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801);  February 28, 1994 (59 
FR 9486); April 29, 1996 (61 FR 18744); November 17, 1997 (62 FR 61332); October 21, 1999 (64 FR 
56792); October 25, 2001 (66 FR 54014); and  November 7, 2003 (68 FR 63098). Section 104(i)(3) of 
CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each 
substance on the list. 
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that 
has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal 
scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a 
nongovernmental panel and is being made available for public review.  Final responsibility for the 
contents and views expressed in this toxicological profile resides with ATSDR. 
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QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions. 
Primary Chapters/Sections of Interest 
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure. 
Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health. 
Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type 
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are 
reported in this section. 
NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting. Please refer to the Public Health Statement to identify general health effects observed 
following exposure. 
Pediatrics: Four new sections have been added to each Toxicological Profile to address child health 
issues: 
Section 1.6 How Can (Chemical X) Affect Children? 

Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)? 

Section 3.7 Children’s Susceptibility 

Section 6.6 Exposures of Children 

Other Sections of Interest: 
Section 3.8 Biomarkers of Exposure and Effect 
Section 3.11 Methods for Reducing Toxic Effects 
ATSDR Information Center  
Phone:  1-800-CDC-INFO (800-232-4636) Fax: (770) 488-4178 
or 1-888-232-6348 (TTY)   
E-mail: cdcinfo@cdc.gov Internet: http://www.atsdr.cdc.gov 
The following additional material can be ordered through the ATSDR Information Center: 
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure 
history is provided.  Other case studies of interest include Reproductive and Developmental 
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies. 
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Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident. Volumes I and II are planning guides to assist first responders and hospital emergency 
department personnel in planning for incidents that involve hazardous materials.  Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials. 
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances. 
Other Agencies and Organizations 
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, 
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015. 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH. 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for 
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212. 
Referrals 
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact: 
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone:  202-347-4976 
• FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/. 
The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk 
Grove Village, IL 60007-1030 • Phone:  847-818-1800 • FAX:  847-818-9266. 




Jessilynn Taylor, M.S. 









ATSDR, Division of Toxicology and Environmental Medicine, Atlanta, GA 

Julie M. Klotzbach, Ph.D., 

Mario Citra, Ph.D., 

Antonio Quiñones-Rivera, Ph.D. 

Syracuse Research Corporation, North Syracuse, NY 

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS: 
1. 	 Health Effects Review.  The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying 
end points. 
2.	 Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs. 
3. 	 Data Needs Review.  The Applied Toxicology Branch reviews data needs sections to assure 
consistency across profiles and adherence to instructions in the Guidance. 
4. 	 Green Border Review.  Green Border review assures the consistency with ATSDR policy. 
***DRAFT FOR PUBLIC COMMENT*** 
x ETHYLBENZENE 
This page is intentionally blank. 




A peer review panel was assembled for ethylbenzene.  The panel consisted of the following members:  
1.	 John DeSesso, Ph.D., Senior Fellow, Noblis, Falls Church, VA;  
2.	 James McDougal, Ph.D., Professor and Director of Toxicology Research, Boonshoft School of 
Medicine, Wright State University, Department of Pharmacology and Toxicology, Dayton, OH;  
3.	 Andrew Salmon, Ph.D., Senior Toxicologist and Chief, Air Toxicology and Risk Assessment 
Unit, Office of Environmental Health Hazard Assessment, California Environmental Protection 
Agency, Oakland, CA 
These experts collectively have knowledge of ethylbenzene's physical and chemical properties, 
toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans.  All reviewers were selected in conformity with the conditions for peer 
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended. 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile.  A listing of the 
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound.   
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
content. The responsibility for the content of this profile lies with the ATSDR. 
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1. PUBLIC HEALTH STATEMENT 
This public health statement tells you about ethylbenzene and the effects of exposure to it. 
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the 
nation. These sites are then placed on the National Priorities List (NPL) and are targeted for long-term 
federal clean-up activities. Ethylbenzene has been found in at least 829 of the 1,689 current or former 
NPL sites. Although the total number of NPL sites evaluated for this substance is not known, the 
possibility exists that the number of sites at which ethylbenzene is found may increase in the future as 
more sites are evaluated.  This information is important because these sites may be sources of exposure 
and exposure to this substance may harm you. 
When a substance is released either from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment.  Such a release does not always lead to exposure.  You 
can be exposed to a substance only when you come in contact with it.  You may be exposed by breathing, 
eating, or drinking the substance, or by skin contact. 
If you are exposed to ethylbenzene, many factors will determine whether you will be harmed.  These 
factors include the dose (how much), the duration (how long), and how you come in contact with it.  You 
must also consider any other chemicals you are exposed to and your age, sex, diet, family traits, lifestyle, 
and state of health. 
What is ethylbenzene? 
Colorless liquid 
 You can smell ethylbenzene in the air at 2 parts of ethylbenzene per million 

parts of air (2 ppm).  It evaporates at room temperature and burns easily. that smells like 
gasoline 
Used in industry Ethylbenzene is found naturally in oil.  Large amounts of ethylbenzene are 
produced in the United States.  Most of it is used to make styrene.  and in consumer 
Ethylbenzene is also used in fuels.  products 
Consumer products containing ethylbenzene include: 
• gasoline 
• paints and inks 
• pesticides 
• carpet glues 
• varnishes and paints 
• tobacco products  
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For more information on the physical and chemical properties of ethylbenzene, and its production, 
disposal, and use, see Chapters 4 and 5. 
What happens to ethylbenzene when it enters the environment?   
Ethylbenzene moves easily into the air from water and soil.  Ethylbenzene in Most commonly 
soil can also contaminate groundwater. found in air 
Air:  Ethylbenzene in air is broken down in less than 3 days with the aid of Rapidly broken 
sunlight.   
Water:  In surface water such as rivers and harbors, ethylbenzene breaks 
down by reacting with other compounds naturally present in water.  
Soil:  In the soil, ethylbenzene is broken down by soil bacteria.  
down in air 
For more information on ethylbenzene in the environment, see Chapter 6. 
How might I be exposed to ethylbenzene?  
Air If you live in a city or near many factories or heavily traveled highways, you 
may be exposed to ethylbenzene in the air.  Releases of ethylbenzene into 
the air occur from burning oil, gas, and coal and from industries using 
ethylbenzene. 
The median levels of ethylbenzene in air are: 
• 0.62 ppb in city and suburban locations 
• 0.01 ppb in rural locations 
• 1 ppb in indoor air  
Water  Ethylbenzene is infrequently detected in private and public groundwater 
wells used for drinking water.  Higher levels of ethylbenzene may be found in 
private residential wells near landfills, waste sites, or leaking underground 
fuel storage tanks.  
People with ethylbenzene-contaminated tap water could be exposed by 
drinking the water or eating foods prepared with it.  Exposure could also 
result from breathing in ethylbenzene while showering, bathing, or cooking 
with contaminated water. 
Soil Background levels in soils have not been reported.  Ethylbenzene may get 
into the soil by gasoline or other fuel spills and poor disposal of industrial 
and household wastes. 
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Workplace air Gas and oil workers may be exposed to ethylbenzene either through skin 
contact or by breathing ethylbenzene vapors.  Varnish workers, spray 
painters, and people involved in gluing operations may also be exposed to 
high levels of ethylbenzene.  Exposure may also occur in factories that use 
ethylbenzene to produce other chemicals. 
Consumer 
products 
You might be exposed to ethylbenzene by using any of the following 
products: 
• gasoline 
• carpet glues 
• varnishes and paints 
• tobacco products 
For more information on human exposure to ethylbenzene, see Chapter 6.  
How can ethylbenzene enter and leave my body?   
Rapidly enters When you breathe air containing ethylbenzene, it enters your body rapidly 
your body and almost completely through your lungs.  Ethylbenzene in food or water 
may also rapidly and almost completely enter your body through the 
digestive tract.  It may enter through your skin when you come into contact 
with liquids containing ethylbenzene. 
Typically leaves Once in your body, ethylbenzene is broken down into other chemicals.  
your body within Most of these other chemicals leave your body in the urine within 2 days.   
2 days 
Small amounts can also leave through the lungs and in feces.   
For more information on how ethylbenzene enters and leaves the body, see Chapter 3. 
How can ethylbenzene affect my health?   
Scientists use many tests to protect the public from harmful effects of toxic chemicals and to find ways 
for treating persons who have been harmed 
The effect of ethylbenzene on human health depends on how much ethylbenzene is present, how you are 
exposed to it, and the length of exposure.  
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Short-term 
exposure in air 
Humans:  Exposure to high levels of ethylbenzene in the air for short 
periods can cause eye and throat irritation.  Exposure to higher levels can 
result in vertigo and dizziness. 
Animals:  Exposure to very high levels (about 2 million times the usual level 
in urban air) can cause death.   
Long-term 
exposure in air 
Hearing:  Exposure to relatively low concentrations of ethylbenzene for 
several days to weeks resulted in potentially irreversible damage to the 
inner ear and hearing of animals.   
Kidney:  Exposures to relatively low concentrations of ethylbenzene for 
several months to years caused in kidney damage in animals.  
Reproduction:  There is no clear evidence that ethylbenzene affects fertility. 
Cancer:  An increase in kidney tumors in rats and lung and liver tumors in 
mice were found after they were exposed to ethylbenzene in air for 2 years.  
The International Agency for Research on Cancer (an expert group that is 
part of the World Health Organization) has determined on that long-term 




Hearing:  Rats exposed to large amounts of ethylbenzene by mouth had 
severe damage to the inner ear. 
Short-term eye 
and skin contact 
Irritation:  Liquid ethylbenzene caused eye damage and skin irritation in 
rabbits.   
Further information on the health effects of ethylbenzene in humans and animals can be found in 
Chapters 2 and 3. 
How can ethylbenzene affect children?  
This section discusses potential health effects in humans from exposures during the period from 
conception to maturity at 18 years of age. 
Children are likely 
to have similar 
effects as adults 
No information is available about the effect of exposure to ethylbenzene on 
children or immature animals.  It is likely that children would show the same 
health effects as adults.  We do not know whether children will have effects 
at the same exposure levels as adults.   
Birth defects We do not know whether ethylbenzene causes birth defects in people.  
Minor birth defects and low birth weights have occurred in newborn animals 
whose mothers were exposed air contaminated with ethylbenzene. 
Exposure from 
breast milk 
We do not know whether ethylbenzene can accumulate in breast milk. 
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Use adequate ventilation to minimize exposure to ethylbenzene vapors from 
consumer products such as 
• gasoline 
• pesticides 
• varnishes and paints 
• newly installed carpeting 
Sometimes older children sniff household chemicals in an attempt to get 
high. Your children may be exposed to ethylbenzene by inhaling products 
containing it, such as paints, varnishes, or gasoline.  Talk with your children 
about the dangers of sniffing chemicals.   
Store household 
chemicals out of 
reach of young 
children 
Always store household chemicals in their original labeled containers out of 
reach of young children to prevent accidental poisonings.  Never store 
household chemicals in containers children would find attractive to eat or 
drink from, such as old soda bottles.   
Gasoline should be stored in a gasoline can with a locked cap. 
Follow directions 
on label 
Always follow directions on household products, such as use with good 
ventilation. 
Limit exposure to 
tobacco smoke 
Ethylbenzene is a component of tobacco smoke.  Avoid smoking in 
enclosed spaces like inside the home or car in order to limit exposure to 
children and other family members. 
Is there a medical test to determine whether I have been exposed to 
ethylbenzene? 
Can be measured Ethylbenzene can be measured in blood and in the breath of people 
in blood and 
breath 
exposed to ethylbenzene.  
This should be done within a few hours after exposure occurs because 
these metabolites leave the body very quickly. 
Metabolites can 
be measured in 
urine 
The presence of ethylbenzene breakdown products (metabolites) in urine 
might indicate that you were exposed to ethylbenzene; however, these 
breakdown products can also form when you are exposed to other 
substances, such as styrene. 
The detection of these metabolites in your urine cannot be used to predict 
the kind of health effects that might develop from that exposure.   
You should have this test done within a few hours after exposure occurs 
because these metabolites leave the body very quickly.   
For more information on the different substances formed by ethylbenzene breakdown and on tests to 
detect these substances in the body, see Chapters 3 and 7. 
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What recommendations has the federal government made to protect human 
health? 
The federal government develops regulations and recommendations to protect public health.  Regulations 
can be enforced by law.  The EPA, the Occupational Safety and Health Administration (OSHA), and the 
Food and Drug Administration (FDA) are some federal agencies that develop regulations for toxic 
substances. Recommendations provide valuable guidelines to protect public health, but cannot be 
enforced by law.  The Agency for Toxic Substances and Disease Registry (ATSDR) and the National 
Institute for Occupational Safety and Health (NIOSH) are two federal organizations that develop 
recommendations for toxic substances. 
Regulations and recommendations can be expressed as “not-to-exceed” levels, that is, levels of a toxic 
substance in air, water, soil, or food that do not exceed a critical value that is usually based on levels that 
affect animals; they are then adjusted to levels that will help protect humans.  Sometimes these not-to-
exceed levels differ among federal organizations because they used different exposure times (an 8-hour 
workday or a 24-hour day), different animal studies, or other factors. 
Recommendations and regulations are also updated periodically as more information becomes available.  
For the most current information, check with the federal agency or organization that provides it.   
Some regulations and recommendations for ethylbenzene include the following: 
Levels in drinking
water set by EPA 
The EPA has determined that exposure to ethylbenzene in drinking water at 
concentrations of 30 ppm for one day or 3 ppm for 10 days is not expected 
to cause any harmful effects in a child. 
The EPA has determined that lifetime exposure to 0.7 ppm ethylbenzene is 
not expected to cause any harmful effects.   
Levels in surface 
water set by EPA 
If you eat fish and drink water from a body of water, the water should 
contain no more than 0.53 ppm ethylbenzene.   
Levels in 
workplace air set 
by OSHA 
OSHA set a legal limit of 100 ppm ethylbenzene in air averaged over an 
8-hour work day.   
For more information on regulations and advisories, see Chapter 8. 
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Where can I get more information? 
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department, or contact ATSDR at the address and phone number below. 
ATSDR can also tell you the location of occupational and environmental health clinics.  These clinics 
specialize in recognizing, evaluating, and treating illnesses that result from exposure to hazardous 
substances. 
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM.  You may 
request a copy of the ATSDR ToxProfiles™ CD-ROM by calling the toll-free information and technical 
assistance number at 1-800-CDCINFO (1-800-232-4636), by e-mail at cdcinfo@cdc.gov, or by writing 
to: 
Agency for Toxic Substances and Disease Registry

Division of Toxicology and Environmental Medicine 

  1600 Clifton Road NE 

  Mailstop F-32 

  Atlanta, GA 30333 

  Fax: 1-770-488-4178 

Organizations for-profit may request copies of final Toxicological Profiles from the following: 
National Technical Information Service (NTIS) 

5285 Port Royal Road 

  Springfield, VA 22161 

  Phone: 1-800-553-6847 or 1-703-605-6000 

Web site: http://www.ntis.gov/ 
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2.1 	 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO ETHYLBENZENE IN THE 
UNITED STATES 
Ethylbenzene is widely distributed in the environment.  It is primarily used for the production of styrene, 
which is the monomeric unit for polystyrene materials.  Ethylbenzene is also used as a solvent and in the 
manufacture of several organic compounds other than styrene; however, these uses are very minor in 
comparison to the amounts used for styrene production.  The production volume of ethylbenzene is 
typically among the highest of all chemicals manufactured in the United States.  In 2005, nearly 12 billion 
pounds of ethylbenzene were produced domestically, with historical levels ranging anywhere from 
approximately 7 to 13 billion pounds annually.  Routine human activities, such as driving automobiles, 
boats, or aircraft, or using gasoline powered tools and equipment, release ethylbenzene to the 
environment.  Environmental and background levels of ethylbenzene are generally small and therefore, 
have minimal impact on public health.  Trace levels of ethylbenzene are found in internal combustion 
engine exhaust, food, soil, water, and tobacco smoke, but usually at levels well below those that have 
been shown to exhibit toxic effects in laboratory animals or human exposure studies. 
Ethylbenzene is not considered highly persistent in the environment.  It partitions primarily to air and 
removal via photochemically generated hydroxyl radicals is an important degradation mechanism.  The 
half-life for this reaction in the atmosphere is approximately 1–2 days.  Biodegradation under aerobic 
conditions and indirect photolysis are important degradation mechanisms for ethylbenzene in soil and 
water. Based on a vapor pressure of 9.53 mm Hg and Henry’s law constant of 7.9x10-3 atm-m3/mol, 
volatilization from water and soil surfaces is expected to be an important environmental fate process for 
ethylbenzene.  If released to soil, ethylbenzene is expected to possess moderate mobility based on a soil 
adsorption coefficient (Koc) value of 240. 
Ethylbenzene is ubiquitous in ambient air, primarily as a result of automobile emissions.  The median 
level of ethylbenzene in city and suburban air was reported as 2.7 μg/m3 (0.62 ppb). In contrast, the 
median level of ethylbenzene measured in rural locations was 0.056 μg/m3 (0.013 ppb). Ethylbenzene 
levels in indoor air tend to be higher than corresponding levels monitored in outdoor air, as a result of 
contributions from environmental tobacco smoke (ETS) and various consumer products, in addition to the 
permeation indoors of ethylbenzene from outside air.  A study analyzed the components of ETS for the 
50 top-selling U.S. cigarette brand styles in 1991 and for the University of Kentucky Research cigarette, 
K1R4F. The ethylbenzene concentrations measured were 8.68 μg/m3 for full-flavor cigarettes, 
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8.24 μg/m3 for full-flavor, low-tar cigarettes, and 8.72 μg/m3 for ultra-low-tar cigarettes.  The mean 
ethylbenzene concentration for all cigarettes was 8.50 μg/m3. A study reported a maximum outdoor air 
concentration of 7.4 μg/m3 (1.7 ppb) for ethylbenzene at four residential locations, while indoor air 
concentrations at these same homes ranged from 5 to 110 μg/m3 (1–25.3 ppb).  Ethylbenzene is detected 
infrequently in surface water.  Data from the EPA STOrage and REtrieval Database (STORET), indicated 
that ethylbenzene was detected in <3% of the surface water samples analyzed in the United States from 
January 2005 to March 2007, with a maximum concentration of 2 ppb.  
Ethylbenzene was identified in 82 different food items at a maximum concentration of 0.129 ppm in data 
obtained from the FDA Total Diet Study Market Basket Surveys collected between September 1991 and 
October 2003. Trace concentrations of ethylbenzene have been reported in split peas (0.013 mg/kg 
[ppm]), lentils (0.005 mg/kg [ppm]), and beans (mean concentration 0.005 mg/kg [ppm]; maximum 
concentration 0.011 mg/kg [ppm]).     
The general population is primarily exposed to ethylbenzene from the inhalation of ambient air.  This is 
due to the direct release of ethylbenzene into the air by the burning of fossil fuels or industrial processes, 
and partitioning into the air from other media (e.g., soil, surface water).  This partitioning of ethylbenzene 
into the air or water would play a role in exposure to populations living near hazardous waste sites.  In 
addition to inhalation exposure, ingestion of ethylbenzene may also occur because trace amounts have 
been found in water supplies and various food items. 
2.2 SUMMARY OF HEALTH EFFECTS  
In humans, eye irritation was observed after exposure to 10,000 ppm ethylbenzene for a few seconds.  
Volunteers reported irritation and chest constriction after acute-duration exposures to 2,000 ppm 
ethylbenzene.  These symptoms worsened as the concentration was increased to 5,000 ppm.  Human 
exposures in the range of 2,000–5,000 ppm ethylbenzene were associated with dizziness and vertigo.  
Complete recovery occurs if exposure is not prolonged.  Momentary ocular irritation, a burning sensation, 
and profuse lacrimation were observed in humans exposed to 1,000 ppm ethylbenzene.  Workers exposed 
occupationally to solvent mixtures that included ethylbenzene showed an increased incidence of hearing 
loss compared to unexposed individuals.  Respiratory effects were not observed in two patients exposed 
to 55.3 ppm ethylbenzene for 15 minutes.  An increase in the mean number of lymphocytes and a 
decrease in hemoglobin levels were observed during a 1-year period in workers exposed chronically to 
solvents including ethylbenzene. However, no adverse hematological effects were observed in workers 
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exposed to ethylbenzene for 20 years.  Although no information on ethylbenzene concentrations was 
reported, an estimated concentration of 6.4 mg/m3 was derived from a mean post-shift in urinary mandelic 
acid concentration in workers, based on the relationship between ethylbenzene concentrations in air and 
urinary mandelic acid concentration in a chamber-exposed group.  No liver lesions or differences in liver 
function tests between exposed and nonexposed workers were observed and no cases of malignancy in 
workers were reported. However, given the low exposure concentration, this study had limited the power 
to detect any effect.  No other studies in humans exposed to ethylbenzene were located.  Given that little 
data in humans are available, it is assumed that adverse effects observed in animals are relevant to 
humans. 
Acute-duration and intermediate-duration studies in animals suggest that the auditory system is a sensitive 
target of ethylbenzene toxicity.  Significant losses of outer hair cells (OHCs) in the organ of Corti have 
been observed in rats after acute-duration exposure ≥400 ppm and intermediate-duration inhalation 
exposure to ≥200 ppm ethylbenzene.  These OHC losses have been observed up to 11 weeks after 
termination of the exposure, suggesting that these effects may be irreversible.  Significant deterioration of 
auditory thresholds is also observed in animals affected with OHC losses.  Auditory deficits have also 
been observed in animals after an intermediate-duration oral exposure to ethylbenzene.  An almost 
complete loss of the three rows of outer hair cells in the organ of Corti was observed in rats 10 days after 
the last dose (900 mg/kg/day) in an acute-duration study.  Effects on the central nervous system, such as 
moderate motor activation, narcotic effects, changes in posture and arousal, and salivation and prostration 
have been observed in animals after acute- and intermediate-duration exposure to ≥400 ppm 
ethylbenzene. 
Results of 4- and 13-week studies indicate that intermediate-duration oral exposure to ethylbenzene 
produces effects to the liver. Effects indicative of liver toxicity observed included increased activity of 
serum liver enzymes (alanine aminotransferase [ALT] and gamma-glutamyltransferase [GGT]) in males 
(≥250 mg/kg/day) and females (750 mg/mg/day), increased absolute and relative liver weights 
(≥250 mg/kg/day in males and females), and a dose-related increase in the incidence of centrilobular 
hepatocyte hypertrophy (≥250 mg/kg/day in males and females).  Increased bilirubin (≤250 mg/kg/day in 
males and 750 mg/kg/day in females), total protein (750 mg/kg/day in females), albumin (750 mg/kg/day 
in males and females), globulins (750 mg/kg/day in females), and cholesterol (≤250 mg/kg/day in males 
and females), and decreased prothrombin time (750 mg/kg/day in males and ≥250 mg/kg/day in females) 
were considered by study investigators as adaptive effects in the liver.  In males in the 75 mg/k/day group, 
relative liver weight was significantly increased by 4% compared to controls; however, no 
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histopathological changes, or increases in absolute liver or serum liver enzyme activities were observed at 
this dosage. Given that ethylbenzene is a microsomal enzyme inducer, and the absence of histopathology 
and other evidence of liver injury at the 75 mg/kg/day dosage, the small increase in relative liver weight 
in male rats was at this dosage not considered evidence for an adverse effect on the liver.  Results of the 
4-week gavage study in rats were similar to those of the 13-week study, identifying no-observed-adverse-
effect level (NOAEL) and lowest-observed-adverse-effect level (LOAEL) values of 250 and 
750 mg/kg/day, respectively, for liver effects.  Observed effects consistent with hepatotoxicity included 
increased absolute and relative liver weights (≥250 mg/kg/day in males and 750 mg/kg/day in females), 
increased incidence of hepatocyte centrilobular (≥250 mg/kg/day in males and 750 mg/kg/day in 
females), and increase serum liver enzyme activity (ALT) (750 mg/kg/day in males and females).  
Histopathological changes characterized by cloudy swelling of parenchymal cells of the liver and an 
increase in liver weight were observed in female rats administered 408 mg/kg/day by gavage for 
6 months.  No other hepatic changes were reported.  No liver effects were observed in female rats 
administered 136 mg/kg/day.  However, this study was poorly reported and did not provide adequate 
descriptions of study methods or results. 
Guinea pigs exposed to sublethal concentrations of ethylbenzene (≤10,000 ppm for <100 minutes) 
showed “moderate” pulmonary edema and congestion.  These findings had disappeared in animals after a 
4–8-day recovery period, suggesting that these pathological effects in the lung are reversible.  A 50% 
respiratory depression was observed in mice exposed to ≥1,432 ppm for 5–30 minutes.  Respiratory 
depression has not been reported in humans exposed to ethylbenzene.  Nasal and eye irritation was 
evident in animals exposed to 1,000 ppm for ≥3 minutes.  One study did not observe weight or 
histopathological effects in the lungs of rats or mice exposed to 782 ppm or rabbits exposed to 1,610 ppm 
ethylbenzene for 4 weeks.  Absolute and relative lung weight was increased in rats, but not mice, exposed 
to ≥250 ppm for 13 weeks; no treatment-related histopathological effects were observed.  One study did 
not report pulmonary injury in rats, guinea pigs, rabbits, or monkeys exposed to 600–2,200 ppm 
ethylbenzene for approximately 6 months; however, only two animals were used in some of the dose 
groups in rabbits and monkeys.  No treatment-related histopathological effects were noted in respiratory 
tissue in rats or female mice exposed to up to 750 ppm ethylbenzene for 2 years.  Although an increase in 
alveolar epithelial hyperplasia was noted in male mice in the 750-ppm group the incidence fell within 
historical controls for the conducting laboratory.  The available data on adverse respiratory effects 
associated with ethylbenzene exposure in animals and the limited data available in humans suggest that 
respiratory effects in humans could result following inhalation exposure to high concentrations of 
***DRAFT FOR PUBLIC COMMENT*** 
13 ETHYLBENZENE  
2. RELEVANCE TO PUBLIC HEALTH 
ethylbenzene.  Respiratory effects from low-level exposure, such as that found in the outdoor air, appear 
to be less likely. 
Developmental effects have been reported in the offspring of pregnant animals exposed to ethylbenzene 
during gestation.  The best reported studies available suggest that developmental effects are generally 
observed at concentrations of approximately ≥1,000 ppm.  Significant increases in the incidence of fetal 
skeletal variations were observed in the offspring of pregnant rats exposed to 2,000 ppm and reductions in 
fetal body weight were observed in the offspring of pregnant rats exposed to ≥1,000 ppm ethylbenzene 
during gestation. Maternal toxicity, manifested as reduced body weight gain, was also observed in rats 
exposed to ≥1,000 ppm.  No developmental effects were observed at concentrations of ≤500 ppm.  In 
contrast, an increased incidence of fetuses with extra ribs was observed in the offspring of rats exposed to 
100 ppm during gestation, but not when the animals were exposed to 100 ppm during pre-mating and 
gestation. No other significant increases in major malformations or minor anomalies were observed.  
Neurodevelopmental assessments conducted on F2 rat offspring indicated no effects in a functional 
observational battery assessment, fore- or hind-limb grip strength, swimming ability, motor activity, 
startle response, or learning and memory assessments at 500 ppm. 
The number of implantations or live fetuses per litter and the percentage of resorptions or non-live 
implants per litter were unaffected in pregnant rats exposed to 2,000 ppm ethylbenzene during gestation.  
In a two-generation study, estrous cycle length was significantly reduced in F0, but not F1, females 
exposed to 500 ppm or in rats or mice exposed to 975 ppm ethylbenzene for 90 days.  Reproductive 
parameters were not affected in F0 or F1 males or females at 500 ppm ethylbenzene.  Exposure of rats 
and rabbits to 100 or 1,000 ppm ethylbenzene for 3 weeks during prior to mating or gestation or both 
resulted in no conclusive evidence of reproductive effects in either species.  Assessments of reproductive 
organs conducted following intermediate- and chronic-duration exposure to ethylbenzene have not 
observed histopathological changes in the testes of rats, mice, or rabbits exposed to concentrations as high 
as 2,400 ppm ethylbenzene for 4 days or in rats or mice exposed to 782 ppm ethylbenzene or rabbits 
exposed to 1,610 ppm for 4 weeks.  No effect was observed on spermatid counts, sperm motility, weight 
of the caudal epididymis, or testicular morphology in rats or mice exposed to 975 ppm ethylbenzene for 
90 days.  No adverse histopathological effects were seen in the testes of rats or guinea pigs exposed to 
concentrations up to 1,250 or 600 ppm, respectively, for 6–7 months.   
Other systemic effects have been observed in animals after acute-, intermediate-, and chronic-duration 
exposures to ethylbenzene.  Eye irritation and lacrimation have been observed after acute-duration 
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exposures in rats, mice, and guinea pigs exposed to ≥1,000 ppm ethylbenzene.  Lacrimation was observed 
in rats exposed to 382 ppm for 4 weeks.  In contrast, no ocular effects were seen in rats or mice after a 
13-week exposure to 975 ppm ethylbenzene.  Mild irritation, reddening, exfoliation, and blistering have 
been reported in rabbits when ethylbenzene was applied directly on the skin.  Slight irritation of the eye 
and corneal injuries were observed in rabbits when ethylbenzene was instilled onto the eyes.   
One study examined the possible association between occupational exposure to ethylbenzene and 
increased cancer risk; no cases of malignancy were observed in workers exposed to ethylbenzene for 
20 years.  Animal studies have found increased incidences of neoplasms in rats and mice following 
inhalation or oral exposure, which are considered relevant to humans.  The inhalation studies found clear 
evidence of carcinogenic activity in male rats based on increased incidences of renal tubule neoplasm's 
and testicular adenomas, some evidence of carcinogenic activity in female rats based on increased 
incidences of renal tubule adenomas, some evidence of carcinogenic activity in male mice based on 
increased incidences of alveolar/bronchiolar neoplasms, and some evidence of carcinogenic activity in 
female mice based on increased incidences of hepatocellular neoplasms.  In a reevaluation of the 
histopathology of rat kidneys from the NTP study, a study confirmed the NTP findings and suggested that 
the increased incidence of kidney tumors in rats in the high-dose group was related to a chemical-induced 
exacerbation of chronic progressive nephropathy (CPN) with a minor contributing factor in male rats 
being α2µ-globulin nephropathy.  The author suggests that since CPN is an age-related disease of rodents 
without a counterpart in humans, the kidney results of the NTP study are not relevant to humans for risk 
assessment purposes.  However, in an analysis of the association between CPN and renal tubule cell 
neoplasms in male F344 rats, a study concluded that the association between CPN and renal tubule cell 
neoplasms is marginal.  Results of this analysis suggest that the number of renal tubule cell neoplasms 
secondary to CPN would be few.  An increase in the total number of malignant tumors was observed in 
rats orally exposed to ethylbenzene; however, data on specific tumor types were not provided.  On the 
basis of the NTP study, IARC has classified ethylbenzene as a Group 2B carcinogen (possibly 
carcinogenic to humans).  In the most recent carcinogenicity assessment by the EPA conducted in 1991, 
ethylbenzene was classified as Group D (not classifiable as to human carcinogenicity) due to the lack of 
animal bioassays and human studies; however, the EPA assessment predated the NTP study. Ethyl-
benzene is not included in the NTP’s Report on Carcinogens; however, this may reflect that NTP has not 
recently considered the carcinogenicity of ethylbenzene, rather than a judgment that ethylbenzene is not 
carcinogenic. 
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Acute- and intermediate-duration studies provide strong evidence that ototoxicity is a sensitive effect 
following inhalation exposure to ethylbenzene.  A more detailed discussion of this effect follows.  The 
reader is referred to Section 3.2, Discussion of Health Effects by Route of Exposure, for additional 
information on other effects.   
A study of workers exposed occupationally to solvent mixtures that include ethylbenzene (mean exposure 
level 1.8 ppm) showed a 58% incidence of hearing loss compared to 36% in the reference (unexposed) 
group. The role of ethylbenzene in the observed losses cannot be ascertained from this study given that 
ethylbenzene was only one of several solvents, most of which were present at mean concentrations 1.5– 
3.5 times higher than ethylbenzene.  Consistent with the outcome of occupational studies showing hearing 
loss, significant and persistent adverse auditory effects have been shown in animals after acute- and 
intermediate-duration inhalation exposures to ethylbenzene and after acute-duration oral exposures.  
OHCs in the organ of Corti (located in the cochlea) are a sensitive target of toxicity of ethylbenzene.  
Significant losses of OHCs in the organ or Corti were observed in male rats after acute-duration 
inhalation exposure to ≥400 ppm and intermediate-duration inhalation exposure to ≥200 ppm ethyl-
benzene. These losses in OHC were observed 8–11 weeks after the last exposures.  Inhalation of 
≥400 ppm ethylbenzene for 5 days or 4 weeks also resulted in a significant deterioration of auditory 
thresholds. The magnitude of the shifts in auditory thresholds observed after the first 4 weeks of exposure 
did not change during a 13-week exposure period or after an 8-week post-exposure recovery period.  
Inner hair cells were affected by ethylbenzene only at ≥600 ppm in the intermediate-duration study. 
Guinea pigs exposed to ethylbenzene at 2,500 ppm for 5 days did not show auditory deficits or losses in 
outer hair cells, whereas significant deficits and hair cell loss were observed in rats exposed to ethyl-
benzene at 550 ppm.  An almost complete loss of OHC was reported in male rats 10 days after an acute-
duration oral exposure to ethylbenzene.  The mechanisms of the species differences between rats and 
guinea pigs are not understood.  However, given the observations of hearing loss in workers exposed to 
1.8 ppm ethylbenzene, the rat appears to be an appropriate animal model. 
2.3 MINIMAL RISK LEVELS (MRLs) 
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for ethylbenzene.  
An MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure.  MRLs are 
derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive 
health effect(s) for a specific duration within a given route of exposure.  MRLs are based on 
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noncancerous health effects only and do not consider carcinogenic effects.  MRLs can be derived for 
acute, intermediate, and chronic duration exposures for inhalation and oral routes.  Appropriate 
methodology does not exist to develop MRLs for dermal exposure. 
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990a), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis. As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised. 
Inhalation MRLs 
•	 An MRL of 10 ppm has been derived for acute-duration inhalation exposure (14 days or less) to 
ethylbenzene based on a NOAEL for significant deterioration in CAP auditory threshold and 
significant OHC loss at 400 ppm (LOAEL). 
The database for acute-duration inhalation exposure to ethylbenzene is composed mostly of studies in 
laboratory animals.  Some of the available reports and studies in humans are of limited use for dose-
response assessment because insufficient information was provided to clearly characterize the exposure to 
ethylbenzene.  Several studies with laboratory animals identify ototoxicity as the most sensitive end point 
for acute-duration inhalation exposure to ethylbenzene.  Damage to the OHCs of the organ of Corti and, 
in some cases, significant reductions in auditory thresholds were observed in rats exposed to ≥400 ppm 
ethylbenzene by inhalation for 5 days (Cappaert et al. 1999, 2000, 2001, 2002).  Losses of OHCs 
appeared to be concentration related as losses were 52–66% in animals exposed to 800 ppm ethylbenzene 
(Cappaert et al. 1999), 40–75% at 550 ppm, and approximately 25% at 400 ppm (Cappaert et al. 2000, 
2001). OHC losses in rats exposed to 300 ppm were small (12%) and not statistically significant 
(Cappaert et al. 2000).  Significant auditory deterioration, manifested as shifts in auditory thresholds, was 
also observed in rats exposed to ≥400 ppm ethylbenzene for 5 days (Cappaert et al. 1999, 2000, 2001, 
2002).  Auditory thresholds in rats exposed to ethylbenzene at ≥400 ppm were significantly affected in 
the mid-frequency region; however, an increasingly broader range of frequencies were affected with 
increasing concentrations of ethylbenzene (Cappaert et al. 1999, 2000).  Cappaert et al. (2002) 
demonstrated a significant species difference in the susceptibility of rats and guinea pigs to the ototoxic 
effects of ethylbenzene with guinea pigs showing no auditory deficits or losses in OHCs at 2,500 ppm 
***DRAFT FOR PUBLIC COMMENT*** 
17 ETHYLBENZENE  
2. RELEVANCE TO PUBLIC HEALTH 
ethylbenzene after 5 days (Cappaert et al. 2002).  Auditory assessments indicate that effects were evident 
shortly after exposure and persisted for up to 11 weeks (termination of the observation period) (Cappaert 
et al. 1999, 2000, 2001, 2002).  The data suggest that these auditory effects might be irreversible. 
The observed damage to the auditory capacity of rats exposed to ethylbenzene during acute-duration 
studies reported in Cappaert et al. study (2000) was chosen as a critical effect to derive the acute-duration 
inhalation MRL.  Ototoxicity was observed at relatively low exposure levels (400 ppm) and was a serious 
adverse effect that the impaired auditory threshold; no other adverse effects were observed at lower 
levels. An acute-duration MRL based on ototoxicity would be considered as protective of other effects 
observed in acute-exposure studies. 
In the study by Cappaert et al. (2000), Wag/Rij rats (eight rats/group; sex not provided) were exposed to 
0, 300, 400, or 550 ppm ethylbenzene (99% pure) 8 hours/day for 5 days.  Animal weight was recorded 
weekly.  Measurement of Distortion Product Otoacoustic Emissions (DPOAE), Compound Action 
Potential (CAP), and hair cell counts were conducted 3–6 weeks after the last ethylbenzene exposure.  
Exposed animals did not show clinical signs of intoxication and there were no significant differences in 
terminal body weight between exposed and control rats.  DPOAE amplitude growth curves showed a 
significant reduction in rats exposed to 550 ppm, but not to 300 or 400 ppm ethylbenzene.  Effects were 
significant at 5.6, 8, and 11.3 kHz, but not at other frequencies.  The DPOAE thresholds were 
significantly shifted (increased stimulus was needed to elicit the threshold response) at 5.6, 8, 11.3, and 
16 kHz in rats in the 550-ppm group.  DPOAE threshold shifts were not observed in other exposure 
groups. Animals exposed to 550 ppm showed a significant shift in the CAP amplitude growth curves at 
8, 12, and 16 kHz.  In the 400-ppm group, the CAP growth curves were affected only at 12 kHz and there 
was no effect in animals in the 300-ppm group.  CAP thresholds were significantly shifted at 8, 12, and 
16 kHz in the 550-ppm group and at 12 and 16 kHz in the 400-ppm group.  There was no deterioration of 
CAP thresholds in the 300-ppm group.  Significant OHC losses of approximately 33 and 75% were 
observed in the 550-ppm group in the auditory regions corresponding to 11 and 21 kHz, respectively.  In 
the 400-ppm group, significant losses (25%) were observed in the 11 kHz region.  OHC losses in the 
21 kHz region in the 300-ppm group were approximately 12%, but were not statistically significantly 
different from controls.  This study identifies a NOAEL of 300 ppm and a LOAEL of 400 ppm for 
significant deterioration in CAP auditory thresholds and significant OHC losses. 
A LOAEL/NOAEL approach was used to derive a point of departure to estimate an acute-duration 
inhalation MRL for ethylbenzene using the NOAEL of 300 ppm and the LOAEL of 400 ppm.  
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Application of a benchmark dose analysis was precluded because the results in Cappaert et al. (2000) 
were presented graphically and the details necessary to conduct a benchmark dose assessment, such as 
standard errors or standard deviations, were not clearly discernible.  The NOAEL of 300 ppm was not 
adjusted for intermittent exposure given that the pharmacokinetics of ethylbenzene indicate that 
ethylbenzene will rapidly be absorbed, attain equilibrium with blood, be metabolized, and be eliminated 
from the body.  Steady-state blood ethylbenzene concentrations achieved within 2 hours of initiating 
inhalation exposure to ethylbenzene concentration ranging from 75 to 500 ppm (Charest-Tardif et al. 
2006).  The blood elimination kinetics of inhaled ethylbenzene show that ethylbenzene is rapidly 
eliminated from the blood, with elimination half-times ranging from 3.3 to 63 minutes (e.g., nonlinearity 
of clearance with exposure concentration, similar elimination half-times (Charest-Tardif et al. 2006; 
Tardif et al. 1997). To calculate the human equivalent NOAEL (NOAELHEC), the NOAEL was multiplied 
by the ratio of the animal-to-human blood/gas partition coefficients for ethylbenzene.  The blood/air 
partition coefficients for ethylbenzene were estimated to be 42.7 for the rat and 28.0 for the human 
(Tardif et al. 1997).  Since the ethylbenzene blood/gas partitioning coefficient in animals is greater than 
the partitioning coefficient in humans, a default value of 1 is used for the animal-to-human blood/gas ratio 
(EPA 1994o).  Thus, the NOAELHEC is 300 ppm.  The NOAEL[HEC] was divided by an uncertainty factor 
of 30 (3 for extrapolation from animals to humans with dosimetric adjustment and 10 for human 
variability), resulting in an acute-duration inhalation MRL of 10 ppm. 
The developmental effects of inhaled ethylbenzene have been examined in high quality, guideline-
compliant studies, which included complete examination of fetuses (Faber et al. 2006, 2007; NIOSH 
1981; Saillenfait et al. 2003, 2006, 2007).  Results of studies in rats indicate that ethylbenzene produces 
reduced fetal weight, skeletal anomalies, and delayed development of urogenital tract; skeletal anomalies 
and delayed urogenital development were observed in the presence of maternal toxicity (Faber et al. 2006; 
NIOSH 1981). Urogenital malformations (not specified) in mice and decreased fetal weight in rabbits 
also have been observed (Ungváry and Tátrai 1985); however, the usefulness of this study is hampered by 
the incomplete descriptions of the results and because an analysis of the results on a per litter basis was 
not provided.  Malformations of the uropoietic apparatus at the ethylbenzene concentrations reported by 
Ungváry and Tátrai (1985) were not observed in longer-duration studies (Faber et al. 2006, 2007; 
Saillenfait et al. 2003, 2006, 2007). 
Neurotoxic and respiratory effects were observed after acute-duration exposure to ethylbenzene at 
concentrations equal to or higher than those that elicited auditory effects in animals.  Effects observed 
after acute-duration exposure to ethylbenzene include moderate activation of motor behavior in rats 
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exposed to 400 ppm (Molnar et al. 1986) and reduced activity and prostration and shallow breathing in 
rats and mice at 1,200 ppm (Ethylbenzene Producers Association 1986a).  Rats or mice exposed to 
≥2,000 ppm showed posture changes, reduced grip strength, reduced motor coordination (Tegeris and 
Balster 1994), narcotic effects (Molnar et al. 1986), and neurotransmission disturbances in the forebrain 
and hypothalamus (Andersson et al. 1981).  Mice exposed to 4,060 ppm for 20 minutes showed a 50% 
reduction in respiratory rate (Nielsen and Alarie 1982).  A 50% respiratory depression observed in mice at 
1,432 ppm was attributed to sensory irritation (De Ceaurriz et al. 1981).  Ethylbenzene concentrations of 
1,000 ppm caused momentary ocular irritation, a burning sensation, and profuse lacrimation in humans 
(Thienes and Haley 1972; Yant et al. 1930).  Male volunteers exposed to 2,000 ppm ethylbenzene 
reported throat irritation and chest constriction (Yant et al. 1930).  No histopathological findings were 
made in the lungs of surviving rats, mice, or rabbits exposed to 1,200, 400, or 2,400 ppm ethylbenzene, 
respectively, for 4 days (Ethylbenzene Producers Association 1986a). 
Increased liver weight was reported after acute-duration exposure in rats exposed to ≥400 ppm 
ethylbenzene (Ethylbenzene Producers Association 1986a; Toftgard and Nilsen 1982), but not in mice at 
1,200 ppm or rabbits at 2,400 ppm (Ethylbenzene Producers Association 1986a).  At these same levels 
and durations of exposures, induction of microsomal enzymes and related ultrastructural changes (e.g., 
proliferation of the smooth endoplasmic reticulum) were observed.  These effects occurred in the absence 
of histopathological changes to the liver.  Therefore, the effects on the liver appear to be related to 
induction of microsomal enzymes in smooth endoplamic reticulum.   
Kidney weight was increased in rats exposed to ≥1,200 ppm (Ethylbenzene Producers Association 1986a; 
Toftgard and Nilsen 1982), but not in mice at 1,200 ppm or rabbits at 2,400 ppm (Ethylbenzene Producers 
Association 1986a). However, increased kidney weights occurred in the absence of histological changes 
(Ethylbenzene Producers Association 1986a). 
•	 An MRL of 0.7 ppm has been derived for intermediate-duration inhalation exposure (15–

364 days) to ethylbenzene based on a loss of cochlear OHC at 200 ppm. 

Otoxiticity (loss of cochlear OHC) observed in the study by Gagnaire et al. (2007) was selected as the 
critical effect to derive the intermediate-duration inhalation MRL.  Ototoxicity was observed at relatively 
low exposure levels (200 ppm) and was a serious adverse effect that the impaired auditory threshold; no 
other adverse effects were observed at lower levels.  An intermediate-duration MRL based on ototoxicity 
would be considered as protective of other effects observed in intermediate-exposure studies. 
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Male Sprague-Dawley rats (14 rats/exposure group) were exposed to 0, 200, 400, 600, and 800 ppm 
ethylbenzene (99% pure), 6 hours/day, 6 days/week, for 13 weeks (Gagnaire et al. 2007).  Ototoxicity was 
assessed based on effects on neurophysiological measurements and cochlear total hair cell counts.  
Following the 8th week of recovery, eight rats/group were killed.  In the 800-ppm group, one rat lost its 
head plug and could not undergo neurophysiological testing, one rat died for unknown reasons, and 
another rat was sacrificed due to a large neck tumor.  There were no significant differences in body 
weight gain between the surviving treated animals and controls.  Audiometric thresholds at 2, 4, 8, and 
16 kHz were significantly higher than in animals exposed to 400, 600, and 800 ppm ethylbenzene in 
controls. The effect was evident at week 4, did not change throughout the exposure period, and was not 
reversed after 8 weeks of recovery.  No shift in audiometric thresholds was observed in rats in the 
200-ppm group; however, the morphological assessment of the organ of Corti showed significant losses 
(up to 30% of the outer hair cells in the mid frequency region) in the third row of the OHC in four of eight 
rats exposed to 200 ppm.  A concentration-related loss in third row OHC (OHC3) was evident with 
almost complete loss observed in the 600- and 800-ppm groups.  The data suggest that the extent of the 
damage at each concentration was greatest in the OHC3 followed, in decreasing order, by damage in 
OHC2, OHC1, and IHC.  There was no significant hair cell loss in the control animals.  The LOAEL for 
OHC3 loss was 200 ppm, the lowest concentration tested. 
A LOAEL/NOAEL approach was used to derive a point of departure to estimate an intermediate-duration 
inhalation MRL for ethylbenzene.  Application of a benchmark dose analysis was precluded because the 
results in the Gagnaire et al. (2007) study were presented graphically and the details necessary to conduct 
a benchmark dose assessment, such as standard errors or standard deviations, were not clearly discernible 
or, for those results where the necessary data were available, the benchmark models tested did not fit the 
data adequately. 
The LOAEL of 200 ppm was not adjusted for intermittent exposure given that the pharmacokinetics of 
ethylbenzene indicate that ethylbenzene will rapidly be absorbed, attain equilibrium with blood, be 
metabolized, and be eliminated from the body.  Steady-state blood ethylbenzene concentrations achieved 
within 2 hours of initiating inhalation exposure to ethylbenzene concentration ranging from 75 to 
500 ppm (Charest-Tardif et al. 2006).  The blood elimination kinetics of inhaled ethylbenzene show that 
ethylbenzene is rapidly eliminated from the blood, with elimination half-times ranging from 3.3 to 
63 minutes (e.g., nonlinearity of clearance with exposure concentration, similar elimination half-times 
(Charest-Tardif et al. 2006; Tardif et al. 1997).  To calculate the human equivalent LOAEL (LOAELHEC), 
the LOAEL is multiplied by the ratio of the animal-to-human blood/gas partition coefficients for 
***DRAFT FOR PUBLIC COMMENT*** 
21 ETHYLBENZENE  
2. RELEVANCE TO PUBLIC HEALTH 
ethylbenzene.  Since the ethylbenzene blood/gas partitioning coefficient in animals is greater than the 
partitioning coefficient in humans, a default value of 1 is used for the animal-to-human blood/gas ratio 
(EPA 1994o).  Thus, the LOAELHEC is 200 ppm.  The LOAELHEC was divided by an uncertainty factor of 
300 (10 for use of a LOAEL, 3 for extrapolation from animals to humans with dosimetric adjustment, and 
10 for human variability) resulting in an intermediate-duration inhalation MRL of 0.7 ppm. 
The database of toxicity studies of intermediate-duration inhalation exposures includes several studies in 
animals, but no studies in humans.  The available animal studies indicate that rats are sensitive to the 
ototoxic effects of ethylbenzene (Gagnaire et al. 2007).  This is in agreement with the results of acute-
duration studies (Cappaert et al. 1999, 2000, 2001, 2002).  Rats exposed to ≥400 ppm ethylbenzene via 
inhalation for 13 weeks showed significant increases in auditory thresholds after 4 weeks.  These 
threshold shifts persisted unchanged for the duration of the exposure period and during an 8-week post-
exposure recovery period (Gagnaire et al. 2007).  Cell counts conducted in the organ of Corti after the 
8-week recovery period showed significant losses of outer hair cells in rats exposed to ≥200 ppm. 
Concentration-related losses of inner hair cells (IHC) (14 and 32%) were observed in animals in the 600- 
and 800-ppm groups, respectively, with occasional IHC losses in the 400-ppm group. Exposed rats did 
not show clinical signs of toxicity or differences in body weight gain relative to unexposed animals 
(Gagnaire et al. 2007). 
Systemic effects have been observed at concentrations equal to or higher than those that elicited ototoxic 
effects in rats. Increased liver, kidney, lung, and spleen weights have been observed in animals exposed 
to ethylbenzene concentrations in the 250- to 1,000-ppm range (Cragg et al. 1989; Elovaara et al. 1985; 
NIOSH 1981; NTP 1992; Wolf et al. 1956).  For instance, significant increases in absolute and relative 
liver weights were observed in rats and mice exposed to 782 ppm for 4 weeks, but not in animals in the 
382-ppm groups (Cragg et al. 1989).  Liver weight was not affected in rabbits at concentrations as high as 
1,610 ppm.  No other organs, including lung or kidney, showed weight changes in rats or mice at 
782 ppm or in rabbits at 1,610 ppm (Cragg et al. 1989).  Gross and microscopic examination of over 
30 organs (including organs of the respiratory, endocrine, digestive, renal, and nervous systems) did not 
show treatment-related effects in rats or mice exposed to 782 ppm or rabbits at 1,610 ppm (Cragg et al. 
1989). Absolute and relative lung weights were significantly increased in female rats exposed to 
≥250 ppm for 13 weeks; male rats showed an increased relative lung weight at 1,000 ppm (NTP 1992); 
however, there was no evidence of histopathological injury. Increased absolute and/or relative liver and 
kidney weights without evidence of histopathological injury were observed in male and female rats or 
mice exposed to ≥250 ppm ethylbenzene for 13 weeks (NTP 1992).  Some of the organ weight increases 
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reported at the lower concentrations were <10% (NTP 1992) or deemed to be slight (Wolf et al. 1956).  
Neurological effects (sporadic salivation) were reported in rats at ≥382 ppm (Cragg et al. 1989).  Cragg et 
al. (1989) observed small, but statistically significant, increases in platelet counts in male rats and 
leukocyte counts in female rats exposed to 782 ppm ethylbenzene for 4 weeks.  Although no details were 
provided, Wolf et al. (1956) did not report hematological changes in animals exposed to up to 2,200 ppm. 
Increased incidence of skeletal variations or all variations combined were observed in the offspring of 
pregnant rats exposed to ≥1,000 ppm ethylbenzene; however, on a per litter basis, significant increases 
were observed only at 2,000 ppm (Saillenfait et al. 2003).  Fetal malformations in the offspring of rats 
exposed to ≤500 ppm ethylbenzene occurred at a low frequency and did not appear to be attributable to 
ethylbenzene exposure (Saillenfait et al. 2003, 2006, 2007).  Significant reductions in fetal body weight 
were observed in the offspring of pregnant rats exposed to ≥1,000 ppm ethylbenzene during gestation 
(Saillenfait et al. 2003, 2006, 2007), but not in rats exposed to ≤500 ppm (Saillenfait et al. 2003, 2006, 
2007).  Maternal toxicity was observed only in rats exposed to ≥1,000 ppm as evidenced by the 
significant reduction in weight gain (corrected for gravid uterine weight) (Saillenfait et al. 2003, 2006, 
2007). NIOSH (1981) observed an increase in the incidence of skeletal anomalies in the offspring of rats 
exposed to approximately 1,000 ppm during pre-mating and gestation.  Increased maternal liver, kidney, 
and spleen weights were observed in that dose group.  Developmental effects were not consistently 
evident at approximately 100 ppm.  Developmental landmarks and neurodevelopment were not 
statistically or biologically significantly affected in the offspring of rats exposed to up to 500 ppm 
ethylbenzene in a two-generation reproductive toxicity test (Faber et al. 2006, 2007).  Reproductive 
parameters were not significantly affected in animals exposed to ethylbenzene concentrations as high as 
1,000 ppm (Saillenfait et al. 2003, 2006, 2007).  Faber et al. (2006) reported a reduction in estrus cycle 
length in F0, but not F1, females exposed to 500 ppm ethylbenzene.  There was no impairment in fertility 
or increased time to mating in the F0 females (Faber et al. 2006). 
•	 An MRL of 0.3 ppm has been derived for chronic-duration inhalation exposure (365 days or 
more) to ethylbenzene based on a LOAEL of 75 ppm for nephropathy in rats. 
In the NTP (1999) study, groups of F344/N rats (50 animals/sex/dose group) were exposed to 0, 75, 250, 
or 750 ppm ethylbenzene by inhalation 5 days/week, 6 hours/day, for 104 weeks.  Animals were observed 
twice daily and clinical findings were recorded monthly.  Body weights were recorded at the initiation of 
the study, weekly for the first 13 weeks, at week 16, monthly through the end of exposure, and prior to 
terminal necropsy.  Animals that survived to study termination were killed by asphyxiation with CO2. A 
complete necropsy and microscopic examination of major tissues and organs were performed on all rats 
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that survived to study termination or died early.  Survival of male rats in the 750-ppm group was 
significantly less than that of the chamber controls.  No clinical findings were attributed to ethylbenzene 
exposure. The severity of nephropathy observed in exposed rats was significantly increased in females at 
≥75 ppm and in males at 750 ppm.  In male rats exposed to 750 ppm, the incidences of renal tubule 
proliferative lesions were significantly increased relative to control animals.  The incidences of renal 
tubule adenoma and adenoma or carcinoma (combined) in the 750-ppm group were significantly greater 
than the incidence in control animals.  The incidence of renal tubule hyperplasia in 750 ppm males was 
significantly greater than that in the control group.  An increase was observed in the incidence of cystic 
degeneration of the liver in male rats at 750 ppm.   
In a 2-year study, female mice exposed to ≥250 ppm ethylbenzene showed an increased incidence of 
hyperplasia (characterized as focal, poorly delineated, monomorphic increases of cells lacking 
compressive features or altered arrangement) of the pituitary gland pars distalis relative to the incidence 
in control animals (NTP 1999).  Male and female mice in the 750-ppm group showed an increased 
incidence of follicular cell hyperplasia in the thyroid gland.  Eosinophilic foci of the liver were observed 
in females in the 750-ppm group at a higher incidence that in control animals.  Syncytial alterations of 
hepatocytes were observed in male mice in all ethylbenzene exposure groups, but not in controls, with a 
significant increase in incidence observed at ≥250 ppm.  Other nonneoplastic changes in male mice 
exposed to 750 ppm included mild-to-minimal hepatocellular hypertophy and hepatocyte necrosis (NTP 
1999).  The only available chronic-duration inhalation studies in animals suggest that a concentration-
related increase in the severity of nephropathy in female rats is the most sensitive end point of 
ethylbenzene exposure.  Thus, the study by NTP (1999) was selected to estimate a chronic-duration 
inhalation MRL. 
A LOAEL/NOAEL approach was used to derive a point of departure to estimate a chronic-duration 
inhalation MRL for ethylbenzene.  Application of a benchmark dose analysis was precluded because 
standard errors or standard deviations were not provided for the nephropathy severity ratings in the NTP 
(1999) study.  The LOAEL of 75 ppm was not adjusted for intermittent exposure given that the 
pharmacokinetics of ethylbenzene indicate that ethylbenzene will rapidly be absorbed, attain equilibrium 
with blood, be metabolized, and be eliminated from the body.  Steady-state blood ethylbenzene 
concentrations achieved within 2 hours of initiating inhalation exposure to ethylbenzene concentration 
ranging from 75 to 500 ppm (Charest-Tardif et al. 2006).  The blood elimination kinetics of inhaled 
ethylbenzene show that ethylbenzene is rapidly eliminated from the blood, with elimination half-times 
ranging from 3.3 to 63 minutes (e.g., nonlinearity of clearance with exposure concentration, similar 
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elimination half-times (Charest-Tardif et al. 2006; Tardif et al. 1997).  To calculate the human equivalent 
LOAEL (LOAELHEC), the LOAEL is multiplied by the ratio of the animal-to-human blood/gas partition 
coefficients for ethylbenzene.  Since the ethylbenzene blood/gas partitioning coefficient in animals is 
greater than the partitioning coefficient in humans, a default value of 1 is used for the animal-to-human 
blood/gas ratio (EPA 1994o).  Thus, the LOAELHEC is 75 ppm.  The LOAELHEC was divided by an 
uncertainty factor of 300 (10 for use of a LOAEL, 3 for extrapolation from animals to humans with 
dosimetric adjustment, and 10 for human variability) resulting in an intermediate-duration inhalation 
MRL of 0.3 ppm. 
The database of chronic-duration inhalation studies with ethylbenzene includes a chronic-duration study 
in rats and mice (NTP 1999) and studies in humans.  Hematological effects (increased average number of 
lymphocytes and decreased hemoglobin) were observed in workers exposed to solvents containing 
ethylbenzene (Angerer and Wulf 1985).  Concentration-related increases in the severity of nephropathy 
were observed in female rats exposed to ≥75 ppm for 2 years (NTP 1999).  In male rats, the severity of 
nephropathy was higher than in control animals only at 750 ppm (NTP 1999). Significant increases in the 
incidence of renal tubule hyperplasia were also observed in male and female rats in the 750-ppm groups.   
Oral MRLs 
Acute-duration Exposure.    No studies describing acute-duration oral exposure of humans to 
ethylbenzene were found in the literature.  Two animal studies have examined the acute oral toxicity of 
ethylbenzene.  An almost complete loss of the three rows of OHCs in the organ of Corti were reported in 
male rats administered 900 mg/kg/day (the only dose tested) by gavage for 2 weeks (Gagnaire and 
Langlais 2005). These losses were observed 10 days after the last dose.  Although losses of OHCs have 
also been observed in acute-duration inhalation studies (Cappaert et al. 1999, 2000, 2001, 2002), 
Gagnaire and Langlais (2005) did not have a control group to establish the magnitude of the effects 
relative to unexposed animals. This study was used to rank the ototoxicity of 21 solvents administered by 
gavage. Nevertheless, the OHC losses observed in the ethylbenzene-treated animals were among the 
highest observed among the 21 organic solvents tested (Gagnaire and Langlais 2005).  The 
900 mg/kg/day dose was considered a serious LOAEL for ototoxicity.  In the second study, doses of 
500 or 1,000 mg/kg ethylbenzene decreased luteinizing hormone, progesterone, and 17 β-estradiol levels, 
increased stromal tissue with dense collagen bundles and reduced lumen in the uterus, and delayed the 
estrus cycle in female rats during the diestrus stage (Ungvary 1986).  The poor reporting of the methods 
and results of the Ungvary (1986) study precludes using as the basis on an MRL. 
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Because the only dose tested in the Gagnaire and Langlais (2005) study is a serious LOAEL, an acute-
duration oral MRL cannot be derived for ethylbenzene. 
•	 An MRL of 0.5 mg/kg/day has been derived for intermediate-duration oral exposure to 

ethylbenzene based on the BMDL10 of 48.2 mg/kg/day for hepatotoxicity (centrilobular 

hepatocyte hypertrophy) in male rats. 

Hepatoxicity, specifically the incidence of centrilobular hepatocyte hypertrophy, was selected as the 
critical effect to derive the intermediate-duration oral MRL.  Based on evidence of hepatotoxicity 
(increased serum liver enzyme activity, absolute and relative liver weights, dose-related increased 
incidence of centrilobular hepatocyte hypertrophy, and the lack of evidence for adverse effects in other 
tissues or organ systems at lower oral intermediate-duration dosages, liver effects were selected as the 
basis for deriving the intermediate oral MRL.  The critical study identified NOAEL and LOAEL values 
for hepatotoxicity of 75 and 250 mg/kg/day, respectively (Mellert et al. 2007).  No other adverse effects 
were observed at lower doses. 
In the principal study, groups of 10 male and 10 female Wister rats were administered ethylbenzene (no 
vehicle) by oral gavage at doses of 0, 75, 250, or 750 mg/kg/day for 13 weeks.  The total daily dose of 
ethylbenzene was administered as split morning/evening half doses.  Animals were examined daily for 
mortality and clinical signs.  Food and water consumption and body weights were recorded weekly.  A 
detailed clinical examination (ophthalmology and a functional observational battery [FOB]) and 
assessment of motor activity were conducted during the last week of treatment.  After 13 weeks, 
urinalysis was conducted and blood samples were obtained and analyzed for hematology and clinical 
chemistry; organ weights were recorded and gross histopathologic examinations of the liver, kidney, and 
pancreas were conducted on animals in all groups.  A comprehensive histopathological examination of 
tissues was performed in the control and 750 mg/kg/day groups. 
No mortalities were observed during the course of the study (Mellert et al. 2007). Clinical signs (post-
dosing salivation) in treated animals were observed in all animals administered ≥250 mg/kg/day and in 
one animal administered 75 mg/kg/day.  Terminal body weight in males was significantly decreased by 
14% compared to controls in the 750 mg/kg/day group.  Mean corpuscular volume was increased in males 
and females and platelet count was reduced in females treated with 750 mg/kg/day.  Prothrombin time 
was significantly decreased (<8% compared to controls) in females administered ≥250 mg/kg/kg, but no 
changes in prothrombin times were observed in males in any treatment group.  Effects indicative of liver 
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toxicity included increased activity of serum liver enzymes ALT and GGT in males (≥250 mg/kg/day) 
and females (750 mg/mg/day), increased absolute and relative liver weights (≥250 mg/kg/day in males 
and females), and a dose-related increase in the incidence of centrilobular hepatocyte hypertrophy 
(≥250 mg/kg/day in males and females).  Increased bilirubin (≤250 mg/kg/day in males and 
750 mg/kg/day in females), total protein (750 mg/kg/day in females), albumin (750 mg/kg/day in males 
and females), globulins (750 mg/kg/day in females), and cholesterol (≤250 mg/kg/day in males and 
females), and decreased prothrombin time (750 mg/kg/day in males and ≥250 mg/kg/day in females) were 
considered by study investigators as adaptive effects in the liver.  In males in the 75 mg/k/day group, 
relative liver weight was significantly increased by (4% compared to controls); however, no histopatho-
logical changes or increases in absolute liver or serum liver enzyme activities were observed at this 
dosage. Given that ethylbenzene is a microsomal enzyme inducer and the absence of histopathology and 
other evidence of liver injury at the 75 mg/kg/day dosage, the small increase in relative liver weight in 
male rats at this dosage was not considered indicative of an adverse effect on the liver. 
Renal effects in males included increased serum creatinine (750 mg/kg/day), increased incidences of 
transitional epithelial cells and granular and epithelial cell casts in the urine (≥250 mg/kg/day), increased 
absolute and relative kidney weights (≥250 mg/kg/day), and a dose-related increase in severity of hyaline 
droplet nephropathy (≥250 mg/kg/day) (Mellert et al. 2007).  Adverse renal effects in males were most 
likely related to accumulation of α2µ-globulin accumulation, and, therefore, considered not relevant to 
humans.  Absolute kidney weight was significantly increased by 7 and 13% in females administered 
250 and 750 mg/kg/day, respectively, compared to controls.  However, since no histopathological 
findings or alterations in urinalysis parameters were observed, increased kidney weight in females was 
not considered adverse. Absolute and relative thymus weights were decreased in females treated with 
≥250 mg/kg/day, but no histopathological findings were observed.  Histopathological examination of all 
other tissues did not reveal any abnormalities.  Results of the FOB did not reveal consistent treatment-
related effects. NOAEL and LOAEL values of 250 and 750 mg/kg/day, respectively, were identified 
based on hepatotoxicity in male and female rats. 
Based on evidence of hepatotoxicity (increased serum liver enzyme activity, absolute and relative liver 
weights, and incidence of centrilobular hepatocyte hypertrophy), the liver was identified as the most 
sensitive target for oral ethylbenzene, with NOAEL and LOAEL values of 75 and 250 mg/kg/day, 
respectively. Since serum liver enzyme activities were increased in the mid- and high-dose groups in 
males, but only in the high-dose group in females, males appeared more sensitive than females to hepatic 
effects of oral ethylbenzene.  To determine the point of departure for derivation of the intermediate-
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duration MRL, data sets for serum liver enzymes (ALT and GGT), relative liver weight, and centrilobular 
hepatocyte hypertrophy in male rats were evaluated for suitability for benchmark dose (BMD) modeling.  
Using all available continuous variable models in the EPA Benchmark Dose Software (BMDS) 
version 1.3.2 (EPA 2000), no models provided adequate fit to the data for serum liver enzymes and 
relative liver weights; therefore, these data sets were considered unsuitable for BMD analysis.  Data for 
the incidence of centrilobular hepatocyte hypertrophy were analyzed using all available dichotomous 
models in the EPA Benchmark Dose Software (version 1.3.2).  Predicted doses associated with a 10% 
extra risk were calculated.  As assessed by the chi-square goodness-of-fit statistic, all available 
dichotomous models provided adequate fit (X2 p>0.1).  Comparing across models, a better fit is generally 
indicated by a lower Akaike’s Information Criteria (AIC).  As assessed by AIC, the log-probit model 
(Figure 2-1) provided the best fit to the data.  The BMD10 and BMDL10 predicted by the log-probit model 
for the data on centrilobular hepatocyte hypertrophy in male rats were 78.9 and 48.2 mg/kg/day, 
respectively. The BMDL10 of 48.2 mg/kg/day for male rats was selected as the point of departure for 
deriving the intermediate-duration oral MRL. 
The BMDL10 of 48.2 mg/kg/day was divided by a total uncertainty factor of 100 (10 for extrapolation 
from animals to humans and 10 for human variability), resulting in an intermediate-duration oral MRL of 
0.5 mg/kg/day. 
The intermediate-duration oral database for ethylbenzene is limited to the critical study by Mellert et al. 
(2007) evaluating the effects of oral exposure of rats to ethylbenzene for 4 and 13 weeks, and a poorly 
reported 6-month exposure study in rats (Wolf et al. 1956).  Results of the 4-week exposure study in rats 
are similar to those observed in the 13-week study, showing that the liver is the primary target organ for 
oral ethylbenzene.  Effects consistent with hepatotoxicity include increased absolute and relative liver 
weights (≥250 mg/kg/day in males and 750 mg/kg/day in females), increased incidence of hepatocyte 
centrilobular (≥250 mg/kg/day in males and 750 mg/kg/day in females), and increased serum liver 
enzyme activity (ALT) (750 mg/kg/day in males and females).  The increase in relative kidney weight 
and hyaline droplet nephropathy in males administered ≥250 mg/kg/day was most likely secondary to 
increases accumulation of accumulation of α2µ-globulin accumulation, and, therefore, considered not 
relevant to humans.  The 4-week study identified NOAEL and LOAEL values of 250 and 750 mg/kg/day, 
respectively, for liver in male rats (Mellert et al. 2007).  Histopathological changes characterized by 
cloudy swelling of parenchymal cells of the liver and an increase in liver weight were observed in female 
rats administered 408 mg/kg/day by gavage for 6 months (Wolf et al. 1956).  No other hepatic changes  
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Figure 2-1. Predicted (Log-Probit Model) and Observed Incidence of Centrilobular 
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*BMDs and BMDLs indicated are associated with a 10% extra risk change from the control, and are in units of 
mg/kg/day. 
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were reported.  No liver effects were observed in female rats administered 136 mg/kg/day.  However, this 
study was poorly reported and did not provide adequate descriptions of study methods or results. 
Although no additional data are available regarding the effects of intermediate oral exposure to 
ethylbenzene, results of an acute-duration oral study indicate that ethylbenzene is ototoxic (Gagnaire and 
Langlais 2005).  In male rats administered 900 mg/kg/day (the only dose tested) by gavage for 2 weeks, 
an almost complete loss of the three rows of OHCs in the organ of Corti was observed in male rats 
(Gagnaire and Langlais 2005).  The 4- and 13-week oral studies by Mellert et al. (2007) did not examine 
the cochlea or measure auditory function.  Therefore, it is not possible to determine whether ototoxicity 
occurred in the 4- and 13-week studies.  
Chronic-duration Exposure.    No studies describing the non-carcinogenic effects of chronic-duration 
oral exposure to ethylbenzene in humans or animals were located. 
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3.1 INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of ethylbenzene.  It 
contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health. 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE  
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure 
periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. 
LOAELs have been classified into "less serious" or "serious" effects.  "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR 
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects.  The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
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major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not 
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health. 
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike. 
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs. 
3.2.1 Inhalation Exposure 
3.2.1.1 Death 
No studies were located regarding lethality in humans following inhalation exposure to ethylbenzene.  
Matsumoto et al. (1992) reported the case of a 44-year-old man who died 9 days after exposure to 
gasoline vapors for at least 10 hours in an enclosed car.  The patient’s clothing was saturated with 
gasoline, but there was no apparent ingestion of gasoline.  The patient suffered chemical burns over 50% 
of the total body surface area, and the cause of death was reported as multiple organ failure.  Ethyl-
benzene was detected in the patient’s blood (estimated initial blood concentration of 2.6 µg/mL).  
However, since gasoline contains approximately 1.4% (by weight) ethylbenzene (Agency for Toxic 
Substances and Disease Registry 1995), it is unlikely that death was due to ethylbenzene exposure. 
Studies on the lethality of inhaled ethylbenzene have been conducted using several animal models, with 
exposure times ranging from a few hours to 2 years.  The LC50 values obtained from acute inhalation 
exposure studies were 13,367 ppm following a 2-hour exposure (Ivanov 1962) and 4,000 ppm following a 
4-hour exposure (Smyth et al. 1962); 100% mortality was observed following exposure to 16,698 ppm for 
2 hours (Ivanov 1962) and exposure to 8,000 ppm for 4 hours (Smyth et al. 1962).  Inhalation exposure of 
Fischer 344 rats and B6C3F1 mice to ethylbenzene for 6 hours/day for 4 days produced lethality at 
concentrations of 1,200 and 2,400 ppm, respectively, although exposure to concentrations up to 
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2,400 ppm was not lethal to rabbits (Ethylbenzene Producers Association 1986a).  In intermediate-
duration exposure studies, inhalation exposure of rats and mice to 782 ppm or rabbits to 1,610 ppm 
ethylbenzene for 4 weeks did not produce lethality (Cragg et al. 1989).  No mortality was observed in rats 
or mice exposed to 782 ppm or rabbits exposed to 1,610 ppm ethylbenzene for 4 weeks (Cragg et al. 
1989) or in rats or mice exposed to 975 ppm ethylbenzene for 90 days (NTP 1992).  Survival of male rats, 
but not female rats or male or female mice, exposed to 750 ppm ethylbenzene for 2 years was 
significantly decreased (NTP 1999); survival in male rats exposed to 75 or 250 ppm ethylbenzene was not 
affected. 
The LC50 values and all reliable LOAEL values for death in rats and mice following acute- or chronic-
duration exposure are recorded in Table 3-1 and plotted in Figure 3-1. 
3.2.1.2 Systemic Effects  
Little data are available on the systemic effects of inhaled ethylbenzene in humans.  Most of the 
information available is from case reports in which quantitative data on exposure concentrations and 
durations were not reported.  In addition, most of the available studies have confounding factors (e.g., 
simultaneous exposures to other toxic substances) and insufficient reporting of important study details.  In 
general, the systemic effects observed in humans were respiratory tract and ocular irritation, and possible 
ototoxicity (hearing loss) and hematological alterations (increased lymphocyte counts and decreased 
hemoglobin concentration) (Angerer and Wulf 1985; Cometto-Muñiz and Cain 1995; Thienes and Haley 
1972; Yant et al. 1930). 
Several studies were located on the systemic effects of ethylbenzene in animals following inhalation 
exposure. Acute- and intermediate-duration exposure to inhaled ethylbenzene is associated with 
respiratory irritation, changes to the liver (increased organ weights and induction of microsomal 
enzymes), and effects on the hematological system (decreased platelets and increased leukocyte counts).  
Chronic exposure is associated with adverse effects to the liver (necrosis and hypertrophy), kidney 
(nephropathy and hyperplasia), and endocrine system (thyroid and pituitary hyperplasia). 
No studies were located describing cardiovascular, gastrointestinal, musculoskeletal, renal, endocrine, 
dermal, body weight, or metabolic effects in humans, or dermal effects in animals after inhalation 
exposure to ethylbenzene. 
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Survival of male rats
was not affected at 75
or 250 ppm.  In
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female rats and male
and female mice was
not affected at 750
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Figure 3-1  Levels of Significant Exposure to Ethylbenzene - Inhalation
Acute (≤14 days)













































































































































  Cancer Effect Level-Animals
  LOAEL, More Serious-Animals
  LOAEL, Less Serious-Animals
  NOAEL - Animals
  Cancer Effect Level-Humans
  LOAEL, More Serious-Humans
  LOAEL, Less Serious-Humans
  NOAEL - Humans
  LD50/LC50
   for effects
   other than
   Cancer
Figure 3-1  Levels of Significant Exposure to Ethylbenzene - Inhalation (Continued)
Intermediate (15-364 days)
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Figure 3-1  Levels of Significant Exposure to Ethylbenzene - Inhalation (Continued)
ppm
  Minimal Risk Level
*Doses represent the lowest dose tested per study that produced a tumorigenic
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The systemic effects observed after inhalation exposure are discussed below.  The highest NOAEL values 
and all reliable LOAEL values for systemic effects in each species and duration category are recorded in 
Table 3-1 and plotted in Figure 3-1. 
Respiratory Effects. Male volunteers reported throat and nasal irritation and feelings of “chest 
constriction” during a 6-minute inhalation exposure to 2,000 ppm ethylbenzene (Yant et al. 1930).  More 
severe throat and nasal irritation were reported immediately upon exposure to 5,000 ppm ethylbenzene.  
No data on pulmonary function were reported (Yant et al. 1930). No bronchospastic response was 
observed in two subjects challenged with 55 ppm ethylbenzene for 15 minutes in an inhalation chamber, 
based on comparison of pre- and post-exposure pulmonary function tests (Moscato et al. 1987).   
Results of acute studies in animals indicate that inhalation of ethylbenzene produces adverse respiratory 
effects ranging from irritation to pulmonary congestion.  Nasal irritation (based on nose rubbing) was 
observed in guinea pigs exposed to 1,000 ppm for 3 and 8 minutes and to 2,000, 5,000, and 10,000 ppm 
for 480, 30, and 10 minutes, respectively (Yant et al. 1930).  Gross histopathology revealed congestion 
and edema in the lungs of animals that died after exposure to 10,000 ppm ethylbenzene, with less severe 
effects observed in surviving animals.  Pulmonary congestion also was observed in rats and mice that died 
during exposure a 4-day exposure to 2,400 and ≥1,200 ppm ethylbenzene, respectively (Ethylbenzene 
Producers Association 1986a).  A 50% reduction in breathing rate was observed in mice exposed to 
1,432 ppm for 5 minutes (De Ceaurriz et al. 1981) and 4,060 ppm for 30 minutes (Nielsen and Alarie 
1982).  No adverse respiratory effects were observed in rats exposed to 2,000 ppm for 3 days (Toftgard 
and Nilsen 1982) or in rats, mice, and rabbits exposed to 1,200, 400, or 2,400 ppm, respectively, for 
4 days (Ethylbenzene Producers Association 1986a). 
Adverse respiratory effects attributed to intermediate- or chronic-duration inhalation exposures to 
ethylbenzene have been observed in animals.  Relative lung weight was increased in male rats exposed to 
975 ppm for 90 days, although increased absolute and relative lung weights were observed only in female 
rats exposed to 246 ppm ethylbenzene, but not to higher concentrations (NTP 1992).  Pulmonary lesions 
(inflammatory cell infiltrate) were observed in male rats exposed to ≥246 ppm for 90 days (NTP 1992).  
However, the NTP Pathology Working Group considered these effects to be more typical of an infectious 
agent than a response to the test compound; therefore, pulmonary findings were not attributed to 
ethylbenzene exposure.  No histopathological changes were observed in rats exposed to 2,200 ppm, 
guinea pigs or rabbits exposed 1,250 ppm, or monkeys exposed to 600 ppm ethylbenzene for 6 months 
(Wolf et al. 1956); however, the utility of this study is limited by a general lack of study details (e.g., no 
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exposure or control data were provided) and the small size of exposure groups (1–2 rabbits or monkeys 
per group).  No histopathological findings clearly attributable to ethylbenzene were observed in 
respiratory tissue of rats or mice exposed to up to 750 ppm ethylbenzene for 2 years (NTP 1999).  
Although the incidences of edema, congestion, and hemorrhage observed in male rats in the 750 ppm 
group were increased relative to control rats, observations were considered to be agonal changes in 
moribund animals and not directly related to chemical toxicity (NTP 1999). 
Cardiovascular Effects. Intermediate and chronic exposure of animals to inhaled ethylbenzene does 
not appear to produce adverse cardiovascular effects, based on results of histopathological examinations.  
No adverse histopathological effects were reported in cardiac tissue of rats or mice exposed to 782 ppm or 
rabbits exposed to 1,610 ppm ethylbenzene for 4 weeks (Cragg et al. 1989).  Similarly, no cardiovascular 
effects were observed in rats or mice exposed to 975 ppm ethylbenzene for 90 days (NTP 1992) or in rats 
exposed to 2,200 ppm, guinea pigs or rabbits exposed to 1,250 ppm, or monkeys exposed to 600 ppm 
ethylbenzene for 6 months (Wolf et al. 1956).  No adverse histopathological findings were observed in 
cardiovascular tissues of rats or mice exposed to 750 ppm ethylbenzene for 2 years (NTP 1999). 
Gastrointestinal Effects.    No adverse effects on the gastrointestinal system have been observed 
following intermediate or chronic inhalation exposure of animals. No changes in gross appearance or 
adverse histopathological effects were observed in the intestines of rats and mice exposed to 782 ppm or 
rabbits exposed to 1,610 ppm ethylbenzene for 4 weeks (Cragg et al. 1989).  No adverse histopathological 
changes in gastrointestinal tissue were observed in rats or mice exposed to ≤975 ppm ethylbenzene for 
90 days (NTP 1992) or in rats or mice exposed to ≤750 ppm ethylbenzene for 2 years (NTP 1999). 
Hematological Effects. Two studies involving long-term monitoring of workers occupationally 
exposed to ethylbenzene were located (Angerer and Wulf 1985; Bardodej and Cirek 1988). Angerer and 
Wulf (1985) reported increased lymphocyte count and decreased hemoglobin concentration in male 
varnish workers exposed to a mixture of solvents, including ethylbenzene, compared to an unexposed 
control group.  Workers were employed for an average of 8.2 years and exposed to an average 
ethylbenzene concentration of 1.64 ppm.  Average lymphocyte levels increased (41.5–68.8%) and 
average hemoglobin values decreased (5.2–7.1%) in exposed workers, compared to unexposed controls.  
However, due to concomitant exposure to other chemicals (xylenes, lead, toluene), the relationship of 
adverse hematological effects to inhaled ethylbenzene cannot be established.  No adverse hematological 
effects were seen in male workers employed at an ethylbenzene manufacturing facility over a 20-year 
period, compared to unexposed control workers (Bardodej and Cirek 1988).  Although no information on 
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ethylbenzene concentrations was reported, an estimated concentration of 6.4 mg/m3 was derived from a 
mean post-shift in urinary mandelic acid concentration in workers, based on the relationship between 
ethylbenzene concentrations in air and urinary mandelic acid concentration in a chamber-exposed group 
(Bardodej and Bardodejova 1988).  However, given the low exposure concentration, this study had 
limited power to detect any effect.   
Studies using animal models yield conflicting results regarding hematological effects of inhaled 
ethylbenzene.  Platelet count was significantly decreased in male rats and mean total leukocyte count was 
significantly increased in female rats exposed to 782 ppm ethylbenzene for 4 weeks; hematological 
effects were not observed in male or female rats exposed to ≤382 ppm, mice exposed to ≤782 ppm, or 
rabbits exposed to ≤1,610 ppm (Cragg et al. 1989).  No adverse hematological effects were observed in 
rats or mice exposed to 975 ppm ethylbenzene for 90 days (NTP 1992), or in rats exposed to ≤2,200 ppm, 
guinea pigs or rabbits exposed ≤1,250 ppm, or monkeys exposed to ≤600 ppm ethylbenzene for 6 months 
(Wolf et al. 1956). 
Musculoskeletal Effects. No musculoskeletal effects have been observed in laboratory animals 
exposed to inhaled ethylbenzene for intermediate or chronic durations.  No bone tissue abnormalities 
were observed upon histopathological examination of tissue from rats and mice exposed to 782 ppm and 
rabbits exposed to 1,610 ppm for 4 weeks (Cragg et al. 1989).  Similarly, no adverse effect on bone tissue 
was observed in rats or mice exposed to 975 ppm ethylbenzene for 90 days (NTP 1992) or 750 ppm for 
2 years (NTP 1999). 
Hepatic Effects. No adverse effects on liver function, as measured by serum liver enzyme activities, 
were observed in male workers employed at an ethylbenzene manufacturing facility over a 20-year period 
(Bardodej and Cirek 1988).  Although no information on ethylbenzene concentrations was reported, an 
estimated concentration of 6.4 mg/m3 was derived as described above under hematological effects 
(Section 3.2.1.3 ).  Given the low exposure concentration, this study had limited the power to detect any 
effect. 
Results of studies in laboratory animals have found various effects on the liver, including induction of 
cytochrome P-450, changes in liver weight (at least in part related to induction of cytochrome P-450), 
changes in hepatocyte ultrastructure consistent with induction of smooth endoplasmic reticulum, and 
histopathological changes, including hepatocyte necrosis.  Increased liver weights, induction of hepatic 
drug metabolizing enzymes, and changes in hepatocyte ultrastructure (consistent with induction of 
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smooth endoplasmic reticulum) have been observed in rats following acute inhalation exposure to 
ethylbenzene.  Concentration-related increases in absolute and relative liver weights were reported in 
male rats exposed to ≥400 ppm ethylbenzene for 3–4 days, although no histopathological changes were 
observed (Ethylbenzene Producers Association 1986a).  Increased relative liver weight, increased hepatic 
concentration of cytochrome P-450, and induction of hepatic microsomal enzymes (NADPH-cytochrome 
reductase, 7-ethoxycoumarin O-deethylase) were reported in rats exposed to 2,000 ppm ethylbenzene 
concentrations for 3 days (Toftgard and Nilsen 1982).  Similarly, hepatic drug metabolizing enzymes 
(UDP glucuronyl-transferase, D-glucuronolactone dehydrogenase) were increased in male rats exposed to 
50 ppm ethylbenzene for 2 weeks, and ethyoxycoumarin o-deethylase was increased at 300 ppm 
(Elovaara et al. 1985).  Electron microscopy showed changes in hepatocyte ultrastructure consistent with 
induction of cytochrome P-450 (e.g., smooth endoplasmic reticulum proliferation, slight degranulation of 
rough endoplasmic reticulum) in rats exposed to 600 ppm ethylbenzene for 2 weeks (Elovaara et al. 
1985).  Hepatic changes following acute exposure to ethylbenzene are consistent with induction of 
hepatic microsomal enzymes. 
Similar hepatic effects (liver weights, induction of hepatic drug metabolizing enzymes, and changes in 
hepatocyte ultrastructure) also have been reported in laboratory animals exposed to inhaled ethylbenzene 
for intermediate exposure durations. Significant increases in relative liver weight were observed in 
female rats exposed to ≥250 ppm ethylbenzene for 15 days (Saillenfait et al. 2006), rats and mice exposed 
to 782 ppm ethylbenzene for 4 weeks (Cragg et al. 1989), pregnant and nonpregnant rats and pregnant 
rabbits exposed to 1,000 ppm ethylbenzene for 3 weeks prior to mating and throughout gestation (NIOSH 
1981), and rats and mice exposed to 246 and 740 ppm ethylbenzene, respectively, for 90 days (NTP 
1992). Increased liver weight was also observed in rats exposed to 400 ppm, and guinea pigs and 
monkeys exposed to 600 ppm ethylbenzene for 6 months (Wolf et al. 1956).  Hepatic microsomal 
enzymes (total cytochrome P-450 protein, 7-ethoxycoumarin O-deethylase, aminopyrine N-demthylase) 
were induced in rats exposed to 50 ppm ethylbenzene for 16 weeks and changes in hepatocyte 
ultrastructure (e.g., smooth endoplasmic reticulum proliferation, slight degranulation of rough 
endoplasmic reticulum) in rats exposed to ethylbenzene from 2 to 15 weeks (Elovaara et al. 1985). 
Other histopathological findings in animals exposed to inhaled ethylbenzene were moderate to marked 
hypertrophy of periportal hepatocytes with clear cytoplasm in female rats exposed to ≥250 ppm 
ethylbenzene for 15 days (the investigators noted that minimal hypertrophy was observed in controls) 
(Saillenfait et al. 2006) and a cloudy swelling of hepatocytes of rats exposed to 2,200 ppm for 6 months 
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(Wolf et al. 1956).  No histopathological changes in the liver were observed in rats or mice exposed to 
246 and 740 ppm, respectively, for 90 days (NTP 1992).   
Chronic exposure of mice, but not rats, to inhaled ethylbenzene for 2 years produced hepatic toxicity, as 
indicated by histopathological changes (syncytial alterations of hepatocytes, hepatocellular hypertrophy, 
and hepatocyte necrosis) (NTP 1999). Syncytial alterations (enlarged hepatocytes with multiple nuclei), 
which were concentration-related in incidence and severity, were observed at in male mice exposed to 
≥75 ppm ethylbenzene, and hepatocyte hypertrophy and necrosis were observed in male mice exposed to 
750 ppm.  In female mice exposed to 750 ppm ethylbenzene for 2 years, the incidence and severity of 
eosinophilic foci, which was considered to be a preneoplastic lesion, was increased.   
Renal Effects. Renal effects of acute and intermediate exposure to inhaled ethylbenzene are primarily 
limited to minimally adverse effects, including increased kidney weight in rats and mice and induction of 
microsomal enzymes in rats.  However, chronic exposure of male and female rats results in more serious 
renal effects, including nephropathy, renal tubule hyperplasia, and renal tubular adenomas and 
carcinomas (see Section 3.2.1.7, Cancer).  In addition, effects associated with accumulation of 
α2µ-globulin and hyaline droplets have been observed in male rats exposed to inhaled ethylbenzene.  
Accumulation of α2µ-globulin in the renal tubule epithelial cells of male rats is associated with tubular 
epithelial necrosis, regenerative proliferation, and renal tumors.  This accumulation is not observed in 
female rats, mice, or humans (which lack that protein), or in male rats, which are genetically lacking 
α2µ-globulin.  Adverse effects in male rats associated with renal accumulation of α2µ-globulin are 
therefore not considered relevant to humans (EPA 1991g).  However, since renal toxicity of chronic 
exposure to inhaled ethylbenzene has been observed in female rats, renal effects associated with 
ethylbenzene are relevant to humans. 
Acute exposure to inhaled ethylbenzene had been reported to produce increases in kidney weight, induce 
renal microsomal enzymes, and enhance renal hyaline droplets in rats of both sexes.  In male rats only, 
this accumulation includes α2µ-globulin, but evidently other proteins are involved in females, and 
probably also in the males.  Relative kidney weight was significantly increased (11–20%) in male rats 
exposed to 2,000 ppm for 2 days (Toftgard and Nilsen 1982) and 1,200 ppm ethylbenzene for 4 days 
(Ethylbenzene Producers Association 1986a), and in male and female rats exposed to 750 ppm 
ethylbenzene (6–7%), but not at 75 ppm, for 1 week (Stott et al. 2003).  Although no change in renal 
histopathology accompanied increased kidney weight in rats exposed to 1,200 ppm ethylbenzene for 
4 days (Ethylbenzene Producers Association 1986a), increased accumulation of α2µ-globulin and hyaline 
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droplets were observed after 1 week in the kidneys of male rats exposed to 750 ppm ethylbenzene 
compared to controls (Stott et al. 2003).  Renal congestion was reported in rats and mice that died during 
exposure to 2,400 or 1,200 ppm ethylbenzene, respectively (Ethylbenzene Producers Association 1986a).  
Induction of renal cytochrome P-450 microsomal enzymes (7-ethoxycoumarin, O-deethylase, UDP 
glucuronyl-transferase, NADPH-cytochrome c reductase) was reported in rats following a 3-day exposure 
to 2,000 ppm ethylbenzene (Toftgard and Nilsen 1982). 
Renal effects of intermediate-duration exposure to inhaled ethylbenzene are similar to those observed 
following acute exposure (increased kidney weight, induction of renal microsomal enzymes, and changes 
associated with accumulation of α2µ-globulin).  Several studies have shown that exposure of rats or mice 
to inhaled ethylbenzene for durations of 4 weeks –7 months increases relative kidney weight (Elovaara et 
al. 1985; NIOSH 1981; NTP 1999; Stott et al. 2003; Wolf et al. 1956).  Concentration-related increases in 
renal microsomal enzymes (7-ethoxycoumarin O-deethylase, UDP glucuronyl-transferase) and renal 
glutathione concentration were reported in rats following a 5–16-week exposure to ethylbenzene at 
concentrations ranging from 50 to 600 ppm (Elovaara et al. 1985).  Histopathological changes in the 
kidney include α2µ-globulin-associated changes (nuclear-size and staining variations and vacuolation or 
decreased amount of cytoplasm) in male rats exposed to 750 ppm for 4 weeks (Stott et al. 2003) and 
swelling of the tubular epithelium in rats exposed to 600 ppm ethylbenzene for up to 7 months (Wolf et 
al. 1956). 
Chronic exposure of male and female rats, but not mice, to inhaled ethylbenzene for 2 years resulted in 
nephropathy and renal tubule hyperplasia (NTP 1999).  Although age-related nephropathy was observed 
in control rats, the severity was increased compared to controls in female rats exposed to ≥75 ppm and 
male rats exposed to 750 ppm.  The incidence of renal tubular hyperplasia (considered as a preneoplastic 
effect) was increased in male and female rats exposed to 750 ppm.  NTP (1999) concluded that 
ethylbenzene may have exacerbated the development of age-related nephropathy in rats and that renal 
tubular lesions were related to exposure.  Additional information pertaining to renal carcinogenesis is 
provided in Section 3.2.1.7. 
Endocrine Effects. Adverse endocrine effects, based on histopathological examinations of endocrine 
tissues, have not been observed in laboratory animals exposed to inhaled ethylbenzene for 4 weeks to 
6 months (Cragg et al. 1989; NTP 1992; Wolf et al. 1956), although chronic exposure is reported to 
produce hyperplasia of the thyroid and pituitary (NTP 1999).  Mice exposed to 750 ppm ethylbenzene for 
2 years showed an increased incidence of follicular cell hyperplasia in the thyroid gland.  In female mice 
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exposed to ≥250 ppm ethylbenzene, the incidences of hyperplasia of the pituitary gland pars distalis were 
significantly greater than those in the control group. No effects on other endocrine tissues were observed 
in mice and no effects on any endocrine tissue were observed in rats exposed to 750 ppm ethylbenzene for 
2 years (NTP 1999). 
Ocular Effects.    Ocular effects observed in humans and animals after inhalation exposure to 
ethylbenzene are presumed to be due to direct contact of the eyes with ethylbenzene vapor.  These effects 
are discussed in Section 3.2.3.2. 
Body Weight Effects.    Studies in animals examined body weight effects in acute-, intermediate-, and 
chronic-duration inhalation exposure to ethylbenzene.  Mean body weight was not affected in rats or mice 
exposed to 400 ppm or in rabbits exposed to 2,400 ppm ethylbenzene for 4 days (Ethylbenzene Producers 
Association 1986a). Rats exposed to 1,200 ppm showed a mean body weight that was lower than in 
control animals.  No effect on body weight was observed in rabbits after 7 days of exposure to 750 ppm 
(Romanelli et al. 1986). 
No changes in body weight were observed in pregnant rats or rabbits exposed to 985 and 962 ppm 
ethylbenzene, respectively, for 3 weeks prior to mating and throughout gestation (NIOSH 1981).  A 
decrease in body weight gain of 26–48% at weeks 2, 5, and 9, but not at week 16 was observed in male 
rats exposed to 600 ppm ethylbenzene for 16 weeks (Elovaara et al. 1985).  No adverse effect on body 
weight was observed in rats or mice exposed to 782 ppm or rabbits exposed to 1,610 ppm ethylbenzene 
for 4 weeks (Cragg et al. 1989). No effect on body weight was observed in rats and mice exposed to 
975 ppm ethylbenzene for 90 days (NTP 1992).  Similarly, no biologically significant effect on body 
weight was observed in rats and mice exposed to concentrations of ethylbenzene of up to 750 ppm for 
2 years (NTP 1999). 
3.2.1.3 Immunological and Lymphoreticular Effects  
Angerer and Wulf (1985) reported increased lymphocyte counts in male varnish workers exposed to a 
mixture of solvents, including ethylbenzene, compared to an unexposed control group.  Workers were 
employed for an average of 8.2 years and exposed to an average ethylbenzene concentration of 1.64 ppm.  
Average lymphocyte levels increased (41.5–68.8%) in exposed workers, compared to unexposed controls.  
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However, due to concomitant exposure to other chemicals (xylenes, lead, toluene), the relationship of 
adverse hematological effects to inhaled ethylbenzene cannot be established.   
Mean total leukocyte count was significantly increased in female rats expose to 782 ppm ethylbenzene, 
but not ≤382 ppm, for 4 weeks (Cragg et al. 1989).  Absolute and relative spleen weights were increased 
in pregnant rats exposed to 1,000 ppm ethylbenzene during pre-mating and gestation or gestation alone, 
although histopathological changes were not observed (NIOSH 1981).  Spleen weight was not affected in 
rabbits exposed to 1,000 ppm during gestation (NIOSH 1981).  No histopathological changes were 
observed in bone marrow (sternum), lymph nodes, thymic region, or spleen of rats or mice exposed to 
782 ppm or rabbits exposed to 1,610 ppm ethylbenzene for 4 weeks (Cragg et al. 1989).  No treatment-
related effect on the histopathology of several lymphoreticular tissues, including bronchial lymph nodes, 
regional lymph nodes, mandibular and mesenteric lymph nodes, mediastinal lymph nodes, spleen, or 
thymus were observed in rats and mice exposed to 975 ppm ethylbenzene for 90 days (NTP 1992) or 
750 ppm for 2 years (NTP 1999). 
The highest NOAELs for immunological and lymphoreticular effects in each species for intermediate- or 
chronic-duration exposure are reported in Table 3-1 and plotted in Figure 3-1. 
3.2.1.4 Neurological Effects 
Symptoms of dizziness accompanied by vertigo have been observed in humans acutely exposed to air 
concentrations of ethylbenzene ranging from 2,000 to 5,000 ppm for 6 minutes (Yant et al. 1930). 
Workers exposed occupationally for a mean of 13 years to solvent mixtures that include ethylbenzene 
(mean ethylbenzene exposure level 1.8 ppm) showed a 58% incidence of hearing loss compared to 
36% in the reference group (Sliwinska-Kowalska et al. 2001).  Hearing losses (expressed as increased 
hearing thresholds) were observed at all frequencies and appeared to range from 3 to 8 dB.  The role of 
ethylbenzene in the observed losses cannot be ascertained from this study given that ethylbenzene was 
only one of several solvents, most of which were present at mean concentrations 1.5–3.5 times higher 
than ethylbenzene.   
Neurological effects have been observed in several animals following acute-duration exposure to inhaled 
ethylbenzene, although there is considerable variability in species sensitivity.  In general, central nervous 
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system depression is associated with acute exposure to higher concentrations, whereas stimulation of the 
motor nervous system is associated with lower concentrations.  The most serious adverse neurological 
effect associated with acute- and intermediate-duration inhalation exposure to ethylbenzene is ototoxicity, 
characterized by deterioration in auditory thresholds and alterations of cochlear morphology. 
Clinical signs of general central nervous system depression or increased motor activity have been 
observed in animals acutely exposed to inhaled ethylbenzene.  Moderate activation in motor behavior was 
observed in rats following a 4-hour inhalation exposure to levels of ethylbenzene ranging from 400 to 
1,500 ppm, whereas narcotic effects were observed at higher ethylbenzene concentrations (2,180– 
5,000 ppm) (Molnar et al. 1986).  This study is limited by a lack of methodological detail and appropriate 
statistical analysis.  Central nervous system depression (unconsciousness) and ataxia were observed in 
guinea pigs exposed to 2,000 ppm ethylbenzene for acute-duration periods (Yant et al. 1930).  Salivation, 
prostration, and/or reduced activity were observed in rats and mice exposed to 2,400 or 1,200 ppm 
ethylbenzene, respectively, for 4 days (Ethylbenzene Producers Association 1986a).  However, rabbits 
exposed to 2,400 ppm ethylbenzene for the same period showed no adverse behavioral effects.  Exposure 
of mice to ethylbenzene for 20 minutes to ≥2,000 ppm produced changes in posture; decreased arousal 
and rearing; increased ease of handling; disturbances of gait, mobility, and righting reflex; decreased 
forelimb grip strength; increased landing foot splay; and impaired psychomotor coordination (Tegeris and 
Balster 1994). These acute effects were short-lived and more pronounced during exposure than after 
exposure, with recovery beginning within minutes of removal from the exposure chamber.  Sensorimotor 
reactivity also decreased.  Acute exposure of rats and mice to 245 and 342 ppm, respectively (Frantik et 
al. 1994), resulted in a 30% depression of evoked electrical activity in the brain immediately after 
exposure. 
General signs of neurotoxicity have not been observed in animals exposed to inhaled ethylbenzene for 
intermediate or chronic durations, although ethylbenzene concentrations evaluated in intermediate- and 
chronic-duration studies were lower than those evaluated in acute studies.  No behavioral changes, 
clinical signs of neurotoxicity or histopathological alterations of neurological tissues were observed in 
rats or mice exposed to concentrations of up to 782 ppm or rabbits exposed to concentrations up to 
1,610 ppm ethylbenzene for 4 weeks.  Sporadic salivation was noted in rats at doses of ≥382 ppm (Cragg 
et al. 1989). In a 90-day study (NTP 1992), rats and mice showed no adverse histopathological effects on 
brain tissue at doses up to 975 ppm.  No adverse effects were noted in the brain tissues of rats and mice 
exposed to concentrations of ethylbenzene of up to 750 ppm for 2 years (NTP 1999). 
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Ototoxic effects of inhaled ethylbenzene have been observed following acute- or intermediate-duration 
exposure of rats.  Effects are characterized by deterioration in auditory thresholds and alterations of 
cochlear morphology.  Male rats exposed to ethylbenzene at 800 ppm, 8 hours/day for 5 days showed 
significant deterioration in auditory thresholds (threshold shifts were 10–20 and 17–28 dB using two 
methods) 1 and 4 weeks after the exposure had ceased (Cappaert et al. 1999).  The magnitude of the 
increase in thresholds did not change between assessments conducted on post-exposure weeks 1 and 4; 
threshold shifts were evident at all tested frequencies (1–24 kHz).  Eight to 11 weeks after exposure, a 
significant loss (52–66%) of outer hair cells (OHCs) in the organ of Corti in the auditory region 
corresponding to 11–21 kHz was observed.  No loss of inner hair cells (IHCs) was found in the exposed 
animals (Cappaert et al. 1999).  Similarly, auditory threshold shifts (approximately 15–30 dB) and OHC 
losses (25–75%) were observed 3–6 weeks after exposure in male rats exposed to 400 or 550 ppm 
ethylbenzene, 8 hours/day for 5 days.  Auditory thresholds and OHC counts were not affected in rats 
exposed to 300 ppm ethylbenzene (Cappaert et al. 2000, 2001).  Cappaert et al. (2002) demonstrated a 
significant species difference in the susceptibility of rats and guinea pigs to the ototoxic effects of 
ethylbenzene.  Guinea pigs exposed to ethylbenzene at 2,500 ppm, 6 hours/day for 5 days did not show 
auditory deficits or losses in OHCs.  There was no loss of IHCs in either species (Cappaert et al. 2002).   
Electrophysiological measures showed significant shifts in auditory thresholds in rats exposed to 
ethylbenzene at ≥400 ppm ethylbenzene, 6 hours/day, 6 days/week for 4 weeks (Frantik et al. 1994).  
Auditory deficits persisted unchanged throughout the 13-week exposure period and the 8-week post-
exposure recovery period in rats exposed to ≥400 ppm ethylbenzene (Gagnaire et al. 2007). Histological 
assessments conducted after the 8-week recovery period showed significant losses in OHCs in rats 
exposed to ≥200 ppm ethylbenzene, 6 hours/day, 6 days/week for 13 weeks (Gagnaire et al. 2007).  IHC 
losses (14–32%) were observed in rats exposed to 600 and 800 ppm ethylbenzene, but only occasionally 
in rats exposed to 400 ppm (Gagnaire et al. 2007).   
The highest NOAEL values and all reliable LOAEL values for neurological effects in each species and 
duration category are recorded in Table 3-1 and plotted in Figure 3-1. 
3.2.1.5 Reproductive Effects  
No studies were located regarding reproductive effects in humans following inhalation exposure to ethyl-
benzene. 
***DRAFT FOR PUBLIC COMMENT*** 
68 ETHYLBENZENE  
3. HEALTH EFFECTS 
Adverse reproductive outcome was observed in rabbits exposed to inhaled ethylbenzene during gestation 
(Ungváry and Tátrai 1985); however, adverse reproductive effects have not been observed in other studies 
in rabbits, rats, or mice (Faber et al. 2006; NIOSH 1981; Saillenfait et al. 2003, 2006, 2007; Ungváry and 
Tátrai 1985).  Treatment-related effects on reproductive organs, as assessed by histopathological 
examination, have not been observed (Cragg et al. 1989; Ethylbenzene Producers Association 1986a; 
Faber et al. 2006; NTP 1992; Wolf et al. 1956). 
Pregnant rats exposed to ethylbenzene during gestation exhibited increased postimplantation loss at 
≥138 ppm and rabbits exhibited increased abortions at 230 ppm (Ungváry and Tátrai 1985), however, due 
to inadequate reporting, it is unclear if effects occurred in the presence or absence of maternal toxicity.  
No reproductive effects were noted in mice or rabbits exposed during gestation to 115 ppm (Ungváry and 
Tátrai 1985) or rats exposed to 250–2,000 ppm (Saillenfait et al. 2003, 2006, 2007).  No adverse effects 
on reproduction were observed in female rats and rabbits exposed to approximately 100 or 1,000 ppm 
ethylbenzene for 3 weeks prior to mating and throughout gestation (NIOSH 1981).  Reproductive 
function and outcome was assessed in a 2-generation reproductive toxicity study in rats exposed to 25, 
100, or 500 ppm ethylbenzene starting with a pre-mating exposure of ≥70 days and continuing through 
gestation day 20, lactation day 5–21 (oral exposure of mothers on lactation days 1–4), and postnatal 
day 21 (Faber et al. 2006).  Estrous cycle length was significantly reduced in F0 rats in the 500-ppm 
group (4.0 days vs. 4.4 days in controls), but was not altered in the F1 females.  Reproductive parameters 
(mating or fertility indices, gestation length, number of implantation sites, number of births/litter, and 
litter size) were not affected in F0 or F1 females (or males, as appropriate) exposed to 25–500 ppm 
ethylbenzene.   
No treatment-related histopathological changes were noted in the testes of rats, mice, or rabbits exposed 
to concentrations as high as 2,400 ppm ethylbenzene for 4 days (Ethylbenzene Producers Association 
1986a). No testicular histopathological abnormalities were reported in rats and mice exposed to 782 ppm 
and rabbits exposed to ethylbenzene concentrations as high as 1,610 ppm for 4 weeks (Cragg et al. 1989).  
NTP (1992) reported no effect on sperm or testicular morphology or on the length of the estrous cycle in 
rats or mice exposed to 975 ppm ethylbenzene for 90 days.  Mice showed a decrease in epididymal 
weight in the 1,000-ppm group; however, this observation was not considered biologically significant 
since there was no significant difference in spermatid counts, sperm motility, or weight of the caudal 
epididymis among treated and control animals.  Inhalation exposure of male monkeys and rabbits to 
600 ppm ethylbenzene for 6 months produced degeneration of germinal epithelium in the testes of one 
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monkey and one rabbit (Wolf et al. 1956).  No adverse histopathological effects were seen in the testes of 
rats or guinea pigs exposed to concentrations up to 1,250 or 600 ppm, respectively, for 6–7 months (Wolf 
et al. 1956). In a 2-generation reproduction study, no effects were observed on sperm number, motility, 
and morphology in F0 and F1 rats exposed to 25–500 ppm ethylbenzene (Faber et al. 2006). 
The highest NOAEL values and all reliable LOAEL values for reproductive effects in each species for 
acute-, intermediate-, and chronic-duration are recorded in Table 3-1 and plotted in Figure 3-1. 
3.2.1.6 Developmental Effects 
No studies were located regarding developmental effects in humans following inhalation exposure to 
ethylbenzene. 
The developmental effects of inhaled ethylbenzene have been studied in rats (NIOSH 1981; Ungváry and 
Tátrai 1985), mice (Ungváry and Tátrai 1985), and rabbits (NIOSH 1981; Ungváry and Tátrai 1985) 
exposed during gestation or pre-mating and gestation, rats exposed from pre-gestation through lactation 
(Faber et al. 2006), and in a 2-generation reproduction study in rats (Faber et al. 2007).  Results of studies 
in rats indicate that ethylbenzene produces reduced fetal weight, skeletal anomalies, and anomalies and 
delayed development of urogenital tract; skeletal and urogenital anomalies were observed in the presence 
of maternal toxicity (Faber et al. 2006; NIOSH 1981; Ungváry and Tátrai 1985).  Studies conducted by 
Faber et al. (2006, 2007) and NIOSH (1981) are of high quality and guideline-compliant. However, 
usefulness of the Ungváry and Tátrai (1985) study is hampered by incomplete descriptions of the results 
and because an analysis of the results on a per litter basis was not provided. 
In rats, continuous inhalation exposure to ethylbenzene on gestational days 7–15 to concentrations 
ranging from 138 to 552 ppm resulted in fetal resorption and a concentration-related retardation of 
skeletal development in surviving fetuses (Ungváry and Tátrai 1985).  Retarded skeletal development was 
observed in 28, 30, and 35% of fetuses exposed to 138, 276, and 552 ppm ethylbenzene, respectively. 
Increased incidence of extra ribs and anomalies of the urinary tract (specific effects not reported) were 
observed in 7% of fetuses at 552 ppm, but were not observed in controls.  Maternal toxicity was reported 
to be moderate and dose-dependent, but data were not presented.  In this same study, the incidence of 
anomalies of the uropoietic apparatus (not specified) was observed in the offspring of mice exposed to 
115 ppm ethylbenzene on gestation days 6–15, although no adverse developmental effects were observed 
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after exposure of rats to 138 ppm for 6 hours/day on gestation days 7–15 (Ungváry and Tátrai 1985).  
Anomalies of the uropoietic apparatus were not observed in other developmental studies (Faber et al. 
2006, 2007; Saillenfait et al. 2003, 2006, 2007).  Since Ungváry and Tátrai (1985) did not include 
sufficient details regarding the adverse fetal effects, dictating caution in the interpretation of study 
findings. 
In a NIOSH study conducted by Andrews et al. (NIOSH 1981), increases in the incidences of fetuses with 
extra ribs were observed in the offspring of rats exposed to 100 or 1,000 ppm ethylbenzene through 
gestation day 19 or 1,000 ppm during pre-mating and gestation.  The incidence of supernumerary ribs was 
increased only in the offspring of rats exposed to 1,000 ppm during gestation.  Reduced pup crown-rump 
length and an increased incidence of supernumerary ribs were observed in the offspring of rats exposed to 
1,000 ppm during gestation, but not in the offspring of rats exposed to 1,000 ppm during pre-mating and 
gestation. No other significant increases in major malformations or minor anomalies were observed.  
There was some evidence of maternal toxicity (increased relative liver, kidney, and spleen weights) in rats 
exposed to 1,000 ppm ethylbenzene during pre-mating and gestation or gestation only (NIOSH 1981). 
Statistically significant reductions in fetal body weight were observed in the offspring of pregnant rats 
exposed to ≥1,000 ppm ethylbenzene during gestation (Saillenfait et al. 2003, 2006, 2007), but not in rats 
exposed to 500 ppm (Saillenfait et al. 2003) or 250 ppm (Saillenfait et al. 2006, 2007).  A significant 
increase in the number of fetuses with fetal malformations (mostly skeletal variations) was observed in 
the offspring of rats exposed to ≥1,000 ppm ethylbenzene (Saillenfait et al. 2003, 2006, 2007). On a per 
litter basis, a significant increase in the incidence of fetal malformations was observed only at 2,000 ppm 
(Saillenfait et al. 2003). Maternal toxicity was observed in rats exposed to ≥1,000 ppm, as indicated by 
significant reductions in maternal weight gain compared to control animals (Saillenfait et al. 2003, 2006, 
2007). 
Survival from birth to postnatal days (PND) 4 and 21 was not affected in F1 or F2 offspring of pregnant 
rats exposed to ethylbenzene at 25, 100, or 500 ppm during premating, mating, gestation, and lactation 
(Faber et al. 2006). A statistically significant delay in balanopreputial separation was observed in F1 
males in the 500 ppm group, although the mean age at separation in that group (44.7 days) was similar to 
that observed in historical controls (44.8 days). No exposure-related macroscopic findings or changes in 
organ weight in F1 pups necropsied on PND 21 were observed. 
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Results of a 2-generation reproduction study in rats show that the mean age at acquisition of vaginal 
patency was significantly reduced in F1 females at 25, 100, and 500 ppm; however, the values in the 
treated groups (33.3–33.9 days) were similar to the historical control value (33.4 days) in the conducting 
laboratory (Faber et al. 2006).  F2 generation pups (which were not exposed to ethylbenzene by 
inhalation) did not show differences from controls in the age at preputial separation or vaginal patency 
(Faber et al. 2007). Developmental landmarks (pinna detachment, hair growth, incisor eruption, and eye 
opening) were not affected in F1 male or female pups exposed to 25–500 pm ethylbenzene (Faber et al. 
2006); however, in the F2 generation, statistically significant delays in hair growth were observed in 
males and females in all exposure groups and eye opening was significantly delayed in males the 25 and 
100 ppm groups, but not in the 500 ppm group (Faber et al. 2007).  Neurodevelopmental tests conducted 
on subsets of the F2 offspring (Faber et al. 2007) did not show statistically significant differences from 
controls in a functional observational battery assessment or in fore- or hind-limb grip strength. Although 
the data suggest an increase in motor activity in F2 males and females in the 25–500 ppm groups on 
PNDs 13 and 17, there were no statistical differences in motor activity on PNDs 13, 17, and 21 between 
exposed and control animals (Faber et al. 2007).  A statistically significant increase in motor activity was 
observed on PND 61 in F2 females in the 25 ppm group only.  Startle response was not affected in F2 rats 
of either sex on PND 20 or females on PND 60; F2 males showed statistically lower startle responses, but 
this was attributed to highly variable and abnormal responses in some control animals.  Swimming ability, 
learning, and memory assessments conducted in a Biel water maze did not reveal any significant effects 
in F2 animals in any of the exposure groups (Faber et al. 2007).  No morphometric or histologic effects in 
brains of F2 animals were observed from any exposure group on PND 21 or 72 (Faber et al. 2007). 
Reduced fetal weight was observed in female rats exposed to 115 ppm during gestation (Ungváry and 
Tátrai 1985).  In the offspring of rabbits exposed to ethylbenzene, no treatment-related effects were 
observed in fetal size, placental weight, or intrauterine growth retardation and there were no significant 
incidences of major malformations, minor anomalies, or common variants observed in the absence of 
maternal toxicity (NIOSH 1981). 
The highest NOAEL values and all reliable LOAEL values for developmental effects in each species and 
duration category are recorded in Table 3-1 and plotted in Figure 3-1. 
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3.2.1.7 Cancer 
No association has been found between the occurrence of cancer in humans and occupational exposure to 
ethylbenzene.  No cases of malignancy were observed in workers exposed to ethylbenzene monitored for 
20 years (Bardodej and Cirek 1988).  No information on ethylbenzene concentrations was reported, 
although an estimated concentration of 6.4 mg/m3 was derived as described above under hematological 
effects (Section 3.2.1.3).  However, no clear conclusions can be drawn from this study due to the lack of 
measured ethylbenzene concentrations.  Furthermore, the low exposure concentration limited the power 
of this study to detect any effect.  No other studies were found regarding cancer effects in humans 
exposed to ethylbenzene by inhalation. 
Information concerning the carcinogenicity of ethylbenzene in animals comes from an NTP-sponsored 
bioassay in male and female rats and mice exposed to 0, 75, 250, or 750 ppm ethylbenzene for up to 
2 years (NTP 1999).  NTP (1999) concluded that ethylbenzene showed clear evidence of carcinogenic 
activity in male rats based on increased incidences of renal tubule neoplasms and testicular adenomas, 
some evidence of carcinogenic activity in female rats based on increased incidences of renal tubule 
adenomas, some evidence of carcinogenic activity in male mice based on increased incidences of 
alveolar/bronchiolar neoplasms, and some evidence of carcinogenic activity in female mice based on 
increased incidences of hepatocellular neoplasms (NTP 1999).  
Pathological findings in male and female rats exposed to 750 ppm ethylbenzene showed significant 
increases in the incidence of renal tubule adenoma and adenoma or carcinoma (combined) compared to 
control animals.  An extended histopathological evaluation of the kidneys showed significant increases in 
the incidence of nephropathy and of renal tubular hyperplasia (a preneoplastic lesion) in male rats 
exposed to 750 ppm; in female rats, nephropathy was observed at concentrations ≥75 ppm and renal 
tubular hyperplasia was only observed at a concentration of 750 ppm.  In a reevaluation of the 
histopathology of rat kidneys from the NTP study, Hard (2002) confirmed the NTP (1999) findings and 
suggested that the increase incidence of kidney tumors in rats in the high-dose group was related to a 
chemical-induced exacerbation of chronic progressive nephropathy (CPN), with a minor contributing 
factor in male rats being α2µ-globulin nephropathy.  However, in an analysis of the association between 
CPN and renal tubule cell neoplasms in male F344 rats, Seely et al. (2002) concluded that the association 
between CPN and renal tubule cell neoplasms is marginal.  Results of this analysis suggest that the 
number of renal tubule cell neoplasm's secondary to CPN would be few (Seely et al. 2002). The 
incidence of interstitial cell adenoma in the testes of males exposed to 750 ppm was significantly greater 
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than in the control group and slightly exceeded the historical control range for inhalation studies.  The 
incidence of bilateral testicular adenoma was also significantly increased in males exposed to 750 ppm.   
In male mice, the incidences of alveolar/bronchiolar adenoma and alveolar/bronchiolar adenoma or 
carcinoma (combined) were significantly greater in males exposed to 750 ppm than in the controls.  No 
significant increased in the incidence of neoplastic lung lesions was observed in female rats.  The 
incidences of hepatocellular adenoma and hepatocellular adenoma or carcinoma (combined) were 
significantly greater in female mice exposed to 750 ppm than in the control group. Hepatocellular 
adenomas or carcinomas were not observed in male mice. 
3.2.2 Oral Exposure  
3.2.2.1 Death 
No studies were located regarding death in humans following oral exposure to ethylbenzene.   
Lethality has been observed in laboratory animals following ingestion of ethylbenzene.  The oral LD50 for 
gavage administration of ethylbenzene was reported to be 4,769 mg/kg ethylbenzene in rats (Smyth et al. 
1962).  In another oral study with rats exposed to ethylbenzene, the LD50 was reported to be 
approximately 3,500 mg/kg ethylbenzene (Wolf et al. 1956).  The usefulness of these data is limited since 
the study methodology was not provided. 
An oral LD50 value for rats is recorded in Table 3-2 and plotted in Figure 3-2. 
3.2.2.2 Systemic Effects  
No studies were located describing respiratory, cardiovascular, gastrointestinal, hematological, musculo-
skeletal, hepatic, renal, endocrine, dermal, ocular, body weight, or metabolic effects in humans or gastro-
intestinal, musculoskeletal, endocrine, dermal, ocular, body weight, or metabolic effects in animals after 
oral exposure to ethylbenzene. 
The highest NOAEL values and all reliable LOAEL values are recorded in Table 3-2 and plotted in 
Figure 3-2. 
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a The number corresponds to entries in Figure 3-2.
b Study results used to derive an intermediate-duration oral minimal risk level (MRL) of 0.5 mg/kg/day for ethylbenzene, as described in detail in Appendix A.  Benchmark dose (BMD)
analysis was performed on incidences of centrilobular hepatocyte hypertrophy to select a point of departure (BMDL10 = 48.2), which was divided by an uncertainty factor of 100 (10
for extrapolation from animals to humans and 10 for human variability)
d = day(s); F = Female; (G) = gavage; (GO) = gavage in oil; Hemato = hematological; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; mo =
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Figure 3-2  Levels of Significant Exposure to Ethylbenzene - Oral (Continued)
Intermediate (15-364 days)
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Respiratory Effects. No clinical signs of respiratory effects or histopathological findings in 
respiratory tissues were observed in male and female rats exposed to 750 mg/kg/day by gavage for 4 or 
13 weeks (Mellert et al. 2007). No respiratory effects were observed in female rats orally exposed to 
680 mg/kg ethylbenzene by gavage for 6 months (Wolf et al. 1956).  The utility of this study is limited 
because of poor protocol description. 
Cardiovascular Effects. No histopathological findings were made in cardiac tissue from male and 
female rats exposed to 750 mg/kg/day by gavage for 4 or 13 weeks (Mellert et al 2007) or from female 
rats exposed to 13.6–680 mg/kg via gavage for 6 months (Wolf et al. 1956)   
Hematological Effects. Decreased platelet count was observed in females administered 750 
mg/kg/day and increased mean corpuscular volume was observed in males and females exposed to ≥250 
mg/kg/day ethylbenzene by gavage for 13 weeks (Mellert et al 2007).  No effects on hematological 
parameters were observed in rats treated for 4 weeks (Mellert et al. 2007).  No adverse effects on bone 
marrow counts or histopathology were reported in female rats orally exposed to 13.6–680 mg/kg 
ethylbenzene by gavage for 6 months (Wolf et al. 1956).  The usefulness of this study is limited by the 
poorly described and limited results that were provided. 
Hepatic Effects. Effects indicative of liver toxicity were observed in male and female rats exposed to 
oral ethylbenzene for 4 and 13 weeks (Mellert et al. 2007).  After 4 weeks of exposure, observed effects 
consistent with hepatotoxicity included increased absolute and relative liver weights (≥250 mg/kg/day in 
males and 750 mg/kg/day in females), increased incidence of hepatocyte centrilobular hypertrophy 
(≥250 mg/kg/day in males and 750 mg/kg/day in females), and increase serum liver enzyme activity 
(ALT) (750 mg/kg/day in males and females) (Mellert et al. 2007).  After 13 weeks of exposure, 
increased activity of serum liver enzymes (ALT and GGT) in males (≥250 mg/kg/day) and females 
(750 mg/mg/day), increased absolute and relative liver weights (≥250 mg/kg/day in males and females), 
and a dose-related increase in the incidence of centrilobular hepatocyte hypertrophy (≥250 mg/kg/day in 
males and females) were observed.  Increased bilirubin (≤250 mg/kg/day in males and 750 mg/kg/day in 
females), total protein (750 mg/kg/day in females), albumin (750 mg/kg/day in males and females), 
globulins (750 mg/kg/day in females), and cholesterol (≤250 mg/kg/day in males and females), and 
decreased prothrombin time (750 mg/kg/day in males and ≥250 mg/kg/day in females) were considered 
by study investigators as adaptive effects in the liver.  In males in the 75 mg/k/day group, relative liver 
weight was significantly increased by (4% compared to controls); however, no histopathological changes, 
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or increases in absolute liver or serum liver enzyme activities were observed at this dosage. Given that 
ethylbenzene is a microsomal enzyme inducer, and the absence of histopathology and other evidence of 
liver injury at the 75 mg/kg/day dosage, the small increase in relative liver weight in male rats was at this 
dosage not considered evidence for an adverse effect on the liver (Mellert et al. 2007).  Histopathological 
changes characterized by cloudy swelling of parenchymal cells of the liver and an increase in liver weight 
were observed in female rats administered 408 mg/kg/day for 6 months (Wolf et al. 1956).  No other 
hepatic changes were reported. No liver effects were observed in female rats administered 136 
mg/kg/day. No conclusions could be drawn from these results because of serious weaknesses in the 
methodology and reporting of the data, including incidence data and statistical analyses. 
Renal Effects. Renal effects in males administered ethylbenzene by gavage for 13 weeks included 
increased serum creatinine (750 mg/kg/day), increased incidences of transitional epithelial cells and 
granular and epithelial cell casts in the urine (≥250 mg/kg/day), increased absolute and relative kidney 
weights (≥250 mg/kg/day), and a dose-related increase in severity of hyaline droplet nephropathy 
(≥250 mg/kg/day) (Mellert et al. 2007). Adverse renal effects in males were most likely related to 
accumulation of α2µ-globulin accumulation, and, therefore, considered not relevant to humans.  Similar 
renal findings were observed in male rats exposed for 4 weeks (administered ethylbenzene by gavage for 
13 weeks). Absolute kidney weight was significantly increased by 7 and 13% in females administered 
250 and 750 mg/kg-day, respectively, compared to controls.  However, since no histopathological 
findings or alterations in urinalysis parameters were observed, increased kidney weight in females was 
not considered evidence for renal toxicity in female rats.  The only animal study that investigated renal 
effects following ethylbenzene exposure involved female rats administered 13.6–680 mg/kg/body weight 
ethylbenzene by gavage for 6 months (Wolf et al. 1956).  Histopathological changes characterized as 
cloudy swelling of the tubular epithelium in the kidney and an increase in kidney weight were observed at 
the 408 mg/kg/day dose level.  No other renal changes were reported.  As in hepatic effects, no 
conclusions could be drawn from these results because of serious weaknesses in the methodology and 
reporting of the data (e.g., no data on the number of animals with renal effects).  Furthermore, no 
statistical analysis was performed. 
3.2.2.3 Immunological and Lymphoreticular Effects  
No studies were located regarding immunological effects in humans following oral exposure to ethyl-
benzene. 
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Absolute and relative thymus weights were significantly decreased in females treated with 
≥250 mg/kg/day for 13 weeks, but no histopathological findings were observed (Mellert et al. 2007).  
Therefore, effects were not considered adverse. 
3.2.2.4 Neurological Effects 
No studies were located regarding neurological effects in humans following oral exposure to ethyl-
benzene. 
Significant ototoxic effects were observed in male rats administered 900 mg/kg/day (the only dose tested) 
by gavage for 2 weeks (Gagnaire and Langlais 2005).  The authors reported an almost complete loss of 
the three rows of OHCs in the organ of Corti 10 days after the last exposure to ethylbenzene.  This study 
did not have a control group to clearly establish the magnitude of the effects relative to unexposed 
animals; nevertheless, this study showed that the losses observed in ethylbenzene-exposed animals were 
among the highest observed among 21 organic solvents tested (Gagnaire and Langlais 2005). No 
ethylbenzene-related behavioral changes were observed in female rats administered 13.6–680 mg/kg/day 
ethylbenzene by gavage for 6 months (Wolf et al. 1956).  No other parameters were investigated.  The 
utility of this study is limited because the monitored behavioral changes were not reported, and the study 
protocol was poorly described. 
In male and female rats exposed to 75–750 mg/kg/day ethylbenzene by gavage for 13 weeks, no 
neurological effects were observed, based on negative results of motor activity tests and a functional 
observational battery (FOB) (Mellert et al. 2007).  However, assessments of ototoxicity were not 
conducted; therefore, it is not possible to determine whether ototoxicity occurred in the 13-week study. 
3.2.2.5 Reproductive Effects  
No studies were located regarding reproductive effects in humans following oral exposure to 
ethylbenzene. 
The only available reproduction study reported that acute oral exposure to 500 or 1,000 mg/kg ethyl-
benzene decreases peripheral hormone levels and may block or delay the estrus cycle in female rats 
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during the diestrus stage (Ungváry 1986).  Decreased levels of hormones, including luteinizing hormone, 
progesterone, and 17 β-estradiol, were accompanied by uterine changes, which consisted of increased 
stromal tissue with dense collagen bundles and reduced lumen.  No dose response was noted. The study 
is limited by the absence of statistical analysis of the data. 
No histopathological findings of reproductive tissues were observed in male and female rats exposed to 
750 mg/kg/day by gavage for 4 or 13 weeks (Mellert et al. 2007). 
3.2.2.6 Developmental Effects 
No studies were located regarding developmental effects in humans or animals following oral exposure to 
ethylbenzene. 
3.2.2.7 Cancer 
No studies were located regarding carcinogenic effects in humans following oral exposure to 
ethylbenzene. 
The carcinogenicity of ethylbenzene by the oral route has been evaluated in a chronic-duration study in 
Sprague-Dawley rats (Maltoni et al. 1985).  A statistically significant increase in total malignant tumors 
was reported in females and in combined male and female groups exposed to 500 mg kg/day via gavage 
for 104 weeks and observed until after week 141.  No data on specific tumor type were presented, only 
one dose was tested, and no information on survival was provided. 
3.2.3 Dermal Exposure  
3.2.3.1 Death 
No studies were located regarding lethal effects in humans following only dermal exposure to ethyl-
benzene. Matsumoto et al. (1992) reported the case of a 44-year-old man who died 9 days after being 
massively exposed to gasoline (which contained ethylbenzene) dermally and by inhalation for ≥10 hours. 
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The dermal LD50 in rabbits exposed to liquid ethylbenzene (applied to clipped skin subsequently covered 
with an impervious plastic film) was calculated to be 15,433 mg/kg/body weight (Smyth et al. 1962).  No 
additional studies were located regarding death in animals following dermal exposure to ethylbenzene. 
3.2.3.2 Systemic Effects  
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, 
musculoskeletal, hepatic, renal, endocrine, body weight, or metabolic effects in humans or animals after 
dermal exposure to ethylbenzene. 
The systemic effects observed after dermal exposure to ethylbenzene are discussed below.  The highest 
NOAEL values and all reliable LOAEL values for each species and duration category are recorded in 
Table 3-3. 
Dermal Effects.    No studies were located regarding dermal effects in humans following dermal 
exposure to ethylbenzene. 
Liquid ethylbenzene applied directly to the skin of an unspecified number of rabbits caused irritation 
characterized by reddening, exfoliation, and blistering (Wolf et al. 1956).  Mild dermal irritation (grade 2 
on a scale of 10) was also noted in New Zealand White rabbits 24 hours after application of ethylbenzene 
to clipped skin (Smyth et al. 1962). 
Ocular Effects.    Ocular effects observed in humans and animals after inhalation exposure are assumed 
to be due to exposure of the mucous membranes of the eye to ethylbenzene vapor.  Volunteers reported 
eye irritation and burning, and profuse lacrimation, which gradually decreased with continued exposure to 
1,000 ppm for 1–6 minutes (Yant et al. 1930).  Upon entering the chamber with an ethylbenzene 
concentration of 2,000 or 5,000 ppm, the volunteers also experienced severe eye irritation.  
Cometto-Muñiz and Cain (1995) reported eye irritation in humans after exposure to ethylbenzene vapor.  
Eye irritation was observed at 10,000 ppm.   
Liquid ethylbenzene applied directly to the eyes of rabbits for an unspecified duration caused slight 
irritation of conjunctival membranes (Wolf et al. 1956) and slight corneal injury (Smyth et al. 1962; Wolf 
et al. 1956). 
***DRAFT FOR PUBLIC COMMENT*** 























Rabbit 24 hr Dermal 8.67 (grade 4 skin irritation)
mg
mg













B = both male and female; d = day(s); hr = hour(s); LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; NOAEL = no-observed-adverse-effect
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Irritant effects from exposure to ethylbenzene vapor have been reported in animals.  Tegeris and Balster 
(1994) reported lacrimation and palpebral closure in mice after 20 minutes of exposure to 2,000 ppm 
ethylbenzene.  Eye irritation was observed in guinea pigs exposed to 1,000 ppm for 8 minutes, and in 
animals exposed to 2,000, 5,000, and 10,000 ppm for 480, 30, and 10 minutes, respectively (Yant et al. 
1930).  Lacrimation was observed in rats exposed to 1,200 ppm ethylbenzene and in mice and rabbits 
exposed to 400 ppm ethylbenzene for 4 days (Ethylbenzene Producers Association 1986a).  After 4 weeks 
of exposure to 382 ppm, rats showed sporadic lacrimation, whereas mice and rabbits showed no ocular 
effects at 782 and 1,610 ppm, respectively (Cragg et al. 1989).  No ocular effects were seen in rats or 
mice after a 13-week exposure to 975 ppm ethylbenzene (NTP 1992). 
No studies were located regarding the following health effects in humans or animals after dermal 
exposure to ethylbenzene: 
3.2.3.3 Immunological and Lymphoreticular Effects  
3.2.3.4 Neurological Effects 
3.2.3.5 Reproductive Effects  
3.2.3.6 Developmental Effects 
3.2.3.7 Cancer 
3.3 GENOTOXICITY  
Holz et al. (1995) reported no increase in sister chromatid exchanges, DNA adduct formation, 
micronuclei, or DNA single-strand breaks in the peripheral lymphocytes of workers exposed to low levels 
of ethylbenzene and other aromatic hydrocarbons (benzene, toluene, and xylene) in a styrene plant.  NTP 
(1992) showed no increase in micronucleated peripheral erythrocytes in mice exposed to 1,000 ppm 
ethylbenzene for 13 weeks.  Another in vivo study investigated the genotoxic effects of ethylbenzene and 
reported no dose-dependent increase in the frequency of micronucleated polychromatic erythrocytes in 
mice (Mohtashamipur et al. 1985).  This study is limited by inadequate sampling time.  In addition, the 
type of clastogenic effect occurring cannot be defined.  These data are shown in Table 3-4. 
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Table 3-4. Genotoxicity of Ethylbenzene In Vivo 
Results 
With Without 
Species (test system) End point activation activation Reference 
Mammalian cells: 
 Mouse (peripheral Micronuclei NA – NTP 1999 
erythrocytes) 
 Human (occupational DNA adducts, NA – Holz et al. 1995 
exposure/peripheral micronuclei, sister 





– = negative result; NA = not applicable 
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The genotoxic potential of ethylbenzene has been investigated primarily using in vitro assays in 
Salmonella typhimurium (Dean et al. 1985; Degirmenci et al. 2000; Florin et al. 1980; Kubo et al. 2002; 
Nestmann et al. 1980; NTP 1986, 1999), Escherichia coli (Dean et al. 1985), Saccharomyces cerevisiae 
(Dean et al. 1985; Nestmann and Lee 1983), Chinese hamster ovary cells (NTP 1986, 1999), mouse 
lymphoma cells (McGregor et al. 1988; NTP 1999), and human lymphocytes (Norppa and Vainio 1983a).  
Results of these in vitro genotoxicity studies are shown in Table 3-5.  The available data indicate that 
ethylbenzene is not mutagenic in bacteria or yeast cells in the presence or absence of metabolic activation.  
Ethylbenzene also failed to induce sister-chromatid exchanges and chromosomal aberrations in Chinese 
hamster cells.  However, ethylbenzene was found to be mutagenic at 80 mg/L without metabolic 
activation, and lethal to cells at 100 mg/L in the mouse lymphoma assays (McGregor et al. 1988).  No 
dose-response was reported. A weak positive response was observed when ethylbenzene was tested for 
sister chromatid exchanges in human lymphocytes (Norppa and Vainio 1983a).  Chromosomal 
aberrations were observed in peripheral blood lymphocytes of workers concomitantly exposed to 
ethylbenzene (0.2–13.1 mg/m3) and benzene (0.4–15.1 mg/m3). Although reduction in exposure (reduced 
ethylbenzene and benzene concentrations not reported) reduced chromosomal aberrations, due to 
concomitant exposure to benzene, an association between chromosomal damage and ethylbenzene 
exposure cannot be established (Sram et al. 2004).  Metabolites of ethylbenzene (ethylhydroquinone and 
4-ethylcatechol) produced oxidative damage to DNA from the human P53 tumor suppressor gene and 
from calf thymus (Midorikawa et al. 2004). 
In summary, genotoxicity studies on ethylbenzene have provided negative results in a variety of in vitro 
assays using numerous prokaryotic organisms, S. cerevisiae, and Chinese hamster ovary cells and rat liver 
epithelial cells, and in an in vivo assay using mouse bone marrow cells.  Ethylbenzene has, however, 
caused a mutagenic effect in mouse lymphoma cells and has been shown to induce a marginal, yet 
statistically significant, increase in sister chromatid exchanges in human lymphocytes.  In addition, 
ethylbenzene metabolites have been shown to produce DNA damage.  Thus, although the majority of the 
data suggest that ethylbenzene is not mutagenic in most systems, the two studies that showed positive 
results suggest that ethylbenzene might cause an increased potential for genotoxicity in humans. 
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Table 3-5. Genotoxicity of Ethylbenzene In Vitro 
Results 
With Without 
Species (test system) End point activation activation Reference 
Prokaryotic organisms: 
Salmonella typhimurium Gene mutation – – Dean et al. 1985a; Florin et 
(plate incorporation assay) al. 1980b; Nestmann et al. 
1980c 
S. tymphimurium (plate Gene mutation – – NTP 1986d

incorporation assay; strains 





S. tymphimurium (plate Gene mutation – – NTP 1999d

incorporation assay; strains 










Saccharomyces cerevisiae Gene mutation – – Dean et al. 1985 
JD1 gene conversion assay 
S. cerevisiae Dy, Gene mutation – No data Nestmann and Lee 1983 
XV185-14C 
Mammalian cells: 
Mouse lymphoma cells Gene mutation No data + McGregor et al. 1988 
Mouse lymphoma cells Gene mutation No data + NTP 1999 

Rat liver (RL4) epithelial type Chromosome – – Dean et al. 1985 

cells/chromosome assay damage 













aConcentrations of ethylbenzene tested:  0, 0.2, 2, 20, 500, or 2,000 μg/plate (>99% pure)

bConcentrations of ethylbenzene tested:  0, 3, 31, 318, or 3,184 μg/plate (0, 0.03, 0.3, 3, or 30 μmole/plate) 

cConcentrations of ethylbenzene tested:  up to 0.4 mg/plate, a concentration causing lethality

dConcentrations of ethylbenzene tested:  0, 10, 33, 110, 333, 666, or 1,000 μg/plate 

C = negative result; + = positive result 
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3.4 TOXICOKINETICS 
Ethylbenzene is absorbed from the lungs, gastrointestinal tract, and through the skin.  Absorbed 
ethylbenzene is rapidly eliminated (blood t1/2 #1 hour) by metabolism and excretion of metabolites.  The 
major metabolic pathways are side chain and ring hydroxylation with subsequent formation of 
O-glucuronide and sulfate conjugates.  Conjugates, mandelic acid and phenylgyoxyilic acid are the 
primary excreted metabolites.  The distribution of ethylbenzene to tissues has been modeled as a flow-
limited process (i.e., clearance from blood to tissues can be predicted by tissue blood flow) with rapid 
equilibrium achieved between blood and tissues.  Measured blood:tissue partition coefficients in the rat 
are approximately as follows:  fat, 36; liver, 2; and muscle, 0.6.  These values predict the same order for 
tissue concentrations for any given blood concentration; however, this order has not been verified 
experimentally with simultaneously measured blood and tissue ethylbenzene concentrations in vivo. 
3.4.1 Absorption 
3.4.1.1 Inhalation Exposure 
Inhalation studies in humans demonstrate that ethylbenzene is rapidly absorbed via this route.  Volunteers 
exposed for 8 hours to ethylbenzene at concentrations of 23–85 ppm were shown to retain 64% of the 
inspired vapor, with only trace amounts detected in expired air at the end of the exposure period 
(Bardodej and Bardodejova 1970).  Another inhalation study that involved humans exposed to similar 
levels of ethylbenzene demonstrated mean retention rates of 49% (Gromiec and Piotrowski 1984).  The 
differences may be attributable to human variability in absorption rates although they could also be due to 
differences in methodology.  
An initial concentration of ethylbenzene in blood of 2.6 μg/mL and a half-life of 27.5 hours were 
estimated in a 44-year-old man who died after a massive inhalation and dermal exposure of ≥10 hours to 
gasoline (Matsumoto et al. 1992).  This absorption value may have been slightly overestimated, however, 
because possible contributions from dermal exposure were not addressed. 
In a study conducted in Italy, blood concentrations of ethylbenzene in non-smoking policemen working as 
traffic wardens showed no significant differences between before and after work shift values or from 
blood ethylbenzene concentrations in policemen working indoors (Fustinoni et al. 1995).  Indoor and 
***DRAFT FOR PUBLIC COMMENT*** 
91 ETHYLBENZENE  
3. HEALTH EFFECTS 
outdoor mean air concentrations (measured by personal air samplers) were 21 and 37 mg/m3, respectively. 
Before and after shift blood ethylbenzene concentrations were 140 and 163 ng/L in indoor workers, 
respectively, and were 158 and 184 ng/L in outdoor workers, respectively. 
Ethylbenzene concentrations in whole blood collected from workers at the end of their work shifts 
correlated significantly with the average concentrations of occupational exposure to ethylbenzene (Kawai 
et al. 1992). The maximum ethylbenzene concentration in air in the workplace was 5 ppm (Kawai et al. 
1992). 
Inhalation studies in animals exposed to ethylbenzene showed results similar to those found in humans.  
Harlan-Wistar rats rapidly absorbed radiolabeled ethylbenzene during respiration, with a retention rate of 
44% (Chin et al. 1980b).  This absorption value may have been slightly overestimated, however, because 
possible contributions from dermal exposure were not addressed.  The concentrations of ethylbenzene in 
the blood of rats and guinea pigs exposed to ethylbenzene at 550 ppm for 8 hours reached 23 and 
3 µg/mL, respectively.  Ethylbenzene concentrations in blood after the last of three daily exposures 
(8 hours each) had diminished to 6 µg/mL in rats and to <2 µg/mL in guinea pigs (Cappaert et al. 2002).  
These data demonstrate a marked interspecies difference among rats and guinea pigs in the disposition of 
inhaled ethylbenzene.  In mice, steady-state blood ethylbenzene concentrations achieved within 2 hours of 
initiating inhalation exposures were approximately 0.71 mg/L at 75 ppm, 2.3 mg/L at 200 ppm, and 
20 mg/L at 500 ppm (Charest-Tardif et al. 2006).  Ethylbenzene concentrations in blood in adult rats and 
their offspring increased at a rate that was greater than proportional to dose (Faber et al. 2006).  
Ethylbenzene levels in maternal blood, collected on PND 22, after a 6-hour exposure to 25, 100, or 
500 ppm, were 0.11, 0.56, and 11 mg/L, respectively.  The mean concentrations in the blood of pups 
(males/females), culled from the dams sampled above, in the 25-, 100-, and 500-ppm groups were 
0.021/0.025, 0.26/0.24, and 11.4/12.7 mg/mL, respectively (Faber et al. 2006). 
No studies describing factors specifically affecting absorption of ethylbenzene following inhalation 
exposure were available. 
3.4.1.2 Oral Exposure  
No studies were located regarding the absorption of ethylbenzene in humans following oral exposure.  
Studies in animals, however, indicate that ethylbenzene is quickly and effectively absorbed by this route.  
***DRAFT FOR PUBLIC COMMENT*** 
92 ETHYLBENZENE  
3. HEALTH EFFECTS 
Recovery of ethylbenzene metabolites in the urine of rabbits administered a single dose of 593 mg/kg was 
between 72 and 92% of the administered dose 24 hours following exposure (El Masry et al. 1956).  
Similarly, 84% of the radioactivity from a single oral dose of 30 mg/kg ethylbenzene administered to 
female rats was recovered within 48 hours (Climie et al. 1983).  Ethylbenzene was detected at 0.49, 3.51, 
and 18.28 mg/L in maternal blood of rats 1 hour after the last of four daily administrations of 26, 90, or 
342 mg/kg/day (distributed over three equal doses), respectively; however, ethylbenzene was not detected 
(limit of detection:  0.006 mg/L) in blood of weanlings culled from the same dams (Faber et al. 2006).  It 
is unclear if the latter finding is due to low transfer of ethylbenzene to milk or if the 1-hour exposure-to-
sampling time-lapse was too long to allow detection of ethylbenzene.  
3.4.1.3 Dermal Exposure  
Studies in humans dermally exposed to liquid ethylbenzene demonstrate rapid absorption through the 
skin, but absorption of ethylbenzene vapors through the skin appears to be minimal (Dutkiewicz and 
Tyras 1967; Gromiec and Piotrowski 1984).  Absorption rates of 24–33 mg/cm2/hour and 0.11– 
0.23 mg/cm2/hour have been measured for male subjects exposed to liquid ethylbenzene and ethylbenzene 
from aqueous solutions, respectively (Dutkiewicz and Tyras 1967).  The average amounts of 
ethylbenzene absorbed after volunteers immersed one hand for up to 2 hours in an aqueous solution of 
112 or 156 mg/L ethylbenzene were 39.2 and 70.7 mg ethylbenzene, respectively.  These results indicate 
that skin absorption could be a major route of uptake of liquid ethylbenzene or ethylbenzene in water.  In 
contrast, ethylbenzene metabolite levels in urine following dermal exposure to 150–300 ppm (650– 
1,300 mg/m3) ethylbenzene vapors for two hours did not differ from values taken prior to exposure, 
indicating minimal, if any, dermal absorption of ethylbenzene vapors (Gromiec and Piotrowski 1984). 
Susten et al. (1990) conducted in vivo percutaneous absorption studies of ethylbenzene in mice.  Results 
showed total absorption (sums of radioactivity found in the excreta, carcass, skin application site, and 
expired breath) was 3.4% of the nominal dose.  The total percentage recovered (includes wipe of skin 
area, ethylbenzene 0.03%) was 95.2%.  The amount of ethylbenzene absorbed at an estimated contact 
time of 5 minutes was 148.55 μg with an absorption rate of 37 μg/cm2/minute. 
The volumes of ethylbenzene absorbed in rats treated dermally for 24 hours with aqueous solutions of 
ethylbenzene (neat [99% pure], saturated, 2/3 or 1/3 saturated), were 0.24, 0.20, 0.18, and 0.17 mL, 
respectively (Morgan et al. 1991).  Peak blood level during exposure to neat ethylbenzene was reported at 
***DRAFT FOR PUBLIC COMMENT*** 
93 ETHYLBENZENE  
3. HEALTH EFFECTS 
5.6 μg/mL, attained after 1 hour of exposure, which decreased during the remainder of the exposure 
period. The concentration of ethylbenzene in the blood was highest after exposure to saturated aqueous 
solutions, followed by the 2/3 and 1/3 saturated solutions.   
Results of dermal penetration studies in excised rat skin indicate that the penetration rate of pure 
ethylbenzene (Tsuruta 1982) is faster than that of ethylbenzene from JP-8 jet fuel (McDougal et al. 2000). 
The penetration rates of pure liquid ethylbenzene following 3-, 4-, and 5-hour exposure durations in rat 
skin were approximately 2.38, 3.12, and 3.22 µg/cm2/hour (calculated by ATSDR from reported data on 
exposure area, exposure time, and mass transfer); these rates are substantially lower than the rate of 
dermal absorption determined for humans (Tsuruta 1982).  This might be attributed to differences 
between in vitro and in vivo testing and/or differences in rat versus human skin.  McDougal et al. (2000) 
reported an ethylbenzene flux of 0.377 µg/cm2/hour (0.0004 mg/cm2/hour) for ethylbenzene and a 
permeability coefficient of 3.1x10-4 cm/hour during a 4-hour period in excised rat skin which had 
received 2 mL of JP-8 fuel containing approximately 1,200 µg ethylbenzene/mL fuel (0.15% w/w).  It 
was recognized that the choice of vehicle (JP-8) could affect dermal penetration of ethylbenzene.  The 
steady state flux, permeability, and diffusivity values of ethylbenzene in pig skin treated with JP-8 ex vivo 
were 1.04 µg/cm2/hour, 0.06x10-3 cm/hour, and 715x10-6 cm2/hour (Muhammad et al. 2005). 
3.4.2 Distribution  
3.4.2.1 Inhalation Exposure 
In humans exposed for 2 hours to a mixture of industrial xylene containing 40.4% ethylbenzene, the 
estimated solvent retention in adipose tissue was 5% of the total uptake (Engstrom and Bjurstrom 1978).  
Since there was no indication of differences in turnover rates of chemicals within the mixture, it is likely 
that the retention of ethylbenzene in adipose tissue was approximately 2% of the total uptake. No studies 
were located concerning the distribution of ethylbenzene in humans following exposure to ethylbenzene 
alone. However, studies by Pierce et al. (1996) suggest that in vitro, the partitioning of ethylbenzene 
from air into human adipose tissue is similar to that observed in rats. 
In rats, the concentrations of ethylbenzene in perirenal adipose tissue were reported to increase, although 
not linearly, with increasing concentrations of ethylbenzene (Engstrom et al. 1985) and in a mixture of 
solvent vapors containing ethylbenzene (Elovaara et al. 1982).  The less-than-linear increase of 
ethylbenzene in adipose tissue with increasing dose was partially attributed to the induction of drug-
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metabolizing enzymes occurring with increasing exposure concentrations, altered blood flow to adipose 
tissue, changes in lung excretion, and changes in the distribution of ethylbenzene in different tissues.  
Ethylbenzene was shown to be efficiently distributed throughout the body in rats following inhalation 
exposure to radiolabeled ethylbenzene (Chin et al. 1980b).  The highest amounts of radioactivity in 
tissues 42 hours after exposure to 230 ppm ethylbenzene for 6 hours were found in the carcass, liver, and 
gastrointestinal tract, with lower amounts detected in the adipose tissue. 
3.4.2.2 Oral Exposure  
No studies were located regarding distribution of ethylbenzene in humans or animals following oral 
exposure. 
3.4.2.3 Dermal Exposure  
No studies were located regarding distribution in humans following dermal exposure to ethylbenzene. 
The percentages of absorbed doses following dermal application of [14C]-ethylbenzene in hairless mice 
were: 15.5%, carcass; 4.5%, application site; 14.3%, expired breath; and 65.5%, excreta (Susten et al. 
1990). 
3.4.3 Metabolism 
The metabolism of ethylbenzene has been studied in humans and other mammalian species.  The data 
demonstrate that ethylbenzene is metabolized mainly through hydroxylation and then through conjugation 
reactions from which numerous metabolites have been isolated.  Figure 3-3 summarizes the proposed 
metabolic pathway for ethylbenzene in humans (Engstrom et al. 1984).  The major urinary metabolites 
have been identified (Kiese and Lenk 1974; Sullivan et al. 1976).  Comparisons of in vitro data with data 
from intact animals indicate that liver microsomal enzymes participate in ethylbenzene hydroxylation 
(McMahon and Sullivan 1966; McMahon et al. 1969; Sams et al. 2004).  In microsomes prepared from 
human liver, hydroxylation of ethylbenzene to 1-phenylethanol is catalyzed by cytochrome P-450 
isoforms CYP2E1 and CYP2B6 (Sams et al. 2004). Adrenal cortex may be a major site of extra-hepatic 
ethylbenzene metabolism (Greiner et al. 1976).  No significant qualitative differences in metabolism 
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Figure 3-3. Metabolic Scheme for Ethylbenzene in Humans 
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Source: Engstrom et al. 1984 
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between oral and inhalation routes were reported in humans or animals.  The metabolism of ethylbenzene 
has been found to vary with species, sex, and nutritional status.  These differences are described below. 
In humans exposed via inhalation, the major metabolites of ethylbenzene are mandelic acid 
(approximately 64–71%) and phenylglyoxylic acid (approximately 19–25%) (Bardodej and Bardodejova 
1970; Engstrom et al. 1984).  Based on data from human, animal, and in vitro studies, the metabolic 
pathway for ethylbenzene in humans was proposed (Engstrom et al. 1984).  This pathway is shown in 
Figure 3-3.  Evidence indicates that the initial step in this metabolic pathway is oxidation (hydroxylation) 
of the side chain of ethylbenzene to produce 1-phenylethanol.  Microsomal preparations from rat liver 
have shown that the oxidation of ethylbenzene proceeds with the incorporation of atmospheric oxygen, as 
opposed to oxygen from water molecules (McMahon et al. 1969).  Filipovic et al. (1992) have shown that 
cytochrome P-450(cam) from Pseudomonas putida provides a useful metabolic model for ethylbenzene 
hydroxylation, converting ethylbenzene to 1-phenylethanol at 98%.  1-Phenylethanol is conjugated to 
glucuronide, which then is either excreted or converted to subsequent metabolites.  Oxidation of 
1-phenylethanol yields acetophenone, which is both excreted in the urine as a minor metabolite and 
further transformed. Continued oxidation of the side chain leads to the sequential formation of 
2-hydroxyacetophenone, 1-phenyl-1,2-ethanediol, mandelic acid, and phenylglyoxylic acid.  Minor 
pathways (e.g., ring hydroxylation) include glucuronide and sulfate conjugation with hydroxylated 
derivatives to form glucuronides and sulfates that are excreted in the urine.  Analysis of urine from 
humans exposed to ethylbenzene via the inhalation route showed that approximately 70 and 25% of the 
retained dose of ethylbenzene is excreted as mandelic acid and phenylglyoxylic acid, respectively 
(Bardodej and Bardodejova 1970; Engstrom et al. 1984).  Additional metabolites detected in human urine 
include 1-phenylethanol (4%), p-hydroxyacetophenone (2.6%), m-hydroxyacetophenone (1.6%), and 
trace amounts of 1-phenyl-1,2-ethanediol, acetophenone, 2-hydroxyacetophenone, and 4-ethylphenol. 
Following dermal exposure of humans, however, excretion of mandelic acid was shown to be only 
4.6% of the absorbed dose (Dutkiewicz and Tyras 1967), which may indicate differences in the metabolic 
fate between inhalation and dermal exposure routes.  However, the small percentage of absorbed dose 
accounted for limits the interpretation.  No animal data were located which could confirm these metabolic 
differences following dermal exposure.  Generally, ethylbenzene metabolites and intermediates are 
thought to be only slightly toxic, since no adverse effects from human experimental exposure have been 
reported (Bardodej and Bardodejova 1970). 
Qualitative and quantitative differences in the biotransformation of ethylbenzene in animals as compared 
to humans have been reported (Bakke and Scheline 1970; Climie et al. 1983; El Masry et al. 1956; 
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Engstrom et al. 1984, 1985; Smith et al. 1954a, 1954b; Sollenberg et al. 1985).  The major metabolites of 
ethylbenzene differ from species to species, and different percentages of the metabolites are seen in 
different species. The principal metabolic pathway in rats is believed to begin with oxidation 
(hydroxylation) of the side chain as in humans (Climie et al. 1983; Engstrom et al. 1984, 1985; Smith et 
al. 1954a). In rats exposed by inhalation or orally to ethylbenzene, the major metabolites were identified 
as hippuric and benzoic acids (approximately 38%), 1-phenylethanol (approximately 25%), and mandelic 
acid (approximately 15–23%), with phenylglyoxylic acid making up only 10% of the metabolites (Climie 
et al. 1983; Engstrom et al. 1984, 1985).  The urinary excretion rate of mandelic acid in rats exposed to 
250 ppm ethylbenzene, 6 hours/day for 15 days was the same after the first exposure as it was after the 
last exposure. In contrast, excretion in the 1,000 ppm group was 2–5 times higher after the last exposure 
than it was after the first exposure (Saillenfait et al. 2006). Both in vivo studies using rats and in vitro 
studies using rat liver microsomes showed that 4-ethylphenol was also produced from ethylbenzene, 
perhaps by rearrangement of corresponding arene oxides (Bakke and Scheline 1970; Kaubisch et al. 
1972).  Kaubisch et al. (1972) also showed that 2-hydroxyethylbenzene was produced from ethylbenzene 
in vitro in the presence of rat liver microsomes.  The level of ethylbenzene exposure was shown to affect 
the metabolic pattern. This was thought to be due either to selective enzymatic induction in the 
biotransformation of ethylbenzene or to delayed excretion of certain metabolites with increasing doses. 
Acetophenone was detected (quantitative data were not provided) in blood of rats and guinea pigs 
exposed to ethylbenzene in air at 500 ppm, 8 hours/day for 3 days (Cappaert et al. 2002).  Further 
clarification of ethylbenzene metabolic pathways was provided by Sullivan et al. (1976).  Using 
intraperitoneally dosed rats, the authors demonstrated that the conversion of 1-phenylethanol to mandelic 
acid initially involves oxidation to acetophenone.  Acetophenone was considered to be the precursor of 
mandelic acid, benzoylformic acid, and benzoic acid.  A similar study in which rabbits were 
intraperitoneally injected with a single dose of 250 mg ethylbenzene/kg body weight was conducted by 
Kiese and Lenk (1974).  This study showed that between 1 and 10% of the dose was excreted as 
1-phenylethanol in the urine and <1% was excreted in the urine as 2-hydroxyacetophenone, p-hydroxy-
acetophenone, and m-hydroxyacetophenone. 
Rabbits given an oral dose of ethylbenzene showed the major metabolic pathway to be hydroxylation of 
the α-carbon to 1-phenylethanol, which is oxidized further to a number of intermediates and metabolites 
(El Masry et al. 1956; Smith et al. 1954a).  Many of these intermediates are subsequently conjugated to 
glucuronides and sulfates and excreted.  In rabbits, the most important metabolite is hippuric acid, which 
is probably formed by oxidative decarboxylation of phenylglyoxylic acid (El Masri et al. 1958).  
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Oxidation of the methyl group of ethylbenzene was also shown to occur, as evidenced by the presence of 
phenaceturic acid in the urine. A slight increase in the excretion of thioether suggests that glutathione 
conjugation may also play a minor role. 
The nutritional status of animals was demonstrated to have a marked effect on ethylbenzene metabolism 
in rats (Nakajima and Sato 1979).  The in vitro metabolic activity of liver microsomal enzymes on ethyl-
benzene was shown to be significantly enhanced in fasted rats despite a marked loss of liver weight.  No 
significant increases in the microsomal protein and cytochrome P-450 contents were detected in fasted 
rats compared with fed rats.  In addition, the metabolic rate in fasted males was significantly higher than 
in fasted females, but the difference in rates decreased following food deprivation for 3 days.  These 
results suggest possible sex differences in the rate of ethylbenzene metabolism. However, it is not known 
if such differences exist in the normally fed rats. 
Metabolism of ethylbenzene has not been studied in children or immature animals.  However, some 
members of two of the enzyme superfamilies involved in conjugation of phase I ethylbenzene metabolites 
are known to be developmentally regulated.  In humans, UDP glucuronosyltransferase activity does not 
reach adult levels until about 6–18 months of age, although the development of this activity is isoform 
specific. Activity of sulfotransferases seems to develop earlier, although again, it is isoform specific.  The 
activity of some sulfotransferase isoforms may even be greater during infancy and early childhood than in 
adults (Leeder and Kearns 1997). 
3.4.4 Elimination and Excretion 
3.4.4.1 Inhalation Exposure 
Excretion of ethylbenzene has been studied in humans and in a number of animal species.  Ethylbenzene 
has been shown to be rapidly metabolized and then eliminated from the body, primarily as urinary 
metabolites. The major metabolic products have been previously described in Section 3.4.3. 
Elimination of ethylbenzene has been studied in volunteers exposed by inhalation (Bardodej and 
Bardodejova 1970; Dutkiewicz and Tyras 1967; Engstrom and Bjurstrom 1978; Gromiec and Piotrowski 
1984; Yamasaki 1984) and in humans exposed by inhalation in the occupational setting (Holz et al. 1995; 
Kawai et al. 1991, 1992; Ogata and Taguchi 1988). The elimination of the ethylbenzene metabolite, 
mandelic acid, was reported to be rapid, with the acid detected in the first urine sample following the 
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initiation of an 8-hour inhalation exposure to 0, 4, 8, 18, 35, or 46 ppm ethylbenzene (Gromiec and 
Piotrowski 1984).  Elimination of mandelic acid was reported to be biphasic, with half-lives of 3.1 hours 
for the rapid phase and 25 hours for the slow phase (Gromiec and Piotrowski 1984).  During the 8-hour 
exposure, 23% of the retained ethylbenzene was eliminated in the urine, and 14 hours following 
termination of exposure an additional 44% of the retained ethylbenzene was eliminated.  The highest 
excretion rate of urinary metabolites in humans exposed to ethylbenzene by inhalation occurred 6– 
10 hours after the beginning of exposure (Gromiec and Piotrowski 1984; Yamasaki 1984).  The metabolic 
efficiency was reported to be independent of the exposure dose.   
Concentrations of ethylbenzene metabolites in before-shift and after-shift urine were significantly higher 
in workers exposed to 85 to >921 ppm ethylbenzene in a styrene plant than in control workers exposed to 
33.4–66.8 ppm (Holz et al. 1995). 
A statistically significant correlation was observed between urinary excretion of mandelic acid and 
ethylbenzene exposure in workers exposed to mixed solvents (including an ethylbenzene time-weighted 
average [TWA] of 0.9 ppm) in a metal-coating factory (Kawai et al. 1991).  No correlation was observed 
between ethylbenzene exposure and phenylglyoxylic acid urinary excretion.  In a study of chronic-
duration exposure at lower levels (2.1 and 2.3 ppm for geometric and arithmetic mean, respectively), no 
significant correlation was observed between ethylbenzene exposure and urinary excretion of 
phenylglyoxylic acid and mandelic acid (Kawai et al. 1992).  
In animals, elimination of 14C-ethylbenzene following inhalation exposure is rapid and occurs primarily 
via urinary excretion (Chin et al. 1980a, 1980b; Engstrom et al. 1984, 1985) and to a much lesser degree 
via the feces, and expired “gasses” and carbon dioxide (Chin et al. 1980b).  Rats exposed to 230 ppm 
radiolabeled ethylbenzene for 6 hours via inhalation excreted virtually all of the radioactivity within 
24 hours after the onset of exposure (Chin et al. 1980a, 1980b).  Ninety-one percent of the radioactivity 
was recovered, primarily in the form of urinary metabolites.  In a similar inhalation experiment using rats 
exposed to 300 or 600 ppm, urinary excretion was reported to be 83 and 59% of the absorbed dose within 
48 hours after the onset of exposure, with 13% eliminated during the first 6 hours of exposure (Engstrom 
et al. 1984). 
Quantitative differences between species in the percentages of metabolites excreted in the urine were also 
reported by Chin et al. (1980a).  In this report, urinary metabolites in dogs and rats exposed to 
ethylbenzene by inhalation were studied.  Although similarities in the types of metabolites recovered 
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following inhalation exposure were reported, quantitative differences, albeit minor ones, were noted in the 
ratio of metabolites present in the urine.  These results were attributed to differences in metabolism 
between dogs and rats. 
Blood elimination rate constants for ethylbenzene measured at the conclusion of 4-hour exposures to 
concentrations ranging from 75 to 1,000 ppm were 0.21 minute-1 (t1/2=3.3 minute) at 75 ppm and 
0.011 minute-1 (t1/2=63 minutes) at 1,000 ppm (Charest-Tardif et al. 2006).  The concentration dependence 
on elimination is consistent with a capacity limitation in metabolism of ethylbenzene. 
3.4.4.2 Oral Exposure  
No studies were located regarding the excretion of ethylbenzene metabolites in humans following oral 
exposure to ethylbenzene. 
Elimination of ethylbenzene and its metabolites in animals after oral exposure has been shown to be 
similar to that following inhalation exposure.  Female rats administered a single oral dose of 30 mg 
radiolabeled ethylbenzene/kg/body weight showed very rapid elimination, mostly in the urine (Climie et 
al. 1983).  Eighty-two percent of the radioactivity was detected in the urine, while 1.5% was detected in 
the feces. The major metabolites were mandelic acid (23%) and hippuric acid (34%), with 1-phenylethyl 
glucuronide detected as a minor metabolite.  Relatively minor metabolites (e.g., 4-ethylphenol, 2-phenyl-
ethanol, 1-phenylethanol) were shown to be excreted in the urine of male rats exposed to a single oral 
dose of 100 mg/kg ethylbenzene administered by gavage in oil (Bakke and Scheline 1970). No data on 
the major metabolites were provided in this study. 
In a similar study in which male rats were given single oral doses of 350 mg/kg/body weight ethyl-
benzene, the excretion of mandelic acid and phenylglyoxylic acid was detected in the first urine sample 
after exposures. Peak concentration was reached within 17 hours, and ethylbenzene was virtually 
eliminated 48 hours following the onset of exposure (Sollenberg et al. 1985). 
As in inhalation experiments, quantitative and qualitative differences between species were shown to exist 
in the percentages of metabolites excreted in the urine.  Rabbits orally exposed to ethylbenzene excreted 
large amounts of glucuronide conjugates in the urine (El Masry et al. 1956; Smith et al. 1954a, 1954b) 
instead of mandelic acid, hippuric acid, and phenylglyoxylic acid, which are the major metabolites in rats 
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(see above). Glucuronide conjugates accounted for 32% of the administered dose, with mandelic acid 
making up only 2% of the administered dose (El Masry et al. 1956).  These results were confirmed in a 
study by Smith et al. (1954a, 1954b), who detected 32% of a single oral dose of ethylbenzene 
(433 mg/kg) administered to rabbits as glucuronide conjugates excreted in the urine. 
3.4.4.3 Dermal Exposure  
In humans, the pattern of excretion of ethylbenzene metabolite following dermal exposure has been 
shown to differ significantly from the pattern in which humans have been exposed by inhalation.  Dermal 
absorption of ethylbenzene in aqueous solutions was estimated as the difference of the ethylbenzene 
concentrations in solution before and after exposure.  The urinary excretion of mandelic acid in humans 
dermally exposed to ethylbenzene for 2 hours was only 4.6% of the absorbed ethylbenzene (Dutkiewicz 
and Tyras 1967).  Urine was collected periodically during the 2-hour exposure period and a 10-hour 
follow-up. Interpretation is difficult due to the small percentage of absorbed dose accounted for.  No 
ethylbenzene was reported to be excreted in exhaled air.  No further details on the excretion patterns were 
provided. 
Susten et al. (1990) conducted in vivo percutaneous absorption studies of ethylbenzene in Hairless mice.  
Results showed total absorption (sums of radioactivity found in the excreta, carcass, skin application site, 
and expired breath) was 3.4% of the nominal dose.  The absorbed dose collected in expired breath during 
the first 15 minutes of ethylbenzene application was 9.3%.  The percentage of absorbed doses following 
dermal application of [14C]-ethylbenzene are as follows:  15.5% in the carcass; 4.5% at the application 
site; 14.3% in expired breath; and 65.5% in excreta. 
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models  
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry 
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
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pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.   
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and 
Krishnan 1994; Andersen et al. 1987). These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from 
route to route, between species, and between subpopulations within a species.  The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors. 
The PBPK model for a chemical substance is developed in four interconnected steps:  (1) model 
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these 
solutions. 
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment. 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
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sites) based on the results of studies where doses were higher or were administered in different species.  
Figure 3-4 shows a conceptualized representation of a PBPK model. 
If PBPK models for ethylbenzene exist, the overall results and individual models are discussed in this 
section in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species 
extrapolations. 
Several models have been developed that simulate the kinetics of inhaled ethylbenzene in animals and 
humans (Dennison et al. 2003; Tardif et al. 1997).  The Dennison et al. (2003) and Tardif et al. (1997) 
inhalation models have been incorporated into models of gasoline component mixture models (Dennison 
et al. 2004, 2005; Haddad et al. 2001). A model of dermal absorption ethylbenzene in human has also 
been reported (Shatkin and Brown 1991).  Models that simulate kinetics of ingested ethylbenzene have 
not been reported. 
The Tardif et al. (1997) Model 
Description of the Model.    Tardif et al. (1997) developed a PBPK model for simulating the kinetics 
of ethylbenzene, toluene, and xylene in blood following inhalation exposures to the individual chemicals 
or the ternary mixture (in rats and humans).  The structure of the model is essentially identical the generic 
model depicted in Figure 3-4, with tissue compartments limited to lungs, liver, fat, richly perfused tissues 
(RPT), and poorly perfused tissues (SPT).  All metabolism was attributed to the liver and represented as 
functions of the concentration of parent compound in liver venous blood, affinity constant (Km), and 
maximum reaction velocity (Vmax). Transfers of parent compound between blood and tissues were 
assumed to be flow-limited, with clearance represented by tissue blood flow (L/hour).  Parameters for the 
ethylbenzene model are presented in Table 3-6.  Partition coefficients for ethylbenzene were derived from 
vial equilibrium studies of isolated rat tissues.  Metabolism parameter values for ethylbenzene were 
derived by fitting the model to observations of blood ethylbenzene kinetics measured in rats during and 
following 4-hour exposures to ethylbenzene in a dynamic exposure chamber (Tardif et al. 1996).  
Physiological parameters, cardiac output (QC), alveolar ventilation rate (QP), and metabolism Vmax were 
allometrically scaled across species (i.e., rat to human) as a function of body weight (BW, scaling 
factor=BW0.75) 
Validation of the Model.    Optimization of the metabolism parameters against observed blood 
kinetics of ethylbenzene in rats exposed for 4 hours to 100 or 200 ppm ethylbenzene achieved predicted  
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Figure 3-4. Conceptual Representation of a Physiologically Based 
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Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by 
ingestion, metabolized in the liver, and excreted in the urine or by exhalation. 
Source: adapted from Krishnan and Andersen 1994 
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Table 3-6. Parameter Values for Tardif et al. (1997) Ethylbenzene PBPK Models 
Parameter Definition Rat model Human model 
Physiological parameters 
VLC Liver volume (fraction of body) 0.049 0.026 
VFC Fat volume (fraction of body) 0.09 0.19 
VSC Slowly-perfused tissue volume (fraction of body) 0.72 0.62 
VRC Richly-perfused tissue volume (fraction of body) 0.05 0.05 
QCC Cardiac output (L/hour-kg BW) 15a 18a 
QPC Alveolar ventilation rate (L/hour-kg body weight) 15a 18a 
QLC Liver blood flow (fraction of cardiac output) 0.25 0.26 
QFC Fat blood flow (fraction of cardiac output) 0.09 0.05 
QSC Slowly-perfused blood flow (fraction of cardiac output) 0.15 0.25 
QRC Richly-perfused blood flow (fraction of cardiac output) 0.51 0.44 
Chemical parameters 
PB Blood:air partition coefficient 42.7 28.0 
PL Liver:blood partition coefficient 1.96b (83.8) 2.99b 
PF Fat:blood partition coefficient 36.44b (1,556) 55.57b 
PS Slowly-perfused partition coefficient 0.61b (26.0) 0.93b 
PR Readily-perfused partition coefficient 1.41b (60.3) 2.15b 
VmaxC Maximum rate of metabolism (mg/hour-kg body weight) 7.3a,c 7.3a,c
 KmC Michaelis-Menten coefficient for metabolism (mg/L) 1.39c 1.39c 
aScaled to body weight (BW0.74) 

bTissue:blood partition coefficients calculated based on reported, experimentally determined (vial equilibrium), 
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blood concentration of ethylbenzene that were within 1–2 standard deviations (SD) of the observations.  
Most of the validation efforts reported in Tardif et al. (1997) were directed at exploring how well the 
mixture model predicted observed blood kinetics of ethylbenzene, toluene, or xylene in rats during and 
following exposures to binary or ternary mixtures of the chemicals.  Interactions were simulated as 
competitive, noncompetitive, or uncompetitive inhibition of metabolism, with the values of the inhibition 
constants derived by fitting the model to observed blood kinetics during and following exposures to 
binary mixtures.  Although the mixture model achieved predictions similar to observations (i.e., within 1– 
2 SD of observations), this outcome would have been highly influenced by the parameter values selected 
for each of the individual chemicals, including fitted interaction constants.  A more direct evaluation of 
the ethylbenzene model was explored by comparing predictions of the human model (allometrically 
scaled from the rat) to ethylbenzene concentrations observed in human subjects who were exposed to 
ethylbenzene (33 ppm) for 7 hours/day on 4 different days (Tardif et al. 1991). Predicted blood 
concentrations of ethylbenzene in subjects exposed to ethylbenzene were within 1–2 SD of observations.  
The Tardif et al. (1997) model has been incorporated into a mixtures model of JP-8 vapor and its 
components (Campbell and Fisher 2007).  The model included simulations of the kinetics of m-xylene 
and ethylbenzene, with other aromatic components of JP-8 vapor represented as a lumped component.  
Interactions between m-xylene and ethylbenzene were simulated as competitive inhibition of metabolism. 
The mixtures model predicted kinetics liver concentrations of ethylbenzene in rats during and following 
4-hour exposures to JP-8 vapor (380–2,700 mg/m3) that were similar to observed kinetics (i.e., predicted 
liver concentrations were within 1–2 SD of observations). 
Risk Assessment. The ethylbenzene model predicts blood kinetics of ethylbenzene and kinetics of 
metabolism of ethylbenzene that occur in association with inhalation exposures.  These predictions are 
potentially useful for predicting inhalation-derived internal doses of ethylbenzene in rats and/or humans 
(e.g., blood concentrations, liver concentrations of parent compound, or amounts of total metabolites 
formed in the liver), and for making extrapolations of these internal dose metrics across species.  The 
applicability any of the above dose metrics to risk assessment will depend on the mechanism for the 
specific toxicity end point being assessed, and contribution of the parent compound and/or metabolism 
metabolites to toxicity.  Current knowledge of the mechanism of toxicity of ethylbenzene does not include 
an understanding of the relative contributions of parent compound or metabolites as proximate toxic 
agents in the major end points of ethylbenzene toxicity (i.e., kidney, liver, otic, cancer).    
The Tardif et al. (1997) ethylbenzene model has been incorporated into a mixtures model for 
alkylbenzenes (ethylbenzene, toluene, m-xylene), benzene, and dichloromethane (DCM), (Haddad et al. 
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2001).  This mixture model has been applied to the derivation of interaction coefficients for various 
endpoints of dichloromethane toxicity (i.e., hypoxia, central nervous system effects, and cancer) based on 
predictions of corresponding relevant DCM internal dose metrics (i.e., carboxyhemoglobin concentration, 
area under concentration-time curve for DCM in richly perfused tissues; time-integrated amount of DCM 
conjugated with GSH). Interactions were simulated as dose addition, with internal dose metrics 
representing dose and the sole interaction mechanism assumed to be competitive inhibition of cytochrome 
P-450-mediated metabolism of DCM.  The Tardif et al. (1997) model also has been incorporated into a 
mixtures model of JP-8 vapor and its components (Campbell and Fisher 2007). The model included 
simulations of the kinetics of m-xylene and ethylbenzene, with other aromatic components of JP-8 vapor 
represented as a lumped component.  Interactions between m-xylene and ethylbenzene were simulated as 
competitive inhibition of metabolism. The Tardif et al. (1997) mixtures model was also utilized to 
evaluate occupational exposure limits for ethylbenzene, toluene, m-xylene for hypothetical exposures to 
ternary mixtures of the chemicals (Dennison et al. 2005). These analyses demonstrate the potential utility 
of the ethylbenzene model for predicting metabolic interactions with other chemicals that share a common 
mechanism of metabolic elimination, and the potential impacts of such interactions on risk (e.g., hazard 
index, cancer risk, occupation exposure limits). 
Target Tissues. The Tardif et al. (1997) ethylbenzene model was calibrated and evaluated to predict 
blood kinetics of ethylbenzene that occur in association with inhalation exposures.  Essential to this 
prediction is the accurate prediction of rates of metabolism of ethylbenzene, which, in the model, is 
attributed solely to the liver.  The model has potential utility for predicting, in addition to blood kinetics 
of ethylbenzene, kinetics of concentrations of ethylbenzene in important toxicity target tissues, including 
liver and richly perfused tissues (which includes kidney and central nervous system), and rates of 
metabolism of ethylbenzene and total amount of metabolites formed in liver.  The model does not 
simulate, specifically, the kidney or central nervous system. 
Species Extrapolation. The Tardif et al. (1997) model was initially developed and calibrated to 
simulate ethylbenzene kinetics in the rat, and was allometrically scaled to the human.  The scaled human 
model was evaluated for predicting ethylbenzene blood concentrations observed in human subjects who 
were exposed to ethylbenzene (33 ppm) for 7 hours/day on 4 different days (Tardif et al. 1991).  Predicted 
blood concentrations of ethylbenzene in subjects exposed to ethylbenzene were within 1–2 SD of 
observations.  Studies of the robustness of the model for predicting ethylbenzene kinetics in other species 
(after allometric scaling to those species) were not located. 
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Interroute Extrapolation.    Studies that evaluated the model for predicting ethylbenzene kinetics 
following oral or dermal exposure were not located. 
The Dennison et al. (2003, 2004) Model 
Description of the Model.    Dennison et al. (2003, 2004) developed a PBPK model for simulating the 
blood and elimination kinetics of components of gasoline, including benzene, ethylbenzene, n-hexane, 
toluene, o-xylene, and other volatile components (represented as a single lumped composition) in rats.  
The structure of the model is essentially identical the generic model depicted in Figure 3-4, with tissue 
compartments limited to lungs, liver, fat, richly perfused tissues (RPT), and slowly perfused tissues 
(SPT). All metabolism was attributed to the liver and represented as functions of the concentration of 
parent compound in liver venous blood, affinity constant (Km), and maximum reaction velocity (Vmax). 
Transfers of parent compound between blood and tissues were assumed to be flow-limited, with clearance 
represented by tissue blood flow (L/hour).  Parameters for the ethylbenzene portion of the model are 
presented in Table 3-7. Partition coefficients for ethylbenzene were derived from vial equilibrium studies 
of isolated rat tissues (Gargas et al. 1989).  Metabolism parameter values for ethylbenzene were derived 
by fitting the model to observations of blood ethylbenzene kinetics measured in rats during closed-
chamber exposures to ethylbenzene (Dennison et al. 2003).  Physiological parameters, cardiac output 
(QC), and alveolar ventilation rate (QP), and metabolism Vmax were allometrically scaled to body weight 
(BW, scaling factor=BW0.74) 
Validation of the Model.    Optimization of the metabolism parameters for rats against observed 
closed chamber air concentration kinetics achieved predicted elimination kinetics of ethylbenzene that 
were similar to observations (Dennison et al. 2003).  Validation efforts reported in Dennison et al. (2004) 
were directed at exploring how well the mixture model predicted observed closed chamber air kinetics of 
ethylbenzene, toluene, or xylene during exposures of rats to gasoline (1, 10, 100, 1,000 ppm).  
Interactions were simulated as competitive inhibition of metabolism, with the values of the inhibition 
constants derived by fitting to chamber air concentration kinetics during exposures to binary mixtures.  
Although the mixture model achieved predictions similar to observations, this outcome would have been 
highly influenced by the parameter values selected for each of the individual chemicals (or lumped 
chemicals), including fitted interaction constants and, therefore, does not directly address the validity of 
the ethylbenzene model.    
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Table 3-7. Parameter Values for Dennison et al. (2003) Ethylbenzene PBPK Model 
Parameter Definition Rat model 
Physiological parameters 
VLC Liver volume (fraction of body) 0.037 
VFC Fat volume (fraction of body, scaled to body weight) 0.036(body weight)+0.205 
VSC Slowly-perfused tissue volume (fraction of body) 0.91-remaininga 
VRC Richly-perfused tissue volume (fraction of body) 0.054 
VLBV Lung blood volume (fraction of body) 0.002 
QCC Cardiac output (L/hour-kg body weight) 15b 
QPC Alveolar ventilation rate (L/hour-kg body weight) 15b,c 
QLC Liver blood flow (fraction of cardiac output) 0.183 
QSC Fat blood flow (fraction of cardiac output) 0.07 
QFC Slowly-perfused blood flow (fraction of cardiac output) 0.237d 
QRC Richly-perfused blood flow (fraction of cardiac output) 0.51 
Chemical parameters 
PB Blood:air partition coefficient 42.7e 
PL Liver:blood partition coefficient 1.96e 
PF Fat:blood partition coefficient 36.4e 
PS Slowly-perfused partition coefficient 0.609e 
PR Readily-perfused partition coefficient 1.96 
VmaxC Maximum rate of metabolism (mg/hour-kg body weight) 7.6b,f 
KmC Michaelis-Menten coefficient for metabolism (mg/L) 0.10f 
aVSC=0.91-(VLC+VFC+VRC+VLB) 

bScaled to body weight (BW0.74) 





eTissue:blood partition coefficients calculated based on reported, experimentally determined (vial equilibrium) 

tissue:air partition coefficients for rats (Tardif et al. 1997). 
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Risk Assessment. The Dennison et al. (2003) ethylbenzene model predicts blood kinetics of 
ethylbenzene and kinetics of metabolism of inhaled ethylbenzene.  These predictions are potentially 
useful for predicting internal doses of inhaled ethylbenzene in rats (e.g., blood concentrations, liver 
concentrations of parent compound, or amounts of total metabolites formed in the liver).  The 
applicability any of the above dose metrics to risk assessment will depend on the mechanism for the 
specific toxicity endpoint being assessed, and contribution of the parent compound and/or metabolism to 
toxicity.  Current knowledge of the mechanism of toxicity of ethylbenzene does not include an 
understanding of the relative contributions of parent compound or metabolites as proximate toxic agents 
in the major end points of ethylbenzene toxicity (i.e., kidney, liver, otic, cancer).    
The Dennison et al. (2003) ethylbenzene model has been incorporated into a mixtures model for gasoline 
(benzene, ethylbenzene, n-hexane, toluene, o-xylene, and other volatile components).  In the mixtures 
model, chemical interactions were attributed to competitive inhibition of metabolism and inhibition 
constants were derived by fitting model predictions of closed chamber air concentration kinetics during 
exposures to binary mixtures.  The model was used to predict the effect of increasing exposure 
concentration to gasoline on blood concentrations and amounts of individual mixture components 
metabolized (Dennison et al. 2004).   
Target Tissues. The Dennison et al. (2003) ethylbenzene model was calibrated and evaluated to 
predict elimination (i.e., metabolism) kinetics of ethylbenzene that occur in association with inhalation 
exposures. Essential to this prediction is the accurate prediction of rates of metabolism of ethylbenzene, 
which, in the model, is attributed solely to the liver.  The model has potential utility for predicting, in 
addition to elimination kinetics of ethylbenzene, kinetics of concentrations of ethylbenzene in important 
toxicity target tissues, including liver, richly perfused tissues (which includes kidney and central nervous 
system), and rates of metabolism of ethylbenzene and total amount of metabolites formed in liver.  The 
model does not simulate, specifically, the kidney or central nervous system. 
Species Extrapolation. The Dennison et al. (2003) ethylbenzene model was developed and 
calibrated to simulate ethylbenzene kinetics in the rat; however, it could be allometrically scaled to the 
human.  Studies of the robustness of the model for predicting ethylbenzene kinetics in species other than 
the rat (after allometric scaling to those species) were not located. 
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Interroute Extrapolation.    Studies that evaluated the model for predicting ethylbenzene kinetics 
following oral or dermal exposure were not located. 
The Shatkin and Brown (1991) Model 
Description of the Model.    Shatkin and Brown (1991) described a model of dermal absorption of 
several nonpolar organic nonelectrolytes in dilute aqueous solution, one of which was ethylbenzene.  The 
structure of the model is depicted in Figure 3-5; model parameters are presented in Table 3-8.  The model 
includes three compartments:  stratum corneum, viable epidermis, and blood.  Transfers of ethylbenzene 
in solution through the fully hydrated stratum corneum and viable epidermis are assumed to be diffusive, 
with passage through the stratum corneum being the rate-limiting step.  A uniform thickness of 40 μm 
was assumed for the stratum corneum, with adjustments for different body parts.  Immersion of the hand 
or of the full body was assumed for the predicted models.  The viable epidermis was assumed to be 
200 μm, although the thickness was varied to test the outcome of the model.  Transfer from the viable 
epidermis to blood was assumed to be flow-limited.  Elimination from blood (i.e., distribution to tissues, 
excretion to urine and air, and metabolism) was represented with a single first-order rate constant.  A 
sensitivity analysis revealed a relatively high influence of epidermal blood flow (as expected for flow-
limited transfer to blood), epidermal thickness (increasing thickness decreased absorption), and stratum 
corneum fat (increasing fat content decreased absorption).  
Validation of the Model.    Model predictions were compared to the estimates of dermal absorption of 
ethylbenzene in humans (Dutkiewicz and Tyras 1967, 1968).  In this study, adult males (n=7) immersed 
their hands into a bath solution of 151 mg/L ethylbenzene for 1 hour and the absorbed dose was estimated 
from the change in concentration of the exposure bath.  The model predicted absorption of 34–37% of the 
bath ethylbenzene in 1 hour, compared to the observed mean absorption of 39% (range, 0.33–0.54). The 
simulated kinetics of absorption were not reported or compared to observations. 
Risk Assessment. The Shatkin and Brown (1991) model is potentially useful for predicting dermal 
absorption of ethylbenzene in risk assessment applications.  An example of one application is prediction 
of the dermal-absorbed dose of ethylbenzene for a bathing scenario (20-minute immersion in 0.1 mg 
ethylbenzene/L); the predicted absorbed dose, 0.47–0.50 mg, was higher than the absorbed dose predicted 
for ingestion of 2 L of water at the same concentration, or from inhalation during a 20-minute shower 
(Shatkin and Brown 1991).  The model may be useful in predicting absorbed doses of ethylbenzene 
resulting from bathing, swimming, and other activities (Shatkin and Brown 1991).  
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Source: Shatkin and Brown 1991 
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Table 3-8. Parameters Used in the Shatkin and Brown PBPK Model of Dermal 

Absorption of Ethylbenzene 

Parametera Value 	 Reference 
Stratum corneum/water NG Calculated from Roberts et al. 1975 
partition coefficient (Km) 
Stratum corneum diffusion NG Calculated from Guy and Maibach 
coefficient (Dsc) 1984 
Skin surface 320 cm2 (adult, hands and forearms) Dutkiewicz and Tyras 1967, 1968 
NG (adult, body) 	 Guy and Maibach 1984 
Skin surface (infant) 1,900 cm2	 Guy and Maibach 1984 
Epidermis diffusion coefficient 3.6x10-4 cm2/minute 	 Scheuplein 1976; Scheuplein et al. 
(De) 	 1969 
Stratum corneum thickness 0.004 cm 	 Blank and Scheuplein 1969 
(Hsc) 
Epidermis thickness (He) 0.02–0.1 cm 	 Blank and McAuliffe 1985; Blank 
and Scheuplein 1969; Guy et al. 
1982 
Epidermal blood flow (Feb) 280 mL/minute–m2	 Wade et al. 1962 
(adult, at rest) 
Epidermal blood flow (Feb) 4,000 mL/minute–m2	 Rowell 1986 
(adult, heavy exercise) 
Epidermis/blood partition 2.75 	 Shatkin and Brown 1991 
coefficient (Keb) 
Stratum corneum/epidermis NG 	 Shatkin and Brown 1991 
partition coefficient (Ksc/e) 
Blood volume (Vb) (adults) 5,000 mL 	 Shatkin and Brown 1991 
Blood volume (Vb) (infants) 693 mL 	 Shatkin and Brown 1991 
Fat in blood 0.7–0.9% 	 Brown and Hattis 1989 
Fat in stratum corneum 3–6% 	 Raykar et al. 1988 
Fat in epidermis 2–2.5% 	 Scheuplein 1976 
Elimination rate constant (Ke) 0.1 minute-1	 Hagemann 1979 
Octanol/water partition 2,230 	 Shatkin and Brown 1991 
coefficient (Kow) 
aTaken from Shatkin and Brown 1991.  All parameters used were either taken from published experimental work of 
others or calculated from previously reported mathematical relationships. 
NG = value not given 
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Target Tissues. The Shatkin and Brown (1991) model was developed to simulate dermal absorption 
of ethylbenzene (and other volatile organics); it does not predict concentrations of ethylbenzene in 
specific tissues, other than skin.  However, if the model were integrated into PBPK models of the 
distribution and elimination of absorbed ethylbenzene (e.g., Dennison et al. 2003; Tardif et al. 1997), the 
combined models might be useful for predicting internal doses of ethylbenzene associated with dermal 
exposures. 
Species Extrapolation. The Shatkin and Brown (1991) model was developed to simulate dermal 
absorption of ethylbenzene in humans and has been evaluated with observations in humans.  The major 
physiological parameters in the model are scalable or could be determined in different species (e.g., 
dermal thickness, dermal fat content, dermal blood flow), and the chemical parameters could be evaluated 
in other species (e.g., partition coefficients) or predicted from physical-chemical properties (e.g., diffusion 
coefficients).  These features improve the feasibility of scaling the model to other species. 
Interroute Extrapolation.    The Shatkin and Brown (1991) model, in combination with existing 
PBPK ethylbenzene inhalation models (e.g., Dennison et al. 2003; Tardif et al. 1997), may have utility for 
estimating dermal exposures (i.e., concentration, time) that would be expected to yield equivalent 
absorbed doses from inhalation exposures.  
3.5 MECHANISMS OF ACTION  
3.5.1 Pharmacokinetic Mechanisms 
Studies of the in vitro metabolism of ethylbenzene in microsomes prepared from human liver have 
identified high and low affinity catalytic pathways for the initial hydroxylation to 1-phenylethanol (Sams 
et al. 2004). In human liver microsomes, the high affinity pathway exhibited a lower Km and lower Vmax 
(Km=8 :M, Vmax=689 pmol/minute/mg protein) than the low affinity pathway (Km=391 :M, 
Vmax=3,039 pmol/min/mg protein) and was inhibited by diethyldithiocarbamate.  Studies conducted in 
microsomes prepared from insect cells expressing recombinant human isoforms of cytochrome P-450 also 
revealed a relatively high affinity, low Vmax catalysis by CYP2E1and lower affinity, higher Vmax catalysis 
by CYP1A2 and CYP2B6, suggesting that the latter two isoforms may contribute to the low affinity 
pathway observed in human liver microsome (Sams et al. 2004). 
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Blood kinetics of inhaled ethylbenzene have been successfully modeled with assumptions of flow-limited 
transfer of ethylbenzene to tissues and capacity-limited elimination by metabolism (Dennison et al. 2003, 
2004; Tardif et al. 1997, see Section 3.4.5).  These models have been successfully scaled from the rat to 
humans by applying species physiological parameter values (e.g., tissue volumes) and partition 
coefficients (i.e., blood:air partition coefficient) and allometrically scaling flows (i.e., cardiac output, 
alveolar ventilation rate) and metabolism parameters (i.e., Km, Vmax) to body weight (Tardif et al. 1997).  
These studies suggest a general similarity of the distribution and elimination kinetics in rats and humans.  
The robustness of these models for predicting ethylbenzene kinetics in other species has not been 
reported; however, the blood elimination kinetics of inhaled ethylbenzene in the mouse show similarities 
to that in the rat (e.g., nonlinearity of clearance with exposure concentration, similar elimination half-
times (Charest-Tardif et al. 2006; Tardif et al. 1997). 
3.5.2 Mechanisms of Toxicity 
Mechanisms of ototoxicity, toxicity to the liver and kidney, and carcinogenicity have not been identified.  
Since metabolites of ethylbenzene have been shown to produce oxidative damage to DNA (Midorikawa et 
al. 2004), it is possible that ethylbenzene metabolites contribute to the toxicity observed following 
ethylbenzene exposure.  Likewise, a genotoxic mechanism of carcinogencity is plausible. 
Ethylbenzene has been shown to exert adverse central nervous system effects on both humans (Yant et al. 
1930) and animals (Cragg et al. 1989; Ethylbenzene Producers Association 1986a; Molnar et al. 1986; 
Tegeris and Balster 1994; Yant et al. 1930). In vivo animal studies of ethylbenzene toxicity at the cellular 
level indicate that changes in brain levels of dopamine and other biochemical alterations, and in evoked 
electrical activity in the brain may be involved in ethylbenzene central nervous system toxicity 
(Andersson et al. 1981; Frantik et al. 1994; Mutti et al. 1988; Romanelli et al. 1986). 
Based on in vitro studies conducted with toluene, Cappaert et al. (2001) briefly speculated that increased 
intracellular calcium levels might be responsible for the obliteration of outer hair cells exposed to solvents 
such as ethylbenzene. 
In vitro studies of the mechanism of toxicity have focused on the effect of ethylbenzene on cell 
membranes, particularly that of the astrocyte (Engelke et al. 1993; Naskali et al. 1993, 1994; Sikkema et 
al. 1995; Vaalavirta and Tähti 1995a, 1995b).  In a review by Sikkema et al. (1995), changes in the 
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structure and integrity of the cell membrane after partitioning of ethylbenzene into the lipid bilayer may 
be a mechanism of toxicity.  Changes in the integrity of the cell membrane may subsequently affect the 
function of membrane, particularly as a barrier and in energy transduction, and in the formation of a 
matrix for proteins and enzymes. 
The work of Vaalavirta and Tähti (1995a, 1995b) and Naskali et al. (1993, 1994) has investigated the 
effect of ethylbenzene on the membrane of the rat astrocyte, as an in vitro model for the membrane-
mediated effects of solvents on the central nervous system.  Cultured astrocytes from the cerebella of 
neonatal Sprague-Dawley rats were sensitive to the effects of ethylbenzene, as measured by the inhibition 
of activity of Na+, K+-ATPase, and Mg++-ATPase (Vaalavirta and Tähti 1995a, 1995b).  This effect was 
found to be dose-dependent (Naskali et al. 1994).  Inhibition of these membrane-bound enzymes that 
regulate the ion channels of the membrane may disturb the ability of the cells to maintain homeostasis.  
Experiments with rat synaptosome preparations, similar to those using microsomal preparations by 
Engelke et al. (1993), showed that membrane fluidity was increased after exposure to ethylbenzene.  
ATPase and acetylcholinesterase activity were also decreased, as seen in the astrocyte preparations. 
3.5.3 Animal-to-Human Extrapolations 
Species differences have been shown for ethylbenzene metabolism. In humans exposed via inhalation, 
the major metabolites of ethylbenzene are mandelic acid (approximately 70% of the absorbed dose) and 
phenylglyoxylic acid (approximately 25% of the absorbed dose), which are excreted in the urine 
(Bardodej and Bardodejova 1970; Engstrom et al. 1984).  Evidence indicates that the initial step in this 
metabolic pathway is oxidation of the side chain of ethylbenzene to produce 1-phenylethanol.  In rats 
exposed by inhalation or orally to ethylbenzene, the major metabolites were identified as hippuric and 
benzoic acids (approximately 38%), 1-phenylethanol (approximately 25%), and mandelic acid 
(approximately 15–23%), with phenylglyoxylic acid making up only 10% of the metabolites (Climie et al. 
1983; Engstrom et al. 1984, 1985).  In rabbits, the most important metabolite is hippuric acid, which is 
probably formed by oxidative decarboxylation of phenylglyoxylic acid (El Masri et al. 1958). Rabbits 
have been shown to excrete higher levels of glucuonidated metabolites than do humans or rats (El Masry 
et al. 1956; Smith et al. 1954a, 1954b). Thus, there are no animal models of ethylbenzene metabolism 
that are completely consistent with human metabolism.  However, of the experimental models 
investigated, rats appear to be a more appropriate model than rabbits. 
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Models of the pharmacokinetic mechanisms and mechanisms of toxicity of ethylbenzene have focused on 
cellular processes (see Sections 3.5.1 and 3.5.2, above).  In these, humans and animals appear to be 
similar.  Although some species differences exist with respect to toxicity, adverse effects observed after 
ethylbenzene exposure in both humans and animals seem to be similar in scope (i.e., respiratory, hepatic, 
renal, and neurological). Rats may be more sensitive than mice or rabbits (Cragg et al. 1989; NTP 1992). 
Thus, the rat may be the most appropriate animal model for studying the mechanism of toxicity of 
ethylbenzene as it relates to human health effects assessment.   
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS  
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate 
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”.  To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine 
disruptors. In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to 
convey the fact that effects caused by such chemicals may not necessarily be adverse.  Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to 
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist 
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens 
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are 
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial, 
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or 
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997b).  Stated differently, such compounds may cause toxicities that 
are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering, 
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for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought 
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994; 
Giwercman et al. 1993; Hoel et al. 1992). 
No studies were located regarding endocrine disruption in humans or animals after exposure to 
ethylbenzene.  Nishihara et al. (2000) concluded that ethylbenzene was not estrogenic as established in an 
in vitro yeast two-hybrid assay.  No additional in vitro studies were located regarding endocrine 
disruption of ethylbenzene. 
3.7 CHILDREN’S SUSCEPTIBILITY  
This section discusses potential health effects from exposures during the period from conception to 
maturity (most development is complete by early in the third decade) in humans (that most development 
is complete by the early 20’s), when all biological systems will have fully developed.  Potential effects on 
offspring resulting from exposures of parental germ cells are considered, as well as any indirect effects on 
the fetus and neonate resulting from maternal exposure during gestation and lactation.  Relevant animal 
and in vitro models are also discussed. 
Children are not small adults.  They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the 
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children. 
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are 
critical periods of structural and functional development during both prenatal and postnatal life, and a 
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage 
may not be evident until a later stage of development.  There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
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infants have a larger proportion of their bodies as extracellular water, and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975).  Many 
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly 
relevant to cancer. 
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993). 
There are no data describing the effect of exposure to ethylbenzene in children.  Respiratory and eye 
irritation, and dizziness are the most prevalent signs of exposure to high levels of ethylbenzene (Yant et 
al. 1930), and it is expected that children would also exhibit these effects, as well as other effects 
observed in adults.  Minor birth defects have occurred in newborn rats, but not rabbits, whose mothers 
were exposed by breathing air contaminated with ethylbenzene (NIOSH 1981; Ungváry and Tátrai 1985).  
These defects consisted of urinary tract anomalies (not specified) and supernumerary ribs.  
Supernumerary ribs were observed in the presence of minimal maternal changes.  Although 
developmental effects were reported in the offspring of animals exposed to <500 ppm ethylbenzene 
(Ungváry and Tátrai 1985) several longer duration studies have shown developmental effects at 
biologically or statistically significant levels only in the offspring of rats exposed to >500 ppm 
ethylbenzene (Faber et al. 2006, 2007; Saillenfait et al. 2003, 2006, 2007).  Furthermore, the report by 
Ungváry and Tátrai (1985) lacks pertinent experimental details, including specific data on the urinary 
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tract anomalies, dictating caution in the interpretation of study findings.  Section 3.2.1.6, Developmental 
Effects, contains a more detailed discussion of these results.  It is not known whether these developmental 
effects observed in animals would be observed in people.  Ethylbenzene has been detected in human 
breast milk at unspecified concentrations (Pellizzari et al. 1982), but no pharmacokinetic experiments 
have been done to confirm that it is actually transferred to breast milk in mammals.  No specific 
information was found concerning ethylbenzene concentrations in placenta, cord blood, or amniotic fluid.  
Since there is no information about health effects in children, it is unknown whether they differ from 
adults in their susceptibility to health effects from ethylbenzene.  However, in general, the principle that 
early-in-life exposures may increases susceptibility to carcinogens may apply to ethylbenzene (EPA 
2005). 
There is no specific information about the metabolism of ethylbenzene in children or immature adults.  
However, since two of the enzyme families responsible for the conjugation and elimination of 
ethylbenzene are developmentally regulated, it is possible that the activity of these enzymes would differ 
in children or immature animals compared to adults.  In humans, UDP glucuronosyltransferase activity 
does not reach adult levels until about 6–18 months of age, although the development of this activity is 
isoform specific.  Activity of sulfotransferases (which is also isoform specific) seems to develop earlier.  
The activity of some sulfotransferase isoforms may even be greater during infancy and early childhood 
than in adulthood (Leeder and Kearns 1997).  In addition, age-dependence of elimination kinetics (e.g., 
glomerular filtration and tubular secretion of organic anion metabolites of ethylbenzene), potentially, 
could contribute to age-related differences in sensitivity to ethylbenzene. 
3.8 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 
1989). 
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers 
as tools of exposure in the general population is very limited.  A biomarker of exposure is a xenobiotic 
substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target 
molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989).  The 
preferred biomarkers of exposure are generally the substance itself, substance-specific metabolites in 
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readily obtainable body fluid(s), or excreta.  However, several factors can confound the use and 
interpretation of biomarkers of exposure.  The body burden of a substance may be the result of exposures 
from more than one source.  The substance being measured may be a metabolite of another xenobiotic 
substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic 
compounds).  Depending on the properties of the substance (e.g., biologic half-life) and environmental 
conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the 
body by the time samples can be taken.  It may be difficult to identify individuals exposed to hazardous 
substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as 
copper, zinc, and selenium).  Biomarkers of exposure to ethylbenzene are discussed in Section 3.8.1. 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989).  This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity.  Note that these markers are not often substance specific.  They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused 
by ethylbenzene are discussed in Section 3.8.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability 
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible. 
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Ethylbenzene  
Information on ethylbenzene concentrations in human tissue or fluids is available.  Exposure to 
ethylbenzene may be determined by the detection of mandelic acid and phenylglyoxylic acid in urine 
(Bardodej and Bardodejova 1970) or by direct detection of ethylbenzene in whole human blood (Antoine 
et al. 1986; Ashley et al. 1992; Cramer et al. 1988).  However, mandelic acid and phenylglyoxilic acid are 
also metabolites of styrene (Agency for Toxic Substances and Disease Registry 1992). 
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The 1982 National Human Adipose Tissue Survey conducted by EPA measured ethylbenzene in 96% of 
the 46 composite samples analyzed for volatile organic compounds (EPA 1986a).  A wet tissue 
concentration range of not detected (detection limit=2 ng/g) to 280 ng/g was reported, but an average 
concentration was not provided. 
Numerous studies indicate that environmental exposures to ethylbenzene can result in detectable levels in 
human tissues (Antoine et al. 1986; Cramer et al. 1988; Pellizzari et al. 1982; Wolff 1976; Wolff et 
al. 1977) and in expired air (Conkle et al. 1975; Engstrom and Bjurstrom 1978; EPA 1984e).  Analysis of 
blood specimens from a test population of 250 patients (Antoine et al. 1986) and composite samples 
obtained from blood donations of laboratory personnel with potentially low-level exposure (Cramer et 
al. 1988) indicated ethylbenzene concentrations in the blood to range from below detection limits to 
59 ppb. Similarly, ethylbenzene was detected in 8 of 12 milk samples from lactating women living in 
various urban areas of the United States with high probability of emissions of pollutants (Pellizzari et 
al. 1982).  Subcutaneous fat samples taken from individuals exposed to an average of 1–3 ppm ethyl-
benzene in the workplace contained ethylbenzene levels as high as 0.7 ppm (Wolff 1976; Wolff et 
al. 1977). 
Studies examining the correlation of ethylbenzene concentrations in ambient air with concentrations 
measured in expired or alveolar air have also been conducted (Conkle et al. 1975; Engstrom and 
Bjurstrom 1978; EPA 1984e).  Ethylbenzene concentrations in breath samples were reported to correlate 
well with ethylbenzene concentrations in indoor samples taken with personal air monitors (EPA 1984e).  
A correlation was also found between ethylbenzene uptake and ethylbenzene concentrations in alveolar 
air during, but not after, inhalation exposure in volunteers (Engstrom and Bjurstrom 1978).  Rates of 
ethylbenzene expiration measured in volunteers with no known previous exposure to ethylbenzene ranged 
from 0.78 to 14 μg/hour, with higher rates detected in smokers than in nonsmokers (Conkle et al. 1975). 
3.8.2 Biomarkers Used to Characterize Effects Caused by Ethylbenzene  
For more information on biomarkers for renal and hepatic effects of chemicals see ATSDR/CDC 
Subcommittee Report on Biological Indicators of Organ Damage (Agency for Toxic Substances and 
Disease Registry 1990) and for information on biomarkers for neurological effects see OTA (1990). 
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No specific biomarkers of effect for ethylbenzene were identified.  Most of the information on humans is 
from case reports in which the effects are general and non-specific, such as eye and throat irritation and 
chest constriction (Yant et al. 1930). 
3.9 INTERACTIONS WITH OTHER CHEMICALS  
The metabolism of ethylbenzene includes pathways involving mono-oxygenases (e.g., cytochrome P-450) 
and formation of glucuronide and sulfate conjugates. Therefore, the metabolism of ethylbenzene could be 
markedly altered by inhibitors (e.g., carbon monoxide, SKF 525A) and inducers (e.g., phenobarbital, 
described above) of drug-metabolizing enzymes (Gillette et al. 1974) and by the availability of 
conjugation reactants (e.g., glucuronic acid, sulfate) that facilitate the excretion of ethylbenzene 
metabolites. Mono-oxygenases (MOs) are a class of enzymes involved in the detoxication of xenobiotics, 
including ethylbenzene.  Substances that induce MO enzymes may decrease the toxicity of ethylbenzene 
by increasing the rate of production of its less toxic metabolites.  Conversely, MO enzyme inhibitors 
would be expected to have the opposite effect. Compounds that affect glucuronic acid availability could 
also affect the excretion rate of ethylbenzene metabolites. 
Numerous studies have demonstrated interactions between ethylbenzene and chemicals that inhibit 
cytochrome P-450 (e.g., carbon monoxide; Maylin et al. 1973), compete with ethylbenzene for 
metabolism by cytochrome P-450 (e.g., alkylbenzenes, ethanol; Angerer and Lehnert 1979; Elovaara et al. 
1984; Engstrom et al. 1984; Romer et al. 1986), or induce cytochrome P-450 (e.g. phenobarbital; Maylin 
et al. 1973; McMahon and Sullivan 1966).  Competitive inhibition of metabolism by alkylbenzenes, 
including ethylbenzene, has been introduced into PBPK models of alkylbenzene mixtures and gasoline 
component mixtures (Dennison et al. 2003, 2004; Haddad et al. 2001; Tardif et al. 1997). 
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to ethylbenzene than will most 
persons exposed to the same level of ethylbenzene in the environment.  Reasons may include genetic 
makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  
These parameters result in reduced detoxification or excretion of ethylbenzene, or compromised function 
of organs affected by ethylbenzene.  Populations who are at greater risk due to their unusually high 
exposure to ethylbenzene are discussed in Section 6.7, Populations with Potentially High Exposures. 
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Even though ethylbenzene is not known to bioaccumulate (Aster 1995; Meylan et al. 1999; Nuns and 
Benville 1979; Ogata et al. 1984), human and animal studies suggest that several factors can contribute to 
an increased probability of adverse health effects following ethylbenzene exposure (NIOSH/OSHA 
1978).  Exposure to ethylbenzene has been shown to produce hearing loss in humans and animals; 
therefore, individuals with pre-existing hearing loss (e.g., congenital or infection-related) or individuals 
participating in activities that may result in hearing loss (e.g., sharpshooting) may be more susceptible to 
the ototoxic effects of ethylbenzene.  Exposure of individuals with impaired pulmonary function to ethyl-
benzene in air has been shown to exacerbate symptoms because of ethylbenzene's irritant properties.  
Because ethylbenzene is detoxified primarily in the liver and excreted by the kidney, individuals with 
liver or kidney disease might be more susceptible to ethylbenzene toxicity, as would persons taking 
medications or other drugs (e.g., alcohol) that are known hepatotoxins.  Persons with dermatitis or other 
skin diseases may be at greater risk, since ethylbenzene is a defatting agent and may aggravate these 
symptoms.  Children’s susceptibility is discussed in Section 3.7. 
In summary, groups that might be more susceptible to the toxic effects of ethylbenzene are individuals 
with hearing loss and diseases of the respiratory system, liver, kidney, or skin; young children; fetuses; 
pregnant women; and individuals taking certain medications such as hepatotoxic medications or drugs. 
3.11 METHODS FOR REDUCING TOXIC EFFECTS  
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to ethylbenzene.  However, because some of the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment of exposures to ethylbenzene.  When 
specific exposures have occurred, poison control centers and medical toxicologists should be consulted 
for medical advice. The following texts provide specific information about treatment following exposures 
to ethylbenzene:   
Leikin JB, Poloucek FP.  2002.  Poisoning and toxicology handbook.  Hudson, OH:  Lexi-Comp, Inc., 
554. 
Proctor NH, Hughes JP. 1978.  Chemical hazards of the workplace.  Philadelphia, PA: J.B. Lippincott 
Company, 251-252. 
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3.11.1 Reducing Peak Absorption Following Exposure  
Human exposure to ethylbenzene can occur by inhalation, oral, or dermal contact.  General 
recommendations for reducing absorption of ethylbenzene following exposure include removing the 
exposed individual from the contaminated area and removing the contaminated clothing.  Removal of the 
patient from the source of contamination is an initial priority along with proper ventilation and cardiac 
monitoring.  If the eyes and skin were exposed, they should be flushed with water.  Emesis or lavage is 
not recommended following oral exposure due to the risk of aspiration pneumonia (Leikin and Paloucek 
2002).  Activated charcoal may be administered to adsorb ethylbenzene (Leikin and Paloucek 2002).  
Benzodiazepines may be used to control seizures (Leikin and Paloucek 2002).  Administration of 
catecholamines should be avoided due to the risk of ventricular arrhythmia (Leikin and Paloucek 2002). 
3.11.2 Reducing Body Burden  
Following absorption into the blood, ethylbenzene is rapidly distributed throughout the body. The initial 
stage of ethylbenzene metabolism in humans is the formation of 1-phenylethanol via hydroxylation of the 
of the side chain. Further oxidation leads to the formation of mandelic acid and phenylglyoxylic acid, the 
major urinary metabolites of ethylbenzene in humans.  Detoxication pathways generally involve the 
formation of glucuronide or sulfate conjugates of 1-phenylethanol or its subsequent metabolites.  Urinary 
excretion is the primary route of elimination of metabolized ethylbenzene.  Studies in humans and 
animals indicate that urinary excretion occurs in several phases, with half-lives of hours.  Hence, 
ethylbenzene and its metabolites have relatively short half-lives in the body, and while some of these 
metabolites are clearly toxic, substantial body burdens are not expected.  
No methods are currently used for reducing the body burden of ethylbenzene.  It is possible that methods 
could be developed to enhance the detoxication and elimination pathways. 
3.11.3 Interfering with the Mechanism of Action for Toxic Effects  
Treatments interfering with the mechanism of action for toxic effects have not been identified. 
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3.12 ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of ethylbenzene is available.  Where adequate information is 
not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure 
the initiation of a program of research designed to determine the health effects (and techniques for 
developing methods to determine such health effects) of ethylbenzene. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
3.12.1 Existing Information on Health Effects of Ethylbenzene  
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
ethylbenzene are summarized in Figure 3-6.  The purpose of this figure is to illustrate the existing 
information concerning the health effects of ethylbenzene.  Each dot in the figure indicates that one or 
more studies provide information associated with that particular effect.  The dot does not necessarily 
imply anything about the quality of the study or studies, nor should missing information in this figure be 
interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision Guide for Identifying 
Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic Substances and 
Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public 
health assessments.  Generally, ATSDR defines a data gap more broadly as any substance-specific 
information missing from the scientific literature. 
Figure 3-6 graphically describes the existing health effects information on ethylbenzene by route and 
duration of exposure.  Little information concerning humans exposed via inhalation to ethylbenzene is 
available. Most of the information concerning health effects in humans is reported in occupational 
studies, which are difficult to interpret given the limitations of the studies (e.g., simultaneous exposure to 
other hazardous substances, unquantified exposure concentrations, and exposure probably occurring by a 
combination of routes).  No data were available concerning human health effects following oral exposures 
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to ethylbenzene.  Dermal effects in humans exposed to ethylbenzene vapors include respiratory and 
ocular irritation. 
In animals, the lethality of ethylbenzene is documented for all routes of exposure.  Systemic, 
immunologic, neurologic, developmental, and reproductive effects have been reported following acute-, 
intermediate-, or chronic-duration inhalation exposures to ethylbenzene.  Limited data on the health 
effects resulting from oral or dermal exposure to ethylbenzene were located.   
3.12.2 Identification of Data Needs 
In general, data on the toxic effects of ethylbenzene in humans and animals are limited.  In many areas for 
which studies have been conducted, the lack of reliable data precludes any definitive conclusions from 
being drawn. 
Acute-Duration Exposure.    The database for acute-duration inhalation exposure to ethylbenzene is 
largely composed of inhalation studies in laboratory animals with a limited number of human studies.  
The available acute-duration studies in humans (Sliwinska-Kowalska et al. 2001; Yant et al. 1930) and 
animals (Andersson et al. 1981; Cappaert et al. 1999, 2000, 2001, 2002; Ethylbenzene Producers 
Association 1986a; Molnar et al. 1986; Tegeris and Balster 1994; Yant et al. 1930) indicate that the 
nervous system, and particularly the auditory system, is sensitive to the toxic effects of ethylbenzene.  
The available reports and studies in humans are of limited use for dose-response assessment because 
insufficient information was provided to clearly characterize the exposure to ethylbenzene or because 
exposures were for mixtures of solvents, not ethylbenzene alone.  Ethylbenzene is an acute ocular and 
respiratory irritant in humans (Cometto-Muñiz and Cain 1995; Thienes and Haley 1972; Yant et al. 
1930); however, animal studies suggest that acute sublethal inhalation exposures do not result in 
pulmonary histopathology (Ethylbenzene Producers Association 1986a).  Developmental and 
reproductive effects were reported in animals exposed to ethylbenzene by inhalation during gestation 
(Ungváry and Tátrai 1985); however, the latter study is limited by incomplete description of the results 
and the absence of an analysis on a per litter basis.  Increased organ weight (liver, kidneys) has been 
observed in a number of studies in animals (Ethylbenzene Producers Association 1986a; Toftgard and 
Nilsen 1982); however, no findings are made upon microscopic examination of the liver or kidneys 
(Ethylbenzene Producers Association 1986a).  An acute-duration inhalation MRL of 10 ppm was derived 
based on ototoxicity in animals.  No studies describing acute-duration oral exposure of humans to 
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ethylbenzene were found in the literature.  Although two animal studies have examined the acute oral 
toxicity of ethylbenzene (Gagnaire and Langlais 2005; Ungvary 1986), they were not adequate for the 
derivation of an acute-duration oral MRL.  Mild irritation (Smyth et al. 1962), reddening, exfoliation, and 
blistering (Wolf et al. 1956) have been reported in rabbits when ethylbenzene was applied directly on the 
skin. Slight irritation of the eye (Wolf et al. 1956) and corneal injuries (Smyth et al. 1962; Wolf et al. 
1956) were observed in rabbits when ethylbenzene was instilled onto the eyes.  There is a data need for 
additional acute-duration oral and dermal toxicity studies in animals exposed to ethylbenzene. 
Intermediate-Duration Exposure.    The database of intermediate-duration inhalation studies 
includes several studies in animals, but no studies in humans.  It has been shown that the auditory system 
is sensitive to the toxic effects of ethylbenzene after intermediate-duration inhalation exposure (Gagnaire 
et al. 2007). Systemic effects have been observed at concentrations equal to or higher than those that 
elicited ototoxic effects in rats.  Effects at even higher concentrations include neurological and 
hematological effects (Cragg et al. 1989; Wolf et al. 1956) and increased organ weight (Cragg et al. 1989; 
Elovaara et al. 1985; NIOSH 1981; NTP 1992; Wolf et al. 1956).  Organs showing increased weight did 
not show treatment-related histopathological effects (Cragg et al. 1989; NTP 1992).  Developmental 
and/or reproductive effects have been reported in offspring of animals following intermediate-duration 
inhalation exposures to ethylbenzene during gestation (Faber et al. 2006, 2007; NIOSH 1981; Saillenfait 
et al. 2003, 2006, 2007) at concentrations that were higher than those that elicited ototoxic effects.  An 
intermediate-duration inhalation MRL of 0.7 ppm was derived based on the observed ototoxic effects in 
animals (Gagnaire et al. 2007).  The intermediate-duration oral database for ethylbenzene is limited to the 
critical study by Mellert et al. (2007) evaluating the effects of oral exposure of rats to ethylbezene for 
4 and 13 weeks, and a poorly reported 6-month exposure study in rats (Wolf et al. 1956).  Results of the 
13-week gavage study in rats observed effects indicative of liver toxicity, including increased activity of 
serum liver enzymes (ALT and GGT), increased absolute and relative liver weights, and a dose-related 
increase in the incidence of centrilobular hepatocyte hypertrophy. Results of the 4-week exposure study 
in rats are similar to those observed in the 13-week study, showing that the liver is the primary target 
organ for oral ethylbenzene; effects consistent with hepatotoxicity, including increased absolute and 
relative liver weights, increased incidence of hepatocyte centrilobular, and increased serum liver enzyme 
activity (ALT) (Mellert et al. 2007).  Wolf et al. (1956) reported slight weight and histopathological 
effects in the liver and kidney of female rats.  An intermediate-duration oral MRL of 0.5 mg/kg/day was 
derived based on the observed liver effects in animals exposed for 13 weeks (Mellert et al. 2007). 
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Chronic-Duration Exposure and Cancer.    The database of chronic-duration/carcinogenicity 
inhalation studies with ethylbenzene includes a chronic duration study in rats and mice (NTP 1999) and a 
limited number of studies in humans.  Hematological effects were observed in workers exposed to 
solvents containing ethylbenzene (Angerer and Wulf 1985), but no hematological effects, liver lesions or 
effects on liver function, or cases of malignancy were reported in a study of workers exposed chronically 
(>20 years) to ethylbenzene (Bardodej and Cirek 1988).  The severity of nephropathy was significantly 
increased in female and male rats exposed to ≥75 or 750 ppm ethylbenzene, respectively, for 2 years 
(NTP 1999). At higher concentrations rats showed significant increases in renal tubule hyperplasia; male 
rats showed an increased incidence of interstitial cell adenoma in the testis.  Effects observed in male or 
female mice exposed to ethylbenzene for 2 years include an increased incidence of hyperplasia of the 
pituitary gland pars distalis, increased incidence of follicular cell hyperplasia in the thyroid gland, an 
increased incidence of syncytial alterations of the hepatocytes, hypertrophy, and hepatic necrosis, and an 
increased incidence of eosinophilic foci (NTP 1999). Ethylbenzene showed clear evidence of 
carcinogenic activity in male rats based on increased incidences of renal tubule neoplasms, some evidence 
of carcinogenic activity in female rats based on increased incidences of renal tubule adenomas, some 
evidence of carcinogenic activity in male mice based on increased incidences of alveolar/bronchiolar 
neoplasms, and some evidence of carcinogenic activity in female mice based on increased incidences of 
hepatocellular neoplasms (NTP 1999). The 2-year inhalation study in rats suggests that an increase in the 
severity of nephropathy in female rats is the most sensitive end point of ethylbenzene exposure.  This end 
point was selected to estimate a chronic-duration inhalation MRL of 0.3 ppm.  There is no need to 
conduct additional carcinogenicity studies of ethylbenzene via inhalation.  A statistically significant 
increase in total malignant tumors was reported in female rats and in combined male and female groups 
exposed to 500 mg kg/day via gavage for 104 weeks (Maltoni et al. 1985).  No data on specific tumor 
type were presented, only one dose was tested, and no information on survival was provided.  It might be 
useful to conduct a toxicity and carcinogenicity study of ethylbenzene administered orally to at least two 
animal species.  It might be useful to conduct chronic-duration studies in at least two species with an 
emphasis in ototoxic effects. 
Genotoxicity.    Available human data (Holz et al. 1995) indicate that ethylbenzene may be marginally 
genotoxic.  A weak induction of sister chromatid exchanges in human lymphocytes following 
ethylbenzene exposure was seen (Norppa and Vainio 1983a).  Data are available regarding the genotoxic 
potential of ethylbenzene from in vitro assays in bacteria, yeast, and mammalian cell cultures (McGregor 
et al. 1988; NTP 1999).  Although the results generally indicate that ethylbenzene is not genotoxic, 
marginal genotoxic effects have been reported in some tests.  Independent confirmation or refutation of 
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these studies, as well as further genotoxicity studies, especially in mammalian systems, would help 
provide clarification of these conflicting results.  In particular, chromosome aberrations in occupationally 
exposed persons would provide useful information. 
Reproductive Toxicity. No studies were located regarding reproductive effects in humans following 
inhalation exposure to ethylbenzene.  Reproductive end points have been assessed after acute- (Ungváry 
and Tátrai 1985) and intermediate-duration exposures of animals exposed during gestation (Saillenfait et 
al. 2003, 2006, 2007) and in a two-generation reproductive toxicity study (Faber et al. 2006, 2007).  
Effects on reproductive organs (Cragg et al. 1989; NTP 1992, 1999; Wolf et al. 1956) in animals exposed 
to ethylbenzene have also been evaluated.  The only available oral-exposure reproduction study reported 
decreased hormone levels and blockage or delay of the estrus cycle in female rats (Ungvary 1986).  
Additional inhalation exposure reproductive toxicity studies are not deemed necessary at this time.  It 
might be useful to conduct additional oral exposure reproductive toxicity studies in at least two species. 
Developmental Toxicity.    No studies of developmental effects in humans following inhalation 
exposure to ethylbenzene were located.  The available studies have reported developmental effects in the 
offspring of animals exposed to ethylbenzene during gestation (NIOSH 1981; Saillenfait et al. 2003, 
2006, 2007; Ungváry and Tátrai 1985).  The report by Ungváry and Tátrai (1985) has many deficiencies, 
including poor reporting of the experimental conditions and poor description of the maternal and fetal 
observations.  Maternal toxicity has been generally reported at the highest doses tested (Saillenfait et al. 
2003, 2006, 2007; Ungváry and Tátrai 1985).  Biologically or statistically significant developmental or 
neurodevelopmental effects were not observed in the offspring of animals in a two-generation inhalation 
study (Faber et al. 2006, 2007).  No studies were located regarding developmental effects in humans and 
animals following oral or dermal exposure to ethylbenzene.  A data need exists for oral and dermal 
developmental toxicity studies. 
Immunotoxicity.  No studies were found regarding immunological effects in humans following 
inhalation exposure to ethylbenzene.  Studies were located that examined organs of the immune system in 
animals after intermediate- (Cragg et al. 1989; NIOSH 1981; NTP 1992) or chronic-duration (NTP 1999) 
exposure to ethylbenzene.  No studies were located regarding immunological effects in humans or 
animals following oral or dermal exposure to ethylbenzene.  No additional immunological studies are 
deemed to be necessary at this time. 
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Neurotoxicity.  Human studies have established that acute exposure to ethylbenzene may result in 
dizziness and vertigo (Yant et al. 1930) and that hearing loss is significantly increased in workers exposed 
to solvent mixtures that include ethylbenzene (Sliwinska-Kowalska et al. 2001).  The role of ethylbenzene 
in the observed hearing losses cannot be ascertained from this study given that ethylbenzene was only one 
of several solvents. 
Animal studies indicate that the auditory system is the most sensitive target of ethylbenzene toxicity after 
acute- (Cappaert et al. 1999, 2000, 2001, 2002) or intermediate-duration (Gagnaire et al. 2007) inhalation 
exposures and after acute-duration oral exposures to ethylbenzene (Gagnaire and Langlais 2005).  The 
effects of ethylbenzene on the central nervous system have been assessed in animals after acute-duration 
exposure to ethylbenzene (Ethylbenzene Producers Association 1986a; Molnar et al. 1986; Tegeris and 
Balster 1994; Yant et al. 1930). Neurobiochemical and electrical activity alterations have been reported 
in animals after acute-duration exposure to ethylbenzene (Andersson et al. 1981; Frantik et al. 1994; 
Mutti et al. 1988; Romanelli et al. 1986).  No adverse histopathological findings were observed in brain 
tissue of animals after intermediate- (NTP 1992) or chronic-duration (NTP 1999) exposure to 
ethylbenzene.  No studies were located regarding neurological effects in humans following oral exposure 
to ethylbenzene.  Ototoxicity is also observed in animals after acute-duration oral exposure to 
ethylbenzene (Gagnaire and Langlais 2005).  Additional studies are needed to establish the mechanism of 
action by which ethylbenzene elicits ototoxicity, as no information on the mechanism of ethylbenzene-
induced ototoxicity was identified.  Furthermore, due to the large differences between rats and guinea 
pigs in susceptibility to ethylbenzene-induced ototoxicity, additional studies on hearing and ear 
physiology in rodents are needed to evaluate which species is most similar to humans.  No studies were 
located regarding neurological effects in humans or animals following dermal exposure to ethylbenzene.  
Additional inhalation studies are needed to establish an intermediate-duration NOAEL for ototoxic 
effects. Additional studies are also needed to characterize the concentration-response pattern for 
ototoxicity after acute- and intermediate-duration oral exposures to ethylbenzene. 
Epidemiological and Human Dosimetry Studies.    The few available epidemiological studies on 
the health effects of ethylbenzene were primarily limited to occupational studies in which quantitative 
estimates of exposure were lacking and other limitations (e.g., multiple exposure routes, simultaneous 
exposure to other hazardous chemicals) were present.  Studies using volunteers exposed to low concen-
trations of ethylbenzene have provided useful information on effects of acute-duration inhalation 
exposure on the central nervous system (Yant et al. 1930).  No studies were available in which humans 
were exposed orally or dermally to ethylbenzene.  Epidemiological studies conducted in populations 
***DRAFT FOR PUBLIC COMMENT*** 
133 ETHYLBENZENE 
3. HEALTH EFFECTS 
exposed to ethylbenzene alone may provide useful information on the effects of ethylbenzene in humans.  
Emphasis should be placed in the detection of ototoxic effects as this end point is the most sensitive effect 
observed in animal studies. 
Biomarkers of Exposure and Effect.    Sensitive methods are available for determining ethyl-
benzene and ethylbenzene metabolites in biological tissues and fluids.  However, limited data are 
available associating levels of ethylbenzene in human tissues and fluids with adverse health effects.  
Additional animal or epidemiological studies evaluating the association between levels in tissue or fluids 
and adverse health effects would be useful to devise more sensitive and more specific early biomarkers of 
effect. 
Exposure.  Exposure to ethylbenzene can be monitored through levels of ethylbenzene in breath, blood, 
or tissue, or levels of its metabolites, mandelic or phenylglyoxylic acid in urine. A statistically significant 
correlation was observed between urinary excretion of mandelic acid and ethylbenzene exposure in 
workers exposed to mixed solvents (including an ethylbenzene TWA of 0.9 ppm) in a metal-coating 
factory (Kawai et al. 1991).  However, neither one of the metabolites is specific to ethylbenzene.  
Additional studies to identify a biomarker or biomarkers of exposure specific to ethylbenzene are needed. 
Effect. There are currently no known specific biomarkers of effect for ethylbenzene.  Development of 
methods to identify biomarkers that would indicate toxic effects, and the extent of those toxic effects after 
exposure to ethylbenzene, would be helpful in managing health effects that occur after significant 
exposure to ethylbenzene. 
Absorption, Distribution, Metabolism, and Excretion.    Ethylbenzene is absorbed by humans 
following inhalation (Bardodej and Bardodejova 1970; Gromiec and Piotrowski 1984) and dermal 
(Dutkiewicz and Tyras 1967) exposures.  Absorption rates were 49–64% by inhalation.  Dermal 
absorption rates were in the range of 24–33 and 0.11–0.23 mg/cm2/hour for male subjects exposed to 
liquid ethylbenzene and ethylbenzene from aqueous solutions, respectively (Dutkiewicz and Tyras 1967).  
Animal data support these findings and indicate that absorption rates are high following oral exposures as 
well (Climie et al. 1983; El Masry et al. 1956). 
Only one study (Engstrom and Bjurstrom 1978) is available that outlines the distribution of ethylbenzene 
in humans following inhalation exposure.  This study indicates rapid distribution to adipose tissues 
throughout the body.  Inhalation studies in animals support these results (Elovaara et al. 1982; Engstrom 
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et al. 1985). Ethylbenzene is accumulated primarily in the intestine, liver, kidney, and fat, which provides 
some basis for ethylbenzene-induced effects observed in the liver and kidney.  No data on distribution of 
ethylbenzene following dermal exposure were located.  Such information would be useful because 
absorption of liquid ethylbenzene via this route is rapid in humans and because the potential exists in 
humans for dermal exposure. 
The metabolism of ethylbenzene in humans and animals has been studied.  Although some differences in 
the metabolic pattern according to route of exposure, sex, nutritional status (Nakajima and Sato 1979), 
and species (Bakke and Scheline 1970; Climie et al. 1983; El Masry et al. 1956; Engstrom et al. 1984, 
1985; Smith et al. 1954a, 1954b; Sollenberg et al. 1985) have been documented, pharmacokinetic data 
show no significant differences in metabolism between oral and inhalation routes in either humans or 
animals (Climie et al. 1983; Engstrom et al. 1984, 1985).  Further studies that correlate these differences 
in metabolism with differences in health effects would be useful.  Data on metabolism following dermal 
exposure are sparse, because it is difficult to accurately measure absorption of volatile compounds.  
Additional data on metabolism following dermal exposure would be useful as these exposures could 
occur both from contaminated soil or groundwater. 
Ethylbenzene has been shown to be rapidly eliminated from the body following inhalation exposure 
(primarily in the urine) in both humans and animals.  These studies (Gromiec and Piotrowski 1984; 
Yamasaki 1984) are sufficient to characterize the elimination of ethylbenzene following inhalation 
exposure. A small number of studies in animals exposed orally and humans exposed dermally support 
these findings.  Further studies on elimination of ethylbenzene via these exposure routes would be useful, 
especially because differences in the excretion patterns have been observed with different routes of 
exposure. 
PBPK models have been developed for predicting ethylbenzene kinetics (including metabolism) in rats 
and humans exposed by inhalation (Dennison et al. 2003, 2004; Tardif et al. 1997).  No models have been 
developed for simulating kinetics or oral exposures.  Oral models would be potentially useful for route-to-
route extrapolations (e.g., inhalation to oral) of internal doses of ethylbenzene. 
Comparative Toxicokinetics.    Quantitative and qualitative variations in the absorption, distribution, 
metabolism, and excretion of ethylbenzene were observed depending on exposure routes, sex, nutritional 
status, and species, as previously outlined.  Further studies that focus on these differences and their 
implications for human health would be useful. Additionally, in vitro studies using human tissue and 
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PBPK modeling would contribute significantly to the understanding of the kinetics of ethylbenzene, since 
they would provide information on half-lives and saturation kinetics associated with the metabolism of 
ethylbenzene. 
Methods for Reducing Toxic Effects.    No information was found that specifically addressed the 
reduction of toxic effects after absorption of ethylbenzene.  Development of clinical procedures for 
minimizing the effects of ethylbenzene on the respiratory, hepatic, and renal systems, and the central 
nervous system would be useful in situations where significant exposure had occurred. 
Children’s Susceptibility.    Data needs relating to both prenatal and childhood exposures, and 
developmental effects expressed either prenatally or during childhood, are discussed in detail in the 
Developmental Toxicity subsection above. 
There are no data describing the effects of ethylbenzene exposure in children or developing postnatal 
animals.  Data needs relating to development are discussed in more detail above under developmental 
effects. In order to evaluate whether ethylbenzene presents a unique hazard to children, additional 
information on the health effects, pharmacokinetics, metabolism, and mechanism of action in children is 
needed. It is unknown whether children differ from adults in their susceptibility to health effects from 
exposure to ethylbenzene.  Pharmacokinetic studies investigating whether ethylbenzene or its active 
metabolites cross the placenta or are transferred into breast milk would be useful.  Studies to determine 
whether there are specific biomarkers of exposure in children would be helpful in monitoring the 
exposure of children to this chemical.  In addition, information describing methods of reducing toxic 
effects and decreasing body burden in children might be helpful.   
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:  
Exposures of Children. 
3.12.3 Ongoing Studies 
Ongoing studies pertaining to ethylbenzene have been identified and are shown in Table 3-9 (FEDRIP 
2007). 
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Table 3-9. Ongoing Studies on Ethylbenzene 
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4.1 CHEMICAL IDENTITY  
Ethylbenzene is an aromatic hydrocarbon that occurs naturally in petroleum and is a component of 
aviation and automotive fuels.  It is used as a solvent and in the production of synthetic rubber and 
styrene.  Information regarding the chemical identity of ethylbenzene is located in Table 4-1. 
4.2 PHYSICAL AND CHEMICAL PROPERTIES  
Ethylbenzene is a colorless liquid with an aromatic odor.  Information regarding the physical and 
chemical properties of ethylbenzene is located in Table 4-2.  Ethylbenzene is a flammable and 
combustible liquid.  Vapors are heavier than air and may travel to a source of ignition and flash back.  
Liquid ethylbenzene floats on water and may travel to a source of ignition and spread fire.  Combustion 
may produce irritants and toxic gases (NFPA 1994). Ethylbenzene may accumulate static electricity and 
will react with oxidizing materials (NFPA 1994). 
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Table 4-1. Chemical Identity of Ethylbenzene 
Characteristic Information Reference 
Chemical name Ethylbenzene Budavari and O'Neil 1989 
Synonym(s) EB; ethyl benzene; ethylbenzol; HSDB 2007 
phenylethane; etilbenzene; 
ethylbenzeen; aethylbenzol 
Registered trade name(s) No data 
Chemical formula C8H10 Budavari and O'Neil 1989 
Chemical structure CH3 Verschueren 1983 
CH2 
Identification numbers: 
CAS registry 100-41-4 Budavari and O'Neil 1989 
 NIOSH RTECS NIOSH/DA0700000 RTECS 2007 
EPA hazardous waste F003 HSDB 2007 
 OHM/TADS 7216709 HSDB 1995 
DOT/UN/NA/IMDG shipping UN 1175; IMDG 3.2  HSDB 2007 
HSDB 84 HSDB 2007 
NCI NCI-C56393 HSDB 2007 
STCC 49 091 63 HSDB 2007 
CAS = Chemical Abstracts Service; DOT/UN/NA/IMDG = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency; 
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for 
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System; 
RTECS = Registry of Toxic Effects of Chemical Substances; STCC = Standard Transport Commodity Code 
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Table 4-2. Physical and Chemical Properties of Ethylbenzene 
Property Information Reference 
Molecular weight 106.17 Lide 1994 
Color Colorless Budavari and O'Neil 1989 
Physical state Liquid Budavari and O'Neil 1989 
Melting point -95 °C Lide 1994 
Boiling point 136.2 °C Lide 1994 
Density at 20 °C/4 °C 0.8670 Lide 1994 
at 25 °C/25 °C 0.866 Budavari and O'Neil 1989 
Odor Sweet, gasoline-like CHRIS 1985 
Odor threshold: 
 Water 0.029 mg/L Amoore and Hautala 1983
0.140 mg/L Rosen et al. 1963; Verschueren 1983 
Air 2.3 ppm Amoore and Hautala 1983
2–2.6 mg/m3 Verschueren 1983 
Solubility: 
Water at 0 °C 197 mg/L Polak and Lu 1973 
at 15 °C 140 mg/L Verschueren 1983 
at 20 °C 152 mg/L Verschueren 1983 
at 25 °C 160 mg/L Amoore and Hautala 1983 
at 25 °C 177 mg/L Polak and Lu 1973 
at 25 °C 208 mg/L Bohon and Claussen 1951 
Organic solvents Miscible with usual organic solvents Budavari and O'Neil 1989 
Soluble in alcohol and ether Lide 1994 
Partition coefficients: 
 Log Kow 4.34 EPA 1982 
3.13 Yalkowsky and Valvani 1976 
3.15 Hansch and Leo 1979 
 Log Koc 2.22 (calculated) Chiou et al. 1983 
2.38 (measured) Hodson and Williams 1988 
2.40 (calculated) Vowles and Mantoura 1987 
Vapor pressure  
at 20 °C 7 mm Hg Verschueren 1983 
at 25 °C 1.27 kPa (9.53 mm Hg) Mackay and Shiu 1981 
at 25.9 °C 10 mm Hg Sax and Lewis 1989 
at 30 °C 12 mm Hg Verschueren 1983 
Henry's law constant: 
at 20 °C 6.6x10-3 atm-m3/mol EPA 1982 
at 20 °C 8.7x10-3 atm-m3/mol Lyman et al. 1982 
at 25 °C 8.43x10-3 atm-m3/mol Mackay et al. 1979 
at 25 °C 7.9x10-3 atm-m3/mol Mackay and Shiu 1981 
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Table 4-2. Physical and Chemical Properties of Ethylbenzene 
Property Information Reference 
Autoignition temperature 810 °F (432 °C) NFPA 1994 

Flash point 70 °F (21 °C) NFPA 1994 

Flammability limits 0.8 (lower) vol% –6.7 (upper) vol% NFPA 1994 

Conversion factors 1 mg/m3=0.230 ppm Verschueren 1983 

(25 °C, 1 atm) 1 ppm=4.35 mg/m3
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5.1 PRODUCTION 
Ethylbenzene is primarily produced by the alkylation of benzene with ethylene in liquid-phase slurry 
reactors promoted with aluminum trichloride catalysts or by vapor-phase reaction of benzene with dilute 
ethylene-containing feedstock with a boron trifluoride catalyst supported on alumina (Clayton and 
Clayton 1981; HSDB 2007; Ransley 1984).  Other methods of manufacturing ethylbenzene include 
preparation from acetophenone, dehydrogenation of naphthenes, catalytic cyclization and aromatization, 
separation from mixed xylenes via fractionation, reaction of ethylmagnesium bromide and chlorobenzene, 
extraction from coal oil, and recovery from benzene-toluene-xylene (BTX) processing (Clayton and 
Clayton 1981; HSDB 2007; Ransley 1984).  Commercial grades of ethylbenzene may also contain small 
amounts of m-xylene, p-xylene, cumene, and toluene (HSDB 2007). 
Ethylbenzene is traditionally ranked as one of the top 50 chemicals produced in the United States.  
Table 5-1 shows the historical production volumes of ethylbenzene from 1983 to 2005 (C&EN 1994a, 
1994b, 1995, 2006; Kirschner 1995).   
Table 5-2 lists the facilities in each state that manufacture or process ethylbenzene, the intended use, and 
the range of maximum amounts of ethylbenzene that are stored on site.  There are currently 
3,558 facilities that produce, process, or use ethylbenzene in the United States.  The data listed in 
Table 5-2 are derived from the Toxics Release Inventory (TRI05 2007).  These data should be used with 
caution however since only certain types of facilities are required to report (EPA 1995d).  Therefore, this 
is not an exhaustive list. 
Currently, there are eight major producers of ethylbenzene in the United States, with a combined annual 
production capacity of approximately 15.8 billion pounds (SRI 2006).  These producers and their 
respective plant locations are provided in Table 5-3. 
5.2 IMPORT/EXPORT 
According to the Chemical Marketing Reporter, import volumes were negligible in 2002 and were 
4.95x107 kg (109 million pounds) in 2003 (CMR 2004).  Import volumes for ethylbenzene have been  
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Table 5-1. Ethylbenzene Production in the United States from 1983 to 2005 
Production in thousands of Production in billions of 
Year metric tons pounds 
1983 3,583 7.9 
1984 3,447 7.6 
1985 3,357 7.4 
1986 4,082 9.0 
1987 4,218 9.3 
1988 4,491 9.9 
1989 4,173 9.2 
1990 3,810 8.4 
1991 5,171 11.4 
1992 5,035 11.1 
1993 5,352 11.8 
1994 5,398 11.9 
1995 6,194 13.7 
1996 4,699 10.4 
1997 5,432 12.0 
1998 5,743 12.7 
1999 5,945 13.1 
2000 5,968 13.2 
2001 4,642 10.2 
2002 5,412 11.9 
2003 5,578 12.3 
2004 5,779 12.7 
2005 5,251 11.6 
Source: C&EN 1994a, 1994b, 1995, 2006; Kirschner 1995 
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Table 5-2. Facilities that Produce, Process, or Use Ethylbenzene 
Minimum 
Number of amount on site Maximum amount 
Statea facilities in poundsb on site in poundsb Activities and usesc 
AK 21 0 49,999,999 1, 2, 3, 4, 5, 7, 8, 9, 10, 12 
AL 105 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
AR 48 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
AS 1 100,000 999,999 9 
AZ 33 100 9,999,999 1, 2, 4, 5, 7, 8, 9, 10, 11, 12, 13 
CA 230 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
CO 32 0 9,999,999 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13 
CT 37 0 999,999,999 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14 
DE 17 0 49,999,999 1, 2, 3, 6, 7, 8, 10, 11, 12, 13 
FL 61 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 
GA 81 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
GU 7 100 9,999,999 2, 3, 4, 7, 9, 12 
HI 20 100 9,999,999 1, 2, 3, 4, 5, 6, 7, 9, 10, 12, 13, 14 
IA 53 0 9,999,999 1, 2, 3, 6, 7, 8, 9, 10, 11, 12, 13 
ID 4 1,000 999,999 1, 5, 7, 9, 11, 12 
IL 149 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
IN 131 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
KS 90 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
KY 90 0 49,999,999 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14 
LA 223 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
MA 42 100 99,999,999 1, 2, 4, 5, 7, 8, 9, 10, 11, 12, 14 
MD 52 100 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
ME 15 100 49,999,999 2, 3, 4, 7, 9, 10, 11, 12 
MI 178 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
MN 79 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
MO 92 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 
MP 7 0 999,999 2, 3, 4, 7, 9 
MS 72 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
MT 19 10,000 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 13, 14 
NC 67 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
ND 11 1,000 9,999,999 1, 2, 3, 4, 6, 7, 9, 10, 12 
NE 22 0 9,999,999 1, 2, 3, 7, 8, 10, 11, 12 
NH 15 0 999,999 2, 7, 9, 10, 11, 12, 13 
NJ 101 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
NM 29 1,000 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13 
NV 13 100 999,999 1, 2, 4, 7, 8, 9, 11, 12 
NY 81 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
OH 168 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
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Table 5-2. Facilities that Produce, Process, or Use Ethylbenzene 
Minimum 
Number of amount on site Maximum amount 
Statea facilities in poundsb on site in poundsb Activities and usesc 
OK 57 100 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
OR 35 0 9,999,999 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13 
PA 136 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
PR 57 100 10,000,000,000 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 
SC 52 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
SD 8 100 99,999 7, 10, 11 
TN 78 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
TX 393 0 10,000,000,000 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
UT 45 100 9,999,999 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13 
VA 66 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 
VI 8 10,000 49,999,999 1, 2, 3, 4, 6, 7, 8, 9 
VT 5 0 999,999 7, 11 
WA 66 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
WI 72 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
WV 58 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 
WY 35 1,000 9,999,999 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14 
aPost office state abbreviations used 









8. Formulation Component 
9. Article Component 
10. Repackaging 
11. Chemical Processing Aid 
12. Manufacturing Aid  
13. Ancillary/Other Uses 
14. Process Impurity 
Source: TRI05 2007 (Data are from 2005) 
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Table 5-3. Manufacturers and Annual Production Capacity of Ethylbenzene 
Annual capacity  
Manufacturer Plant location (millions of pounds) 
Chevron Phillips Chemical Company St. James, Louisiana 2,083 
Pascagoula, Mississippi 289 
Cos-Mar Company Carville, Louisiana 2,822 
The Dow Chemical Company Freeport, Texas 1,896 
INEOS America Texas City, Texas 1,124 
Lyondell Chemical Company Channelview, Texas 3,245 
NOVA Chemical Corporation Bayport, Texas 1,940 
Sterling Chemicals Incorporated Texas City, Texas 1,920 
Westlake Styrene Corporation Sulphur, Louisiana 450 
Total capacity  15,769 
Source: SRI 2006 
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relatively small as compared to annual production, typically representing ≤1% of the annual domestic 
production volume. 
U.S. exports for 2002 and 2003 were reported as 1.86x107 kg (41 million pounds) and 1.50x107 kg 
(33 million pounds), respectively (CMR 2004).  Export volumes for ethylbenzene have been relatively 
small typically representing ≤1% of the annual domestic production volume.  
5.3 USE 
Ethylbenzene is used primarily as a precursor in the production of styrene (ACGIH 2002; Ransley 1984; 
Verschueren 1983).  It is estimated that >99% of the ethylbenzene manufactured in the United States is 
ultimately used in styrene production, while the remainder is exported or sold in solvent applications 
(CMR 2004; HSDB 2007).  Minor uses of ethylbenzene include use as a solvent, as a constituent of 
asphalt and of naphtha, and in fuels (ACGIH 2002; Verschueren 1983).  Ethylbenzene is also used in the 
manufacture of acetophenone, cellulose acetate, diethylbenzene, ethyl anthraquinone, ethylbenzene 
sulfonic acids, propylene oxide, and α-methylbenzyl alcohol (HSDB 2007; Verschueren 1983). 
5.4 DISPOSAL 
Regulations governing the treatment and disposal of wastes containing ethylbenzene are detailed in 
Chapter 8. Recommended methods for the disposal of ethylbenzene include burial in a landfill and rotary 
kiln incineration, liquid injection incineration, and fluidized bed incineration (EPA 1981d; HSDB 2007).  
Ethylbenzene may be disposed of by adsorbing it in vermiculite, dry sand, earth, or a similar material and 
then by burial in a secured sanitary landfill or by atomizing in a suitable combustion chamber (IRPTC 
1985).  Ethylbenzene is a good candidate for liquid injection incineration at a temperature range of 650– 
1,600 °C and a residence time of 0.1–2 seconds; a candidate for rotary kiln incineration at a temperature 
range of 820–1,600 °C and a residence time of seconds for gases and liquids and hours for solids; and a 
good candidate for fluidized bed incineration at a temperature range of 450–980 °C and a residence time 
of seconds for gases and liquids, and longer for solids (HSDB 2007). 
The following waste water treatment technologies have been investigated for disposal of ethylbenzene; 
biological treatment, air and steam stripping, or activated carbon treatment (HSDB 2007).  Spent ethyl-
benzene solvents and still bottoms from the recovery of these solvents are designated hazardous wastes 
***DRAFT FOR PUBLIC COMMENT*** 
149 ETHYLBENZENE 
5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
and, as such, are subject to the Resource Conservation and Recovery Act (RCRA) of 1976 handling and 
record-keeping requirements (EPA 1992c). 
According to the TRI, in 2005, an estimated 177,331 pounds (80,436 kg) were transferred off-site, which 
includes releases to publicly owned treatment works (POTWs) (TRI05 2007).  No additional information 
was located on the trends in disposal methods related to ethylbenzene.  
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6.1 OVERVIEW 
Ethylbenzene has been identified in at least 829 of the 1,689 hazardous waste sites that have been 
proposed for inclusion on the EPA National Priorities List (NPL) (HazDat 2007).  However, the number 
of sites evaluated for ethylbenzene is not known.  The frequency of these sites can be seen in Figure 6-1. 
Of these sites, 825 are located within the United States, 2 are located in the Commonwealth of Puerto 
Rico, and 2 are located in the Virgin Islands (not shown). 
Ethylbenzene is an aromatic hydrocarbon naturally present in crude petroleum.  It is also a combustion 
byproduct of biomass.  It is widely distributed in the environment because of human activities such as the 
use of fuels and solvents (which account for the bulk of emissions) and through chemical manufacturing 
and production activities. Because of its volatile nature, ethylbenzene tends to partition to the atmosphere 
when it is released to the environment; therefore, exposure to this chemical is most likely to occur by 
inhalation. However, it is also present in trace amounts in some water supplies and food items.  Thus, 
ingestion also may be an important exposure pathway in some cases.  Exposures from contaminated water 
may also occur via inhalation and dermal absorption during showering and other household activities 
(Beavers et al. 1996). 
Physical, chemical, and biological processes can remove ethylbenzene from the medium of concern and 
reduce human exposures. In the atmosphere, ethylbenzene exists primarily in the vapor phase.  Vapor 
phase ethylbenzene is removed from air by reacting with photochemically produced hydroxyl radicals, 
with an approximate half-life of 2 days.  Photolytic transformations may also take place in surface water 
in the presence of naturally occurring humic materials (sensitized photolysis).  Biologically induced 
transformations take place largely in soil and surface water in the presence of oxygen; however, anaerobic 
degradation can also occur in soil, sediment, and groundwater, but at a much slower rate than aerobic 
biodegradation.  Although chemical transformations can result in reduced exposures to ethylbenzene in 
the atmosphere, one toxic by-product of ethylbenzene photodegradation, peroxyacetylnitrate (PAN), may 
be of concern. Ethylbenzene, as well as a variety of other hydrocarbons, has been implicated in the 
atmospheric formation of PAN in smog (Yanagihara et al. 1977). 
The kinetics of partitioning and/or transformation processes are site-specific and depend upon many 
external factors.  For example, the extent of biodegradation observed in an environmental medium 
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depends upon the type and population of microorganisms present, the concentration of ethylbenzene, the 
presence of other compounds that may act as a substrate, and the presence or absence of oxygen.  
Biodegradation in soil will also compete with transport processes such as volatilization and infiltration to 
groundwater. Because ethylbenzene migration is only moderately retarded by adsorption onto soil, 
leaching of the compound to an anaerobic environment (groundwater) before biotransformation in soil is 
possible and may allow ethylbenzene to persist in an aquifer. 
Although information is limited on dietary exposures, ethylbenzene does not appear to significantly 
bioaccumulate in aquatic or terrestrial food chains, and human exposure through this route is not likely to 
be of concern. 
Exposure of the general population to ethylbenzene is possible through contact with gasoline, automobile 
emissions, solvents, pesticides, printing ink, varnishes, coatings, and paints.  Cigarette smoke also has 
been identified as a source of exposure to this chemical.  Ethylbenzene is widely present at low 
concentrations in rural, suburban, and urban atmospheres with the highest concentrations generally 
detected in areas of gasoline stations, tunnels, highways, and parking lots.  Ethylbenzene is also present in 
indoor air.  Very often ethylbenzene levels in indoor air exceed the levels typically found in outdoor air.  
Occupational exposures are expected within the petroleum industry; within industries using solvents, 
paints, and coatings; and during the manufacture and handling of ethylbenzene and styrene (which is 
manufactured from ethylbenzene).  
Several groups within the general population may have potentially higher exposures to ethylbenzene by 
inhalation, oral, or dermal contact with contaminated drinking water or soil.  These groups include 
individuals living near manufacturing and processing facilities, petroleum refineries, and hazardous waste 
disposal sites. Exposures associated with the consumption of contaminated drinking water as well as with 
inhalation and dermal exposure during showering and bathing in contaminated water would be expected 
for individuals that derive their primary drinking water supply from residential wells downgradient of 
uncontrolled landfills, hazardous waste sites, and leaking underground storage tanks that are contaminated 
with ethylbenzene.  Individuals living near these sites may also be exposed via dermal contact with, or 
ingestion of soil contaminated with ethylbenzene.  
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6.2 RELEASES TO THE ENVIRONMENT 
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of 
facilities are required to report (EPA 2005).  This is not an exhaustive list.  Manufacturing and processing 
facilities are required to report information to the TRI only if they employ 10 or more full-time 
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the 
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust 
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to 
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in 
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities 
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces, 
imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI 
chemical in a calendar year (EPA 2005). 
6.2.1 Air 
Estimated releases of 4,887,109 pounds (~2,217 metric tons) of ethylbenzene to the atmosphere from 
1,508 domestic manufacturing and processing facilities in 2005, accounted for about 83% of the estimated 
total environmental releases from facilities required to report to the TRI (TRI05 2007).  These releases are 
summarized in Table 6-1. 
The majority of ethylbenzene releases to the environment occur to the atmosphere.  Because of its 
frequent use, and production in manufacturing operations, ethylbenzene is an important industrial 
chemical.  Ethylbenzene is consistently ranked among the top 50 chemicals produced in the United States, 
with total production ranging from approximately 11 to 13 billion pounds annually (C&EN 1995, 2006; 
Kirschner 1995). In 2005, 11.6 billion pounds of ethylbenzene were produced by U.S. manufacturers 
(C&EN 2006). Its release can occur during manufacturing, processing, and handling.  In 1978, emissions 
of ethylbenzene in the United States from catalytic reformate production alone were estimated at over 
2 million pounds (Fishbein 1985).  Fuels and solvents, however, are considered to account for the bulk of 
emissions (Fishbein 1985).  Ethylbenzene has been measured from tail pipe emissions of gasoline-
powered vehicles at a weighted average rate of 12 mg/km (considering both catalyst and noncatalyst 
equipped cars) (Hampton et al. 1983).  Exposures to ethylbenzene can also occur while individuals are 
***DRAFT FOR PUBLIC COMMENT*** 
155 ETHYLBENZENE 
6. POTENTIAL FOR HUMAN EXPOSURE 




Reported amounts released in pounds per yearb 
Total release 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek 
On- and off-
site 
AK 10 6,087 16 0 119 7 6,222 7 6,229 
AL 33 255,783 735 0 225 333 256,523 553 257,076 
AR 13 27,082 1 0 27 0 27,083 27 27,110 
AZ 15 37,016 17 0 5 250 37,038 250 37,288 
CA 95 70,285 41 20 9,996 2,179 79,382 3,139 82,521 
CO 11 3,821 0 0 255 0 3,821 255 4,076 
CT 11 3,902 1 0 0 0 3,903 0 3,903 
DE 4 5,326 1,200 0 38 0 6,526 38 6,564 
FL 35 85,985 10 0 0 227 85,995 227 86,222 
GA 33 138,453 3 0 282 2,591 138,456 2,873 141,329 
GU 2 2,528 1 0 0 164 2,529 164 2,693 
HI 8 2,193 50 0 420 16 2,248 431 2,679 
IA 22 50,060 0 0 0 0 50,060 0 50,060 
ID 3 1,234 No data 0 14 49,480 1,246 49,482 50,728 
IL 71 198,784 439 0 17,644 6,922 199,369 24,420 223,789 
IN 73 302,906 561 0 45 562 303,477 597 304,074 
KS 26 140,531 23 50 1,075 5 140,855 829 141,684 
KY 39 172,670 30 0 17,524 9 172,701 17,532 190,234 
LA 71 277,504 797 0 1,465 8 278,347 1,427 279,774 
MA 17 8,392 32 0 53 5,647 8,468 5,655 14,124 
MD 22 23,765 6 0 2 21 23,771 23 23,794 
ME 4 1,110 10 0 0 1,301 1,120 1,301 2,421 
MI 72 477,436 6 2 19,915 839 477,441 20,756 498,197 
MN 24 68,457 13 0 70 16 68,470 86 68,556 
MO 47 262,200 1 0 251 335 262,201 586 262,787 
MP 2 165 0 0 0 1 165 1 166 
MS 24 165,820 39 0 288 0 165,859 288 166,147 
MT 6 5,177 1 0 55 0 5,182 52 5,234 
NC 28 70,213 0 0 63 321 70,220 378 70,598 
ND 2 3,800 1 0 0 2 3,801 2 3,803 
NE 6 3,784 No data 0 3,253 0 3,830 3,207 7,037 
NH 3 253 No data 0 0 0 253 0 253 
NJ 42 38,157 255 0 1,701 131 39,737 507 40,244 
NM 10 11,878 5 5 14 1,843 11,895 1,850 13,745 
NV 4 733 No data 0 0 0 733 0 733 
NY 53 44,128 257 0 2,560 3,126 45,664 4,407 50,071 
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Reported amounts released in pounds per yearb 
Total release 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek 
On- and off-
site 
OH 112 386,690 79 87 3,991 1,945 387,970 4,822 392,792 
OK 19 64,380 27 18 659 705 64,939 850 65,789 
OR 13 19,002 0 0 85 0 19,002 85 19,087 
PA 74 153,444 111 0 1,660 2,528 153,555 4,187 157,742 
PR 11 24,646 6 0 47 17 24,699 17 24,715 
RI 2 576 4 0 0 1,228 580 1,228 1,808 
SC 14 50,350 7 17 39 11,326 50,357 11,382 61,739 
SD 4 32,447 No data 0 0 0 32,447 0 32,447 
TN 36 340,519 23 0 760 250 340,542 1,010 341,552 
TX 168 571,385 2,884 788,674 8,853 2,814 1,364,743 9,866 1,374,610 
UT 12 3,955 750 0 18 22 4,710 35 4,745 
VA 24 82,340 141 0 254 0 82,482 254 82,736 
VI 3 10,738 0 0 10 0 10,738 10 10,748 
VT 1 510 No data 0 0 0 510 0 510 
WA 19 20,050 10 0 54 18 20,082 51 20,133 
WI 34 69,451 5 0 826 453 69,456 1,278 70,735 
WV 15 81,962 8 0 250 398 81,970 648 82,618 
WY 6 7,046 0 0 505 0 7,296 255 7,551 
Total 1,508 4,887,109 8,606 788,874 95,372 98,040 5,700,669 177,331 5,878,000 
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 

exhaustive list.  Data are rounded to nearest whole number.

bData in TRI are maximum amounts released by each facility.

cPost office state abbreviations are used. 

dNumber of reporting facilities.

eThe sum of fugitive and point source releases are included in releases to air by a given facility. 

fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal 

and metal compounds). 

gClass I wells, Class II-V wells, and underground injection. 

hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other on-site landfills, land treatment, surface 

impoundments, other land disposal, other landfills. 





jThe sum of all releases of the chemical to air, land, water, and underground injection wells. 

kTotal amount of chemical transferred off-site, including to POTWs. 

RF = reporting facilities; UI = underground injection 
Source: TRI05 2007 (Data are from 2005) 
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traveling in the passenger compartment of automobiles, and the chemical has been found at much higher 
concentrations during automobile engine malfunctions (Lawryk and Weisel 1996; Lawryk et al. 1995).   
Emissions from gasoline-powered vehicles were found to be somewhat higher than from diesel trucks 
(Hampton et al. 1983).  Similarly, ethylbenzene has been measured in jet fuel emissions (Katzman and 
Libby 1975) and has been reported in waste incinerator stack emissions (Jay and Steiglitz 1995; Junk and 
Ford 1980). Ethylbenzene has also been shown to be released into the atmosphere from volatile organic 
compound (VOC)-laden waste water in municipal sewer systems (Quigley and Corsi 1995). 
Emissions of ethylbenzene can arise from transport of hot asphalt from a manufacturing plant to a paving 
site and from subsequent road paving operations.  Kitto et al. (1997) measured the emissions of volatile 
organic compounds from Type I and Type II hot asphalts.  At 150 °C, the concentration of the ethyl-
benzene emissions from Type I asphalt was 800 μg/m3; at 200 °C, the concentration was 2,200 μg/m3, an 
increase by a factor of 2.8.  At 150 °C, the concentration of the ethylbenzene emissions from Type II 
asphalt was 7,000 μg/m3; at 200 °C, the concentration was 21,000 μg/m3, an increase by a factor of 3.   
Mukund et al. (1996) conducted chemical mass balance source apportionment modeling on a data set of 
142 3-hour integrated air samples collected at six different sites in three separate campaigns during the 
summer of 1989 in Columbus, Ohio.  The contributions (± standard error) to the observed atmospheric 
levels of ethylbenzene from the sources considered, expressed as percentage of measured average 
concentration, were: 55±11 from vehicle exhaust; 0.7±0.2 from gasoline vapor; 0±3 from natural gas; 
20±4 from industrial solvents; and 0±1 from the dry cleaning/degreasing/waste water composite source.  
These five sources contributed an estimated 76±12% of the measured average concentration of 1.1 μg/m3. 
Ethylbenzene releases to the air especially in indoor environments can occur with the use of consumer 
products such as pesticides, liquid process photocopiers and plotters, solvents, carpet glue, paints, 
varnishes, automotive products, adhesives, and fabric and leather treatments that contain ethylbenzene 
(Hodgson et al. 1991; Lillo et al. 1990; NAS 1980; Otson et al. 1994; Sack et al. 1992; Wallace et al. 
1987b). Ethylbenzene (in addition to other aromatic hydrocarbons, such as benzene, styrene, and 
xylenes) has also been measured in cigarette smoke (Barrefors and Petersson 1993; Wallace et al. 1986, 
1987c). An analysis of indoor air in a home using gasoline-contaminated tap water found that exposures 
to ethylbenzene could occur via inhalation during showering and other household activities (Beavers et al. 
1996).  Ethylbenzene concentrations in the shower area were often one to two orders of magnitude higher 
than in other areas of the home.  
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Ethylbenzene has been identified in air samples collected at 121 of the 829 NPL hazardous waste sites 
respectively, where it was detected in some environmental media (HazDat 2007). 
6.2.2 Water 
Estimated releases of 8,606 pounds (~3.9 metric tons) of ethylbenzene to surface water from 
1,508 domestic manufacturing and processing facilities in 2005, accounted for <1% of the estimated total 
environmental releases from facilities required to report to the TRI (TRI05 2007).  An additional 
177,331 pounds (80.4 metric tons) were transferred off-site or released to publicly owned treatment works 
(POTWs) (TRI05 2007).  These releases are summarized in Table 6-1. 
Releases to water can occur as a result of industrial discharges (Snider and Manning 1982), fuel spillage 
(Gschwend et al. 1982; Tester and Harker 1981), leaking petroleum pipelines or underground storage 
tanks (Cotruvo 1985), landfill leachate (Barker 1987; Beavers et al. 1996; Chen and Zoltek 1995; 
Hallbourg et al. 1992), and the inappropriate disposal of wastes containing ethylbenzene (Eiceman et al. 
1986). Ethylbenzene emissions to oceans occur as a result of offshore oil production, hydrocarbon 
venting, oil field brines, and tanker oil spills (Sauer et al. 1978).  Sauer and Tyler (1995) reported that 
ethylbenzene was one of the most commonly detected VOCs in motor vehicle waste fluids released from 
routine vehicle maintenance shops entering catch basins and septic tanks in Wisconsin.  Ethylbenzene 
was detected at a mean concentration of 11 ppb (range 3–98 ppb) in catch basin waste water, 1.5 ppb 
(range 7–23 ppb) in septic tank effluent, and 8 ppb (range 9–53 ppb) in septic tank sludge.  
Ethylbenzene has been identified in surface water at 123 sites and groundwater collected at 557 of the 
829 NPL hazardous waste sites respectively, where it was detected in some environmental media (HazDat 
2007). 
6.2.3 Soil 
Estimated releases of 95,372 pounds (~43.3 metric tons) of ethylbenzene to soils from 1,508 domestic 
manufacturing and processing facilities in 2005, accounted for about 2% of the estimated total 
environmental releases from facilities required to report to the TRI (TRI05 2007).  An additional 
788,874 pounds (~357.8 metric tons), constituting about 13% of the total environmental emissions, were 
released via underground injection (TRI05 2007).  These releases are summarized in Table 6-1. 
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Ethylbenzene can be released to soils through the spilling of gasoline and other fuels (Sauer and Tyler 
1995; Tester and Harker 1981); through the disposal of solvents and household products such as paint, 
cleaning and degreasing solvents, varnishes, and pesticides; through emissions from leaking underground 
storage tanks (Cotruvo 1985); and leaching from landfill sites (Barker 1987). 
Ethylbenzene has been identified in soil and sediment samples collected at 469 and 144 of the 829 NPL 
hazardous waste sites respectively, where it was detected in some environmental media (HazDat 2007). 
6.3 ENVIRONMENTAL FATE 
6.3.1 Transport and Partitioning 
The large vapor pressure and Henry’s law constant of ethylbenzene (Table 4-2) suggests a moderate to 
strong tendency for ethylbenzene to partition into the atmosphere where it will exist predominantly in the 
vapor phase (Eisenreich et al. 1981; Mackay 1979; Masten et al. 1994).  Depending upon site-specific 
conditions, releases to surface soil can result in substantial losses to the atmosphere in addition to 
subsurface infiltration. Since it has a moderately high vapor pressure, ethylbenzene will evaporate fairly 
rapidly from dry soil.  Vapor phase transport will occur from subsurface releases (i.e., from leaking 
underground storage tanks) and during migration through unsaturated soil pore spaces (Rhue et al. 1988).  
Atmospheric reaction with hydroxyl radicals can limit the atmospheric transport of ethylbenzene (Dewulf 
and van Langenhove 1997). 
The large Henry's law constant (Table 4-2), which measures partitioning between water and air, indicates 
that a significant proportion of ethylbenzene will partition from water into air (Mackay 1979; Masten et 
al. 1994).  Ethylbenzene dissolved in surface water, soil pore water, or groundwater will thus migrate into 
an available atmospheric compartment until its saturated vapor concentration is reached.  The 
volatilization half-life of ethylbenzene in a constructed wetland (length=228 m, width=60 m, depth=0.5– 
1.5 m) located in Phoenix, Arizona ranged from approximately 40 to 200 hours (Keefe et al. 2004). 
Based on log Koc values in the range of 2.2–2.4 (Table 4-2) and using the classification scheme of Swann 
et al. (1983), ethylbenzene is classified as having moderate mobility in soils.  Sorption and retardation by 
soil organic carbon content will occur to a moderate extent, but sorption is not significant enough to 
completely prevent migration in most soils.  Particularly in soils with low organic carbon content, 
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ethylbenzene will tend to leach into groundwater.  Mobility is also possible in aquifers that contain very 
little solid-phase organic matter, a condition common to sand and gravel aquifers (Ptacek et al. 1984).  
Sorption and desorption experiments performed by Dewulf et al. (1996) demonstrated that the sorption 
process of ethylbenzene on marine sediments is reversible and that the sorption is even lower than 
expected from the log Kow data and the organic carbon content of the sediment.  They concluded that the 
marine sediment compartment is not an important sink for the VOCs investigated when they are released 
to water. 
When ethylbenzene is part of a complex mixture of hydrocarbons associated with a petroleum spill or 
leak, the proportion of ethylbenzene that will bind to soil versus the amount that will migrate toward 
groundwater depends primarily on the type of soil, the particular petroleum product in which the 
ethylbenzene is dissolved, the size of the spill, and the amount of rainfall (Stokman 1987).  For example, 
the solubility of ethylbenzene varies in accordance with the presence of other petroleum products (Ptacek 
et al. 1984). While the pure compound solubility of ethylbenzene in water is 180 mg/L, its solubility in 
water equilibrated with JP-jet fuel is 10.6 mg/L (Burris and MacIntyre 1984).  Potter (1993) also reported 
that the equilibrium aqueous solubility of ethylbenzene was 2.4 mg/L with gasoline, 0.18 mg/L with 
diesel fuel, and 0.007 mg/L with #6 fuel oil equilibrated with groundwater.  Both of these authors 
calculated the solubility concentrations of ethylbenzene in water equilibrated with various petroleum 
products. In addition, solvent spills of chemicals such as ethylbenzene may enhance the mobility of other 
organic chemicals, which do strongly adsorb to soil (Rao et al. 1985).  No information was found 
concerning bioavailability of ethylbenzene from soil for human dermal or oral uptake. 
Boyd et al. (1990) reported that corn residues high in organic matter that were left on the surface of a no 
tillage field, adsorbed a significantly greater amount of ethylbenzene as compared with surface soil.  The 
authors suggested that the highly lipophilic plant cuticle appears to be the sorptive component.  Kango 
and Quinn (1989) also reported that humic acid adsorbed higher amounts of ethylbenzene and xylenes 
ranging from 40 to 77 times greater than soil. 
Once in the atmosphere, ethylbenzene will be transported until it is removed by physical or chemical 
processes. Physical removal processes, which involve partitioning into clouds or rainwater, are relevant 
to ethylbenzene, which has been measured in Los Angeles rainwater (Kawamura and Kaplan 1983).  The 
concentrations of several dissolved organic chemicals in rainwater and in the atmosphere during rainfall 
events were measured by Ligocki et al. (1985).  The authors found that the concentration of ethylbenzene 
in rain water was approximately equal to the inverse of the dimensionless Henry's law constant 
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(Table 4-2) at atmospheric temperatures.  This indicates that ethylbenzene is removed from the 
atmosphere through precipitation, but it can re-enter the atmospheric environment upon evaporation. 
In comparison to chemicals such as polychlorinated biphenyls (PCBs), DDT, and other chlorinated 
pesticides, which are of great concern with respect to bioaccumulation, ethylbenzene does not 
significantly bioaccumulate in aquatic food chains.  A measured bioconcentration factor (BCF) of 15 was 
reported for ethylbenzene in goldfish (Ogata et al. 1984).  A BCF value of 53 was estimated in fish, using 
a log Kow of 3.15 and a regression derived equation (Meylan et al. 1999).  A 3% weighted average lipid 
content in fish and shellfish was assumed by EPA in the calculation.  The calculated BCF is a theoretical 
value based on known constants, and is a conservative estimate of the bioconcentration of this chemical in 
fish. A calculated BCF of 167 was also estimated for fathead minnows (Pimephales promelas) (ASTER 
1995).  In a shellfish study, the ethylbenzene concentration in clam tissue was 5 times higher than that 
measured in water after an 8-day continuous-flow exposure to the water-soluble fraction of Cook Inlet 
crude oil (Nunes and Benville 1979). 
Ethylbenzene has also been found to partition into human tissues; primarily as a result of inhalation 
exposures (see Section 6.5).  Ethylbenzene has been detected in human adipose tissue (Sections 3.4.2.1 
and 3.8.1), blood (Section 3.4.1.1), and in breast milk (Section 3.7).  No information was located 
concerning the bioavailability of ethylbenzene from contaminated soil or sediment either with respect to 
dermal exposure or oral intake via consumption of soil particles from unwashed hands. 
6.3.2 Transformation and Degradation  
6.3.2.1 Air 
Ethylbenzene undergoes atmospheric transformations through reaction with photochemically generated 
hydroxyl radicals (Atkinson et al. 1978; Ohta and Ohyama 1985; Ravishankara et al. 1978), NO3 radicals 
(Atkinson et al. 1987), and atomic oxygen (Grovenstein and Mosher 1970; Herron and Huie 1973).  Gas 
phase reactions with ozone and structurally similar molecules such as toluene have been observed 
(Atkinson and Carter 1984).  The predominant degradation pathway for ethylbenzene in the atmosphere 
occurs via reaction with hydroxyl radicals and nitrate radicals (which are only present during non daylight 
hours), with the other degradation mechanisms being of only minor importance.  The rate constant for the 
vapor phase reaction of ethylbenzene with photochemically generated hydroxyl radicals was measured as 
7.1x10-12 cm3 per molecule-second (Kwok and Atkinson 1994).  This corresponds to an atmospheric half-
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life of approximately 2 days using a hydroxyl radical concentration of 5x105 hydroxyl radicals per cm3. 
The rate constant for the degradation of ethylbenzene with nitrate radicals was measured as 6x10-16 cm3 
per molecule-second (Atkinson et al. 1987).  Using a nighttime nitrate radical concentration of 
5x108 nitrate radicals per cm3, a half-life of approximately 26 days is estimated.  Atmospheric degradation 
occurs more rapidly during summer months as opposed to winter since the concentration of hydroxyl 
radicals in the atmosphere peaks during summer (Ravishankara et al. 1978; Singh et al. 1981), and is also 
faster under photochemical smog conditions (Dilling et al. 1976).  Oxidation by-products from the 
reaction with hydroxyl radicals and nitrogen oxides include ethylphenols, benzaldehyde, acetophenone, 
and m- and p-nitroethylbenzene (Hoshino et al. 1978).  The major degradation pathways for ethylbenzene 
in the atmosphere are summarized in Figure 6-2. 
Experiments conducted with various hydrocarbons on the formation of photochemical aerosols or the 
haze associated with smog revealed that aromatics such as ethylbenzene produced only low yields of 
aerosol when compared with more reactive compounds such as alkenes (O'Brien et al. 1975). The 
formation of PAN is related to the photoreactivity of the reacting hydrocarbon.  The photoreactivity of 
ethylbenzene is intermediate relative to other atmospheric hydrocarbons, and it is less reactive than 
gasoline, toluene, and alkenes such as propene (Yanagihara et al. 1977). 
6.3.2.2 Water 
In surface water, transformations of ethylbenzene may occur through two primary processes— 
photooxidation and biodegradation.  Since ethylbenzene does not contain hydrolysable functional groups 
at environmental pH (pH 5–9), hydrolysis is not considered an important environmental fate process.  
Although ethylbenzene does not absorb light in the environmental ultraviolet spectrum, it is capable of 
undergoing photooxidation in water through an indirect reaction with other light-absorbing molecules, a 
process known as sensitized photolysis.  The compounds 1-methylphenyl ketone (acetophenone), 
1-phenylethanol, and benzaldehyde were identified as degradation products from the laboratory 
photooxidation of ethylbenzene in both distilled water and seawater with anthraquinone used as a 
sensitizer (Ehrhardt and Petrick 1984).  In the environment, similar degradation is expected to occur in the 
presence of ubiquitous, naturally occurring humic material sensitizers.  The major degradation pathways 
for ethylbenzene in water are summarized in Figure 6-3. 
Biodegradation in aerobic surface water will compete with sensitized photolysis and transport processes 
such as volatilization. Volatilization and biodegradation of ethylbenzene in seawater have been observed  
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by Gschwend et al. (1982), Masten et al. (1994), and Wakeham et al. (1983).  Migration from surface 
water to subsurface soil with low amounts of oxygen or to aquifers with lower microbial populations, 
however, will limit the rate of transformation.  No significant disappearance of ethylbenzene during 
11 weeks of incubation with bacteria under low oxygen (anoxic) conditions was observed by Bouwer and 
McCarty (1983).  Slow degradation of ethylbenzene was reported in anaerobic aquifer materials known to 
support methanogenesis, although a long acclimation period or lag time was required (Wilson et al. 1986).  
Less than 1% of the initial concentration of ethylbenzene remained after 120 weeks, indicating that, given 
sufficient time, ethylbenzene will be essentially completely biodegraded.   
Laboratory microcosm tests were conducted to determine optimum conditions for ethylbenzene bio-
degradation by aquifer microorganisms under denitrifying condition (Hutchins 1991).  Ethylbenzene was 
degraded to <5 μg/L when present as a sole source substrate and stoichiometric calculations indicated that 
nitrate removal was sufficient to account for 70–80% of the compound being mineralized.  Bio-
degradation did not occur without the presence of nitrate, and nitrate removal was minimal without the 
presence of the ethylbenzene over a 55-day incubation period.  In a laboratory microcosm containing 
aquifer material and groundwater from the North Bay site in Ontario, Canada, no significant loss of ethyl-
benzene was observed compared to unamended controls over a period of 187 days.  In another experiment 
conducted at the North Bay site that used in situ biodegradation columns, ethylbenzene was completely 
degraded in at least 1 of the 8 in situ columns in <100 days (Acton and Barker 1992).  In all cases, the 
authors attributed the ethylbenzene attenuation to biodegradation by methanogenic and fermentative 
bacteria. In another study using a laboratory scale flow-through aquifer column system, low dissolved 
oxygen (<1 mg/L) conditions were initiated with the nitrate-amended column influent in order to mimic 
contaminated groundwater conditions distal from a nutrient injection well (Anid et al. 1993). The authors 
reported that 40% of the ethylbenzene was removed after several months of operation.  In a similar study, 
using batch incubations seeded with four different aquifer materials, ethylbenzene was not degraded 
within 4 months in any of the denitrifying enrichments tested, even though nitrate reduction occurred.  
Burback and Perry (1993) reported than Mycobacterium vaccae can catabolize a number of major 
groundwater pollutants, including ethylbenzene.  At a concentration of 100 ppm, ethylbenzene was not 
measurably degraded; however, at 50 ppm, 80% of the added ethylbenzene was degraded.  A product 
peak of 4-ethylphenol was detected as well as a small amount of 1-phenylethanol.  
The contrast between biodegradation rates in the presence or absence of oxygen was demonstrated by a 
biofilm reactor study designed to simulate an aquifer (Bouwer and McCarty 1984).  Continuous-flow 
laboratory column studies under aerobic and methanogenic conditions were performed with mixed 
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bacterial cultures on glass beads.  In the aerobic biofilm column, 99% of the ethylbenzene initially present 
was degraded within a 20-minute detention time, while under methanogenic (anaerobic) conditions, only 
7% was degraded within a 2-day detention time. 
6.3.2.3 Sediment and Soil 
Biodegradation of ethylbenzene by aerobic soil microbes has been reported by various researchers.  The 
common soil microorganism Pseudomonas putida is able to utilize ethylbenzene as a sole source of 
carbon and energy (Fukuda et al. 1989; Gibson et al. 1973).  In some instances, co-oxidation or co-
metabolism was observed (i.e., ethylbenzene was degraded by Nocardia sp. in the presence of other 
compounds that are more readily metabolized by the microorganism) (Jamison et al. 1970; 
Van der Linden and Thijsse 1965).  Yadav and Reddy (1993) reported that the white-rot fungus 
Phanerochaete chrysosporium efficiently degraded ethylbenzene as well as other benzene, toluene, ethyl-
benzene, and xylenes (BTEX) compounds when these chemicals were added either individually or as a 
composite mixture.  In addition, substantially greater degradation of all the BTEX compounds was 
observed in static rather than in shaken liquid cultures.  Furthermore, degradation was greater at 25 °C 
than at 37 °C, but pH variations between 4.5 and 7 had little effect on the extent of the degradation.  Chen 
and Taylor (1995) reported that two thermophilic bacterial strains, Thermus aquaticus and an unidentified 
Thermus sp. degraded ethylbenzene (in a mixture with other BTEX chemicals) by 18% after 45 days of 
incubation at 70 °C and by 32% after 45 days of incubation at 60 °C, respectively.  Zappi et al. (1996) 
reported that ethylbenzene degraded rapidly in a pilot scale bioslurry reactor under aerobic conditions.  
The initial concentration (0.35 mg/kg) was degraded by 94% in 2 days.  
Biotic transformations by aerobic soil microbes involve oxidation of the ethyl side chain to form pheny-
lacetic acid (Van der Linden and Thijsse 1965) and 1-phenylethanol (Bestetti and Galli 1984); ring 
hydroxylation to form 2,3-dihydroxy-1-ethylbenzene (Gibson et al. 1973), 2-hydroxyphenlacetic acid, 
4-hydroxyphenylacetic acid, and 2,5- and 3,4-dihydroxyphenylacetic acid (Van der Linden and Thijsse 
1965); and ultimate ring cleavage to form straight chain carboxylic acids such as fumaric and acetoacetic 
acids (Van der Linden and Thijsse 1965).  The major degradation pathways for ethylbenzene are 
summarized in Figure 6-3. 
Anaerobic degradation of ethylbenzene based on observations from studies conducted under anaerobic 
conditions in other media and as discussed above (Bouwer and McCarty 1983, 1984; Wilson et al. 1986), 
would be much slower than that observed under aerobic conditions.  Ramanand et al. (1995) studied the 
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biodegradation of several organic pollutants including ethylbenzene in soil columns under denitrifying 
conditions. These authors reported that one of the significant factors governing biodegradation is the 
availability of suitable electron acceptors.  The biodegradation of ethylbenzene, toluene, and xylenes has 
been demonstrated in laboratory samples obtained from subsurface habitats or in pure cultures under 
dinitrifying conditions (Hutchins 1991; Hutchins et al. 1991).  Ramanand et al. (1995) reported that soil 
column bacteria, after sufficient acclimation time, metabolized 100–500 μM of toluene and ethylbenzene 
in <6 days under denitrifying conditions.  These compounds were successfully degraded under anoxic 
conditions by the addition of nitrate and by stimulating the indigenous soil denitrifying bacteria. 
The kinetics of biodegradation appear to be site specific, and depend upon factors such as the type and 
population of microbes present, the environmental temperature, the concentration of ethylbenzene, the 
presence of other compounds that may act as a substrate, and the amount of oxygen and electron 
acceptors present. Biodegradation in soil will also compete with migration processes such as 
volatilization and infiltration to groundwater.   
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT  
Reliable evaluation of the potential for human exposure to ethylbenzene depends in part on the reliability 
of supporting analytical data from environmental samples and biological specimens.  Concentrations of 
ethylbenzene in unpolluted atmospheres and in pristine surface waters are often so low as to be near the 
limits of current analytical methods.  In reviewing data on ethylbenzene levels monitored or estimated in 
the environment, it should also be noted that the amount of chemical identified analytically is not 
necessarily equivalent to the amount that is bioavailable.  The analytical methods available for monitoring 
ethylbenzene in a variety of environmental media are detailed in Chapter 7. 
6.4.1 Air 
Ambient air levels of volatile organic compounds, including ethylbenzene, were monitored as a part of a 
multi-media study known as the Lower Rio Grande Valley Environmental Scoping Study.  Monitoring 
was preformed at a “central” site and at a “border” site in the Brownsville, Texas, air shed in the spring 
and summer of 1993.  The median ambient concentration of ethylbenzene at the central site was 
0.80 μg/m3 (0.18 ppbv) (n=22; range=0.20–1.7 μg/m3 [0.046–0.39 ppbv]) in the spring and 0.4 μg/m3 
(0.09 ppb) (n=14; range=0.2–1.0 μg/m3 [0.04–0.2 ppbv]) in the summer.  These concentrations are either 
lower or comparable to those found in previous EPA and other monitoring investigations (Ellenson et al. 
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1997). The median indoor concentration of ethylbenzene for nine Rio Grande Valley residences 
measured in the spring was 1.00 μg/m3 (0.230 ppbv) compared to a median outdoor concentration of 
0.70 μg/m3 (0.16 ppbv); in the summer, the median indoor concentration of ethylbenzene for five 
residences was 1.40 μg/m3 (0.321 ppbv) compared to a median outdoor concentration of 0.35 μg/m3 
(0.080 ppbv) (Mukerjee et al. 1997).  The mean indoor concentration of ethylbenzene at the homes of 
46 high school students residing in New York City was 3.57 μg/m3 (0.821 ppbv) in the winter months as 
compared to a mean indoor concentration of 1.99 μg/m3 (0.458 ppbv) during the summer months (Kinney 
et al. 2002). The corresponding mean outdoor levels of ethylbenzene were 1.27 (0.292 ppbv) and 
1.88 μg/m3 (0.432 ppbv) in the winter and summer months, respectively.    
An update of the 1980 National Ambient Volatile Organic Compounds (VOC) database prepared for EPA 
summarized concentrations of ethylbenzene by site type (EPA 1988c).  Median values are reported 
because they are less biased by a few high or low concentrations and, thus, may better represent the data 
than would average values.  The median indoor concentration of ethylbenzene detected at 95 locations 
was 1.0 ppbv (4.4 μg/m3) (mean 2.9 ppbv), while personal air monitoring of 1,650 individuals found a 
median concentration of 1.3 ppbv (5.6 μg/m3) (mean 3.2 ppbv). 
Of particular interest is that personal air monitoring of indoor air found higher concentrations of ethyl-
benzene than those observed in outdoor air.  This was also observed during the Total Exposure 
Assessment Methodology (TEAM) Study conducted by EPA between 1979 and 1985 in an effort to 
measure exposures to 20 VOCs in personal air, outdoor air, and drinking water.  The major cause for the 
higher personal air concentrations was felt to be the presence of ethylbenzene sources in the home.  In the 
TEAM study, tobacco smoke was reported to be a main source of exposure to volatile aromatic 
compounds such as ethylbenzene (Wallace et al. 1987a, 1987c).  Based on the results of a stepwise 
regression carried out on data collected during the fall in New Jersey from 352 participants, overnight 
geometric mean ethylbenzene exposures of persons living in homes with smokers were approximately 
1.5 times the geometric mean exposures of persons living in homes without smokers.  The amount of 
ethylbenzene measured in mainstream smoke of a single cigarette containing 16 mg of tar and nicotine 
was 8 μg (Wallace et al. 1987c). Wallace et al. (1989) reported that a maximum outdoor air concentration 
of ethylbenzene of 7.4 μg/m3 (1.7 ppbv) was detected in nine outdoor samples collected at each of three 
houses while maximum indoor air concentrations at these same residences ranged from 5 to 110 μg/m3 
(1–25.3 ppbv).  Mean personal exposures averaged 28 μg/m3 (6.4 ppbv) (range 4.6–144 μg/m3 [1.0– 
33.1 ppbv]) and the personal/outdoor ratio for ethylbenzene was 16.  
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The poor quality of indoor air has been linked to a number of symptoms (headache; nausea; irritation of 
the eyes, mucous membranes, and respiratory system; drowsiness; fatigue; and general malaise) which 
have been defined as "sick building" syndrome.  Kostiainen (1995) identified over 200 VOCs in the 
indoor air of 26 normal houses.  Ethylbenzene was detected in 100% of the houses studied at an average 
concentration of 3.2 μg/m3 [0.74 ppbv] (median 2.41 μg/m3 [0.554 ppbv], minimum 0.62 μg/m3 
[0.14 ppbv], and maximum 10.54 μg/m3 [2.42 ppbv] concentration).  The median concentration of ethyl-
benzene (2.41 μg/m3 [0.554 ppbv]) in these normal houses was lower in all but one case than ethyl-
benzene concentrations detected in houses with "sick building" syndrome where the concentrations 
ranged from 2.25 to 747.24 μg/m3 (0.517–172 ppbv). 
A nationwide study of indoor air concentration of 26 VOCs was conducted in Canada in 1991 (Fellin and 
Otson 1994).  These authors reported that mean indoor ethylbenzene concentrations were 6.46 μg/m3 
(1.48 ppbv), 8.15 μg/m3 (1.87 ppbv), 4.35 μg/m3 (1.00 ppbv) , and 13.98 μg/m3 (3.21 ppbv) in the winter, 
spring, summer and fall months, respectively  and that the concentrations declined with an increase in 
ambient air temperature.  At ≤0, 0–15, and ≥15 °C, the mean ethylbenzene concentrations were 
12.76 μg/m3 (2.93 ppbv), 7.78 μg/m3 (1.79 ppbv), and 6.46 μg/m3 (1.48 ppbv), respectively. These 
authors concluded that indoor sources of ethylbenzene (primarily from household products) are likely to 
have a more significant influence on indoor air concentrations than climatic variables. 
Concentrations of ethylbenzene were measured in soil gas, and indoor and outdoor air of a home located 
near a landfill in California (Hodgson et al. 1992).  During the first sampling in September, ethylbenzene 
concentrations were not detected in soil gas or outdoor air, but were detected at 0.6 ppbv (3 μg/m3) in 
basement air.  In October, ethylbenzene concentrations averaged 3.3 ppbv (14 μg/m3) in soil gas, 0.8 ppbv 
(4 μg/m3) in basement air, and 0.7 ppbv (3 μg/m3) in bedroom air.  In this study, the authors found that the 
existence of soil gas contamination alone is not sufficient to result in significantly elevated indoor 
exposures. The entry rate of ethylbenzene and VOCs form the soil into the house was low.  The limited 
entry that occurred at the conditions of the study was apparently the result of diffusive and advective flux 
of VOC through the cement blocks used in the basement wall construction.  The authors suggest that there 
is a general need to identify variables associated with residential sites with the highest potential for 
significantly elevated indoor exposures resulting from soil gas contamination.  
Indoor VOC concentrations were analyzed in 12 California office buildings as part of the California 
Healthy Building Study (Daisey et al. 1994).  These authors reported that ethylbenzene was detected at a 
geometric mean of 0.50 μg/m3 (0.11 ppbv) (range 0.27–0.98 μg/m3 [0.062–0.22 ppbv]).  These authors 
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also reported that an estimated 82% of indoor air concentrations were contributed from motor vehicle 
emissions.  Hodgson et al. (1991) reported that concentrations of ethylbenzene in indoor air of a new 
office building ranged from 7 to 18.7 μg/m3 (2–4.30 ppbv) over the course of a 14-month sampling 
period. Furthermore, ethylbenzene indoor air concentrations were higher than those in outdoor air and 
that the dominant source of VOCs in the building was liquid-process photocopiers and plotters which 
emitted a characteristic mixture of C10–C11 isoparaffinic hydrocarbons.   
Wadden et al. (1995) reported average VOC concentrations for indoor air monitored in a sheetfed offset 
printing shop. These authors reported mean ethylbenzene concentrations ranging from 0.27 to 
0.84 mg/m3 (0.062–0.19 ppmv) based on 12 1-hour samples. 
Levels of ethylbenzene monitored in ambient air show great variation (Jonsson et al. 1985). Generally, 
air concentrations are much lower in rural areas than in urban areas, where vehicle emissions are thought 
to be a major contributor of ethylbenzene to ambient air.  Ethylbenzene concentrations range from below 
detection limits in rural areas to 100 μg/m3 (23.0 ppbv) on busy urban streets (Jonsson et al. 1985).  Kelly 
et al. (1994) reported a median concentration of ethylbenzene of 1.1 μg/m3 (0.25 ppbv) for 8,723 samples 
collected from 93 locations throughout the United States. 
Median outdoor air concentrations of ethylbenzene for 6 remote and 122 rural locations are reported as 
0.156 and 0.013 ppbv (0.679 and 0.056 μg/m3), respectively (EPA 1988c).  Median concentrations of 
0.62 ppbv (2.7 μg/m3) were reported for 886 suburban and 1,532 urban locations.  The daily median 
concentration of ethylbenzene considering all site types including source dominated areas and workplace 
air was 0.60 ppbv (2.6 μg/m3). Table 6-2 lists some monitoring results reported for ethylbenzene in 
various cities. 
Ethylbenzene concentrations at four locations along U.S. Highway 70 near Raleigh, North Carolina, 
during the month of May were reported to range from 10 to 16 ppbv (44–70 μg/m3) that were corrected to 
include upwind concentrations (Zweidinger et al. 1988). 
Concentrations of ethylbenzene were measured in two tunnels:  the Fort McHenry Tunnel in Baltimore, 
Maryland (June 18–24, 1992) and the Tuscarora Mountain Tunnel in Pennsylvania (September 2–8, 
1992) (Zielinska et al. 1996).  These authors reported minimum and maximum ethylbenzene 
concentrations (on a carbon basis) for the Fort McHenry Tunnel of 6.3 and 89.2 ppbC (0.79 and 
11.2 ppbv) for bore #3, respectively, and 0.5 and 114.1 ppbC (0.06 and 14.26 ppbv) for bore #4,  
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Location Concentration Comments Reference 
Downey,  
California 
4.6±3.7 ppb (mean±SD) 
16.1 ppba 
February 18–27, 1984; 
n=100 
Singh et al. 1985 
Los Angeles, 3–12 ppb (range) September 29– Grosjean and Fung 
California November 13, 1981 1984 
Riverside, 
California 
1.3±0.8 ppb (mean±SD) 
4.0 ppba 
July 1–13, 1980;  
n=100 
Singh et al. 1985 
Denver,  
Colorado 
2.2±3.1 ppb (mean±SD) 
18.5 ppba 
June 15–28, 1980;  
n=100 
Singh et al. 1985 
Chicago,  
Illinois 
0.8±1.2 ppb (mean±SD) 
9.5 ppba 
April 20–May 2, 1981; 
n=100 
Singh et al. 1985 
St. Louis, 
Missouri 
0.6±0.5 ppb (mean±SD) 
2.1 ppba 
May 29–June 9, 1980;  
n=100 
Singh et al. 1985 
Camden,  0.17 ppb (mean) July 6–August 16, 1981; Harkov et al. 1983 
New Jersey n=35 
Elizabeth, 0.26 ppb (mean) July 6–August 16, 1981; Harkov et al. 1983 
New Jersey n=37 
Newark,  0.33 ppb (mean) July 6–August 16, 1981; Harkov et al. 1983 
New Jersey n=38 
Staten Island, 
New York 
1.7±2.5 ppb (mean±SD) 
17.2 ppba 
March 26–April 5, 1981; 
n=100 
Singh et al. 1985 
Staten Island, 
New York 
2.7±4.2 ppb (mean±SD) 
16.7 ppba 
April 25–May 1, 1984; 
n=100 
Singh et al. 1985 
Philadelphia, 
Pennsylvania 
0.8±0.8 ppb (mean±SD) 
7.3 ppba 
April 4–22, 1983  
n=100 
Singh et al. 1985 
Pittsburgh, 
Pennsylvania 
0.8±1.6 ppb (mean±SD) 
10.5 ppba 
April 7–17, 1981;  
n=100 
Singh et al. 1985 
Houston,  
Texas 
1.5±1.6 ppb (mean±SD) 
8.2 ppba 
March 8–17, 1984;  
n=100 
Singh et al. 1985 
Jones State Forest, 2.8 ppbb January 4–6, 1978 EPA 1979 
Texas 
aMaximum measured concentration 

bMedian concentration in 10 bag samples (median concentration in 5 can samples was 1.0 ppb) 

n = number of samples; SD = standard deviation 
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respectively, and concentrations for the Tuscarora Tunnel of 1.2 and 11.1 ppbC (0.15 and 6.04 ppbv) , 
respectively. The total number of light-duty vehicles (LDV) and heavy-duty vehicles (HDV) that passed 
through each tunnel was 12,273 LDV and 187 HDV for bore #3 and 11,788 LDV and 2,417 HDV for 
bore #4 of the Fort McHenry Tunnel and 4,887 LDV and 1,041 HDV for the Tuscarora Tunnel. 
Ethylbenzene and other VOCs have been found to be removed from waste water in municipal sewers and 
were emitted to the ambient atmosphere prior to entering a downstream waste water treatment facility in 
Toronto, Ontario (Quigley and Corsi 1995). These authors measured concentrations of ethylbenzene 
during four monitoring events and found that concentrations ranged from not detectable to 5 ppm.  
Headspace concentrations of ethylbenzene exhibited a significant weekday/weekend trend.  Significant 
emissions of all VOCs monitored occurred during three of the four monitoring events.  Ethylbenzene had 
the second highest emissions during all periods and ranged from 7 to 14 g/hour (62–130 kg/year) for 
event 1 and from 1 to 13 g/hour (9–115 kg/year) for event 2.  Ethylbenzene emissions at five municipal 
treatment facilities ranged from 0.08 to 93 g/day (0.003–3.9 g/hour).  Results of this study suggest that 
sewers that accept VOC-laden waste water, and that are characterized by significant ventilation and drop 
structures, can be significant sources of VOC emissions (including ethylbenzene) relative to municipal 
waste water treatment facilities.  
Assmuth and Kalevi (1992) reported that ethylbenzene was detected in municipal solid waste landfill gas 
at minimum and maximum concentrations of 6.6–7.6 mg/m3 (1.5–1.7 ppmv), <0.1–9.6 mg/m3 (<0.02– 
2.2 ppmv), 0.2–1.2 mg/m3 (0.04–0.28 ppmv), and 85–98 mg/m3 (20–22 ppmv) at four different landfill 
sites in Finland. Concentrations of ethylbenzene measured in a biogas collection system at the Miron 
Quarry Municipal Waste Landfill Site in Montreal, Quebec ranged from 2 to 36 mg/m3 (0.5–8.3 ppmv) 
(Goldberg et al. 1995). 
6.4.2 Water 
The median ethylbenzene concentration in ambient surface waters in the United States in 1980–1982 was 
<5.0 μg/L (ppb) according to EPA's STORET water quality database (Staples et al. 1985).  The chemical 
was detected in 10% of the 1,101 samples collected during that period.  Ethylbenzene was also detected in 
7.4% of the 1,368 industrial effluent samples collected during 1980–1982 at a median concentration of 
<3.0 μg/L (ppb). More recent data from the STORET database indicated that ethylbenzene was only 
detected in 15 out of 548 surface water samples obtained from January 2005 to March 2007, at a 
maximum concentration of 2 ppb (EPA 2007i).   
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From 1989 to 1993, New York City municipal waste waters were analyzed to determine the frequency of 
detection of organic priority pollutants, including ethylbenzene (Stubin et al. 1996).  Ethylbenzene was 
detected in 14 of 84 (17%) influent samples at concentrations ranging from 1 to 11 μg/L (ppb) and in only 
1 of 84 (1%) effluent samples at a concentration of 2 μg/L (ppb). 
Ethylbenzene and other VOCs have been detected in waste water in municipal sewers prior to entering a 
downstream waste water treatment facility in Toronto, Ontario (Quigley and Corsi 1995).  These authors 
measured concentrations of ethylbenzene in waste water during several monitoring events and found that 
concentrations ranged from 0.059 to 0.086 mg/L (ppm) in one event and from 7 to 11 mg/L (ppm) in 
another event. The authors also determined that the stripping efficiency across two drop structures with 
waste water fall heights of 1.4–3 meters within the sewer system removed 31–36% of the ethylbenzene in 
the waste water.  Results of this study suggest that sewers that accept VOC-laden waste water, and that 
are characterized by significant ventilation and drop structures, can be significant sources of VOC 
emissions (including ethylbenzene) relative to municipal waste water treatment facilities.  
As part of EPA's Nationwide Urban Runoff Program, ethylbenzene was measured in 4% of the municipal 
runoff samples collected in 15 cities throughout the United States (Cole et al. 1984).  The measured ethyl-
benzene concentration range was 1–2 μg/L (ppb).  Ethylbenzene was detected in 41 out of 249 (16.5%) 
storm water runoff samples collected at 46 different sampling locations in North Carolina over a 1-year 
period (Borden et al. 2002).  The mean, median, and maximum ethylbenzene levels were 0.10, 0.07, and 
0.36 μg/L (ppb), respectively. 
Ethylbenzene was measured in seawater at an average concentration of 0.011 μg/L (ppb) and a 
concentration range of 0.0018–0.022 μg/L (ppb) over a 15-month observation period at Vineyard Sound, 
Massachusetts (Gschwend et al. 1982).  Ethylbenzene also has been reported in surface waters of the Gulf 
of Mexico at a concentration range of 0.0004–0.0045 μg/L (ppb) (Sauer et al. 1978). 
Ethylbenzene has been detected in a relatively remote location (Mt. Mitchell, North Carolina) in cloud 
water at a mean concentration of 170 ng/L (range 0–450 ng/L) (Aneja 1993).  The average concentration 
of ethylbenzene in precipitation was 34 ng/L.  Ethylbenzene has also been detected in snow samples from 
two remote sites in the province of Québec, Canada (Kos and Ariya 2006).  Ethylbenzene levels reported 
in μg/L±3σ were: 2.65±1.28 (Resolute Bay); 0.22±0.02 (Gaspé Peninsula); and 0.31±0.06 (Gaspé 
Peninsula). 
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From 1989 to 1990 and from 1992 to 1993, ethylbenzene was monitored in wetland-treated leachate water 
at a municipal solid waste landfill in central Florida (Chen and Zoltek 1995).  During the first sampling 
period, ethylbenzene was detected in surface water samples ranging from 0.06 to 0.09 ppb and in 
groundwater samples ranging from 0.06 to 9.75 ppb.  During the second sampling period (1992–1993), 
ethylbenzene was not detected in surface water samples, but was detected in groundwater samples at 
concentrations ranging from below detection limits to 10.55 ppb.  Ethylbenzene was detected in a study of 
three landfills in central Florida (Hallbourg et al. 1992).  These authors reported concentrations of ethyl-
benzene in groundwater of 1.63–9.75, <1–83.8, and <1–8.6 μg/L (ppb) at the three different landfill sites.  
The mean concentration of ethylbenzene detected in landfill leachate from these disposal areas was 
17.5 μg/L. 
Ethylbenzene was measured in all three drinking water plants sampled as part of the New Orleans Area 
Water Supply Study conducted by EPA in 1974 (Keith et al. 1976).  The reported concentrations were 
1.6, 1.8, and 2.3 μg/L (ppb).  The 1982 Ground Water Supply Survey conducted by EPA reported ethyl-
benzene in only 3 out of 466 random samples at a mean concentration of 0.8 μg/L (ppb) and a maximum 
concentration of 1.1 μg/L (ppb) (Cotruvo 1985).  Chemical monitoring of 617 private and 1,174 public 
groundwater wells in the state of Wisconsin revealed that ethylbenzene was detected in 3 community and 
12 private wells (Krill and Sonzongni 1986).  The concentration of ethylbenzene detected exceeded the 
state's recommended drinking water advisory limit of 1,400 μg/L (ppb) in 9 of the 12 private wells, but no 
exceedences were observed in the public wells.   
Ethylbenzene was infrequently detected in a comprehensive survey conducted by the United States 
Geological Survey (USGS) of volatile organic compounds in private and public groundwater wells used 
for drinking water (USGS 2006).  Ethylbenzene was identified in 18 out of 3,497 aquifer samples at a 
median concentration of 0.035 μg/L for the 18 samples having positive detections.  In an analysis of 
domestic groundwater wells, the median concentration of ethylbenzene was reported as 0.041 μg/L for 
samples having positive detections.  Ethylbenzene was identified in 7 out of 1,083 samples obtained from 
public wells across the United States at a median concentration of 0.32 μg/L for samples having positive 
detections. 
Although ethylbenzene does not appear to be a frequent contaminant in public water supplies, private 
residential wells near landfills, hazardous waste sites, or gas stations are more likely to contain detectable 
levels of this compound.  Ethylbenzene was listed as one of the 58 most frequently detected chemicals 
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associated with groundwater contamination near superfund sites (Knox and Canter 1994).  Ethylbenzene 
was listed as having a medium priority with respect to its frequency of occurrence.  Ethylbenzene has 
been detected in wells downgradient from landfills in Southern Ontario at concentrations ranging from 
12 to 74 μg/L (ppb) (Barker 1987).  Ethylbenzene was detected at levels of 1–22, 1–5, and <1 μg/L in 
groundwater 0–37, 50–114, and 170–254 meters, respectively, downgradient from a municipal landfill 
located in Grindsted, Denmark (Baun et al. 2000).   
Borden and Yanoschak (1990) compared ground and surface water quality impacts associated with North 
Carolina sanitary landfills.  These authors found that ethylbenzene was detected at ≈25% of the waste 
water effluents (receiving secondary treatment) and only 3% of the groundwater sampled in the vicinity 
of sanitary landfill sites.  Groundwater monitoring at 479 hazardous waste disposal sites indicated that 
ethylbenzene, like the other 9 VOCs monitored, was detected at more than 100 of the 479 sites tested 
(Plumb 1991).  Ethylbenzene was also one of the VOCs detected in groundwater samples from hazardous 
waste sites in all 10 EPA regions.  Rosenfeld and Plumb (1991) reported that ethylbenzene was detected 
in groundwater at 19% of wood-treatment industry sites based on its frequency of detection and average 
concentration. Groundwater near an underground coal gasification site in northeastern Wyoming 
contained concentrations of ethylbenzene ranging from 92 to 400 μg/L (ppb) (Stuermer et al. 1982).  
Groundwater samples near a fuel spill in the Great Ouse Basin in Great Britain contained ethylbenzene 
concentrations as high as 1,110 μg/L (ppb) (Tester and Harker 1981). 
6.4.3 Sediment and Soil 
The median ethylbenzene concentration (dry weight) detected in sediment in the United States in 1980– 
1982 was 5 μg/kg (ppb) according to EPA's STORET water quality database (Staples et al. 1985).  The 
compound was detected in 11% of 350 sediment samples analyzed.  More recent data from the STORET 
database indicated that ethylbenzene was identified, but not quantified, in 25 out of 68 sediment samples 
obtained from January 2005 to March 2007 (EPA 2007i). 
6.4.4 Other Environmental Media 
Data from the FDA Total Diet Study Market Basket Surveys collected between September 1991 and 
October 2003 indicate that ethylbenzene was detected in 82 different food items at a maximum 
concentration of 0.129 ppm (FDA 2006b).  In a previous Market Basket Survey, ethylbenzene was 
identified in 15 out of 234 table-ready food items at an average concentration of 0.0146 ppm and a range 
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of 0.00637–0.0387 ppm (Heikes et al. 1995).  Trace concentrations of ethylbenzene have been reported in 
split peas (0.013 mg/kg [ppm]), lentils (0.005 mg/kg [ppm]), and beans (mean concentration 0.005 mg/kg 
[ppm]; maximum concentration 0.011 mg/kg [ppm]) (Lovegren et al. 1979).  Ethylbenzene was reported 
as one of 227 organic chemicals present in roasted filbert nuts (Kinlin et al. 1972).  Gorna-Binkul et al. 
(1996) reported concentrations of ethylbenzene in orange peel (0.0236 μg/g [ppm] dry weight) and in 
parsley leaves (0.2567 μg/g [ppm] dry weight).  The author reported that the differences in concentrations 
of the VOCs were dependent on the plant species and the morphological part of the plant analyzed.  In 
underground parts (i.e., roots and bulbs) not directly exposed to polluted ambient air during growth, no 
VOC concentrations were detected.  Biedermann et al. (1995) reported concentrations of several VOCs in 
extra virgin olive oil collected in northwest Italy.  These authors measured ethylbenzene levels in raw 
olives of 6 μg/kg (ppb), which increased with time as they were milled to 25 μg/kg (ppb).  Levels in the 
finished olive oils ranged from 11 to 27 μg/kg (ppb) depending on the preparation method used.  These 
authors reported that while some of the ethylbenzene was accumulated in the olives in the orchards, a 
larger proportion was accumulated as a result of exposure of the oil to air in the milling areas.  Ethyl-
benzene concentrations in olive oil increased from 6 to 235 ppb after 2 days of exposure.  The authors 
concluded that the production process increased the concentration of ethylbenzene in the oil as a result of 
uptake from the air that was likely to be contaminated with gasoline vapors associated with small vehicles 
used to move the olives from area to area within the olive oil mill.  
Ethylbenzene was also found to migrate from thermoset polyester cooking containers (composed of cross-
linking chains of styrene) into belly pork during cooking (Gramshaw and Vandenburg 1995). Migration 
ranged from <6 to 34 μg/kg for ethylbenzene.  The authors also found that the migration measured during 
the second use of the cookware was generally higher than that during the first use.  These authors also 
reported that ethylbenzene concentrations in food cooked in foil-covered dishes was higher than that in 
the same food cooked uncovered.  This was especially true for ethylbenzene that was more volatile than 
the styrene tested.  Ehret-Henry et al. (1994) also reported migration of ethylbenzene from polystyrene 
containers into dairy products.  Concentrations of ethylbenzene were 2–4 μg/kg for yogurt and 4 μg/kg for 
chocolate dessert.  
Sack et al. (1992) conducted a survey of VOCs in 1,159 household items, including automotive products, 
household cleaners and polishes, paint related products, fabric and leather treatments, cleaners for 
electronic equipment, oils, greases, and lubricants, adhesive-related products, and miscellaneous products.  
Ethylbenzene was detected in 157 of 658 (24%) of the products tested.  The highest mean ethylbenzene 
concentrations and percentage of products in each category in which ethylbenzene was detected are as 
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follows; 7.2% w/w (wet weight) in 7.5% of automotive products, 2.4% w/w in 47.8% of paint-related 
products, and 1.0% w/w in 11.8% of fabric and leather treatments. 
Hodgson et al. (1996) determined the contribution of environmental tobacco smoke (ETS) to 
concentrations of VOCs in smoking environments.  These authors reported that the average emission 
factor for ethylbenzene for six brands of cigarettes was 101 μg/cigarette (range 83–142 μg/cigarette). The 
average concentration of ethylbenzene in five smoking areas ranged from 1.3 to 8.7 μg/m3 (0.3–2 ppbv).  
Martin et al. (1997) determined the ETS yield of selected analytes, including ethylbenzene, for the 50 top-
selling U.S. cigarette brand styles in 1991 and for the University of Kentucky Research cigarette, K1R4F.  
The ETS was generated by smokers in an environmental test chamber.  The ethylbenzene concentrations 
measured were 8.68 μg/m3 for full flavor cigarettes, 8.24 μg/m3 for full flavor low tar cigarettes, and 
8.72 μg/m3 for ultra-low-tar cigarettes. The mean ethylbenzene concentration for all cigarettes was 
8.50 μg/m3. The mean ethylbenzene yields by tar category weighted by market share were 
81.18 μg/cigarette for full flavor cigarettes, 76.79 μg/cigarette for full flavor low tar cigarettes, and 
81.66 μg/cigarette for ultra low tar cigarettes. The mean ethylbenzene yield for all cigarettes was 
79.57 μg/cigarette. 
Ethylbenzene was not detected (at a detection limit of 0.025 mg/kg [ppm] wet weight) in any of the 
97 biota samples collected from all STORET stations in 1980–1983 (Staples et al. 1985).  Ethylbenzene 
was detected at low concentrations (0.8 ng/g [0.8 ppb]) in oyster tissue, but not in clam tissue from Lake 
Pontchartrain at Passes, Louisiana (Ferrario et al. 1985).  The highest average ethylbenzene concentration 
measured in tissue of bottomfish from Commencement Bay in Tacoma, Washington was reported as 
0.01 mg /kg (ppm) (Nicola et al. 1987). 
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE  
The highest exposure to ethylbenzene for the general public is most likely to occur via inhalation 
associated with the use of self-service gasoline pumps or while driving a gasoline-powered motor vehicle 
especially in high traffic areas or in tunnels (Lawryk et al. 1995).  Backer et al. (1997) performed a study 
that measured exposures associated with the pumping two different blends of fuel under cold conditions 
in Fairbanks, Alaska.  The subjects in the study had significantly higher levels of gasoline components in 
their blood after pumping gasoline than before.  The changes in VOC levels in blood were similar 
whether the individuals pumped regular or oxygenated gasoline.  Prior to pumping regular gasoline, the 
median concentration of ethylbenzene in blood was 0.10 ppb (n=26) with a range of 0.02–0.73 ppb; after 
***DRAFT FOR PUBLIC COMMENT*** 
178 ETHYLBENZENE 
6. POTENTIAL FOR HUMAN EXPOSURE 
pumping, the median concentration was 0.16 ppb with a range of 0.06–1.40 ppb.  Before pumping an 
oxygenated fuel blend that was 10% ethanol, the median concentration of ethylbenzene in blood was 
0.11 ppb (n=22) with a range of 0.04–0.55 ppb; after pumping, the ethanol blend, the median 
concentration was 0.16 ppb with a range of 0.06–0.64 ppb.  
Lawryk and Weisel (1996) measured in-vehicle concentrations of selected gasoline-derived volatile 
organic compounds on 113 commutes through suburban New Jersey and 33 New Jersey/New York 
commutes.  In a typical suburban commute, the mean in-vehicle concentration of ethylbenzene was 
11.5±18.8 μg/m3 (2.64±4.32 ppbv; n=52) under low ventilation conditions and 8.5±11.2 μg/m3 
(1.9±2.57 ppbv; n=43) under high ventilation conditions.  On the New Jersey turnpike and in the Lincoln 
Tunnel, the mean in-vehicle concentrations of ethylbenzene were 8.8±10.8 μg/m3 (2.0±2.48 ppbv; n=32) 
and 14.3±10.2 μg/m3 (3.29±2.34 ppbv; n=32), respectively.  
Ethylbenzene is ubiquitous in urban and rural atmosphere resulting from vehicular and industrial 
emissions (EPA 1988c).  Tobacco smoke also provides a general source of exposure to ethylbenzene in 
indoor air (Wallace et al. 1987c).  Wallace et al. (1989) also reported that two activities, painting and the 
use of automotive products (carburetor cleaner), led to increased indoor exposure to ethylbenzene by 
100-fold.  Information on exposure from foods is limited, but is not likely to be a significant source of 
ethylbenzene for the general population. 
Human exposure to styrene and ethylbenzene was assessed by considering inhalation exposure (including 
cigarette smoking) and food intake (Tang et al. 2000).  The daily exposure to ethylbenzene for the general 
population was calculated as 1.8 μg/kg bodyweight/day, with up to 99% of the exposure due to inhalation 
routes and only 1–2% caused by food consumption.   
One-half of the household drinking water used in the United States is supplied by groundwater, and 
contamination of groundwater by petroleum products is an increasingly common problem (Beavers et al. 
1996).  Beavers et al. (1996) conducted a study in a New England household that used groundwater 
contaminated by gasoline from a leaking underground storage tank.  A total daily dose of 379 μg 
ethylbenzene (204 μg ingested and 175 μg inhaled) was estimated for an exposed subject compared to a 
median daily dose of 32 μg for unexposed subjects. Of the 175 μg inhaled by the exposed subject, 108 μg 
was attributed to shower activities. The exposed subject and the three non-exposed subjects all were 
smokers. 
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The 1982 National Human Adipose Tissue Survey conducted by EPA measured ethylbenzene in 96% of 
the 46 composite samples analyzed for VOCs (EPA 1986a).  A wet tissue concentration range of not 
detected (detection limit=2 ng/g) to 280 ng/g (ppb) was reported, but an average concentration was not 
provided.  
Ethylbenzene has been detected in breast milk samples collected from 8 of 12 women from various cities 
in the United States; however, the concentrations were not reported (Pellizzari et al. 1982).  The 
12 women sampled in the study were residents of Bayonne, New Jersey (6 women), Jersey City, New 
Jersey (2 women), Bridgeville, Pennsylvania (2 women), and Baton Rouge, Louisiana (2 women).   
Mean and median concentrations of ethylbenzene detected in 631 blood samples from participants in the 
Third National Health and Nutrition Examination Survey (NHANES III 1998–1994 data) were 0.11 and 
0.06 ppb (95 percentile value of 0.25 ppb), respectively (Ashley et al. 1994).  In an earlier study (Ashley 
et al. 1992), these authors reported a mean ethylbenzene concentration of 0.12 ppb in 13 blood samples.  
Hajimiragha et al. (1989) conducted a study of 13 nonsmokers and 14 smokers with no known 
occupational or hobby-related exposure to volatile organic hydrocarbons.  These authors reported a mean 
and median ethylbenzene concentration of 651 ng/L (0.651 ppb) and 431 ng/L (0.431 ppb) for the 
nonsmokers and 837 ng/L (0.837 ppb) and 533 ng/L (0.533 ppb) for the smokers.  Ethylbenzene 
concentrations tended to occur at higher concentrations in the blood of smokers than in nonsmokers; 
however, the difference was not significant.  Ashley et al. (1995) also reported that smoking elevated the 
blood levels of ethylbenzene and was highly correlated with blood levels of 2,5-dimethylfuran.  These 
authors reported a mean concentration of 0.10 ng/mL (ppb) (median 0.048 ng/mL; range from below 
detection limit to 2.7 ng/mL) for nonsmokers and a mean concentration of 0.17 ng/mL (ppb) (median 
0.16 ng/mL; range 0.036–0.88 ng/mL) for smokers.  To aid in understanding the kinetics of uptake and 
elimination of volatile organics (including ethylbenzene), Ashley and Prah (1997) measured blood 
concentrations before, during, and after exposure of five individuals to a mixture of volatile organics in a 
controlled chamber.  The half-lives of the compounds measured were <0.5 hour, but the elimination time 
courses were multiexponential and suggested that, with repeated exposure, bioaccumulation may occur in 
humans.     
Occupational exposure to ethylbenzene in the petroleum industry has been reported in a study that 
measured ethylbenzene concentrations in air for 49–56 workers during the summer of 1984 (Rappaport et 
al. 1987).  The average air concentrations of ethylbenzene measured over the full work shift for gasoline 
service station attendants, transport drivers, and outdoor refinery personnel were comparable at 0.063, 
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0.079, and 0.079 mg/m3, respectively (14.5, 18.2, and 18.2 ppbv, respectively).  The authors noted that 
exposures of service station attendants were significantly lower when vapor recovery systems were 
present. 
Personal air monitoring of 35 varnish workers (spraymen) has revealed an average ethylbenzene 
concentrations of 4.0 ppm, while the average concentration in blood was 61.4 μg/L (Angerer and Wulf 
1985).  Concentrations of ethylbenzene were monitored in auto paint shops in Spain that used organic 
solvents (de Medinilla and Espigares 1988). These authors reported air concentrations of ethylbenzene 
ranging from 0.50 to 125.0 mg/m3 (0.12–28.75 ppmv).  
The indoor air of screen printing plant workrooms located directly below houses in Amsterdam, Holland 
was found to contain median TWA concentrations of ethylbenzene ranging from <0.03 mg/m3 (7 ppbv) to 
1.30 mg/m3 (299 ppbv) and maximum TWA concentrations ranging from 0.11 mg/m3 (25 ppbv) to 
3.21 mg/m3 (738 ppbv) (Verhoeff et al. 1988). 
Spray-painting and gluing operations can also result in exposure to ethylbenzene; personal air monitoring 
of workers measured average exposures of approximately 0.50 ppmv (2.2 mg/m3) (Whitehead et al. 
1984).  Most of the operations measured during the study were performed in ventilation hoods. 
Holz et al. (1995) reported that ethylbenzene air concentrations detected from air sampling in all areas of 
a styrene production facility located in the former German Democratic Republic ranged from 365 to 
2,340 μg/m3 (0.08–0.53 ppmv).   
According to the National Occupational Exposure Study (NOES) conducted by NIOSH from 1981 to 
1983, an estimated 201,838 workers were potentially exposed to ethylbenzene in the workplace (NIOSH 
1990).  The NOES database does not contain information on the frequency, concentration, or duration of 
occupational exposure to any of the chemicals listed.  The survey provides only estimates of the numbers 
of workers for whom potential exposure in the workplace is an issue.  
The Occupational Safety and Health Administration (OSHA) has set a Permissible Exposure Limit (PEL) 
based on a TWA of 100 ppm (≈435 mg/m3 at 1 atm and 25 °C) in the workplace (OSHA 1974).  The 
American Conference of Governmental Industrial Hygienists also recommends a Threshold Limit Value 
(TLV-TWA) of 100 ppm (≈435 mg/m3) for occupational exposures (ACGIH 1992).  The recommended 
exposure limit (REL) for occupational exposures (TWA) set by the NIOSH is also 100 ppm 
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(≈435 mg/m3) for ethylbenzene based on a 10-hour average workday and a 40-hour workweek (NIOSH 
2005). 
6.6 EXPOSURES OF CHILDREN  
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from 
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility. 
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age:  from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s 
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993). 
Children can be exposed to ethylbenzene by inhalation in urban and rural atmospheres contaminated by 
vehicular and industrial emissions. Tobacco smoke also provides a general source for exposure of 
children to ethylbenzene in indoor air, especially in the homes where one or both parents smoke.  Some 
household activities, such as painting, can lead to short-term exposures to higher levels of ethylbenzene if 
ventilation is inadequate.  The limited information available on exposure from foods indicates that food is 
not likely to be a significant source of ethylbenzene for children.  Ethylbenzene is heavier than air, and 
since young children are closer to the ground or floor because of their height, during accidental exposures 
they may be exposed to more ethylbenzene vapors than adults. 
A 2- year monitoring study (2000–2001) involving 134 children aged 6–10 was conducted in 
Minneapolis, Minnesota in order to assess exposure to VOCs, including ethylbenzene (Sexton et al. 
2005). The distribution of ethylbenzene measured in the blood of these children (416 samples) is 
provided in Table 6-3. Comparing these data to monitoring results from NHANES III, the levels of 
ethylbenzene in children’s blood is approximately 2 or more times lower than in non-occupationally 
exposed adults (Sexton et al. 2005). Ethylbenzene has been detected in breast milk samples collected 
from 8 of 12 women from various cities in the United States; however, the concentrations were not 
reported (Pellizzari et al. 1982).  The 12 women sampled in the study were residents of Bayonne, New 
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period Samples detection limit 10th 25th 50th 75th 90th 95th 99th 
February 2000 92 79.1 0.02 0.02 0.03 0.05 0.07 0.08 0.12 
May 2000 86 66.7 0.01 0.02 0.03 0.04 0.05 0.07 0.17 
February 2001 63 61.1 0.02 0.02 0.02 0.03 0.03 0.03 0.04 
May 2001 88 98.9 0.03 0.04 0.05 0.06 0.08 0.09 0.10 
Source: Sexton et al. 2005 
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Jersey (6 women); Jersey City, New Jersey (2 women); Bridgeville, Pennsylvania (2 women); and Baton 
Rouge, Louisiana (2 women).  No direct pharmacokinetic experiments have been done to investigate 
whether significant amounts of ethylbenzene are transferred to breast milk in mammals.  No studies were 
located that expressed the level of ethylbenzene or its metabolites in amniotic fluid, meconium, cord 
blood or neonatal blood. 
Although no data were found in the literature, it is possible that children playing near hazardous waste 
sites could be dermally exposed to ethylbenzene in soil or orally exposed by hand-to-mouth activity 
and/or soil pica. Ethylbenzene, however, is only moderately adsorbed by soil.  Since it has a moderately 
high vapor pressure, it will evaporate fairly rapidly from dry soil.  However, under certain soil conditions, 
ethylbenzene may persist for longer periods of time; it has been detected in soil samples collected at 
469 of the 829 NPL hazardous waste sites where it has been detected in some environmental media 
(HazDat 2007). No information was found concerning dermal and oral bioavailability of ethylbenzene in 
soil. In the home, intentionally sniffing solvents could lead to high levels of exposure.  No information 
was found concerning differences in the weight-adjusted intakes of ethylbenzene by children. 
No exposures of children to ethylbenzene by contamination of workers’ homes were found in the 
Workers’ Home Contamination Study conducted under the Worker’s Family Protection Act (NIOSH 
1995). 
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES  
In addition to individuals who are occupationally exposed to ethylbenzene (see Section 6.5), there are 
several groups within the general population that may receive potentially high exposures (higher than 
background levels) to ethylbenzene.  These populations include individuals living in proximity to sites 
where ethylbenzene is produced or used in manufacturing or sites where ethylbenzene is disposed, and 
includes individuals living near the 829 NPL hazardous waste sites where ethylbenzene has been detected 
in some environmental media (HazDat 2007).  Ethylbenzene has been detected in air and groundwater at 
121 and 557 NPL hazardous waste sites, respectively. 
Individuals living or working near petroleum refineries or chemical manufacturing plants may receive 
higher inhalation exposures than those experienced by the general population.  Residents living in the 
vicinity of gasoline stations, high traffic areas, tunnels, parking lots, and highways may also receive a 
higher than average inhalation exposure since ethylbenzene is a component of gasoline.  Residential wells 
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downgradient of leaking underground storage tanks, landfills, and hazardous waste sites contaminated 
with petroleum products and solvents may contain high levels of ethylbenzene.  If these residential wells 
are the primary source of drinking water, this may pose a risk to human health via consumption of 
contaminated water as well as increased inhalation of and dermal contact with ethylbenzene during 
showering and bathing.  A study of indoor air in a home using gasoline-contaminated drinking water 
found that exposures to ethylbenzene could occur via inhalation during showering and other household 
activities (Beavers et al. 1996). Ethylbenzene concentrations in shower air were often one to two orders 
of magnitude higher than non-shower air.  These authors reported a total daily household dose of 
ethylbenzene of 379 μg, with 204 μg derived from ingestion of drinking water and 175 μg derived from 
inhalation (108 μg from shower-related inhalation and 67 μg from non-shower-related inhalation) to the 
exposed subject living in the home.  The daily dose of ethylbenzene for an unexposed smoker by 
comparison was estimated to be 32 μg. 
6.8 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of ethylbenzene is available.  Where adequate information is 
not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of 
research designed to determine the health effects (and techniques for developing methods to determine 
such health effects) of ethylbenzene.  
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
6.8.1 Identification of Data Needs 
Physical and Chemical Properties. The physical and chemical properties of ethylbenzene are well 
characterized (see Table 4-2) and allow prediction of the transport and transformation of the compound in 
the environment (Amoore and Hautala 1983; Bohon and Claussen 1951; Chiou et al. 1983; EPA 1982; 
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Hansch and Leo 1979; Hodson and Williams 1988; Mackay and Shiu 1981; Polak and Lu 1973; Sutton 
and Calder 1975; Verschueren 1983). No additional studies are needed at the present time. 
Production, Import/Export, Use, Release, and Disposal.    According to the Emergency 
Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required 
to submit substance release and off-site transfer information to the EPA.  The TRI, which contains this 
information for 2005, became available in May of 2007.  This database is updated yearly and should 
provide a list of industrial production facilities and emissions. 
Ethylbenzene has numerous uses (ACGIH 2002; Ransley 1984; Verschueren 1983), and production of the 
chemical has steadily increased since 1983 (C&EN 1994a, 1994b, 1995, 2006; Kirschner 1995).  Releases 
occur from a variety of common sources including manufacturing and production (TRI05 2007), fuels, 
automobile exhaust, and fumes from paints, varnishes, solvents, carpet glue, and hot asphalt (Fishbein 
1985; Hampton et al. 1983; Junk and Ford 1980; Katzman and Libby 1975; Kitto et al. 1997; Mukund et 
al. 1996; NAS 1980; Wallace et al. 1987b).  Ethylbenzene also is released from waste waters to the 
atmosphere in municipal sewer systems (Quigley and Corsi 1995).  Therefore, the potential for human 
exposure to ethylbenzene is considerable.  The medium most likely to be contaminated is air, although 
ethylbenzene has also been detected in trace amounts in water supplies.  Some ethylbenzene-containing 
wastes are designated as hazardous and are subject to EPA handling and recordkeeping requirements.  
Recommended methods for the disposal of ethylbenzene include burial in a landfill and rotary kiln 
incineration, liquid injection incineration, and fluidized bed incineration (EPA 1981d).  No data need is 
identified at this time. 
Environmental Fate. Ethylbenzene is primarily partitioned to and transported in air (Dewulf and 
van Langenhove 1997; Eisenreich et al. 1981; Mackay 1979; Masten et al. 1994).  The partitioning and 
transport processes in water, soil, and aquatic life are also well characterized (ASTER 1995; Dewulf et al. 
1996; Kawamura and Kaplan 1983; Ligocki et al. 1985; Swann et al. 1983).  Transformation and 
degradation processes have also been well characterized in air (Atkinson and Carter 1984; Atkinson et al. 
1978; Grovenstein and Mosher 1970; Herron and Huie 1973; Hoshino et al. 1978; O'Brien et al. 1975; 
Ohta and Ohyama 1985; Ravishankara et al. 1978; Yanagihara et al. 1977), water (Acton and Barker 
1992; Anid et al. 1993; Bouwer and McCarty 1984; Burback and Perry 1993; Ehrhardt and Petrick 1984; 
Gschwend et al. 1982; Hutchins 1991; Masten et al. 1994; Wakeham et al. 1983; Wilson et al. 1986), and 
in soil and sediment (Bestetti and Galli 1984; Chen and Taylor 1995; Hutchins 1991; Hutchins et al. 
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1991; Jamison et al. 1970; Ramanand et al. 1995; Van der Linden and Thijsse 1965; Yadav and Reddy 
1993; Zappi et al. 1996).  No data need is identified at this time. 
Bioavailability from Environmental Media.    Ethylbenzene is absorbed following inhalation, oral, 
and dermal exposures. Information is available on its absorption from air and water, but little data exist 
regarding dermal bioavailability and absorption from soil and food.  Due to its large vapor pressure and 
Henry’s law constant, ethylbenzene is expected to volatilize fairly rapidly from soil surfaces. Based on 
the moderate affinity of ethylbenzene for soil, especially soils with relatively high organic carbon content, 
the amount of ethylbenzene in bioavailable form in soil is expected to be low to moderate.  Because of the 
low BCF values calculated for ethylbenzene, food chain bioaccumulation would not be expected to be 
significant sources of ethylbenzene exposure.  No data need is identified at this time. 
Food Chain Bioaccumulation. Limited data suggests that ethylbenzene does not bioconcentrate in 
aquatic organisms (Ogata et al. 1984), and is not likely to bioaccumulate in aquatic or terrestrial food 
chains. However, little information on food residues in commercially important fish and shellfish species 
is currently available.  Additional monitoring data regarding the levels of ethylbenzene would be helpful 
for several commercially important fish and shellfish species. 
Exposure Levels in Environmental Media. Reliable monitoring data for the levels of 
ethylbenzene in contaminated media at hazardous waste sites are needed so that the information obtained 
on levels of ethylbenzene in the environment can be used in combination with the known body burden of 
ethylbenzene to assess the potential risk of adverse health effects in populations living in the vicinity of 
hazardous waste sites. 
An extensive amount of atmospheric monitoring data exists (EPA 1988c; Goldberg et al. 1995; Kinney et 
al. 2002; Kostiainen 1995; Mukerjee et al. 1997; Quigley and Corsi 1995; Wallace et al. 1987a, 1987c; 
Zielinska et al. 1996; Zweidinger et al. 1988). Ethylbenzene has also been detected in surface water and 
groundwater (Barker 1987; Borden and Yanoschak 1990; Chen and Zoltek 1995; Cole et al. 1984; 
Cotruvo 1985; Gschwend et al. 1982; Krill and Sonzongni 1986; Quigley and Corsi 1995; Staples et al. 
1985; Stubin et al. 1996; Stuermer et al. 1982; Tester and Harker 1981), sediment (Staples et al. 1985), a 
limited number of foodstuffs (Ferrario et al. 1985; Górna-Binkul et al. 1996; Kinlin et al. 1972; Lovegren 
et al. 1979; Nicola et al. 1987), and in cigarette smoke (Hodgson et al. 1996; Martin et al. 1997; Wallace 
1986; Wallace et al. 1987c).  Continued monitoring data at or around hazardous waste sites are needed in 
order to assess human exposure for populations residing in these areas.  
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Exposure Levels in Humans. Ethylbenzene and its metabolites have been detected in human blood 
(Angerer and Wulf 1985; Ashley et al. 1994), urine (Bardodej and Bardodevova 1970; Dutkiewicz and 
Tyras 1967; Engstrom and Bjurstrom 1978; Gromiec and Piotrowski 1984; Kiese and Lenk 1974; 
Sullivan et al. 1976; Yamasaki 1984), breast milk (Pellizzari et al. 1982), and adipose tissue (Engstrom 
and Bjurstrom 1978; EPA 1986a).  Most of the monitoring data have come from occupational studies of 
specific worker populations exposed by inhalation.  Members of the general population can be exposed to 
ethylbenzene through inhalation of fumes while pumping gas or riding in gasoline-powered vehicles 
(Backer et al. 1997; Lawryk and Weisel 1996; Lawryk et al. 1995).  Additional information regarding the 
general population’s exposure to ethylbenzene would be useful.  Dietary intake is expected to be 
insignificant as compared to inhalation exposure (Tang et al. 2000).  Oral exposures are likely to be low, 
except for the consumption of contaminated drinking water by populations living in the vicinity of 
hazardous waste sites, leaking underground storage tanks, or municipal landfills. 
Exposures of Children. Children are exposed to ethylbenzene by the same routes that affect adults.  
Biomonitoring data suggest that blood levels of ethylbenzene are lower in children than non--
occupationally exposed adults (Sexton et al. 2005).  Ethylbenzene has been detected in breast milk 
samples collected from 8 or 12 women from various cities in the United States; however, the 
concentrations were not reported (Pellizzari et al. 1982).  There do not appear to be any childhood 
specific means to decrease exposure to ethylbenzene.  A data need exists to determine current 
ethylbenzene residues and their sources in breast milk of members of the general population. 
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data 
Needs: Children’s Susceptibility. 
Exposure Registries No exposure registries for ethylbenzene were located.  This substance is not 
currently one of the compounds for which a sub-registry has been established in the National Exposure 
Registry.  The substance will be considered in the future when chemical selection is made for sub-
registries to be established.  The information that is amassed in the National Exposure Registry facilitates 
the epidemiological research needed to assess adverse health outcomes that may be related to exposure to 
this substance. 
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6.8.2 Ongoing Studies 
The Federal Research in Progress (FEDRIP 2007) database provides additional information obtainable 
from a few ongoing studies that may fill in some of the data needs identified in Section 6.8.1.  These 
studies are summarized in Table 6-4. 
As part of the Third National Health and Nutrition Evaluation Survey (NHANES III), the Environmental 
Health Laboratory Sciences Division of the National Center for Environmental Health, Centers for 
Disease Control and Prevention, will be analyzing human blood samples for ethylbenzene and other 
volatile organic compounds.  These data will give an indication of the frequency of occurrence and 
background levels of these compounds in the general population. 
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Investigator Affiliation Description Sponsor 
Thrall KD Battelle Pacific The overall research objective for this NIOSH 
Northwest Laboratories, project is to expand prior studies to 
Richland, Washington evaluate the percutaneous absorption of 
compounds commonly encountered 
within similar industries (styrene and 
ethylbenzene) along with focused 
studies to evaluate the dermal 
bioavailability of compounds with both 
lipophilic and hydrophilic properties. 
Burke J EPA The development of a human exposure EPA 
model has been initiated to characterize 
population exposures to air toxics in 
support of risk assessment activities in 
the National Air Toxics Program.  This 
research will develop probabilistic inputs 
for exposure to chemicals such as 
benzene and ethylbenzene for use in the 
model. 
EPA = Environmental Protection Agency; NIOSH = National Institute for Occupational Safety and Health 
Source: FEDRIP 2007 
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The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring ethylbenzene, its metabolites, and other biomarkers of exposure and effect 
to ethylbenzene.  The intent is not to provide an exhaustive list of analytical methods.  Rather, the 
intention is to identify well-established methods that are used as the standard methods of analysis.  Many 
of the analytical methods used for environmental samples are the methods approved by federal agencies 
and organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  
Other methods presented in this chapter are those that are approved by groups such as the Association of 
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).  
Additionally, analytical methods are included that modify previously used methods to obtain lower 
detection limits and/or to improve accuracy and precision. 
7.1 BIOLOGICAL MATERIALS  
Ethylbenzene can be determined in biological fluids, and tissues, and breath using a variety of analytical 
methods. Representative methods are summarized in Table 7-1. Most analytical methods for biological 
fluids and tissues use headspace gas chromatographic (GC) analysis.  Breath samples are usually 
collected on adsorbent traps or in sampling bags or canisters, and then analyzed by GC.  
The headspace method involves equilibrium of volatile analytes such as ethylbenzene between a liquid or 
solid sample phase and the gaseous phase.  The gaseous phase in then analyzed by GC.  There are two 
main types of headspace methodology: static (equilibrium) headspace and dynamic headspace, which is 
usually called the "purge-and-trap" method (Seto 1994).  The static headspace technique is relatively 
simple, but may be less sensitive than the purge-and-trap method.  The purge-and-trap method, while 
providing increased sensitivity, requires more complex instrumentation and may result in artifact 
formation (Seto 1994). Generally, an inert gas such as helium is passed over the biological sample at 
elevated temperature, and the purged volatile organic compound (VOC) is trapped onto an adsorbent 
polymeric resin (Tenax).  The organic compound is thermally desorbed from the adsorbent followed by 
identification and quantitation using various detectors; flame ionization detection (FID) and mass 
spectrometry (MS) are used most often.  Other sample preparation methods have been used, but less 
frequently.  Solvent extraction permits concentration, thereby increasing sensitivity, but the extraction 
solvent can interfere with analysis.  Direct aqueous injection is a very rapid method, but sensitivity is low 
and matrix effects can be a serious problem. 
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Sample Analytical Sample Percent 
matrix Preparation method method detection limit recovery Reference 
Whole blood Whole blood samples Capillary 0.015– 114–118 Ashley et al. 1992, 
were collected by GC/MS 0.020 ppb 1994 
venipuncture, sealed, and 
refrigerated. Extraction 
accomplished using a 
closed system purge and 
trap sampler 
Blood Direct analysis via inertial GC/MS <1 ppb No data St-Germain et al. 
spray extraction interface 1995 
Blood Automated head space Capillary 0.002 μg/mL 90–110 Otson and 
GC/FID (estimated) Kumarathasan 1995 
Blood 	 Extraction using dynamic cap GC/FID 50 ng/L 39 Fustinoni et al. 1996 
headspace purge and trap (calculated) 
system followed by 
thermal desorption to the 
GC 
Urine Purge and trap Capillary No data 64–123 for Michael et al. 1980 
GC/MS model 
compounds 
Urine 	 Extraction using dynamic Capillary 50 ng/L 61 Fustinoni et al. 1996 
headspace purge and trap GC/FID (calculated) 
system followed by 
thermal desorption to the 
GC 
Mother’s Purge and trap Capillary No data 35–88 for Michael et al. 1980 
milk GC/MS model 
compounds 
Brain tissue Modified headspace (full Capillary 0.038 nmoles/ 80–120 Schuberth 1996 
(post evaporation technique) GC-ITD sample 
mortem) 
Fat tissue Add saline; freeze; thaw GC/FID; No data No data Wolff et al. 1977 
to 0 °C prior to analysis; confirmation 
add CS2; inject into GC GC/MS 




Breath Collection via spirometer Capillary low μg/m3 77–82 Thomas et al. 1991 
into passivated canisters GC/MS levels 
Breath 	 Collection via spirometer Capillary 0.2 μg/m3 No data Riedel et al. 1996 
onto charcoal traps; GC/MS-SIM (1 L sampled) 
microwave desorption 
FID = flame ionization detector; GC = gas chromatography; HPLC = high performance liquid chromatography; 
ITD = ion trap detector; MS = mass spectrometry; SIM = selected ion monitoring 
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A spirometer is usually used for the collection of breath samples.  The device is used to provide clean air 
for inhalation and a mechanism for pumping exhaled breath into the collection media (Pellizzari et al. 
1985).  The breath samples are collected into Tedlar bags with subsequent adsorption onto Tenax traps 
(Pellizzari et al. 1985) or into passivated stainless steel canisters (Thomas et al. 1991).  The Tenax traps 
are analyzed by thermal desorption GC techniques, and canister samples are analyzed by GC as well. 
A sensitive and reliable method for identification and quantitation of ethylbenzene in samples of whole 
blood taken from humans following exposure to VOCs has been developed by Ashley and coworkers at 
the Centers for Disease Control and Prevention (Ashley et al. 1992, 1994).  The method involves purge-
and-trap of a 10-mL blood sample with analysis by capillary GC/MS.  Anti-foam procedures were used, 
as well as special efforts to remove background levels of VOCs from reagents and equipment (Ashley et 
al. 1992).  The method is sensitive enough (ppt levels) to determine background levels of VOCs in the 
population and provides adequate accuracy (114–118% recovery) and precision (16–44% relative 
standard deviation [RSD]) for monitoring ethylbenzene in the population. 
Few methods are available for the determination of ethylbenzene in body fluids and tissues other than 
blood. A modified dynamic headspace method for urine, mother's milk, and adipose tissue has been 
reported (Michael et al. 1980). Volatiles swept from the sample are analyzed by capillary GC/FID.  
Acceptable recovery was reported for model compounds, but detection limits were not reported (Michael 
et al. 1980). Ethylbenzene in brain tissue may be determined using a headspace, capillary/ion trap 
detector (ITD) technique (Schuberth 1996).  Recovery was good (80–120%) as was precision 
(≈20% RSD); the detection limit was reported as 4 ng/sample (0.038 nmoles) (Schuberth 1996). 
Sensitive, reliable methods are available for measuring ethylbenzene in breath.  Exhaled breath is 
collected using a spirometer.  The exhaled breath is collected into Tedlar bags for later transfer to 
adsorption tubes (Wallace et al. 1982), into passivated canisters (Thomas et al. 1991), or directly onto 
adsorbent traps (Riedel et al. 1996).  The spirometer system, using adsorption onto Tenax traps and 
analysis by thermal desorption/capillary GC/MS techniques, was field-tested over the course of a very 
large exposure study (EPA 1987).  The quantitation limit was ≈1 μg/m3, recovery was 91–100%, and the 
precision for duplicate samples was ≤30% RSD (EPA 1987). Advances in the methodology include 
development of a more compact system with collection in 1.8-L canisters (Thomas et al. 1992).  Recovery 
of ethylbenzene is 92–104%, precision for duplicate samples is <3% RSD, and the detection limit was 
estimated as 3 μg/m3 for ethylbenzene (Thomas et al. 1992).   
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7.2 ENVIRONMENTAL SAMPLES 
Methods are available for determining ethylbenzene in a variety of environmental matrices.  A summary 
of representative methods is shown in Table 7-2.  Validated methods, approved by agencies and 
organizations such as EPA, ASTM, APHA, and NIOSH, are available for air, water, and solid waste 
matrices.  Gas chromatography is the most widely used analytical technique for quantifying 
concentrations of ethylbenzene in environmental matrices.  Various detection devices used for GC include 
FID, MS, and the photoionization detector (PID).  Because of the complexity of the sample matrix and the 
low concentration of VOCs in most environmental media, sample preconcentration is generally required 
prior to GC analysis.  Air samples may be collected and concentrated on adsorbent or in canisters for 
subsequent analysis.  Methods suitable for determining trace amounts of ethylbenzene in aqueous and 
other environmental media include three basic approaches to the pretreatment of the sample:  gas purge-
and-trap technique, headspace gas analysis, and extraction with organic solvent. 
Gas purge-and-trap is the most widely used method for the isolation and concentration of VOCs in 
environmental samples (Lesage 1993).  The purge-and-trap technique offers advantages over other 
techniques in that it allows facile isolation and concentration of target compounds, thereby improving 
overall limits of detection and recovery of sample.  Detection limits of <1 μg of ethylbenzene per liter of 
sample have been achieved (APHA 1995c; EPA 1984c, 1991e, 1992a).  A serious drawback of this 
technique, particularly for quantitative analysis, is interference by impurities found in the stripping gas 
(EPA 1994c). 
A purge-and-trap method with GC/FID analysis (Otson and Williams 1982) or GC/MS (Otson and Chan 
1987) has been reported for the analysis and quantitation of ethylbenzene in environmental samples.  
Detection limits of <0.1 μg/L for GC/FID analysis and 0.1 μg/L were reported. Accuracy was also good, 
74–88% (Otson and Chan 1987; Otson and Williams 1982). 
Extraction with organic solvents (liquid-liquid extraction) provides a simple, rapid screening method for 
semi-quantitative determination of ethylbenzene in aqueous samples containing limited number of VOCs, 
but is less effective for aqueous samples containing large numbers of VOCs.  Furthermore, interference 
from the organic extraction solvent (hexane) makes it more difficult to completely identify all 
components (Karasek et al. 1987; Otson and Williams 1981). 
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Analytical Sample Percent 
Sample matrix Preparation method method detection limit recovery Reference 
Occupational air Collection on charcoal GC/FID 0.001– Bias -7.6% NIOSH 1994a 
adsorbent tube; 











No data EPA 1988a 
(Method TO-1) 
desorption 
Ambient air Collection in passivated Capillary No data No data EPA 1988b 
stainless steel canisters GC/MS or (Method TO-14) 
PID or FID 
Ambient air Collection on Tenax Capillary 2 nga No data Pellizzari et al. 
adsorbent; thermal GC/MS 1993 
desorption (IARC Method 6) 
Ambient air Collection in canisters GC/MS 0.2 ppbv bias -8.1% McClenny and 
Fortune 1995 
(CLP Method) 
Ambient air Collection on Capillary 0.036 ppbv 102 Oliver et al. 
multisorbent traps; GC/MS 1996 
automated 
preconcentration 
Ambient air Collection on Capillary 0.25 ppbv 98 Oliver et al. 
multisorbent traps; GC/FID 1996 
thermal desorption with 
modified cryofocussing 
Indoor air Collection on Tenax GC/MS 0.05–0.2 μg/m3 No data Kostianinen 
acsorbent; thermal 1995 
desorption 
In-vehicle air Collection on Tenax or Capillary No data No data Lawryk and 
multisorbent traps; GC/MS-SIM Weisel 1996 
thermal desorption 
Flue gas Collection on adsorbent Capillary 0.05 μg/m3 No data Jay and Steiglitz 
traps using probe; GC/FID (estimated) 1995 
thermal desorption 
Product Collection on charcoal Capillary No data No data Wadden et al. 
emissions traps; desorption with GC/FID 1995 
CS2 
Tobacco smoke Collection on fused-silica No data No data Barrefors and 
multisorbent traps; PLOT column Petersson 1993 
thermal desorption GC/MS 
Snow SPME using DVB­ GC/MS 0.20 μg/L No data Kos and Ariya 
coated PDMS fiber with 2006 
a film thickness of 
65 μm 
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Analytical Sample Percent 
Sample matrix Preparation method method detection limit recovery Reference 
Drinking water Purge and trap GC/PID 0.01–0.04 μg/L 98–101 EPA 1991d 
(EPA Method 
502.2) 
Drinking water Purge and trap GC/PID; 0.002 μg/L 93 EPA 1991e 
confirmation (EPA Method 
on second 503.1) 
column or 
GC/MS 
Drinking water Purge and trap GC/MS 1–2 μg/L No data EPA 1991f 
(EPA Method 
524.1) 
Drinking water Purge and trap Capillary 0.06 μg/L 96–99 EPA 1992a 
GC/MS (EPA Method 
524.2) 
Drinking water Purge and trap GC/FID or low μg/L 84–114 ASTM 1999b 
GC/MS (ASTM Method 
D 3871) 
Drinking water Direct injection GC/FID ~1 mg/L No data ASTM 1999a 
(ASTM Method 
D 2908) 
Waste water Purge and trap GC/PID; 0.2 μg/L 98 EPA 1984c 
confirmation (EPA Method 
on second 602) 
column 
Waste water Purge and trap GC/MS 7.2 μg/L 100–103 EPA 1999 
(EPA Method 
624) 
Water Closed-loop stripping Capillary 50 ng/L No data APHA 1995a 
GC/MS (instrumental) (Method 6040B) 
Waste water Purge and trap GC/MS 7.2 μg/L APHA 1995b 
(Method 6210B) 
Waste water Purge and trap GC/PID; 0.2 μg/L 93 APHA 1995c 




Waste water Purge and trap GC/PID 0.01–0.05 μg/L 93 APHA 1995d 
(Method 6220C) 
Solid waste Direct injection or purge Capillary ~1 μg/L (soil, 101 EPA 1994d 
and trap GC/PID sediment); (SW846 Method 
~0.1 mg/kg 8021A) 
(wastes) 
Solid waste Purge and trap Capillary ~1 μg/L (soil, 101 EPA 1995a 
GC/PID sediment); 9SW846 Method 
~0.1 mg/kg 8021B, 
(wastes) proposed) 
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Analytical Sample Percent 
Sample matrix Preparation method method detection limit recovery Reference 
Solid waste Purge and trap Capillary ~5 μg/kg (soil, 99 EPA 1994e 
GC/MS sediment) (SW846 Method 
8260A) 
Solid waste Various options Capillary purge and trap: 90–112 EPA 1995b 
including purge and GC/MS ~5 μg/kg (soil (purge and (SW846 Method 
trap, headspace, closed and sediment); trap) 8260B, 
system vacuum ~0.5 mg/kg proposed) 
distillation (wastes) 
Plant foliage Solvent extraction; Capillary 50 pg/μL No data Keymeulen et al. 
filtration GC/SM-SIM extract 1991 
Fish Solvent extraction; GC/FID 5 μg/gb 98–102 Karasek et al. 
cleanup on florisil 1987 
column; solvent 
microextraction 
Fish and sedi- Homogenization;  Capillary 25 ppbb Sediments, Hiatt 1981, 1983 
ment freezing and vacuum GC/MS 97 recovery; 
extraction fish, 76% 
average for 
all analytes 
Eggs Headspace Capillary 0.002 μg/mL 94 (white); Stein and 
GC/PID; 49 (whole); Narang 1990 
confirmation 21 (yolk) 
by GC/MS 
Fruits and Solvent extraction; Capillary No data No data Górna-Binkul et 
vegetables filtration GC/MS-SIM al. 1996 
Olives and olive Headspace Capillary Low μg/kg No data Biedermann et 
oil GC/MS levels al. 1995 
Cooked meat Azeotropic distillation Capillary 6 μg/kg No data Gramshaw and 
using Kilens-Nickerson GC/MS Vandenburg 
estractor 1995 
Food containers Incubation with DMF; Capillary 10 ppm 96–102 Sugita et al. 
(polystyrene) headspace GC/FID; 1995 
confirmation 
GC/MS 
aSample detection limit will depend upon volume sampled.  Value is estimated instrumental detection limit. 
bMethod detection limits were not provided; estimates cited are based on lowest concentrations used for method 
performance evaluation. 
CS2 = carbon disulfide; DMF = dimethylformamide; DVB = divinylbenzene; FID = flame ionization detector; GC = gas 
chromatography; MeOH = methanol; MS = mass spectrometry; PDMS = polydimethylsiloxane; PID = photoionization 
detector; PLOT = pourous-layer open tubular; SIM = selected ion monitoring; SPME = solid phase microextraction; 
UV = ultraviolet spectrophotometry 
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Ethylbenzene may be determined in occupational air using collection on multisorbent cartridges, solvent 
desorption and analysis by GC/FID (NIOSH 1994a). Accuracy is very good (-7.6% bias); detection limits 
depend upon the amount of air sampled.  Ambient air samples may also be collected on adsorbent traps 
(EPA 1988a; Pellizzari et al. 1993) or in stainless steel canisters (EPA 1988b; McClenny and Fortune 
1995).  Recovery for Tenax traps is very good, ranging from 91 to 100% (EPA 1987).  Little information 
on accuracy is available for multisorbent traps, but good recovery (102%) has been reported (Oliver et al. 
1996).  Bias of -8.1% for canister collection has been reported (McClenny and Fortune 1995).  Detection 
limits depend upon the amount of air sampled, but values in the sub-ppb range have been reported 
(Kostiainen 1995; McClenny and Fortune 1995; Oliver et al. 1996). 
Purge-and-trap methodology is used most often for determination of ethylbenzene in water and hazardous 
wastes (Lesage 1993).  The method was developed by Bellar and Lichtenberg (1974) for waste water.  An 
inert gas is bubbled through the sample to strip out volatile components.  The analytes in the gas stream 
are adsorbed onto sorbent traps, then thermally desorbed into the GC column.  Very low detection limits 
for drinking water are reported for the purge-and-trap method with GC/PID (0.002–0.04 μg/L) (EPA 
1991e). Accuracy is very good (93–101% recovery) (EPA 1991e).  While the method is quite selective, 
confirmation using a second GC column or GC/MS is recommended (EPA 1991e).  A sensitive 
(0.06 μg/L) and reliable method (96–99% recovery; <10% RSD) for drinking water uses capillary column 
GC/MS (EPA 1992a). Purge-and-trap methodology with analysis by GC/PID or GC/MS is used for 
waste waters (APHA 1995b, 1995c, 1995d; EPA 1984c, 1999).  The detection limits are lower for 
GC/PID (0.2 μg/L) (EPA 1984c) than for GC/MS (7.2 μg/L) (EPA 1984b), but confirmation on a second 
column is recommended (EPA 1984c) when PID is used.  Recovery and precision are very good (98– 
103% recovery; ≤10% RSD) (EPA 1984c, 1999). 
Soil, sediment, and solid waste samples are difficult to analyze.  Volatilization during sample handling 
and homogenization can result in ethylbenzene losses.  The wet sample is usually dispersed in a solvent, 
then added to water for purge-and-trap/GC analysis (EPA 1994c).  Capillary GC/PID or GC/MS analysis 
provides detection limits in the low ppb range for soil and sediment and in the sub-ppm range for solid 
wastes (EPA 1994d, 1994e, 1995a, 1995b).  
Few methods are available for the determination of ethylbenzene in fish and biota.  A method for the 
determination of ethylbenzene in fish at low ppm levels using solvent extraction with GC/FID analysis 
has been reported (Karasek et al. 1987).  A procedure to identify and quantify ethylbenzene in fish 
samples by vacuum distillation with capillary column GC/MS has been reported (Hiatt 1981, 1983).  
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Recovery of 98–102% from spiked fish tissue was reported, but detection limits were not reported (Hiatt 
1981).  Purge-and-trap/capillary GC/MS has also been used for the determination of ethylbenzene in fish.  
Performance data for fish tissue samples were not reported (Dreisch and Munson 1983). 
Few methods are available for the determination of ethylbenzene in food.  Available methods involve 
solvent extraction (Górna-Binkul et al. 1996), headspace purge (Biedermann et al. 1995), and azeotropic 
distillation (Gramshaw and Vandenburg 1995) followed by capillary GC/MS or GC/PID analysis.  
Detection limits are in the low μg/kg range (Biedermann et al. 1995; Gramshaw and Vandenburg 1995).  
Little performance data are available.  Recoveries from 21% (egg yolk) to 94% (egg white) were reported 
for headspace/capillary GC/PID analysis of eggs (Stein and Narang 1990). 
Screening methods and field-portable methods may be useful analytical tools.  Soil screening for 
petroleum hydrocarbons, including ethylbenzene, can be conducted using immunoassay procedures (EPA 
1995e). Sensitivity is in the ppm range.  Solid phase microextraction (SPME) has been tested as a 
screening method for water (Shirey 1995).  The method is used in conjunction with capillary GC 
techniques. Portable GCs have been used for field monitoring of air (Berkley et al. 1991), water (Driscoll 
and Atwood 1993), soil (Driscoll and Atwood 1993), and hazardous waste (Overton et al. 1995).  There 
are several studies that compare portable GC methods with laboratory methods (Berkley et al. 1991; 
Driscoll and Atwood 1993).   
7.3 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of ethylbenzene is available.  Where adequate information is 
not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of 
research designed to determine the health effects (and techniques for developing methods to determine 
such health effects) of ethylbenzene.  
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
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7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.    
Exposure. Exposure to ethylbenzene can be determined by the detection of mandelic acid and 
phenylglycolic acid in urine or by direct detection of ethylbenzene in human blood.  Environmental 
exposures to ethylbenzene can result in detectable levels in human tissues.  Existing methods for the 
determination of ethylbenzene in blood have the sensitivity necessary (0.008–0.012 ppb) (Ashley et al. 
1992) to detect and measure low to trace levels of ethylbenzene in blood that might be present in the 
general population, as well as concentrations of ethylbenzene that might be associated with specific health 
effects. Methods for measurement of ethylbenzene in exhaled breath are sensitive enough (low μg/m3) 
(Thomas et al. 1991) to provide background levels of ethylbenzene in the general population as well as to 
measure exposure. Additional performance information would be helpful, as would further development 
of a portable breath collection system.  Information on levels of ethylbenzene in tissues is limited and the 
existing methods are not as well characterized.  Improvements in the sensitivity of the methods for 
measuring concentrations of ethylbenzene in tissues and additional performance data would be helpful. 
Methods for measuring metabolites and biomarkers for ethylbenzene are shown in Table 7-3. Methods 
exist for measuring ppm levels of ethylbenzene metabolites in urine (Ogata and Taguchi 1987, 1988; 
Sollenberg et al. 1985).  They are sufficiently sensitive for measuring occupational exposure to 
ethylbenzene.  These analytical methods are reliable and precise, but may not be sensitive enough to 
measure non-occupational exposure.  Improvements in the sensitivity of the methods for measuring 
concentrations of ethylbenzene in tissues, and improvements in the sensitivity for measurement of 
metabolites in urine would allow better assessment of the correlation between levels in these media and 
observed health effects. 
Effect. No specific biomarkers of effect for ethylbenzene were identified. 
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media. Sensitive methods are available for measuring background levels of ethylbenzene in air, water, 
and wastes, the media of most concern for exposure of the general population and those populations 
located near hazardous waste sites. Few methods are available for measuring levels of ethylbenzene in 
fish, plants and biota. Detection limits in the low ppb range have been reported (Dreisch and Munson 
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Sample Analytical Sample detection Accuracy per-
matrix Sample preparation method limit cent recovery Reference 
Urine (MA) Dilution; centrifugation HPLC/UV MA 5 ng injected MA 100–102 Ogata and 
Taguchi 1988 
Urine (MA MeOH addition; HPLC PGA 8.5x103 μg/L PGA 101 Ogata and 





HPLC/UV MA, PGA 
1.5x103 μg/L 







ITP MA 6.1x103 μg/L 
PGA 3.0x103 μg/L 
No data Sollenberg et al. 
1985 
and dissolution 
HPLC = high performance liquid chromatography; ITP = isotachophoresis; MA = mandelic acid; 
PGA = phenylglyoxylic acid; UV = ultraviolet (detection) 
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1983; Hiatt 1981; Karasek et al. 1987; Keymeulen et al. 1991), but other performance data are generally 
lacking. Few methods are available for measuring levels of ethylbenzene in food.  Little performance 
data are available for the available methods.  Although several good analytical methods are available for 
detecting ethylbenzene in some environmental media, validated, reliable methods for measuring 
ethylbenzene in fish and foods are needed.  These would be helpful in evaluating the potential for human 
exposure and health effects that might result from ethylbenzene contamination. 
Methods for detecting environmental degradation products of ethylbenzene in environmental media are 
summarized in Table 7-4.  Although methods are available for detecting major environmental degradation 
products (1-phenylethanol, acetophenone, benzaldehyde, for example) in reaction mixtures, it is not 
known whether these methods have the sensitivity and specificity for application to environmental media.  
Sensitive, reliable methods for determining degradation products in air, water, and waste would be 
helpful. 
7.3.2 Ongoing Studies 
The Environmental Health Laboratory Sciences Division of the National Center for Environmental 
Health, Centers for Disease Control and Prevention, is developing methods for the analysis of 
ethylbenzene and other volatile organic compounds in blood.  These methods use purge and trap 
methodology, high-resolution gas chromatography, and magnetic sector mass spectrometry, which give 
detection limits in the low ppt range.  
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Table 7-4. Analytical Methods for Determining Environmental Degradation 

Products of Ethylbenzene 

Sample Analytical Sample Accuracy per-
matrix Preparation method method detection limit cent recovery Reference 
Reaction Solvent extraction; Capillary No data No data Ehrhardt and 
mixtures concentration GC/FID Petrick 1984 
Reaction Centrifugation; solvent GC/FID; No data No data Fukuda et al. 1989 
mixtures extraction; confirmation 
concentration GC/MS 
FID = flame ionization detector; GC = gas chromatography; MS = mass spectrometry 
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The international and national regulations and guidelines pertaining to ethylbenzene in air, water, and 
other media are summarized in Table 8-1. 
ATSDR has derived an acute-duration inhalation MRL of 10 ppm for ethylbenzene based on a NOAEL of 
300 ppm and a LOAEL of 400 ppm for significant deterioration of auditory thresholds and significant 
losses of outer hair cells in the organ of Corti in rats exposed 8 hours/day for 5 days (Cappaert et al. 
2000). The MRL was derived by dividing the NOAELHEC of 300 ppm by an uncertainty factor of 
30 (3 for animal to human extrapolation with dosimetric adjustment and 10 for human variability). 
ATSDR has derived an intermediate-duration inhalation MRL of 0.7 ppm for ethylbenzene based on a 
LOAEL of 200 ppm for significant loss of outer hair cells in the organ of Corti in rats exposed for 
6 hours/day, 6 days/week for 13 weeks (Gagnaire et al. 2007).  The MRL was derived by dividing the 
LOAELHEC of 200 ppm by an uncertainty factor of 300 (10 for use of a LOAEL, 3 for animal to human 
extrapolation with dosimetric adjustment, and 10 for human variability). 
ATSDR has derived a chronic-duration inhalation MRL of 0.3 ppm for ethylbenzene based on a LOAEL 
of 75 ppm for a significant increase in the severity of nephropathy in female rats exposed to ethylbenzene 
by inhalation for 5 days/week, 6 hours/day, for 104 weeks (NTP 1999).  The MRL was derived by 
dividing the LOAELHEC of 75 ppm by an uncertainty factor of 300 (10 for use of a LOAEL, 3 for animal 
to human extrapolation with dosimetric adjustment, and 10 for human variability). 
ATSDR has derived an intermediate-duration oral MRL of 0.5 mg/kg/day for ethylbenzene based on a 
BMDL10 of 48.2 mg/kg/day for hepatotoxicity (centrilobular hepatocyte hypertrophy) in male rats 
exposed to ethylbenzene by gavage for 13 weeks (Mellert et al. 2007).  The MRL was derived by dividing 
the BMDL10 of 48.2 mg/kg/day by an uncertainty factor of 100 (10 for animal to human extrapolation 
with dosimetric adjustment and 10 for human variability). 
The EPA oral reference dose (RfD) for ethylbenzene is 0.1 mg/kg/day, based on the LOAEL for liver and 
kidney toxicity in rats administered 291 mg/kg/day ethylbenzene via gavage 5 days/week for 182 days 
(Wolf et al. 1956). The RfD was calculated by dividing the NOAEL of 97 mg/kg/day by an uncertainty 
factor of 1,000 (10 for use of a subchronic study, 10 for interspecies extrapolation, and 10 for intraspecies 
variability). 
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The EPA inhalation reference concentration (RfC) for ethylbenzene is 1 mg/m3 (equivalent to 0.23 ppm), 
based on developmental toxicity seen in rats and rabbits exposed to 4,340 mg/m3 (IRIS 2007). The 
ATSDR intermediate-duration inhalation MRL of 0.3 ppm is comparable to the EPA RfC. 
The EPA has classified ethylbenzene as Group D (not classifiable as to human carcinogenicity), due to 
the lack of animal bioassays and human studies (IRIS 2007).  IARC (2006) has classified ethylbenzene as 
a Group 2B carcinogen (possibly carcinogenic to humans).  NTP has not classified ethylbenzene for its 
carcinogenicity. 
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Table 8-1. Regulations and Guidelines Applicable to Ethylbenzene 
Agency Description Information Reference 
INTERNATIONAL 
Guidelines:  
IARC Carcinogenicity classification Group 2Ba IARC 2006 
WHO Air quality guidelines 









ACGIH TLV (8-hour TWA) 100 ppm ACGIH 2006 
STEL (15-minute TWA) 125 ppm 
EPA AEGL-1, -2, -3 No data EPA 2007a 
Hazardous air pollutant Yes EPA 2007c 
42 USC 7412 
NIOSH REL (10-hour TWA) 100 ppm NIOSH 2005 
STEL (15-minute TWA) 125 ppm 
IDLH 800 ppm 
OSHA PEL (8-hour TWA) for general industry 100 ppm OSHA 2006c 
29 CFR 1910.1000 
PEL (8-hour TWA) for shipyard industry 100 ppm OSHA 2006a 
29 CFR 1915.1000 
PEL (8-hour TWA) for construction 
industry 
100 ppm OSHA 2006b 
29 CFR 1926.55, 
Appendix A 
b. Water 
EPA Designated as hazardous substances 
in accordance with Section 311(b)(2)(A) 
of the Clean Water Act 
Yes EPA 2007b 
40 CFR 116.4 
Designated as a toxic pollutant 
pursuant to Section 307(a)(1) of the 
Clean Water Act 
Yes EPA 2007g 
40 CFR 401.15 
Drinking water standards and health 
advisories 
EPA 2006a 
1-Day health advisory for a 10-kg 
child 
30 mg/L 
10-Day health advisory for a 10-kg 
child 
3 mg/L 
DWEL 3 mg/L 
Lifetime 
10-4 Cancer risk 
0.7 mg/L 
No data 
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Table 8-1. Regulations and Guidelines Applicable to Ethylbenzene 
Agency Description 	 Information Reference 
NATIONAL (cont.) 
EPA National primary drinking water EPA 2003 
standards 
MCLG 0.7 mg/L 
MCL 0.7 mg/Lc 
Public health goal 0.7 mg/L 
Reportable quantities of hazardous 1,000 pounds EPA 2007d 
substances designated pursuant to 40 CFR 117.3 
Section 311 of the Clean Water Act 
Water quality criteria for human health EPA 2006b 
consumption of: 
Water + organism 0.53 mg/L 
Organism only 2.1 mg/L 
c. 	Food 
EPA Inert pesticide ingredients in pesticide List 2d EPA 2004 
products 
FDA Bottled water requirement 0.7 mg/L FDA 2006a 
21 CFR 165.110 
EAFUS No data FDA 2007b 
d. 	Other 
 ACGIH Carcinogenicity classification A3e ACGIH 2006
Biological exposure indices (end of shift 1.5 g/g creatininef 
at end of workweek); sum of mandelic 
acid and phenyl glyoxylic acid in urine 
EPA Carcinogenicity classification Class Dg IRIS 2007 

Oral slope factor No data 

Inhalation unit risk No data 

RfC 1 mg/m3
 RfD 0.1 mg/kg/day 
Master Testing List Yesh EPA 2007j 
Superfund, emergency planning, and 
community right-to-know 
Designated CERCLA hazardous Yesi EPA 2007e 
substance 40 CFR 302.4 
Reportable quantity 1,000 pounds 
Effective date of toxic chemical 01/01/87 EPA 2007f 
release reporting 40 CFR 372.65 
TSCA health and safety data reporting Yes EPA 2007h 
requirements 40 CFR 716.120 
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Table 8-1. Regulations and Guidelines Applicable to Ethylbenzene 
Agency Description Information Reference 
NATIONAL (cont.)

NTP Carcinogenicity classification No data NTP 2005 

aGroup 2B: possibly carcinogenic to humans 
bConcentrations of the substance at or below the health based guideline value may affect the appearance, taste, or 
odor of the water, leading to consumer complaints. 
cPotential health effects from exposure above the MCL include liver or kidneys problems; and the common sources of 
contaminant in drinking water is from the discharge from petroleum refineries. 
dList 2: potentially toxic other ingredients and high priority for testing inerts 
eA3: confirmed animal carcinogen with unknown relevance to humans 
fACGIH (2006) has submitted notice of intended changes for ethylbenzene in which the BEI will be lowered to 
0.7 g/g creatinine. 
gClass D:  not classifiable as to human carcinogenicity 
hEthylbenzene was recommended to the Master Testing List (MTL) by the U.S. EPA’s Office of Pollution Prevention 
and Toxics on the basis of the Screening Information Data Sets (SIDS).  Styrene was added to the MTL in 1993 and 
the chemical testing program is currently underway by way of a VTA.  The testing needs include health effects, 
environmental effects, and environmental fate and exposure.  The Office of Air and Radiation recommended 
ethylbenzene to the MTL in 1995 on the basis that ethylbenzene is a hazardous air pollutant.  EPA is in the process 
of determining the testing needs for the following: acute toxicity, neurotoxicity, developmental toxicity, reproductive, 
and immunotoxicity
iDesignated CERCLA hazardous substance pursuant to Section 311(b)(2) and Section 307(a) of the Clean Water and 
Section 112 of the Clean Air Act. 
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = Acute Exposure Guideline Levels; 
BEI = biological exposure indices; CERCLA = Comprehensive Environmental Response, Compensation, and Liability 
Act; CFR = Code of Federal Regulations; DWEL = drinking water equivalent level; EAFUS = Everything Added to 
Food in the United States; EPA = Environmental Protection Agency; FDA = Food and Drug Administration; 
IARC = International Agency for Research on Cancer; IDLH = immediately dangerous to life or health; 
IRIS = Integrated Risk Information System; MCL = maximum contaminant level; MCLG = maximum contaminant level 
goal; NIOSH = National Institute for Occupational Safety and Health; NTP = National Toxicology Program; 
OSHA = Occupational Safety and Health Administration; PEL = permissible exposure limit; REL = recommended 
exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose; STEL = short-term expsoure 
limit; TLV = threshold limit values; TSCA = Toxic Substances Control Act; TWA = time-weighted average; 
USC = United States Code; WHO = World Health Organization 
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Absorption—The taking up of liquids by solids, or of gases by solids or liquids. 
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact. 
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment. 
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a 
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the 
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.    
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD. 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility. 
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces 
significant increases in the incidence of cancer (or tumors) between the exposed population and its 
appropriate control. 
Carcinogen—A chemical capable of inducing cancer. 
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome. 
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest 
some potential topics for scientific research, but are not actual research studies. 
Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure. These may suggest potential topics for scientific research, but are not actual research studies. 
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Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously. 
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles. 
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group. 
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines 
the relationship between exposure and outcome to a chemical or to chemicals at one point in time. 
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment. 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point 
in the life span of the organism. 
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects. 
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs.  The terms, as used here, include malformations and variations, altered growth, and in utero 
death. 
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water 
levels for a chemical substance based on health effects information.  A health advisory is not a legally 
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials. 
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.   
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome. 
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from 
the body or environmental media. 
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
irreversible health effects. 
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals. 
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Immunological Effects—Functional changes in the immune response. 
Incidence—The ratio of individuals in a population who develop a specified condition to the total 
number of individuals in that population who could have developed that condition in a specified time 
period. 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles. 
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube. 
In Vivo—Occurring within the living organism. 
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals. 
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population. 
Lethal Dose(LO) (LDLO)—The lowest dose of a chemical introduced by a route other than inhalation that 
has been reported to have caused death in humans or animals. 
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population. 
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population. 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control. 
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure. 
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors. The default value for a MF is 1. 
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population. 
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time. 
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Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA. Mutations can lead to birth defects, miscarriages, or cancer. 
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions. 
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical. 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not 
considered to be adverse. 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution. 
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence 
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not 
exposed to the risk factor). An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group. 
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase. 
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek. 
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests. 
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate 
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides 
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body. 
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments, 
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the 
physiologically-based model compartments represent real anatomic regions of the body. 
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end 
points. These models advance the importance of physiologically based models in that they clearly 
describe the biological effect (response) produced by the system following exposure to an exogenous 
substance. 
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Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments 
representing organs or tissue groups with realistic weights and blood flows.  These models require a 
variety of physiological information:  tissue volumes, blood flow rates to tissues, cardiac output, alveolar 
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical 
information, such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also 
called biologically based tissue dosimetry models. 
Prevalence—The number of cases of a disease or condition in a population at one point in time.  
Prospective Study—A type of cohort study in which the pertinent observations are made on events 
occurring after the start of the study.  A group is followed over time. 
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and 
μg/m3 for air). 
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour 
workweek. 
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  
The inhalation reference concentration is for continuous inhalation exposures and is appropriately 
expressed in units of mg/m3 or ppm. 
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious 
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level 
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect 
various types of data used to estimate RfDs and an additional modifying factor, which is based on a 
professional judgment of the entire database on the chemical.  The RfDs are not applicable to 
nonthreshold effects such as cancer. 
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period. 
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related 
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system. 
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is 
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort. 
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Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical. 
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic that is associated with an increased occurrence of disease or other health-related 
event or condition. 
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among 
persons without risk factors. A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed group. 
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial 
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes 
continually. No more than four excursions are allowed per day, and there must be at least 60 minutes 
between exposure periods. The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may 
not be exceeded. 
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population. 
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
Teratogen—A chemical that causes structural defects that affect the development of an organism. 
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.  
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit 
(STEL), or as a ceiling limit (CL). 
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek. 
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population. 
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism. 
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from 
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. 
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; 
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic 
average of 10 and 1. 
Xenobiotic—Any chemical that is foreign to the biological system. 
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The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with 
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most 
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances. 
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance.  During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects.  These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or 
action levels. 
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level 
above the MRL does not mean that adverse health effects will occur. 
MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that 
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are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals. 
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the 
Division of Toxicology and Environmental Medicine, expert panel peer reviews, and agency-wide MRL 
Workgroup reviews, with participation from other federal agencies and comments from the public.  They 
are subject to change as new information becomes available concomitant with updating the toxicological 
profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels.  
For additional information regarding MRLs, please contact the Division of Toxicology and 
Environmental Medicine, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, 
Mailstop F-32, Atlanta, Georgia 30333. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Ethylbenzene 
CAS Numbers: 100-41-4 
Date: August 2007 
Profile Status: Final Pre-Public Draft 
Route: [x] Inhalation  [ ] Oral 
Duration: [x] Acute   [ ] Intermediate   [ ] Chronic 
Graph Key: 13 
Species: Rat 
Minimal Risk Level: 10 [ ] mg/kg/day   [x] ppm 
Reference: Cappaert NLM, Klis SFL, Baretta AB, et al.  2000.  Ethyl benzene-induced ototoxicity in rats: 
A dose-dependent mid-frequency hearing loss.  J Assoc Res Otolaryngol 1(4):292-299. 
Experimental design: Wag/Rij rats (eight rats/group; sex not provided) were exposed to 0, 300, 400, or 
550 ppm ethylbenzene (99% pure), 8 hours/day for 5 days.  Animal weight was recorded weekly.  
Measurement of Distortion Product Otoacoustic Emissions (DPOAE), Compound Action Potential 
(CAP), and hair cell counts were conducted 3–6 weeks after the last ethylbenzene exposure.  
DPOAE:  Stimuli were delivered to the ear canal via a probe system incorporating two speakers and a 
low-noise microphone.  The microphone signal was amplified and the response to the stimulus was 
measured. DPOAE amplitude growth curves with stimulus levels were obtained from both ears.  Growth 
functions were obtained at 4, 5.6, 8, 11.3, 16, and 22.6 kHz.  The DPOAE threshold, defined as the 
stimulus level required to elicit a response of 0 dB SPL DPOAE was determined for each of the six 
frequencies. 
CAP: CAP was conducted immediately after DPOAE measurements.  Auditory-evoked responses were 
recorded via a silverball electrode at the apex of the cochlea after presenting tone bursts of 1, 2, 4, 8, 12, 
16, and 24 kHz.  An isoresponsive criterion of 1 µV level was used to define CAP thresholds. CAP 
amplitude was defined as the difference between the first negative peak and the summating potential in 
the electrophysiologic response.  Hair cell counts: Immediately after conducting the electrocochleography 
(CAP) cochleas were removed and bisected longitudinally.  Hair cell counts were conducted on five 
locations of the organ of Corti. Outer hair cell (OHC) loss was determined and expresses as a percentage 
of the expected number of OHC in different auditory regions. 
Effect noted in study and corresponding doses: Rats did not show signs of ill health.  There were no 
significant differences in terminal body weight between exposed and control rats.   
DPOAE:  DPOAE amplitude growth curves showed a significant reduction in rats exposed to 550 ppm, 
but not 300 or 400 ppm ethylbenzene.  Effects were significant at 5.6, 8, and 11.3 kHz, but not at other 
frequencies. The DPOAE thresholds were significantly shifted (increased stimulus was needed to elicit 
the threshold response) at 5.6, 8, 11.3, and 16 kHz in rats in the 550-ppm group.  DPOAE threshold shifts 
were not observed in other exposure groups.   
CAP:  Animals exposed to 550 ppm showed a significant shift in the CAP amplitude growth curves at 8, 
12, and 16 kHz.  In the 400-ppm group, the growth curves were affected only at 12 kHz and there was no 
effect in animals in the 300-ppm group.  CAP thresholds were significantly shifted at 8, 12, and 16 kHz in 
the 550-ppm group and at 12 and 16 kHz in the 400-ppm group.  There was no deterioration of CAP 
thresholds in the 300-ppm group.  Significant OHC losses of approximately 33 and 75% were observed in 
the 550-ppm group in the auditory regions corresponding to 11 and 21 kHz, respectively.  In the 400-ppm 
group, significant losses (25%) were observed in the 11 kHz region.  OHC losses in the 21 kHz region in 
the 300-ppm group were approximately 12%, but were not statistically significant. 
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Dose and end point used for MRL derivation: The MRL is based on a NOAEL of 300 ppm and a LOAEL 
of 400 ppm for significant deterioration in CAP auditory thresholds and significant OHC losses. 
[x] NOAEL   [ ] LOAEL 
Uncertainty Factors used in MRL derivation: 
[ ]  10 for use of a LOAEL 
[x]  3 for extrapolation from animals to humans with dosimetric adjustment 
[x]  10 for human variability 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: The 
human equivalent concentration (HEC) for the NOAEL was calculated using Formula 4-48 (page 4-60), 
from Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation 
Dosimetry (EPA 1994o).  The recommended equation is that for category 3 gases: 
(H b / g ) ANOAEL[HEC] (ppm) = NOAEL[ADJ] (ppm) x 
(H b / g )H 
= 300 ppm x [1] = 300 ppm 
where: 
(Hb/g)A, (Hb/g)H  = Blood/gas partition coefficient in animal and human blood, 
respectively.  Blood/gas partition coefficients of 30.2 and 28.2 for rat and human 
blood, respectively, were obtained (Abraham et al. 2005).  However, when 
(Hb/g)A > (Hb/g)H, a value of 1 is used for the ratio (EPA 1994o).  Thus, a default 
value of 1.0 was used for the animal-to-human blood gas ratio. 
Was a conversion used from intermittent to continuous exposure? No adjustment for intermittent 
exposure was made because the pharmacokinetics of ethylbenzene indicate that ethylbenzene will rapidly 
be absorbed, attain equilibrium with blood, be metabolized, and be eliminated from the body.  Steady-
state blood ethylbenzene concentrations achieved within 2 hours of initiating inhalation exposure to 
ethylbenzene concentration ranging from 75 to 500 ppm (Charest-Tardif et al. 2006).  The blood 
elimination kinetics of inhaled ethylbenzene show that ethylbenzene is rapidly eliminated from the blood, 
with elimination half-times ranging from 3.3 to 63 minutes (e.g., nonlinearity of clearance with exposure 
concentration, similar elimination half-times (Charest-Tardif et al. 2006; Tardif et al. 1997). 
Other additional studies or pertinent information that lend support to this MRL: Cappaert et al. (1999, 
2001, 2002) showed significant adverse effects in the auditory system of rats after acute-duration 
exposures to ≥400 ppm ethylbenzene via inhalation. OHC losses, generally the most sensitive end point 
evaluated in these studies, showed a concentration-related pattern.  Functional auditory deficits were 
observed at exposure concentrations that were greater than or equal to the concentrations that elicited 
OHC loss. Rats administered ethylbenzene by gavage at 8.47 mmol/kg/day (900 mg/kg/day), 
5 days/week for 2 weeks showed almost complete loss of the three rows of OHCs (Gagnaire and Langlais 
2005).  An intermediate-duration study in rats showed significant irreversible ototoxicity in rats exposed 
to ≥200 ppm ethylbenzene via inhalation. 
Agency Contacts (Chemical Managers): Jessilynn Taylor, Henry Abadin, Heraline Hicks 
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Chemical Name: Ethylbenzene 
CAS Numbers: 100-41-4 
Date: August 2007 
Profile Status: Final Pre-Public Draft 
Route: [x] Inhalation  [ ] Oral 
Duration: [ ] Acute  [x] Intermediate   [ ] Chronic 
Graph Key: 40 
Species: Rat 
Minimal Risk Level: 0.7 [ ] mg/kg/day  [x] ppm 
Reference: Gagnaire F, Langlais C, Grossman S, et al.  2007.  Ototoxicity in rats exposed to 
ethylbenzene and to two xylene vapors for 13 weeks.  Arch Toxicol 81:127-143. 
Experimental design: Male Sprague-Dawley rats (14 rats/exposure group) were exposed to 0, 200, 400, 
600 and 800 ppm ethylbenzene (99% pure), 6 hours/day, 6 days/week, for 13 weeks.  Ototoxicity was 
assessed based on effects on neurophysiological measurements and cochlear total hair cell counts.  For the 
neurophysiologic assessments, rats were surgically fitted with electrodes (active electrode was placed at 
the lamba point over the inferior colliculus, the reference electrode was placed posterior to the bregma 
and to the right of the midline, and the ground electrode was placed over the nasal bone).  Exposure to 
ethylbenzene was conducted starting 3–4 weeks after implantation of the electrodes and neuro-
physiological measurements were conducted at the end of 4th, 8th, and 13th week of exposure and at the 
end of the 8th week of recovery (week 21).  Brainstem auditory responses were evoked with 
50 microsecond clicks at 10 clicks/second presented in 5 dB steps.  The evoked activity was analyzed for 
10 ms following each click.  Audiometric thresholds were determined at 2, 4, 8, and 16 kHz by inspection 
of the auditory brainstem responses.  Following the 8th week of recovery (post-exposure) eight rats/group 
were sacrified.  The organ of Corti and the basilar membrane were dissected from the cochlea and 
prepared for total hair cell counts (cytocochleograms).  Four left and four right cochleas were prepared in 
this manner in all groups including controls. 
Effect noted in study and corresponding doses: In the 800 ppm group, one rat lost its head plug and could 
not undergo neurophysiological testing, one rat died for unknown reasons and another rat was sacrificed 
due to a large neck tumor.  There were no significant differences in body weight gain between the 
surviving treated animals and controls. 
Audiometric thresholds at 2, 4, 8, and 16 kHz were significantly higher in animals exposed to 400, 600, 
and 800 ppm ethylbenzene than in controls (p<0.05). The effect was evident at week 4, did not increase 
significantly throughout the exposure period, and was not reversed after 8 weeks of recovery. No shift in 
audiometric thresholds was observed in rats in the 200 ppm group. 
The morphological assessment of the organ of Corti (conducted after an 8-week recovery period) showed 
significant losses (up to 30% of the OHC in the mid frequency region) in the third row of the OHC in 
4/8 rats exposed to 200 ppm.  A dose related loss in third row OHC (OHC3) was evident with almost 
complete loss observed in the 600- and 800-ppm groups.  The data suggest that the extent of the damage 
at each dose was greatest in the OHC3 followed, in decreasing order, by damage in OHC2, OHC1, and 
inner hair cells (IHC). There was no significant hair loss in the control animals.  The LOAEL for OHC3 
loss was 200 ppm.  A NOAEL was not established. 
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Dose and end point used for MRL derivation: The MRL is based on a LOAEL of 200 ppm for significant 
loss of cochlear OHCs after 13 weeks of exposure. 
[ ] NOAEL   [x] LOAEL 
Uncertainty Factors used in MRL derivation: 
[x]  10 for use of a LOAEL 
[x]  3 for extrapolation from animals to humans with dosimetric adjustment 
[x]  10 for human variability 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable 
If an inhalation study in animals, list conversion factors used in determining human equivalent 
concentration: The human equivalent concentration (HEC) for the LOAEL was calculated using Formula 
4-48 (page 4-60), from Methods for Derivation of Inhalation Reference Concentrations and Application 
of Inhalation Dosimetry (EPA 1994o).  The recommended equation is that for category 3 gases: 
(H b / g ) ALOAEL[HEC] (ppm) = LOAEL[ADJ] (ppm) x 
(H b / g )H 
= 200 ppm x [1] = 200 ppm 
where: 
(Hb/g)A, (Hb/g)H  = Blood/gas partition coefficient in animal and human blood, 
respectively.  Blood/gas partition coefficients of 30.2 and 28.2 for rat and human 
blood, respectively, were obtained (Abraham et al. 2005).  However, when 
(Hb/g)A > (Hb/g)H, a value of 1 is used for the ratio (EPA 1994o).  Thus, a default 
value of 1.0 was used for the animal-to-human blood gas ratio. 
Was a conversion used from intermittent to continuous exposure? No adjustment for intermittent 
exposure was made because the pharmacokinetics of ethylbenzene indicate that ethylbenzene will rapidly 
be absorbed, attain equilibrium with blood, be metabolized, and be eliminated from the body.  Steady-
state blood ethylbenzene concentrations achieved within 2 hours of initiating inhalation exposure to 
ethylbenzene concentration ranging from 75 to 500 ppm (Charest-Tardif et al. 2006).  The blood 
elimination kinetics of inhaled ethylbenzene show that ethylbenzene is rapidly eliminated from the blood, 
with elimination half-times ranging from 3.3 to 63 minutes (e.g., nonlinearity of clearance with exposure 
concentration, similar elimination half-times (Charest-Tardif et al. 2006; Tardif et al. 1997). 
Other additional studies or pertinent information that lend support to this MRL: Significant adverse 
effects on the auditory system was observed in rats after acute-duration exposures to ≥400 ppm 
ethylbenzene via inhalation (Cappaert et al. 1999, 2000, 2001, 2002).  OHC losses, usually the most 
sensitive end point evaluated in these acute-duration studies, showed a concentration-related pattern.  
Functional auditory deficits were observed at exposure concentrations that were greater than or equal to 
the concentrations that elicited OHC loss. Rats administered ethylbenzene by gavage at 
8.47 mmol/kg/day (900 mg/kg/day), 5 days/week for 2 weeks showed almost complete loss of the three 
rows of OHCs (Gagnaire and Langlais 2005). 
Agency Contacts (Chemical Managers):  Jessilynn Taylor, Henry Abadin, Heraline Hicks 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Ethylbenzene 
CAS Numbers: 100-41-4 
Date: August 2007 
Profile Status: Final Pre-Public Draft 
Route: [x] Inhalation  [ ] Oral 
Duration: [ ] Acute  [ ] Intermediate  [x] Chronic 
Graph Key: 60 
Species: Rat 
Minimal Risk Level: 0.3 [ ] mg/kg/day  [x] ppm 
Reference: NTP. 1999.  NTP technical report on the toxicology and carcinogenesis studies of 
ethylbenzene in F344/N rats and B6C3F1 mice (inhalation studies).  Research Triangle Park, NC:  
National Toxicology Program, U.S. Department of Health and Human Services.  NTP TR 466. 
Experimental design: Groups of F344/N rats and B6C3Fl mice (50 animals/sex/dose group) were 
exposed to 0, 75, 250, or 750 ppm ethylbenzene by inhalation for 5 days/week, 6 hours/day, for 104 (rats) 
or 103 (mice) weeks.  Animals were observed twice daily and clinical findings were recorded monthly. 
Body weights were recorded at the initiation of the study, weekly for the first 13 weeks, at week 16, 
monthly through the end of exposure, and prior to terminal necropsy.  Animals that survived to study 
termination were killed by asphyxiation with CO2. A complete necropsy and microscopic examination 
were performed on all rats and mice that survived to study termination or died early.  The tissues 
examined included the adrenal gland, blood vessel (aorta), bone and marrow, brain, clitoral gland, 
esophagus, gall bladder, harderian gland, heart, large intestine (cecum, colon, and rectum), small intestine 
(duodenum, jejunum, ileum), kidney, liver, lung, lymph nodes (mandibular and mesenteric), mammary 
gland, nose, ovary, pancreas, parathyroid gland, preputial gland, prostate gland, salivary gland, spleen, 
stomach (forestomach and glandular stomach), testis with epididymis and seminal vesicle, thymus, 
thyroid gland, trachea, urinary bladder, and uterus.   
Effect noted in study and corresponding doses: Survival of male rats in the 750-ppm group was 
significantly less than that of control animals.  Survival was not affected in rats in other exposure groups 
or in mice at any ethylbenzene concentration.  No clinical findings were attributed to ethylbenzene 
exposure in rats or mice.  The severity of nephropathy observed in exposed rats was significantly 
increased in females at ≥75 ppm and in males at 750 ppm.  Nephropathy was characterized by dilation of 
renal tubules with hyaline or cellular casts, interstitial fibrosis, infiltration of inflammatory cells, tubular 
regeneration, and transitional hyperplasia of the renal papilla.  In male rats exposed to 750 ppm, the 
incidences of renal tubule proliferative lesions were significantly increased relative to control animals.  
The incidences of renal tubule adenoma and adenoma or carcinoma (combined) in the 750-ppm group 
were significantly greater than the incidence in control animals.  The incidence of renal tubule hyperplasia 
in 750-ppm males was significantly greater than that in the control group.  Significant increases were 
observed in the incidence of interstitial cell adenoma and bilateral testicular adenoma in males in the 
750-ppm group.  An increase was observed in the incidence of cystic degeneration of the liver in male 
rats at 750 ppm.  Significant increases in the incidence of hyperplasia of the pituitary gland pars distalis 
were observed in female mice at ≥250 ppm.  A significant increase in the incidence of alveolar epithelial 
metaplasia was observed in male mice in the 750-ppm group.  In 750-ppm males, the incidences of 
alveolar/bronchiolar adenoma and alveolar/bronchiolar adenoma or carcinoma (combined) were 
significantly greater than those in control animals but remained within the historical control ranges.  The 
incidence of hepatocellular adenoma and adenoma or carcinoma (combined) in female mice was 
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significantly increased in the 750-ppm group.  Eosinophilic foci of the liver were observed in females in 
the 750-ppm group at a higher incidence that in control animals.  Syncytial alterations of hepatocytes 
were observed in male mice in all ethylbenzene exposure groups, but not in controls, with a significant 
increase in incidence observed at ≥250 ppm.  Other nonneoplastic changes in male mice exposed to 
750 ppm included mild-to-minimal hepatocellular hypertrophy and hepatocyte necrosis.  A significant 
increase in incidences of follicular cell hyperplasia was observed in male and female mice in the 750-ppm 
groups. 
A NOAEL was not established. 
Dose and end point used for MRL derivation: The MRL is based on a LOAEL of 75 ppm for significant 
increases in the severity of nephropathy in female rats after 2 years of exposure. 
[ ] NOAEL   [x] LOAEL 
Uncertainty Factors used in MRL derivation: 
[x]  10 for use of a LOAEL 
[x]  3 for extrapolation from animals to humans with dosimetric adjustment 
[x]  10 for human variability 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable 
If an inhalation study in animals, list conversion factors used in determining human equivalent 
concentration: The human equivalent concentration (HEC) for the LOAEL was calculated using Formula 
4-48 (page 4-60), from Methods for Derivation of Inhalation Reference Concentrations and Application 
of Inhalation Dosimetry (EPA 1994o).  The recommended equation is that for category 3 gases: 
(H b / g ) ALOAEL[HEC] (ppm) = LOAEL[ADJ] (ppm) x (H b / g )H 
= 75 ppm x [1] = 75 ppm 
where: 
(Hb/g)A, (Hb/g)H  = Blood/gas partition coefficient in animal and human blood, 
respectively.  Blood/gas partition coefficients of 30.2 and 28.2 for rat and human 
blood, respectively, were obtained (Abraham et al. 2005).  However, when 
(Hb/g)A > (Hb/g)H, a value of 1 is used for the ratio (EPA 1994o).  Thus, a default 
value of 1.0 was used for the animal-to-human blood gas ratio. 
Was a conversion used from intermittent to continuous exposure? No adjustment for intermittent 
exposure was made because the pharmacokinetics of ethylbenzene indicate that ethylbenzene will rapidly 
be absorbed, attain equilibrium with blood, be metabolized, and eliminated from the body. Steady-state 
blood ethylbenzene concentrations achieved within 2 hours of initiating inhalation exposure to 
ethylbenzene concentration ranging from 75 to 500 ppm (Charest-Tardif et al. 2006).  The blood 
elimination kinetics of inhaled ethylbenzene show that ethylbenzene is rapidly eliminated from the blood, 
with elimination half-times ranging from 3.3 to 63 minutes (e.g., nonlinearity of clearance with exposure 
concentration, similar elimination half-times (Charest-Tardif et al. 2006; Tardif et al. 1997). 
Other additional studies or pertinent information that lend support to this MRL: A limited number of 
studies have examined the chronic toxicity of ethylbenzene.  Two studies have looked at possible effects 
in workers chronically exposed to ethylbenzene and NTP (1999) examined chronic toxicity in rats and 
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mice. Hematological effects (increased average number of lymphocytes and decreased hemoglobin) were 
observed in workers exposed to solvents containing ethylbenzene (Angerer and Wulf 1985).  No 
hematological effects, liver lesions or effects on liver function were reported in a study of workers 
exposed chronically (>20 years) to ethylbenzene (Bardodej and Cirek 1988).  Exposure levels were not 
indicated in the latter study, but the risk of ethylbenzene exposure in this production plant was reported as 
negligible. An increased incidence of hyperplasia of the pituitary gland pars distalis was observed in 
female mice exposed to 250 ppm (NTP 1999).  At 750 ppm, increased incidence of follicular cell 
hyperplasia in the thyroid gland and syncytial alterations of the hepatocytes, hypertrophy, and hepatic 
necrosis were observed in mice (NTP 1999). 
Agency Contacts (Chemical Managers): Jessilynn Taylor, Henry Abadin, Heraline Hicks 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Ethylbenzene 
CAS Numbers: 100-41-4 
Date: August 2007 
Profile Status: Final Pre-Public Draft 
Route: [ ] Inhalation  [x] Oral 
Duration: [ ] Acute  [x] Intermediate   [ ] Chronic 
Graph Key: 4 
Species: Rat 
Minimal Risk Level: 0.5 [x ] mg/kg/day  [ ] ppm 
Reference: Mellert W, Deckardt K, Kauffmann W, et al.  2007. Ethylbenzene: 4- and 13-week rat oral 
toxicity.  Arch Toxicol 81:361-370. 
Experimental design: Groups of 10 male and 10 female Wister rats were administered ethylbenzene (no 
vehicle) by oral gavage at doses of 0, 75, 250, or 750 mg/kg/day for 13 weeks.  The total daily dose of 
ethylbenzene was administered as split morning/evening half doses.  Animals were examined daily for 
mortality and clinical signs.  Food and water consumption and body weights were recorded weekly.  A 
detailed clinical examination [ophthalmology and a functional observational battery (FOB)] and 
assessment of motor activity were conducted during the last week of treatment.  After 13 weeks, 
urinalysis was conducted and blood samples were obtained and analyzed for hematology and clinical 
chemistry; organ weights were recorded and gross histopathologic examinations of the liver, kidney, and 
pancreas were conducted on animals in all groups.  A comprehensive histopathological examination of 
tissues was performed in the control and 750 mg/kg/day groups. 
Effect noted in study and corresponding doses: Clinical signs (post-dosing salivation) in treated animals 
were observed in all animals administered ≥250 mg/kg/day and in one animal administered 75 mg/kg/day. 
Terminal body weight in males was significantly decreased by 14% compared to controls in the 
750 mg/kg/day group.  Mean corpuscular volume was increased in males and females and platelet count 
was reduced in females treated with 750 mg/kg/day. Effects indicative of liver toxicity included 
increased activity of serum liver enzymes (ALT and GGT) in males (≥250 mg/kg/day) and females 
(750 mg/mg/day), increased absolute and relative liver weights (≥250 mg/kg/day in males and females), 
and a dose-related increase in the incidence of centrilobular hepatocyte hypertrophy (≥250 mg/kg/day in 
males and females). Increased bilirubin (≤250 mg/kg/day in males and 750 mg/kg/day in females), total 
protein (750 mg/kg/day in females), albumin (750 mg/kg/day in males and females), globulins 
(750 mg/kg/day in females), and cholesterol (≤250 mg/kg/day in males and females), and decreased 
prothrombin time (750 mg/kg/day in males and ≥250 mg/kg/day in females) were considered by study 
investigators as adaptive effects in the liver.  In males in the 75 mg/k/day group, relative liver weight was 
significantly increased by (4% compared to controls); however, no histopathological changes or increases 
in absolute liver or serum liver enzyme activities were observed at this dosage. Given that ethylbenzene is 
a microsomal enzyme inducer and the absence of histopathology and other evidence of liver injury at the 
75 mg/kg/day dosage, the small increase in relative liver weight in male rats at this dosage was not 
considered indicative of an adverse effect on the liver. 
Renal effects in males included increased serum creatinine (750 mg/kg/day), increased incidences of 
transitional epithelial cells and granular and epithelial cell casts in the urine (≥250 mg/kg/day), increased 
absolute and relative kidney weights (≥250 mg/kg/day), and a dose-related increase in severity of hyaline 
droplet nephropathy (≥250 mg/kg/day).  Adverse renal effects in males were most likely related to 
accumulation of α2µ-globulin, and, therefore, considered not relevant to humans.  Absolute kidney 
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weight was significantly increased by 7 and 13% in females administered 250 and 750 mg/kg/day, 
respectively, compared to controls; however, since no histopathological findings or alterations in 
urinalysis parameters were observed, the increased kidney weight in females was not considered 
indicative of an adverse kidney effect in female rats.  Absolute and relative thymus weights were 
decreased in females treated with ≥250 mg/kg/day, but no histopathological findings were observed.  
Results of the FOB did not reveal consistent treatment-related effects. 
Dose and end point used for MRL derivation: Based on evidence of hepatotoxicity (increased serum liver 
enzyme activity, absolute and relative liver weights, and dose-related increased incidence of centrilobular 
hepatocyte hypertrophy), and the lack of evidence for adverse effects in other tissues or organ systems at 
lower oral intermediate-duration dosages, liver effects were selected as the basis for deriving the 
intermediate oral MRL, with NOAEL and LOAEL values of 75 and 250 mg/kg/day, respectively. Since 
serum liver enzyme activities were increased in the mid- and high-dose groups in males, but only in the 
high-dose group in females, males appeared more sensitive than females to the adverse hepatic effects of 
oral ethylbenzene.  To determine the point of departure for derivation of the intermediate-duration MRL, 
data sets for serum liver enzymes (ALT and GGT), relative liver weight, and centrilobular hepatocyte 
hypertrophy in male rats were evaluated for suitability for benchmark dose (BMD) modeling. Using all 
available continuous variable models in the EPA Benchmark Dose Software (BMDS) version 1.3.2 (EPA 
2000), no models provided adequate fit to the data for serum liver enzymes and relative liver weights; 
therefore, these data sets were considered unsuitable for BMD analysis.  Data for the incidence of 
centrilobular hepatocyte hypertrophy (Table A-1) were analyzed using all available dichotomous models 
in the EPA Benchmark Dose Software (version 1.3.2).  Predicted doses associated with a 10% extra risk 
were calculated.  As assessed by the chi-square goodness-of-fit statistic, all available dichotomous models 
provided adequate fit (X2 p>0.1) (Table A-2).  Comparing across models, a better fit is generally 
indicated by a lower Akaike’s Information Criteria (AIC).  As assessed by AIC, the log-probit model 
(Figure A-1) provided the best fit to the data.  The BMD10 and BMDL10 predicted by the log-probit model 
for the data on centrilobular hepatocyte hypertrophy in male rats were 78.9 and 48.2 mg/kg/day, 
respectively. The BMDL10 of 48.2 mg/kg/day for male rats was selected as the point of departure for 
deriving the intermediate-duration oral MRL. 
[ ] NOAEL   [ ] LOAEL  [X] BMDL 
Table A-1. Incidence Data for Centrilobular Hepatocyte Hypertrophy in Male Rats 
Exposed to Ethylbenzene for 13 Weeks 





Source: Mellert et al. 2007 
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Table A-2. Modeling Predictions for the Incidence of Centrilobular Hepatocyte 





Model BMD10 (mg/kg/day) BMDL10 (mg /kg/day) x2 p-value AIC 
Gammaa 61.5899 29.1257 1.60 44.152 
Logistic 114.336 73.5251 3.46 43.9535 
Log-logisticb 73.0775 18.2396 1.04 43.5549 
Multi-stagec 46.8785 28.9177 1.62 42.2384 
Probit 112.022 76.3196 3.44 43.9119 
Log-probitb 78.9472 48.2564 0.98 41.482 
Quantal linear 46.8785 28.9177 1.62 42.2384 
Quantal quadratic 173.773 126.831 4.80 44.9624 
Weibulla 54.5432 28.9959 1.62 44.2057 
aRestrict power ≥1. 

bSlope restricted to >1. 

cRestrict betas ≥0; lowest degree polynomial with an adequate fit is reported; degree of polynomial=3.  

Source: Mellert et al. 2007 
Figure A-1. Predicted (Log-Probit Model) and Observed Incidence of 

Centrilobular Hepatocyte Hypertrophy in Male Rats Exposed to Oral  

Ethylbenzene by Gavage for 13 Weeks* 





















15:00 07/26 2007 
*BMDs and BMDLs indicated are associated with a 10% extra risk change from the control, and are in units of 
mg/kg/day. 
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Uncertainty Factors used in MRL derivation: 
[ ]  10 for use of a less serious LOAEL 
[x] 10 for extrapolation from animals to humans 
[x] 10 for human variability 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable. 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable. 
Was a conversion used from intermittent to continuous exposure? Not applicable. 
Other additional studies or pertinent information that lend support to this MRL: The selection of BMDL10 
of 48.2 mg/kg/day, derived for male rats exposed to ethylbenzene for 13 weeks (Mellert et al. 2007), as a 
point of departure for deriving an intermediate-duration oral MRL for ethylbenzene is supported by 
results a 4-week oral gavage study in rats (Mellert et al. 2007) and a 6-month oral study in rats (Wolf et 
al. 1956).  Results of the 4-week gavage study in rats were similar to those of the 13-week study, 
identifying NOAEL and LOAEL values of 250 and 750 mg/kg/day, respectively, for liver effects.  
Observed effects consistent with hepatotoxicity included increased absolute and relative liver weights 
(≥250 mg/kg/day in males and 750 mg/kg/day in females), increased incidence of hepatocyte 
centrilobular (≥250 mg/kg/day in males and 750 mg/kg/day in females), and increased serum liver 
enzyme activity (ALT) (750 mg/kg/day in males and females).  Histopathological changes characterized 
by cloudy swelling of parenchymal cells of the liver and an increase in liver weight were observed in 
female rats administered 408 mg/kg/day by gavage for 6 months (Wolf et al. 1956).  No other hepatic 
changes were reported.  No liver effects were observed in female rats administered 136 mg/kg/day (Wolf 
et al. 1956). However, this study was poorly reported and did not provide adequate descriptions of study 
methods or results. 
Agency Contacts (Chemical Managers): Jessilynn Taylor, Henry Abadin, Heraline Hicks 
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Chapter 1 
Public Health Statement 
This chapter of the profile is a health effects summary written in non-technical language.  Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or 
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical. 
The major headings in the Public Health Statement are useful to find specific topics of concern.  The 
topics are written in a question and answer format.  The answer to each question includes a sentence that 
will direct the reader to chapters in the profile that will provide more information on the given topic. 
Chapter 2 
Relevance to Public Health 
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight-
of-evidence discussions for human health end points by addressing the following questions: 
1.	 What effects are known to occur in humans? 
2. 	 What effects observed in animals are likely to be of concern to humans? 
3. 	 What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites? 
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer 
potency or perform cancer risk assessments.  Minimal Risk Levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed. 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section. 
Interpretation of Minimal Risk Levels 
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 
routes of entry at each duration of exposure (acute, intermediate, and chronic).  These MRLs are not 
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans. 
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MRLs should help physicians and public health officials determine the safety of a community living near 
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational 
exposure. 
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are 
Unusually Susceptible" provide important supplemental information. 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.   
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used 




Tables and Figures for Levels of Significant Exposure (LSE) 
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects.  These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario.  The LSE tables and figures should always be used in 
conjunction with the text.  All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs). 
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends 
correspond to the numbers in the example table and figure. 
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LEGEND 
See Sample LSE Table 3-1 (page B-6) 
(1) 	 Route of Exposure. One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure.  Typically 
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures. 
(2) 	Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.  
In this example, an inhalation study of intermediate exposure duration is reported.  For quick 
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure. 
(3) 	Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.  
Systemic effects are further defined in the "System" column of the LSE table (see key number 
18). 
(4) 	 Key to Figure. Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure.  In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the two "18r" data points in sample Figure 3-1). 
(5) 	Species. The test species, whether animal or human, are identified in this column.  Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL. 
(6) 	Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure 
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from 
different studies. In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 
1981). 
(7) 	System. This column further defines the systemic effects.  These systems include respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular.  "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated. 
(8) 	NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b"). 
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(9) 	LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect. 
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL.  The respiratory effect reported in key 
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from 
Serious LOAELs. 
(10)	 Reference. The complete reference citation is given in Chapter 9 of the profile. 
(11)	 CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies.  CELs are always considered serious effects.  The LSE 
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing 
measurable cancer increases. 
(12)	 Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm. 
LEGEND 
See Sample Figure 3-1 (page B-7) 
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
(13)	 Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated. 
(14) 	Health Effect. These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table. 
(15)	 Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log 
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day. 
(16) 	NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the 
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of 
0.005 ppm (see footnote "b" in the LSE table). 
(17)	 CEL. Key number 38m is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the 
LSE table. 
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(18)	 Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the 
cancer dose response curve at low dose levels (q1*). 
(19)	 Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure. 























































→ Systemic ↓ ↓ ↓ ↓ ↓ ↓ 
→ 
18 Rat 13 wk 
5 d/wk 
6 hr/d 
Resp 3b 10 (hyperplasia) 




18 mo 20 
5 d/wk 
7 hr/d 
89–104 wk 10 
5 d/wk 
6 hr/d 








(CEL, lung tumors, 
nasal tumors) 
(CEL, lung tumors, 
hemangiosarcomas) 
Wong et al. 1982 
NTP 1982 
NTP 1982 
12 →	 a The number corresponds to entries in Figure 3-1. 
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of  5x10-3 ppm; dose adjusted for intermittent exposure and divided 
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APPENDIX C.  ACRONYMS, ABBREVIATIONS, AND SYMBOLS 
ACGIH American Conference of Governmental Industrial Hygienists 
ACOEM American College of Occupational and Environmental Medicine 
ADI acceptable daily intake 
ADME absorption, distribution, metabolism, and excretion 
AED atomic emission detection 
AFID alkali flame ionization detector 
AFOSH Air Force Office of Safety and Health 
ALT alanine aminotransferase 
AML acute myeloid leukemia 
AOAC Association of Official Analytical Chemists 
AOEC Association of Occupational and Environmental Clinics 
AP alkaline phosphatase 
APHA American Public Health Association 
AST aspartate aminotransferase 
atm atmosphere 
ATSDR Agency for Toxic Substances and Disease Registry 
AWQC Ambient Water Quality Criteria 
BAT best available technology 
BCF bioconcentration factor 
BEI Biological Exposure Index 
BMD benchmark dose 
BMR benchmark response 
BSC Board of Scientific Counselors 
C centigrade 
CAA Clean Air Act 
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency 
CAS Chemical Abstract Services 
CDC Centers for Disease Control and Prevention 
CEL cancer effect level 
CELDS Computer-Environmental Legislative Data System 
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
CFR Code of Federal Regulations 
Ci curie 
CI confidence interval 
CL ceiling limit value 
CLP Contract Laboratory Program 
cm centimeter 
CML chronic myeloid leukemia 
CPSC Consumer Products Safety Commission 
CWA Clean Water Act 
DHEW Department of Health, Education, and Welfare 
DHHS Department of Health and Human Services 
DNA deoxyribonucleic acid 
DOD Department of Defense 
DOE Department of Energy 
DOL Department of Labor 
DOT Department of Transportation 
DOT/UN/ Department of Transportation/United Nations/ 
NA/IMDG     North America/Intergovernmental Maritime Dangerous Goods Code 
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DWEL drinking water exposure level 
ECD electron capture detection 
ECG/EKG electrocardiogram 
EEG electroencephalogram 
EEGL Emergency Exposure Guidance Level 
EPA Environmental Protection Agency 
F Fahrenheit 
F1 first-filial generation 
FAO Food and Agricultural Organization of the United Nations 
FDA Food and Drug Administration 
FEMA Federal Emergency Management Agency 
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
FPD flame photometric detection 
fpm feet per minute 
FR Federal Register 
FSH follicle stimulating hormone 
g gram 
GC gas chromatography 
gd gestational day 
GLC gas liquid chromatography 
GPC gel permeation chromatography 
HPLC high-performance liquid chromatography 
HRGC high resolution gas chromatography 
HSDB Hazardous Substance Data Bank  
IARC International Agency for Research on Cancer 
IDLH immediately dangerous to life and health 
ILO International Labor Organization 
IRIS Integrated Risk Information System 
Kd adsorption ratio 
kg kilogram 
kkg metric ton 
Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography 
LC50 lethal concentration, 50% kill 
LCLo lethal concentration, low 
LD50 lethal dose, 50% kill 
LDLo lethal dose, low 
LDH lactic dehydrogenase 
LH luteinizing hormone 
LOAEL lowest-observed-adverse-effect level 
LSE Levels of Significant Exposure 
LT50 lethal time, 50% kill 
m meter 
MA trans,trans-muconic acid 
MAL maximum allowable level 
mCi millicurie 
MCL maximum contaminant level 
MCLG maximum contaminant level goal 
MF modifying factor 
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mmHg millimeters of mercury 
mmol millimole 
mppcf millions of particles per cubic foot 
MRL Minimal Risk Level 
MS mass spectrometry 
NAAQS National Ambient Air Quality Standard 
NAS National Academy of Science 
NATICH National Air Toxics Information Clearinghouse 
NATO North Atlantic Treaty Organization 
NCE normochromatic erythrocytes 
NCEH National Center for Environmental Health 
NCI National Cancer Institute 
ND not detected 
NFPA National Fire Protection Association 
ng nanogram 
NHANES National Health and Nutrition Examination Survey 
NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NIOSHTIC NIOSH's Computerized Information Retrieval System 
NLM National Library of Medicine 
nm nanometer 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NOES National Occupational Exposure Survey 
NOHS National Occupational Hazard Survey 
NPD nitrogen phosphorus detection 
NPDES National Pollutant Discharge Elimination System 
NPL National Priorities List 
NR not reported 
NRC National Research Council 
NS not specified 
NSPS New Source Performance Standards 
NTIS National Technical Information Service 
NTP National Toxicology Program 
ODW Office of Drinking Water, EPA 
OERR Office of Emergency and Remedial Response, EPA 
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System 
OPP Office of Pesticide Programs, EPA 
OPPT Office of Pollution Prevention and Toxics, EPA 
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA 
OR odds ratio 
OSHA Occupational Safety and Health Administration 
OSW Office of Solid Waste, EPA 
OTS Office of Toxic Substances 
OW Office of Water 
OWRS Office of Water Regulations and Standards, EPA 
PAH polycyclic aromatic hydrocarbon 
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PBPD physiologically based pharmacodynamic  
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes 
PEL permissible exposure limit 
pg picogram 
PHS Public Health Service 
PID photo ionization detector 
pmol picomole 
PMR proportionate mortality ratio 
ppb parts per billion 
ppm parts per million 
ppt parts per trillion 
PSNS pretreatment standards for new sources 
RBC red blood cell 
REL recommended exposure level/limit 
RfC reference concentration 
RfD reference dose 
RNA ribonucleic acid 
RQ reportable quantity 
RTECS Registry of Toxic Effects of Chemical Substances 
SARA Superfund Amendments and Reauthorization Act 
SCE sister chromatid exchange 
SGOT serum glutamic oxaloacetic transaminase 
SGPT serum glutamic pyruvic transaminase 
SIC standard industrial classification 
SIM selected ion monitoring 
SMCL secondary maximum contaminant level 
SMR standardized mortality ratio 
SNARL suggested no adverse response level 
SPEGL Short-Term Public Emergency Guidance Level 
STEL short term exposure limit 
STORET Storage and Retrieval 
TD50 toxic dose, 50% specific toxic effect 
TLV threshold limit value 
TOC total organic carbon 
TPQ threshold planning quantity 
TRI Toxics Release Inventory 
TSCA Toxic Substances Control Act 
TWA time-weighted average 
UF uncertainty factor 
U.S. United States 
USDA United States Department of Agriculture 
USGS United States Geological Survey 
VOC volatile organic compound 
WBC white blood cell 
WHO World Health Organization 
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> greater than 
≥ greater than or equal to 
= equal to 
< less than 








* q1 cancer slope factor 
– negative 
+ positive 
(+) weakly positive result 
(–) weakly negative result 
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absorbed dose.......................................................................................... 94, 96, 99, 101, 111, 114, 116, 121 
acetylcholinesterase .................................................................................................................................. 116 
adipose tissue .............................................................................................................. 93, 133, 161, 187, 193 
adsorbed .................................................................................................................................... 160, 183, 198 
adsorption...................................................................................................................................... 9, 153, 193 
aerobic........................................................................................................................... 9, 151, 162, 165, 166 
alanine aminotransferase (see ALT) ........................................................................................................... 11 
ALT (see alanine aminotransferase) ................................................................................. 11, 26, 27, 80, 129 
ambient air .............................................................................................................. 9, 10, 122, 169, 170, 176 
anaerobic ........................................................................................................................... 151, 153, 165, 166 
bioaccumulation........................................................................................................................ 161, 179, 186 
bioavailability ........................................................................................................... 160, 161, 183, 186, 189 
bioconcentration factor ............................................................................................................................. 161 
biodegradation........................................................................................................... 136, 151, 162, 165, 167 
biomarker .................................................................................................................................. 120, 121, 133 
biomarkers ........................................................................................ 120, 121, 122, 123, 133, 135, 191, 200 
body weight effects ..................................................................................................................................... 64 
breast milk............................................................................................. 4, 120, 135, 161, 179, 181, 183, 187 
cancer ................................................................................................................ 4, 14, 72, 106, 107, 110, 119 
carcinogen ................................................................................................................................... 14, 206, 209 
carcinogenic .......................................................................................... 14, 16, 29, 31, 72, 83, 130, 206, 209 
carcinogenicity................................................................................................ 14, 72, 83, 115, 130, 206, 209 
carcinoma........................................................................................................................................ 23, 72, 73 
carcinomas ............................................................................................................................................ 62, 73 
cardiovascular ........................................................................................................................... 33, 59, 73, 84 
Cardiovascular Effects .......................................................................................................................... 59, 80 
chromosomal aberrations ............................................................................................................................ 88 
clearance ........................................................................................................... 18, 20, 23, 90, 103, 108, 115 
death................................................................................................................................ 4, 31, 32, 33, 73, 84 
dermal effects........................................................................................................................................ 33, 84 
DNA................................................................................................................................ 86, 87, 88, 115, 121 
dopamine................................................................................................................................................... 115 
elimination half-time............................................................................................................... 18, 20, 23, 115 
elimination rate ......................................................................................................................................... 100 
endocrine............................................................................................................. 21, 33, 63, 73, 84, 117, 118 
endocrine effects ......................................................................................................................................... 63 
estrogenic .................................................................................................................................................. 118 
fetus........................................................................................................................................................... 118 
Gastrointestinal Effects ............................................................................................................................... 59 
general population............................................................................... 10, 120, 153, 178, 183, 187, 188, 200 
genotoxic......................................................................................................................... 31, 86, 88, 115, 130 
genotoxicity......................................................................................................................................... 88, 131 
germinal epithelium .................................................................................................................................... 68 
groundwater .................................. 2, 134, 136, 151, 153, 158, 159, 160, 165, 167, 174, 175, 178, 183, 186 
growth retardation....................................................................................................................................... 71 
half-life.................................................................................................................... 9, 90, 121, 151, 159, 162 
hematological effects .................................................................................... 10, 59, 60, 65, 72, 80, 129, 130 
hepatic effects ............................................................................................................. 26, 60, 61, 80, 81, 122 
hydrolysis.................................................................................................................................................. 162 
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hydroxyl radical .................................................................................................................... 9, 151, 159, 161 
immune system ......................................................................................................................................... 131 
immunological ........................................................................................................................ 31, 65, 81, 131 
immunological effects......................................................................................................................... 81, 131 
Kow .................................................................................................................................... 113, 141, 160, 161 
LD50....................................................................................................................................................... 73, 84 
lymphoreticular ........................................................................................................................................... 65 
metabolic effects ............................................................................................................................. 33, 73, 84 
micronuclei ........................................................................................................................................... 86, 87 
milk ............................................................................................................. 92, 120, 122, 136, 187, 192, 193 
musculoskeletal effects ............................................................................................................................... 60 
neonatal ............................................................................................................................................. 116, 183 
neoplasm ............................................................................................................................................... 14, 72 
neoplastic .................................................................................................................................................... 73 
neurobehavioral......................................................................................................................................... 118 
neurodevelopmental .................................................................................................................................. 131 
neurophysiological ...................................................................................................................................... 20 
nuclear......................................................................................................................................................... 63 
ocular effects......................................................................................................................................... 14, 86 
partition coefficients ................................................................................. 18, 20, 24, 90, 105, 109, 114, 115 
pharmacodynamic ..................................................................................................................................... 102 
pharmacokinetic........................................................................................ 101, 102, 104, 117, 120, 134, 183 
pharmacokinetics ............................................................................................................ 18, 20, 23, 118, 135 
photolysis ...................................................................................................................................... 9, 151, 162 
placenta ............................................................................................................................................. 120, 135 
rate constant .............................................................................................................................. 111, 113, 161 
renal effects..................................................................................................................................... 26, 62, 81 
retention .......................................................................................................................................... 90, 91, 93 
salivation ................................................................................................................................... 11, 22, 25, 66 
solubility ................................................................................................................................................... 160 
thyroid..................................................................................................................................... 23, 33, 63, 130 
toxicokinetic................................................................................................................................................ 31 
tumors ........................................................................................................................... 4, 14, 62, 72, 83, 130 
vapor phase ............................................................................................................................... 151, 159, 161 
vapor pressure ....................................................................................................................... 9, 159, 183, 186 
volatilization ................................................................................................................. 9, 153, 159, 162, 167 
weanlings .................................................................................................................................................... 92 
 
 

